# CTD Document Archive

This archive contains regulatory documents for drug trials.

## Accessions

| Accession | Drug | License |
|-----------|------|---------|
| RDCP-26-0001 | ALLN-177 | FDA Public Disclosure |
| RDCP-26-0002 | ALLN-346 | FDA Public Disclosure |
| RDCP-26-0003 | Divalent siRNA | Creative Commons Attribution 4.0 |

### Divalent siRNA Attribution (RDCP-26-0003)

> Gentile JE, Corridon TL, Serack FE, et al. **Divalent siRNA for prion disease.**
> bioRxiv. 2024 Dec 5;2024.12.05.627039. https://doi.org/10.1101/2024.12.05.627039

---

## Documents

# RDCP-26-0001 - ALLN-177 Reloxaliase (RDCP-26-0001)

  Oral enzyme therapeutic for enteric hyperoxaluria. Reloxaliase is a recombinant oxalate decarboxylase enzyme designed to degrade dietary oxalate in the gastrointestinal tract.
  - **files/**
    - **Additional-Items/**
      - **ALLN-177-301_ADaM_DEFINE_20210430/**
        - [adae.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adae.txt) (txt) [ALLN-177]
        - [adcm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adcm.txt) (txt) [ALLN-177]
        - [adeff.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adeff.txt) (txt) [ALLN-177]
        - [adeff2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adeff2.txt) (txt) [ALLN-177]
        - [ADEX.AVAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/ADEX.AVAL.pdf) (pdf) [ALLN-177]
        - [adex.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adex.txt) (txt) [ALLN-177]
        - [adfa.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adfa.txt) (txt) [ALLN-177]
        - [adlb.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adlb.txt) (txt) [ALLN-177]
        - [admh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/admh.txt) (txt) [ALLN-177]
        - [adpe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adpe.txt) (txt) [ALLN-177]
        - [adrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adrg.pdf) (pdf) [ALLN-177]
        - [adsl.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/adsl.txt) (txt) [ALLN-177]
        - [advs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/advs.txt) (txt) [ALLN-177]
        - [aeover.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/aeover.txt) (txt) [ALLN-177]
        - [aesi.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/aesi.txt) (txt) [ALLN-177]
        - [aesum.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/aesum.txt) (txt) [ALLN-177]
        - [ALLN7301_IRT_RandData.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/ALLN7301_IRT_RandData.xlsx) (xlsx) [ALLN-177]
        - [ALLN7301_utility.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/ALLN7301_utility.txt) (txt) [ALLN-177]
        - [cm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/cm.txt) (txt) [ALLN-177]
        - [cm_new.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/cm_new.txt) (txt) [ALLN-177]
        - **Data/**
          - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adae.xpt) (xpt) [ALLN-177]
          - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adcm.xpt) (xpt) [ALLN-177]
          - [adeff.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adeff.xpt) (xpt) [ALLN-177]
          - [adeff2.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adeff2.xpt) (xpt) [ALLN-177]
          - [adex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adex.xpt) (xpt) [ALLN-177]
          - [adfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adfa.xpt) (xpt) [ALLN-177]
          - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adlb.xpt) (xpt) [ALLN-177]
          - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/admh.xpt) (xpt) [ALLN-177]
          - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adpe.xpt) (xpt) [ALLN-177]
          - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/adsl.xpt) (xpt) [ALLN-177]
          - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Data/advs.xpt) (xpt) [ALLN-177]
        - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/define.xml) (xml) [ALLN-177]
        - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/define2-0-0.xsl) (xsl) [ALLN-177]
        - [demog.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/demog.txt) (txt) [ALLN-177]
        - [diet.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/diet.txt) (txt) [ALLN-177]
        - [disp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/disp.txt) (txt) [ALLN-177]
        - [dv.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/dv.txt) (txt) [ALLN-177]
        - [eff_ANCOVA.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_ANCOVA.txt) (txt) [ALLN-177]
        - [eff_LogReg.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_LogReg.txt) (txt) [ALLN-177]
        - [eff_LogReg2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_LogReg2.txt) (txt) [ALLN-177]
        - [eff_MMRM.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_MMRM.txt) (txt) [ALLN-177]
        - [eff_MMRM2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_MMRM2.txt) (txt) [ALLN-177]
        - [eff_Summary.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_Summary.txt) (txt) [ALLN-177]
        - [eff_Tipping.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/eff_Tipping.txt) (txt) [ALLN-177]
        - [exp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/exp.txt) (txt) [ALLN-177]
        - [lab.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/lab.txt) (txt) [ALLN-177]
        - [list.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/list.txt) (txt) [ALLN-177]
        - [list16.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/list16.txt) (txt) [ALLN-177]
        - [list_EHH.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/list_EHH.txt) (txt) [ALLN-177]
        - [mh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/mh.txt) (txt) [ALLN-177]
        - [pe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/pe.txt) (txt) [ALLN-177]
        - [pr.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/pr.txt) (txt) [ALLN-177]
        - [prescreen.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/prescreen.txt) (txt) [ALLN-177]
        - [QC_macro.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/QC_macro.txt) (txt) [ALLN-177]
        - [Review of Screening Collections.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Review%20of%20Screening%20Collections.pdf) (pdf) [ALLN-177]
        - [Thumbs.db](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/Thumbs.db) (db) [ALLN-177]
        - [vs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430/vs.txt) (txt) [ALLN-177]
      - [ALLN-177-301_ADaM_DEFINE_20210430.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_ADaM_DEFINE_20210430.zip) (zip) [ALLN-177]
      - **ALLN-177-301_SDTM_DEFINE_20210430/**
        - [acrf.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/acrf.pdf) (pdf) [ALLN-177]
        - [csdrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/csdrg.pdf) (pdf) [ALLN-177]
        - **Data/**
          - [ae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ae.xpt) (xpt) [ALLN-177]
          - [cm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/cm.xpt) (xpt) [ALLN-177]
          - [co.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/co.xpt) (xpt) [ALLN-177]
          - [da.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/da.xpt) (xpt) [ALLN-177]
          - [dm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/dm.xpt) (xpt) [ALLN-177]
          - [ds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ds.xpt) (xpt) [ALLN-177]
          - [dv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/dv.xpt) (xpt) [ALLN-177]
          - [ec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ec.xpt) (xpt) [ALLN-177]
          - [ex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ex.xpt) (xpt) [ALLN-177]
          - [fa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/fa.xpt) (xpt) [ALLN-177]
          - [ho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ho.xpt) (xpt) [ALLN-177]
          - [ie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ie.xpt) (xpt) [ALLN-177]
          - [lb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/lb.xpt) (xpt) [ALLN-177]
          - [mh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/mh.xpt) (xpt) [ALLN-177]
          - [pe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/pe.xpt) (xpt) [ALLN-177]
          - [pr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/pr.xpt) (xpt) [ALLN-177]
          - [qs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/qs.xpt) (xpt) [ALLN-177]
          - [relrec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/relrec.xpt) (xpt) [ALLN-177]
          - [rp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/rp.xpt) (xpt) [ALLN-177]
          - [se.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/se.xpt) (xpt) [ALLN-177]
          - [suppae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppae.xpt) (xpt) [ALLN-177]
          - [suppcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppcm.xpt) (xpt) [ALLN-177]
          - [suppdm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppdm.xpt) (xpt) [ALLN-177]
          - [suppds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppds.xpt) (xpt) [ALLN-177]
          - [suppdv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppdv.xpt) (xpt) [ALLN-177]
          - [suppfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppfa.xpt) (xpt) [ALLN-177]
          - [suppho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppho.xpt) (xpt) [ALLN-177]
          - [suppie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppie.xpt) (xpt) [ALLN-177]
          - [supplb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/supplb.xpt) (xpt) [ALLN-177]
          - [suppmh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppmh.xpt) (xpt) [ALLN-177]
          - [supppe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/supppe.xpt) (xpt) [ALLN-177]
          - [supppr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/supppr.xpt) (xpt) [ALLN-177]
          - [suppqs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppqs.xpt) (xpt) [ALLN-177]
          - [supprp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/supprp.xpt) (xpt) [ALLN-177]
          - [suppsv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppsv.xpt) (xpt) [ALLN-177]
          - [sv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/sv.xpt) (xpt) [ALLN-177]
          - [ta.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ta.xpt) (xpt) [ALLN-177]
          - [te.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/te.xpt) (xpt) [ALLN-177]
          - [ti.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ti.xpt) (xpt) [ALLN-177]
          - [ts.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/ts.xpt) (xpt) [ALLN-177]
          - [tv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/tv.xpt) (xpt) [ALLN-177]
          - [vs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/Data/vs.xpt) (xpt) [ALLN-177]
        - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/define.xml) (xml) [ALLN-177]
        - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430/define2-0-0.xsl) (xsl) [ALLN-177]
      - [ALLN-177-301_SDTM_DEFINE_20210430.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301_SDTM_DEFINE_20210430.zip) (zip) [ALLN-177]
      - [ALLN-177-302_ImagingReviewCharter_V3.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-302_ImagingReviewCharter_V3.0.pdf) (pdf) [ALLN-177]
      - [ALLN-177-206 CSR FINAL 14Feb2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-206%20CSR%20FINAL%2014Feb2022.pdf) (pdf) [ALLN-177]
      - [ALLN-177-301 Investigator Site List final data room.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/ALLN-177-301%20Investigator%20Site%20List%20final%20data%20room.xlsx) (xlsx) [ALLN-177]
      - [713 CSR studycode-body.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/713%20CSR%20studycode-body.pdf) (pdf) [ALLN-177]
      - [713 final TLF 17Jul2017+Aug+Sep 2017](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items/713%20final%20TLF%2017Jul2017+Aug+Sep%202017) (unknown) [ALLN-177]
    - **Additional-Items-Backup/**
      - **ALLN-177-301_ADaM_DEFINE_20210430/**
        - [adae.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adae.txt) (txt) [ALLN-177]
        - [adcm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adcm.txt) (txt) [ALLN-177]
        - [adeff.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adeff.txt) (txt) [ALLN-177]
        - [adeff2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adeff2.txt) (txt) [ALLN-177]
        - [ADEX.AVAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/ADEX.AVAL.pdf) (pdf) [ALLN-177]
        - [adex.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adex.txt) (txt) [ALLN-177]
        - [adfa.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adfa.txt) (txt) [ALLN-177]
        - [adlb.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adlb.txt) (txt) [ALLN-177]
        - [admh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/admh.txt) (txt) [ALLN-177]
        - [adpe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adpe.txt) (txt) [ALLN-177]
        - [adrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adrg.pdf) (pdf) [ALLN-177]
        - [adsl.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/adsl.txt) (txt) [ALLN-177]
        - [advs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/advs.txt) (txt) [ALLN-177]
        - [aeover.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/aeover.txt) (txt) [ALLN-177]
        - [aesi.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/aesi.txt) (txt) [ALLN-177]
        - [aesum.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/aesum.txt) (txt) [ALLN-177]
        - [ALLN7301_IRT_RandData.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/ALLN7301_IRT_RandData.xlsx) (xlsx) [ALLN-177]
        - [ALLN7301_utility.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/ALLN7301_utility.txt) (txt) [ALLN-177]
        - [cm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/cm.txt) (txt) [ALLN-177]
        - [cm_new.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/cm_new.txt) (txt) [ALLN-177]
        - **Data/**
          - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adae.xpt) (xpt) [ALLN-177]
          - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adcm.xpt) (xpt) [ALLN-177]
          - [adeff.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adeff.xpt) (xpt) [ALLN-177]
          - [adeff2.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adeff2.xpt) (xpt) [ALLN-177]
          - [adex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adex.xpt) (xpt) [ALLN-177]
          - [adfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adfa.xpt) (xpt) [ALLN-177]
          - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adlb.xpt) (xpt) [ALLN-177]
          - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/admh.xpt) (xpt) [ALLN-177]
          - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adpe.xpt) (xpt) [ALLN-177]
          - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/adsl.xpt) (xpt) [ALLN-177]
          - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Data/advs.xpt) (xpt) [ALLN-177]
        - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/define.xml) (xml) [ALLN-177]
        - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/define2-0-0.xsl) (xsl) [ALLN-177]
        - [demog.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/demog.txt) (txt) [ALLN-177]
        - [diet.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/diet.txt) (txt) [ALLN-177]
        - [disp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/disp.txt) (txt) [ALLN-177]
        - [dv.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/dv.txt) (txt) [ALLN-177]
        - [eff_ANCOVA.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_ANCOVA.txt) (txt) [ALLN-177]
        - [eff_LogReg.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_LogReg.txt) (txt) [ALLN-177]
        - [eff_LogReg2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_LogReg2.txt) (txt) [ALLN-177]
        - [eff_MMRM.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_MMRM.txt) (txt) [ALLN-177]
        - [eff_MMRM2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_MMRM2.txt) (txt) [ALLN-177]
        - [eff_Summary.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_Summary.txt) (txt) [ALLN-177]
        - [eff_Tipping.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/eff_Tipping.txt) (txt) [ALLN-177]
        - [exp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/exp.txt) (txt) [ALLN-177]
        - [lab.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/lab.txt) (txt) [ALLN-177]
        - [list.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/list.txt) (txt) [ALLN-177]
        - [list16.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/list16.txt) (txt) [ALLN-177]
        - [list_EHH.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/list_EHH.txt) (txt) [ALLN-177]
        - [mh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/mh.txt) (txt) [ALLN-177]
        - [pe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/pe.txt) (txt) [ALLN-177]
        - [pr.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/pr.txt) (txt) [ALLN-177]
        - [prescreen.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/prescreen.txt) (txt) [ALLN-177]
        - [QC_macro.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/QC_macro.txt) (txt) [ALLN-177]
        - [Review of Screening Collections.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Review%20of%20Screening%20Collections.pdf) (pdf) [ALLN-177]
        - [Thumbs.db](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/Thumbs.db) (db) [ALLN-177]
        - [vs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430/vs.txt) (txt) [ALLN-177]
      - [ALLN-177-301_ADaM_DEFINE_20210430.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_ADaM_DEFINE_20210430.zip) (zip) [ALLN-177]
      - **ALLN-177-301_SDTM_DEFINE_20210430/**
        - [acrf.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/acrf.pdf) (pdf) [ALLN-177]
        - [csdrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/csdrg.pdf) (pdf) [ALLN-177]
        - **Data/**
          - [ae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ae.xpt) (xpt) [ALLN-177]
          - [cm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/cm.xpt) (xpt) [ALLN-177]
          - [co.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/co.xpt) (xpt) [ALLN-177]
          - [da.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/da.xpt) (xpt) [ALLN-177]
          - [dm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/dm.xpt) (xpt) [ALLN-177]
          - [ds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ds.xpt) (xpt) [ALLN-177]
          - [dv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/dv.xpt) (xpt) [ALLN-177]
          - [ec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ec.xpt) (xpt) [ALLN-177]
          - [ex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ex.xpt) (xpt) [ALLN-177]
          - [fa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/fa.xpt) (xpt) [ALLN-177]
          - [ho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ho.xpt) (xpt) [ALLN-177]
          - [ie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ie.xpt) (xpt) [ALLN-177]
          - [lb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/lb.xpt) (xpt) [ALLN-177]
          - [mh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/mh.xpt) (xpt) [ALLN-177]
          - [pe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/pe.xpt) (xpt) [ALLN-177]
          - [pr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/pr.xpt) (xpt) [ALLN-177]
          - [qs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/qs.xpt) (xpt) [ALLN-177]
          - [relrec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/relrec.xpt) (xpt) [ALLN-177]
          - [rp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/rp.xpt) (xpt) [ALLN-177]
          - [se.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/se.xpt) (xpt) [ALLN-177]
          - [suppae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppae.xpt) (xpt) [ALLN-177]
          - [suppcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppcm.xpt) (xpt) [ALLN-177]
          - [suppdm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppdm.xpt) (xpt) [ALLN-177]
          - [suppds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppds.xpt) (xpt) [ALLN-177]
          - [suppdv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppdv.xpt) (xpt) [ALLN-177]
          - [suppfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppfa.xpt) (xpt) [ALLN-177]
          - [suppho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppho.xpt) (xpt) [ALLN-177]
          - [suppie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppie.xpt) (xpt) [ALLN-177]
          - [supplb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/supplb.xpt) (xpt) [ALLN-177]
          - [suppmh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppmh.xpt) (xpt) [ALLN-177]
          - [supppe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/supppe.xpt) (xpt) [ALLN-177]
          - [supppr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/supppr.xpt) (xpt) [ALLN-177]
          - [suppqs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppqs.xpt) (xpt) [ALLN-177]
          - [supprp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/supprp.xpt) (xpt) [ALLN-177]
          - [suppsv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/suppsv.xpt) (xpt) [ALLN-177]
          - [sv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/sv.xpt) (xpt) [ALLN-177]
          - [ta.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ta.xpt) (xpt) [ALLN-177]
          - [te.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/te.xpt) (xpt) [ALLN-177]
          - [ti.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ti.xpt) (xpt) [ALLN-177]
          - [ts.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/ts.xpt) (xpt) [ALLN-177]
          - [tv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/tv.xpt) (xpt) [ALLN-177]
          - [vs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/Data/vs.xpt) (xpt) [ALLN-177]
        - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/define.xml) (xml) [ALLN-177]
        - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430/define2-0-0.xsl) (xsl) [ALLN-177]
      - [ALLN-177-301_SDTM_DEFINE_20210430.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301_SDTM_DEFINE_20210430.zip) (zip) [ALLN-177]
      - [ALLN-177-302_ImagingReviewCharter_V3.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-302_ImagingReviewCharter_V3.0.pdf) (pdf) [ALLN-177]
      - [ALLN-177-206 CSR FINAL 14Feb2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-206%20CSR%20FINAL%2014Feb2022.pdf) (pdf) [ALLN-177]
      - [ALLN-177-301 Investigator Site List final data room.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/ALLN-177-301%20Investigator%20Site%20List%20final%20data%20room.xlsx) (xlsx) [ALLN-177]
      - [713 CSR studycode-body.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/713%20CSR%20studycode-body.pdf) (pdf) [ALLN-177]
      - [713 final TLF 17Jul2017+Aug+Sep 2017](https://archive.icosian.net/#documents/RDCP-26-0001/files/Additional-Items-Backup/713%20final%20TLF%2017Jul2017+Aug+Sep%202017) (unknown) [ALLN-177]
    - **Clinical Development/**
      - **Clinical Trials/**
        - **Phase 1 - Study 183/**
          - [Langman et al. A Double-Blind, Placebo Cont_Administered Oxalate Degrading Enzyme 2016.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Langman%20et%20al.%20A%20Double-Blind,%20Placebo%20Cont_Administered%20Oxalate%20Degrading%20Enzyme%202016.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR Appendix 16.2 data listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20Appendix%2016.2%20data%20listings.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR Figure 14.2.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20Figure%2014.2.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR post-hoc table 14.1.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20post-hoc%20table%2014.1.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR table 14.1.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20table%2014.1.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR table 14.2.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20table%2014.2.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR table 14.2.1.1.a.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20table%2014.2.1.1.a.pdf) (pdf) [ALLN-177]
          - [Phase 1 CSR table 14.3.1-6.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Phase%201%20CSR%20table%2014.3.1-6.pdf) (pdf) [ALLN-177]
          - [Study 183 CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Study%20183%20CSR.pdf) (pdf) [ALLN-177]
          - [Study 183 Protocol.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%201%20-%20Study%20183/Study%20183%20Protocol.pdf) (pdf) [ALLN-177]
        - **Phase 2 - Stud_ Basket Study)/**
          - **ALLN-177-206 Data/**
            - **ALLN-177-206 Listings/**
              - [Listing 16.2.1 Subject End of Study Status.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.1%20Subject%20End%20of%20Study%20Status.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.2.1 Eligibility.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.2.1%20Eligibility.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.2.2 Protocol Deviation.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.2.2%20Protocol%20Deviation.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.3 Study Populations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.3%20Study%20Populations.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.1 Demo_line Characteristics.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.1%20Demo_line%20Characteristics.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.2 D_ication and Status.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.2%20D_ication%20and%20Status.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.3 Medical History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.3%20Medical%20History.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.4 Kidney Stone History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.4%20Kidney%20Stone%20History.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.5 Hyperoxaluria History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.5%20Hyperoxaluria%20History.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.6 P_mitant Medications.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.6%20P_mitant%20Medications.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.4.7 Prior _rocedures or Surgeries.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.4.7%20Prior%20_rocedures%20or%20Surgeries.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.5.1 Plas_ng Sample Collections.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.5.1%20Plas_ng%20Sample%20Collections.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.5.2 Pl_lts and Derivations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.5.2%20Pl_lts%20and%20Derivations.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.5.3 S_ Urine Collection.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.5.3%20S_%20Urine%20Collection.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.5.4 Subjec_esults and Derivations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.5.4%20Subjec_esults%20and%20Derivations.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.5.5 B_rboxylase Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.5.5%20B_rboxylase%20Results.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.6.1 Drug Accountability.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.6.1%20Drug%20Accountability.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.6.2 Stu_spensing Records and.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.6.2%20Stu_spensing%20Records%20and.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.6.3 Stu_spensing Records and.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.6.3%20Stu_spensing%20Records%20and.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.6.4 Study_Diary Recorded Records.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.6.4%20Study_Diary%20Recorded%20Records.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.7.1 Adverse Events.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.7.1%20Adverse%20Events.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.7.2 Serious Adverse Events.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.7.2%20Serious%20Adverse%20Events.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.7.3 Adv_ation of Study Drug.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.7.3%20Adv_ation%20of%20Study%20Drug.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.7.4 Adver_g to Study Withdrawal.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.7.4%20Adver_g%20to%20Study%20Withdrawal.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.7.5 Adver_cial Interest (AESIs).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.7.5%20Adver_cial%20Interest%20(AESIs).pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.1.1 _ections and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.1.1%20_ections%20and%20Results.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.1.2 Abno_ollections and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.1.2%20Abno_ollections%20and%20Results.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.1.3 C_n Common Terminology.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.1.3%20C_n%20Common%20Terminology.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.2 Pregnancy Test Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.2%20Pregnancy%20Test%20Results.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.3 Vital Signs.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.3%20Vital%20Signs.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.4 Physical Examination.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.4%20Physical%20Examination.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.5 Elec_llection and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.5%20Elec_llection%20and%20Results.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.8.6 Diet History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.8.6%20Diet%20History.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.9.1 Subject Procedure Review.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.9.1%20Subject%20Procedure%20Review.pdf) (pdf) [ALLN-177]
              - [Listing 16.2.9.2 Subject Daily Diary (ePRO).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.9.2%20Subject%20Daily%20Diary%20(ePRO).pdf) (pdf) [ALLN-177]
              - [Listing 16.2.9.3 Subject Daily Diary (Paper).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Listings/Listing%2016.2.9.3%20Subject%20Daily%20Diary%20(Paper).pdf) (pdf) [ALLN-177]
            - **ALLN-177-206 Tables/**
              - **Baseline/**
                - [Table 14.1.1 Subj_t and Disposition.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Baseline/Table%2014.1.1%20Subj_t%20and%20Disposition.pdf) (pdf) [ALLN-177]
                - [Table 14.1.2.1 Demo_roxaluria Subgroups.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Baseline/Table%2014.1.2.1%20Demo_roxaluria%20Subgroups.pdf) (pdf) [ALLN-177]
                - [Table 14.1.3 Medic_oxaluria Subgroups.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Baseline/Table%2014.1.3%20Medic_oxaluria%20Subgroups.pdf) (pdf) [ALLN-177]
                - [Table 14.1.4 Concomitant Medications.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Baseline/Table%2014.1.4%20Concomitant%20Medications.pdf) (pdf) [ALLN-177]
              - **Efficacy/**
                - [Table 14.2.1.1 _nd by Hyperoxal.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.1%20_nd%20by%20Hyperoxal.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.2 _Hyperoxaluria S.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.2%20_Hyperoxaluria%20S.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.3 _age in Enteric.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.3%20_age%20in%20Enteric.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.4 _ Primary Hypero.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.4%20_%20Primary%20Hypero.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.5 _ic Hyperoxaluri.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.5%20_ic%20Hyperoxaluri.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.6 _ry Hyperoxaluri.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.1.6%20_ry%20Hyperoxaluri.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.1 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.1%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.2 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.2%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.3 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.3%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.4 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.4%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.5 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.5%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.6 _ntage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.2.6%20_ntage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.1 _aseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.3.1%20_aseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.2 _aseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.3.2%20_aseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.3 _aseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.3.3%20_aseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.4 _aseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.3.4%20_aseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.1 _xcretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.4.1%20_xcretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.2 _xcretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.4.2%20_xcretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.3 _xcretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.4.3%20_xcretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.4 _xcretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.4.4%20_xcretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.1 _eline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.5.1%20_eline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.2 _eline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.5.2%20_eline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.3 _eline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.5.3%20_eline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.4 _eline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.5.4%20_eline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.1 _ine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.6.1%20_ine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.2 _ine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.6.2%20_ine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.3 _ine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.6.3%20_ine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.4 _ine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.6.4%20_ine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.7.1 M_dpoints by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.7.1%20M_dpoints%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.7.2 _ge (Adult vs Pe.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.7.2%20_ge%20(Adult%20vs%20Pe.pdf) (pdf) [ALLN-177]
                - [Table 14.2.8.1 _and by Hyperoxa.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.8.1%20_and%20by%20Hyperoxa.pdf) (pdf) [ALLN-177]
                - [Table 14.2.8.2 _and by Hyperoxa.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.8.2%20_and%20by%20Hyperoxa.pdf) (pdf) [ALLN-177]
                - [Table 14.2.9.1 _FR) by Visit (O.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Efficacy/Table%2014.2.9.1%20_FR)%20by%20Visit%20(O.pdf) (pdf) [ALLN-177]
              - **Safety/**
                - [Table 14.3.1.1 _on-Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.1.1%20_on-Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.2 _on-Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.1.2%20_on-Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.4 _rt Date Per Pro.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.1.4%20_rt%20Date%20Per%20Pro.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.5 _rt Date Per Dia.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.1.5%20_rt%20Date%20Per%20Dia.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.6 _ - Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.1.6%20_%20-%20Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.2.1 _peroxaluria Sub.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.2.1%20_peroxaluria%20Sub.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1._an Class and Pr.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1._an%20Class%20and%20Pr.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1._an Class and Pr(1).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1._an%20Class%20and%20Pr(1).pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.1 Inc_ Class and Preferred.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1.1%20Inc_%20Class%20and%20Preferred.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.3 Inc_ontinuation of Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1.3%20Inc_ontinuation%20of%20Study.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.5 Inc_rest by System Organ.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1.5%20Inc_rest%20by%20System%20Organ.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.6 Inc_ Class and Preferred.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.3.3.1.6%20Inc_%20Class%20and%20Preferred.pdf) (pdf) [ALLN-177]
                - [Table 14.4.1 Hemato_ Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.4.1%20Hemato_%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.2 Chemi_ Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.4.2%20Chemi_%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.3 Liver _m Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.4.3%20Liver%20_m%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.4 Abnor_ Results by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.4.4%20Abnor_%20Results%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.5.1 Height,_om Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.5.1%20Height,_om%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.1 ECG an_Screening by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.6.1%20ECG%20an_Screening%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.2 ECG O_retation by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.6.2%20ECG%20O_retation%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.3 ECG _reening by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.6.3%20ECG%20_reening%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.7.1 Diet History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/ALLN-177-206%20Data/ALLN-177-206%20Tables/Safety/Table%2014.7.1%20Diet%20History.pdf) (pdf) [ALLN-177]
          - **Investigator CVs/**
            - **Cook/**
              - [05.1 ALLN-177-206 _Site Cook_PI CV.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Cook/05.1%20ALLN-177-206%20_Site%20Cook_PI%20CV.pdf) (pdf) [ALLN-177]
              - [07.1 ALLN 177-206_ Site Cook _CV SI Rodney Gilbert.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Cook/07.1%20ALLN%20177-206_%20Site%20Cook%20_CV%20SI%20Rodney%20Gilbert.pdf) (pdf) [ALLN-177]
              - [09.1 ALLN 177-206_ Site Cook _Kristin Veighey SI CV.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Cook/09.1%20ALLN%20177-206_%20Site%20Cook%20_Kristin%20Veighey%20SI%20CV.pdf) (pdf) [ALLN-177]
            - **D'Anna/**
              - [SiteFiles_101DAnna_05-SiteMan_101_PICV_DAnnaR_03JAN2018 (1).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/D'Anna/SiteFiles_101DAnna_05-SiteMan_101_PICV_DAnnaR_03JAN2018%20(1).pdf) (pdf) [ALLN-177]
            - **Finlay/**
              - [05.1 ALLN - 177-206_Site 109 Finlay PI CV_09apr2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Finlay/05.1%20ALLN%20-%20177-206_Site%20109%20Finlay%20PI%20CV_09apr2018.pdf) (pdf) [ALLN-177]
              - [07.1 ALLN - 177-206_Site_Pallavi Yadav_17jul2017.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Finlay/07.1%20ALLN%20-%20177-206_Site_Pallavi%20Yadav_17jul2017.pdf) (pdf) [ALLN-177]
            - **Keddis/**
              - [6_PI CV_Keddis_29May2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Keddis/6_PI%20CV_Keddis_29May2018.pdf) (pdf) [ALLN-177]
              - [9a_Sub- I CV_Humphreys_10Jul2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Keddis/9a_Sub-%20I%20CV_Humphreys_10Jul2018.pdf) (pdf) [ALLN-177]
            - **Knauf/**
              - [5. ALLN-177-206_ Site 106_Knauf MD_PI CV_08Mar2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Knauf/5.%20ALLN-177-206_%20Site%20106_Knauf%20MD_PI%20CV_08Mar2018.pdf) (pdf) [ALLN-177]
            - **Lieske/**
              - [10a_Sub- I CV_Rule_31Jul2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Lieske/10a_Sub-%20I%20CV_Rule_31Jul2018.pdf) (pdf) [ALLN-177]
              - [10d_Sub- I CV_Sas_17Jun2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Lieske/10d_Sub-%20I%20CV_Sas_17Jun2018.pdf) (pdf) [ALLN-177]
              - [6_Lieske_11May2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Lieske/6_Lieske_11May2018.pdf) (pdf) [ALLN-177]
              - [9a_Sub- I CV_Erickson_14May2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Lieske/9a_Sub-%20I%20CV_Erickson_14May2018.pdf) (pdf) [ALLN-177]
            - **Luciano/**
              - [PI CV_Luciano_01Feb2018.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/Investigator%20CVs/Luciano/PI%20CV_Luciano_01Feb2018.pdf) (pdf) [ALLN-177]
          - [19-1462-C Intergated Analysis ASN (AN-RELO-19-004)_FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Clinical%20Trials/Phase%202%20-%20Stud_%20Basket%20Study)/19-1462-C%20Intergated%20Analysis%20ASN%20(AN-RELO-19-004)_FINAL.pdf) (pdf) [ALLN-177]
      - [Reloxaliase Investigators Brochure August 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical%20Development/Reloxaliase%20Investigators%20Brochure%20August%202021.pdf) (pdf) [ALLN-177]
    - **Clinical-Studies/**
      - [ALLN-177-302_ImagingReviewCharter_V3.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/ALLN-177-302_ImagingReviewCharter_V3.0.pdf) (pdf) [ALLN-177]
      - **204/**
        - **Datalab-Report/**
          - **204 Datalab report/**
            - **Datalabs 204 RPT 17MAY17/**
              - [204 Datalabs AE Coding.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20AE%20Coding.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs AE.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20AE.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Coding Report.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Coding%20Report.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Con meds.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Con%20meds.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Demography.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Demography.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Hyperoxaluria KS History.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Hyperoxaluria%20KS%20History.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Inc Excl.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Inc%20Excl.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Lab Collection.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Lab%20Collection.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Meal Compliance.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Meal%20Compliance.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Meal 2.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Meal%202.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Medical Hx Coding.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Medical%20Hx%20Coding.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs PE.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20PE.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Premier Pay.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Premier%20Pay.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Screening Urine.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Screening%20Urine.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Study Completion.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Study%20Completion.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Test Meal Day Vitals.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Test%20Meal%20Day%20Vitals.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Test Meal.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Test%20Meal.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Urine 2.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Urine%202.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Visit Dates.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Visit%20Dates.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Visit s.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Visit%20s.xlsx) (xlsx) [ALLN-177]
              - [204 Datalabs Vitals.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Datalabs%20Vitals.xlsx) (xlsx) [ALLN-177]
              - [204 Lab Draw.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Lab%20Draw.xlsx) (xlsx) [ALLN-177]
              - [204 Urine Collection.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Datalab-Report/204%20Datalab%20report/Datalabs%20204%20RPT%2017MAY17/204%20Urine%20Collection.xlsx) (xlsx) [ALLN-177]
        - **Statistics/**
          - **204 statistics/**
            - **11.03 Analysis/**
              - **11.03.02 Analysis QC Documentation/**
                - [Record of Validation_ALLN-177-204_20170509.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Record%20of%20Validation_ALLN-177-204_20170509.pdf) (pdf) [ALLN-177]
                - [Stats Delivery Checklist_ALLN-177-204_Draft 1_20170308.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Stats%20Delivery%20Checklist_ALLN-177-204_Draft%201_20170308.pdf) (pdf) [ALLN-177]
                - [Stats Delivery Checklist_ALLN-177-204_Final 09May2017_20170518.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Stats%20Delivery%20Checklist_ALLN-177-204_Final%2009May2017_20170518.pdf) (pdf) [ALLN-177]
                - [Stats Delivery Checklist_ALLN-177-204_Final 17Mar2017_20170520.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Stats%20Delivery%20Checklist_ALLN-177-204_Final%2017Mar2017_20170520.pdf) (pdf) [ALLN-177]
              - **11.03.07 Final Analysis Raw Datasets/**
                - **Final Analysis Raw Datasets_ALLN-177-204_22May2017_20170522/**
                  - **Data/**
                    - [acmlab.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/acmlab.sas7bdat) (sas7bdat) [ALLN-177]
                    - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/ae.sas7bdat) (sas7bdat) [ALLN-177]
                    - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/cm.sas7bdat) (sas7bdat) [ALLN-177]
                    - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/dm.sas7bdat) (sas7bdat) [ALLN-177]
                    - [dr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/dr.sas7bdat) (sas7bdat) [ALLN-177]
                    - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/ds.sas7bdat) (sas7bdat) [ALLN-177]
                    - [event.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/event.sas7bdat) (sas7bdat) [ALLN-177]
                    - [eventdt.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/eventdt.sas7bdat) (sas7bdat) [ALLN-177]
                    - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/ie.sas7bdat) (sas7bdat) [ALLN-177]
                    - [invalid.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/invalid.sas7bdat) (sas7bdat) [ALLN-177]
                    - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/lb.sas7bdat) (sas7bdat) [ALLN-177]
                    - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/mh.sas7bdat) (sas7bdat) [ALLN-177]
                    - [nextvis.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/nextvis.sas7bdat) (sas7bdat) [ALLN-177]
                    - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/pe.sas7bdat) (sas7bdat) [ALLN-177]
                    - [statfrm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/statfrm.sas7bdat) (sas7bdat) [ALLN-177]
                    - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/sv.sas7bdat) (sas7bdat) [ALLN-177]
                    - [utsw24.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/utsw24.sas7bdat) (sas7bdat) [ALLN-177]
                    - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522/Data/vs.sas7bdat) (sas7bdat) [ALLN-177]
                - [Final Analysis Raw Datasets_ALLN-177-204_22May2017_20170522.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_ALLN-177-204_22May2017_20170522.zip) (zip) [ALLN-177]
              - **11.03.09 Final Analysis Datasets/**
                - **Final Analysis Datasets_ALLN-177-204_22May2017_20170522/**
                  - **Data/**
                    - [ADAE.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADAE.xpt) (xpt) [ALLN-177]
                    - [ADCM.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADCM.xpt) (xpt) [ALLN-177]
                    - [ADDR.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADDR.xpt) (xpt) [ALLN-177]
                    - [ADDV.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADDV.xpt) (xpt) [ALLN-177]
                    - [ADEFF.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADEFF.xpt) (xpt) [ALLN-177]
                    - [ADMH.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADMH.xpt) (xpt) [ALLN-177]
                    - [ADSL.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522/Data/ADSL.xpt) (xpt) [ALLN-177]
                - [Final Analysis Datasets_ALLN-177-204_22May2017_20170522.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_22May2017_20170522.zip) (zip) [ALLN-177]
                - [Final Analysis Datasets_ALLN-177-204_Final_20170510.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_ALLN-177-204_Final_20170510.pdf) (pdf) [ALLN-177]
              - **11.03.10 Final Analysis Output/**
                - [Final Analysis Approval_ALLN-177-204_Final_20170802.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Approval_ALLN-177-204_Final_20170802.pdf) (pdf) [ALLN-177]
                - [Final Analysis Output_ALLN-177-204_Biostatistics Document Review Form_20170510.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_ALLN-177-204_Biostatistics%20Document%20Review%20Form_20170510.pdf) (pdf) [ALLN-177]
                - [Final Analysis Output_ALLN-177-204_Final_20170510.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_ALLN-177-204_Final_20170510.pdf) (pdf) [ALLN-177]
                - [Final Analysis Output_ALLN-177-204_Final_20170727.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/Statistics/204%20statistics/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_ALLN-177-204_Final_20170727.pdf) (pdf) [ALLN-177]
        - **TLFs/**
          - **Final 204 post-hoc 27July2017/**
            - [f14_2_1P_corrhyptype.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/f14_2_1P_corrhyptype.rtf) (rtf) [ALLN-177]
            - [l16_2_1_1P_pop.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/l16_2_1_1P_pop.rtf) (rtf) [ALLN-177]
            - [t14_1_1P_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_1_1P_disp.rtf) (rtf) [ALLN-177]
            - [t14_2_1P_oxalt_abs.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_2_1P_oxalt_abs.rtf) (rtf) [ALLN-177]
            - [t14_2_2P1_oxalt_abs_int.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_2_2P1_oxalt_abs_int.rtf) (rtf) [ALLN-177]
            - [t14_2_2P2_oxalt_abs_int_hyptype.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_2_2P2_oxalt_abs_int_hyptype.rtf) (rtf) [ALLN-177]
            - [t14_2_5P1_uc_summ.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_2_5P1_uc_summ.rtf) (rtf) [ALLN-177]
            - [t14_2_5P2_uc_summ_hyptype.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20post-hoc%2027July2017/t14_2_5P2_uc_summ_hyptype.rtf) (rtf) [ALLN-177]
          - **Final 204 TLFs 9May2017/**
            - [l16_2_1_1_pop.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_1_1_pop.rtf) (rtf) [ALLN-177]
            - [l16_2_1_2_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_1_2_disp.rtf) (rtf) [ALLN-177]
            - [l16_2_4_1_demog.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_4_1_demog.rtf) (rtf) [ALLN-177]
            - [l16_2_4_2_Illspchist.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_4_2_Illspchist.rtf) (rtf) [ALLN-177]
            - [l16_2_4_3_medhis.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_4_3_medhis.rtf) (rtf) [ALLN-177]
            - [l16_2_4_4_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_4_4_pe.rtf) (rtf) [ALLN-177]
            - [l16_2_5_1_compdays123.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_5_1_compdays123.rtf) (rtf) [ALLN-177]
            - [l16_2_5_2_compday4.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_5_2_compday4.rtf) (rtf) [ALLN-177]
            - [l16_2_6_1_urine.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_6_1_urine.rtf) (rtf) [ALLN-177]
            - [l16_2_6_2_urineoxpct.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_6_2_urineoxpct.rtf) (rtf) [ALLN-177]
            - [l16_2_7_1_ae.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_7_1_ae.rtf) (rtf) [ALLN-177]
            - [l16_2_8_1_hema.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_8_1_hema.rtf) (rtf) [ALLN-177]
            - [l16_2_8_2_chem.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_8_2_chem.rtf) (rtf) [ALLN-177]
            - [l16_2_9_1_vs.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_9_1_vs.rtf) (rtf) [ALLN-177]
            - [l16_2_9_2_conmed.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/l16_2_9_2_conmed.rtf) (rtf) [ALLN-177]
            - [t14_1_1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_1_1_disp.rtf) (rtf) [ALLN-177]
            - [t14_1_2_demog.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_1_2_demog.rtf) (rtf) [ALLN-177]
            - [t14_1_3_mealcomp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_1_3_mealcomp.rtf) (rtf) [ALLN-177]
            - [t14_2_1_oxalt_abs.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_2_1_oxalt_abs.rtf) (rtf) [ALLN-177]
            - [t14_2_2_oxalt_abs_int.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_2_2_oxalt_abs_int.rtf) (rtf) [ALLN-177]
            - [t14_2_3_oxalt_abs_corr.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_2_3_oxalt_abs_corr.rtf) (rtf) [ALLN-177]
            - [t14_2_4_oxalt_excr.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_2_4_oxalt_excr.rtf) (rtf) [ALLN-177]
            - [t14_2_5_uc_summ.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_2_5_uc_summ.rtf) (rtf) [ALLN-177]
            - [t14_3_1_ae.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/204/TLFs/Final%20204%20TLFs%209May2017/t14_3_1_ae.rtf) (rtf) [ALLN-177]
      - **206/**
        - **Datasets/**
          - **CRO Datasets and Programming/**
            - **Data/**
              - **Production/**
                - **ADaM/**
                  - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adae.xpt) (xpt) [ALLN-177]
                  - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adcm.xpt) (xpt) [ALLN-177]
                  - [addh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/addh.xpt) (xpt) [ALLN-177]
                  - [adef.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adef.xpt) (xpt) [ALLN-177]
                  - [adeg.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adeg.xpt) (xpt) [ALLN-177]
                  - [adex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adex.xpt) (xpt) [ALLN-177]
                  - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adlb.xpt) (xpt) [ALLN-177]
                  - [adlbx.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adlbx.xpt) (xpt) [ALLN-177]
                  - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/admh.xpt) (xpt) [ALLN-177]
                  - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/adsl.xpt) (xpt) [ALLN-177]
                  - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/ADaM/advs.xpt) (xpt) [ALLN-177]
                - **SDTM/**
                  - [ae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ae.xpt) (xpt) [ALLN-177]
                  - [cm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/cm.xpt) (xpt) [ALLN-177]
                  - [da.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/da.xpt) (xpt) [ALLN-177]
                  - [dm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/dm.xpt) (xpt) [ALLN-177]
                  - [ds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ds.xpt) (xpt) [ALLN-177]
                  - [dv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/dv.xpt) (xpt) [ALLN-177]
                  - [ec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ec.xpt) (xpt) [ALLN-177]
                  - [eg.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/eg.xpt) (xpt) [ALLN-177]
                  - [ex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ex.xpt) (xpt) [ALLN-177]
                  - [fa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/fa.xpt) (xpt) [ALLN-177]
                  - [ho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ho.xpt) (xpt) [ALLN-177]
                  - [ie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ie.xpt) (xpt) [ALLN-177]
                  - [lb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/lb.xpt) (xpt) [ALLN-177]
                  - [mh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/mh.xpt) (xpt) [ALLN-177]
                  - [pe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/pe.xpt) (xpt) [ALLN-177]
                  - [pr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/pr.xpt) (xpt) [ALLN-177]
                  - [rp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/rp.xpt) (xpt) [ALLN-177]
                  - [se.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/se.xpt) (xpt) [ALLN-177]
                  - [suppae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppae.xpt) (xpt) [ALLN-177]
                  - [suppcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppcm.xpt) (xpt) [ALLN-177]
                  - [suppda.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppda.xpt) (xpt) [ALLN-177]
                  - [suppdm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppdm.xpt) (xpt) [ALLN-177]
                  - [suppds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppds.xpt) (xpt) [ALLN-177]
                  - [suppdv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppdv.xpt) (xpt) [ALLN-177]
                  - [suppfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppfa.xpt) (xpt) [ALLN-177]
                  - [suppho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppho.xpt) (xpt) [ALLN-177]
                  - [suppie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppie.xpt) (xpt) [ALLN-177]
                  - [supplb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/supplb.xpt) (xpt) [ALLN-177]
                  - [suppmh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/suppmh.xpt) (xpt) [ALLN-177]
                  - [supppr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/supppr.xpt) (xpt) [ALLN-177]
                  - [supprp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/supprp.xpt) (xpt) [ALLN-177]
                  - [sv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/sv.xpt) (xpt) [ALLN-177]
                  - [ta.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ta.xpt) (xpt) [ALLN-177]
                  - [te.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/te.xpt) (xpt) [ALLN-177]
                  - [ti.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ti.xpt) (xpt) [ALLN-177]
                  - [ts.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/ts.xpt) (xpt) [ALLN-177]
                  - [tv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/tv.xpt) (xpt) [ALLN-177]
                  - [vs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Production/SDTM/vs.xpt) (xpt) [ALLN-177]
              - **Source/**
                - **ACM/**
                  - [alln_177_206_30jan2020.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ACM/alln_177_206_30jan2020.sas7bdat) (sas7bdat) [ALLN-177]
                - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ae.sas7bdat) (sas7bdat) [ALLN-177]
                - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/cm.sas7bdat) (sas7bdat) [ALLN-177]
                - [cont.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/cont.sas7bdat) (sas7bdat) [ALLN-177]
                - **Covance/**
                  - [alln177206_covance_25mar2020.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/Covance/alln177206_covance_25mar2020.sas7bdat) (sas7bdat) [ALLN-177]
                - [cp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/cp.sas7bdat) (sas7bdat) [ALLN-177]
                - [da.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/da.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_asub.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_asub.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_epro.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_epro.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_incomplete_epro.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_incomplete_epro.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_mc_meddra.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_mc_meddra.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_mc_who_drug.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_mc_who_drug.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_missed_epro.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_missed_epro.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_pags.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_pags.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_pgla.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_pgla.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_squ.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_squ.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_squc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_squc.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_study.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_study.sas7bdat) (sas7bdat) [ALLN-177]
                - [dat_sub.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dat_sub.sas7bdat) (sas7bdat) [ALLN-177]
                - [dd.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dd.sas7bdat) (sas7bdat) [ALLN-177]
                - [dd_p.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dd_p.sas7bdat) (sas7bdat) [ALLN-177]
                - [des_codelist.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/des_codelist.sas7bdat) (sas7bdat) [ALLN-177]
                - [des_ddef.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/des_ddef.sas7bdat) (sas7bdat) [ALLN-177]
                - [des_formats.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/des_formats.sas7bdat) (sas7bdat) [ALLN-177]
                - [des_pdef.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/des_pdef.sas7bdat) (sas7bdat) [ALLN-177]
                - [des_vdef.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/des_vdef.sas7bdat) (sas7bdat) [ALLN-177]
                - [dh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dh.sas7bdat) (sas7bdat) [ALLN-177]
                - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/dm.sas7bdat) (sas7bdat) [ALLN-177]
                - [ds_eos.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ds_eos.sas7bdat) (sas7bdat) [ALLN-177]
                - [ds_eot.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ds_eot.sas7bdat) (sas7bdat) [ALLN-177]
                - [ds_ic.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ds_ic.sas7bdat) (sas7bdat) [ALLN-177]
                - [eCOSDataToSAS.log](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/eCOSDataToSAS.log) (log) [ALLN-177]
                - [eCOSDataToSAS.lst](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/eCOSDataToSAS.lst) (lst) [ALLN-177]
                - [eCOSDataToSAS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/eCOSDataToSAS.sas) (sas) [ALLN-177]
                - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/eg.sas7bdat) (sas7bdat) [ALLN-177]
                - [formats.sas7bcat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/formats.sas7bcat) (sas7bcat) [ALLN-177]
                - [hox.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/hox.sas7bdat) (sas7bdat) [ALLN-177]
                - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ie.sas7bdat) (sas7bdat) [ALLN-177]
                - [ks.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ks.sas7bdat) (sas7bdat) [ALLN-177]
                - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/lb.sas7bdat) (sas7bdat) [ALLN-177]
                - [lb_pg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/lb_pg.sas7bdat) (sas7bdat) [ALLN-177]
                - [lb_u24.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/lb_u24.sas7bdat) (sas7bdat) [ALLN-177]
                - **Mayo/**
                  - [alln177206_mayo_29jan2020.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/Mayo/alln177206_mayo_29jan2020.sas7bdat) (sas7bdat) [ALLN-177]
                - [MD5.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/MD5.txt) (txt) [ALLN-177]
                - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/mh.sas7bdat) (sas7bdat) [ALLN-177]
                - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/pe.sas7bdat) (sas7bdat) [ALLN-177]
                - [pox.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/pox.sas7bdat) (sas7bdat) [ALLN-177]
                - [projinfo.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/projinfo.txt) (txt) [ALLN-177]
                - **ProtDev/**
                  - [aln_177_206_protdev_mar2020.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/ProtDev/aln_177_206_protdev_mar2020.sas7bdat) (sas7bdat) [ALLN-177]
                - **Q2/**
                  - [c_200116.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/Q2/c_200116.sas7bdat) (sas7bdat) [ALLN-177]
                - **Rescreen/**
                  - [Allena Rescreened Subject Tracker 07 Nov 2019.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/Rescreen/Allena%20Rescreened%20Subject%20Tracker%2007%20Nov%202019.xlsx) (xlsx) [ALLN-177]
                - [spr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/spr.sas7bdat) (sas7bdat) [ALLN-177]
                - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/sv.sas7bdat) (sas7bdat) [ALLN-177]
                - **TGA/**
                  - [data_transfer_13jan2020.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/TGA/data_transfer_13jan2020.sas7bdat) (sas7bdat) [ALLN-177]
                - [unsch.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/unsch.sas7bdat) (sas7bdat) [ALLN-177]
                - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Data/Source/vs.sas7bdat) (sas7bdat) [ALLN-177]
            - **Dataset Specifications/**
              - [ALLN-177-206_ADaM Dataset Specs_07JUL2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Dataset%20Specifications/ALLN-177-206_ADaM%20Dataset%20Specs_07JUL2020.xlsx) (xlsx) [ALLN-177]
              - [ALLN-177-206_SDTM Dataset Specs_07JUL2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Dataset%20Specifications/ALLN-177-206_SDTM%20Dataset%20Specs_07JUL2020.xlsx) (xlsx) [ALLN-177]
            - **Macros/**
              - [DTC.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/DTC.sas) (sas) [ALLN-177]
              - [LogCheck.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/LogCheck.sas) (sas) [ALLN-177]
              - [Prctmplt.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/Prctmplt.sas) (sas) [ALLN-177]
              - [Resize.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/Resize.sas) (sas) [ALLN-177]
              - [StudyDay.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/StudyDay.sas) (sas) [ALLN-177]
              - [Studyset.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/Studyset.sas) (sas) [ALLN-177]
              - [Sumstat.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/Sumstat.sas) (sas) [ALLN-177]
              - [TOC.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/TOC.sas) (sas) [ALLN-177]
              - [TOC_CSR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/TOC_CSR.sas) (sas) [ALLN-177]
              - [Ttlmaker.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Macros/Ttlmaker.sas) (sas) [ALLN-177]
            - **Outputs/**
              - [ALLN-177-206 TLF Mock Shells_09JAN2020.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/ALLN-177-206%20TLF%20Mock%20Shells_09JAN2020.docx) (docx) [ALLN-177]
              - **Listings/**
                - [Listing 16.2.1 Subject End of Study Status.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.1%20Subject%20End%20of%20Study%20Status.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.2.1 Eligibility.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.2.1%20Eligibility.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.2.2 Protocol Deviation.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.2.2%20Protocol%20Deviation.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.3 Study Populations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.3%20Study%20Populations.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.1 Demographic and Baseline Characteristics.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.1%20Demographic%20and%20Baseline%20Characteristics.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.2 Disease Classification and Status.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.2%20Disease%20Classification%20and%20Status.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.3 Medical History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.3%20Medical%20History.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.4 Kidney Stone History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.4%20Kidney%20Stone%20History.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.5 Hyperoxaluria History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.5%20Hyperoxaluria%20History.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.6 Prior and Concomitant Medications.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.6%20Prior%20and%20Concomitant%20Medications.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.4.7 Prior and Concomitant Procedures or Surgeries.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.4.7%20Prior%20and%20Concomitant%20Procedures%20or%20Surgeries.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.5.1 Plasma Oxalate Fasting Sample Collections.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.5.1%20Plasma%20Oxalate%20Fasting%20Sample%20Collections.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.5.2 Plasma Oxalate Fasting Sample Results and Derivations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.5.2%20Plasma%20Oxalate%20Fasting%20Sample%20Results%20and%20Derivations.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.5.3 Subject 24-Hour Urine Collection.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.5.3%20Subject%2024-Hour%20Urine%20Collection.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.5.4 Subject 24-Hour Urine Results and Derivations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.5.4%20Subject%2024-Hour%20Urine%20Results%20and%20Derivations.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.5.5 Blood Formate and Oxalate Decarboxylase Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.5.5%20Blood%20Formate%20and%20Oxalate%20Decarboxylase%20Results.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.6.1 Drug Accountability.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.6.1%20Drug%20Accountability.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.6.2 Study Drug Compliance - Calculated using Site-Recorded Drug Dispensing Records and.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.6.2%20Study%20Drug%20Compliance%20-%20Calculated%20using%20Site-Recorded%20Drug%20Dispensing%20Records%20and.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.6.3 Study Drug Compliance - Calculated using Site-Recorded Drug Dispensing Records and.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.6.3%20Study%20Drug%20Compliance%20-%20Calculated%20using%20Site-Recorded%20Drug%20Dispensing%20Records%20and.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.6.4 Study Drug Compliance - Calculated using Diary Recorded Records.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.6.4%20Study%20Drug%20Compliance%20-%20Calculated%20using%20Diary%20Recorded%20Records.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.7.1 Adverse Events.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.7.1%20Adverse%20Events.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.7.2 Serious Adverse Events.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.7.2%20Serious%20Adverse%20Events.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.7.3 Adverse Events Leading to Discontinuation of Study Drug.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.7.3%20Adverse%20Events%20Leading%20to%20Discontinuation%20of%20Study%20Drug.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.7.4 Adverse Events Leading to Study Withdrawal.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.7.4%20Adverse%20Events%20Leading%20to%20Study%20Withdrawal.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.7.5 Adverse Events of Special Interest (AESIs).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.7.5%20Adverse%20Events%20of%20Special%20Interest%20(AESIs).pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.1.1 Laboratory Collections and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.1.1%20Laboratory%20Collections%20and%20Results.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.1.2 Abnormal Laboratory Collections and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.1.2%20Abnormal%20Laboratory%20Collections%20and%20Results.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.1.3 Critical Abnormal Laboratory Collections and Results based on Common Terminology.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.1.3%20Critical%20Abnormal%20Laboratory%20Collections%20and%20Results%20based%20on%20Common%20Terminology.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.2 Pregnancy Test Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.2%20Pregnancy%20Test%20Results.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.3 Vital Signs.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.3%20Vital%20Signs.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.4 Physical Examination.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.4%20Physical%20Examination.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.5 Electrocardiogram Collection and Results.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.5%20Electrocardiogram%20Collection%20and%20Results.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.8.6 Diet History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.8.6%20Diet%20History.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.9.1 Subject Procedure Review.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.9.1%20Subject%20Procedure%20Review.pdf) (pdf) [ALLN-177]
                - [Listing 16.2.9.2 Subject Daily Diary (ePRO).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.9.2%20Subject%20Daily%20Diary%20(ePRO).pdf) (pdf) [ALLN-177]
                - [Listing 16.2.9.3 Subject Daily Diary (Paper).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Listings/Listing%2016.2.9.3%20Subject%20Daily%20Diary%20(Paper).pdf) (pdf) [ALLN-177]
              - **Tables/**
                - [Table 14.1.1 Subject Enrollment and Disposition.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.1.1%20Subject%20Enrollment%20and%20Disposition.pdf) (pdf) [ALLN-177]
                - [Table 14.1.2.1 Demographic and Baseline Characteristics Overall and by Hyperoxaluria Subgroups.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.1.2.1%20Demographic%20and%20Baseline%20Characteristics%20Overall%20and%20by%20Hyperoxaluria%20Subgroups.pdf) (pdf) [ALLN-177]
                - [Table 14.1.3 Medical History Overall and by Hyperoxaluria Subgroups.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.1.3%20Medical%20History%20Overall%20and%20by%20Hyperoxaluria%20Subgroups.pdf) (pdf) [ALLN-177]
                - [Table 14.1.4 Concomitant Medications.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.1.4%20Concomitant%20Medications.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.1 Mean Plasma Oxalate (POx) and Change from Baseline by Visit (Overall and by Hyperoxal.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.1%20Mean%20Plasma%20Oxalate%20(POx)%20and%20Change%20from%20Baseline%20by%20Visit%20(Overall%20and%20by%20Hyperoxal.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.2 Mean Plasma Oxalate and Change from Baseline by Visit (Overall and by Hyperoxaluria S.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.2%20Mean%20Plasma%20Oxalate%20and%20Change%20from%20Baseline%20by%20Visit%20(Overall%20and%20by%20Hyperoxaluria%20S.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.3 Mean Plasma Oxalate (POx) and Change from Baseline by Visit and CKD Stage in Enteric.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.3%20Mean%20Plasma%20Oxalate%20(POx)%20and%20Change%20from%20Baseline%20by%20Visit%20and%20CKD%20Stage%20in%20Enteric.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.4 Mean Plasma Oxalate and Change from Baseline by Visit and CKD Stage in Primary Hypero.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.4%20Mean%20Plasma%20Oxalate%20and%20Change%20from%20Baseline%20by%20Visit%20and%20CKD%20Stage%20in%20Primary%20Hypero.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.5 Mean Plasma Oxalate and Change from Baseline by Visit and Age in Enteric Hyperoxaluri.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.5%20Mean%20Plasma%20Oxalate%20and%20Change%20from%20Baseline%20by%20Visit%20and%20Age%20in%20Enteric%20Hyperoxaluri.pdf) (pdf) [ALLN-177]
                - [Table 14.2.1.6 Mean Plasma Oxalate and Change from Baseline by Visit and Age in Primary Hyperoxaluri.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.1.6%20Mean%20Plasma%20Oxalate%20and%20Change%20from%20Baseline%20by%20Visit%20and%20Age%20in%20Primary%20Hyperoxaluri.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.1 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.1%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.2 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.2%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.3 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.3%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.4 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.4%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.5 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.5%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.2.6 Proportion of Subjects with Reduction in Plasma Oxalate by GE 20 Percentage and_or to.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.2.6%20Proportion%20of%20Subjects%20with%20Reduction%20in%20Plasma%20Oxalate%20by%20GE%2020%20Percentage%20and_or%20to.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.1 Mean 24-Hour Urine Oxalate (UOx) Excretion (mg_24hr) and Change from Baseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.3.1%20Mean%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24hr)%20and%20Change%20from%20Baseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.2 Mean 24-Hour Urine Oxalate (UOx) Excretion (mg_24hr) and Change from Baseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.3.2%20Mean%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24hr)%20and%20Change%20from%20Baseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.3 Mean 24-Hour Urine Oxalate (UOx) Excretion (mg_24hr) and Change from Baseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.3.3%20Mean%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24hr)%20and%20Change%20from%20Baseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.3.4 Mean 24-Hour Urine Oxalate (UOx) Excretion (mg_24hr) and Change from Baseline by Visi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.3.4%20Mean%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24hr)%20and%20Change%20from%20Baseline%20by%20Visi.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.1 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate (UOx) Excretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.4.1%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.2 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate (UOx) Excretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.4.2%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.3 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate (UOx) Excretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.4.3%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.4.4 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate (UOx) Excretion (mg_24.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.4.4%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate%20(UOx)%20Excretion%20(mg_24.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.1 Mean 24-Hour Urine Oxalate-Creatinine Ratio (mg_g) and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.5.1%20Mean%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g)%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.2 Mean 24-Hour Urine Oxalate-Creatinine Ratio (mg_g) and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.5.2%20Mean%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g)%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.3 Mean 24-Hour Urine Oxalate-Creatinine Ratio (mg_g) and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.5.3%20Mean%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g)%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.5.4 Mean 24-Hour Urine Oxalate-Creatinine Ratio (mg_g) and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.5.4%20Mean%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g)%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.1 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate-Creatinine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.6.1%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.2 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate-Creatinine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.6.2%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.3 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate-Creatinine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.6.3%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.6.4 Proportion of Subjects with Reduction in 24-Hour Urine Oxalate-Creatinine Ratio (mg_g.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.6.4%20Proportion%20of%20Subjects%20with%20Reduction%20in%2024-Hour%20Urine%20Oxalate-Creatinine%20Ratio%20(mg_g.pdf) (pdf) [ALLN-177]
                - [Table 14.2.7.1 Mean Change from Fasting Value in Exploratory Endpoints by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.7.1%20Mean%20Change%20from%20Fasting%20Value%20in%20Exploratory%20Endpoints%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.2.7.2 Mean Change from Fasting Value in Exploratory Endpoints by Visit and Age (Adult vs Pe.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.7.2%20Mean%20Change%20from%20Fasting%20Value%20in%20Exploratory%20Endpoints%20by%20Visit%20and%20Age%20(Adult%20vs%20Pe.pdf) (pdf) [ALLN-177]
                - [Table 14.2.8.1 Mean Change from Baseline in Other Urine Parameters by Visit (Overall and by Hyperoxa.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.8.1%20Mean%20Change%20from%20Baseline%20in%20Other%20Urine%20Parameters%20by%20Visit%20(Overall%20and%20by%20Hyperoxa.pdf) (pdf) [ALLN-177]
                - [Table 14.2.8.2 Mean Change from Baseline in Other Urine Parameters by Visit (Overall and by Hyperoxa.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.8.2%20Mean%20Change%20from%20Baseline%20in%20Other%20Urine%20Parameters%20by%20Visit%20(Overall%20and%20by%20Hyperoxa.pdf) (pdf) [ALLN-177]
                - [Table 14.2.9.1 Mean Change from Screening in Estimated Glomerular Filtration Rate (eGFR) by Visit (O.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.2.9.1%20Mean%20Change%20from%20Screening%20in%20Estimated%20Glomerular%20Filtration%20Rate%20(eGFR)%20by%20Visit%20(O.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.1 Exposure to Study Medication-Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.1.1%20Exposure%20to%20Study%20Medication-Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.2 Exposure to Study Medication-Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.1.2%20Exposure%20to%20Study%20Medication-Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.4 Study Medication Compliance - Based on Capsule Accountability with Start Date Per Pro.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.1.4%20Study%20Medication%20Compliance%20-%20Based%20on%20Capsule%20Accountability%20with%20Start%20Date%20Per%20Pro.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.5 Study Medication Compliance - Based on Capsule Accountability with Start Date Per Dia.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.1.5%20Study%20Medication%20Compliance%20-%20Based%20on%20Capsule%20Accountability%20with%20Start%20Date%20Per%20Dia.pdf) (pdf) [ALLN-177]
                - [Table 14.3.1.6 Study Medication Compliance - Diary Method.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.1.6%20Study%20Medication%20Compliance%20-%20Diary%20Method.pdf) (pdf) [ALLN-177]
                - [Table 14.3.2.1 Overall Summary of Treatment-Emergent Adverse Events Overall and by Hyperoxaluria Sub.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.2.1%20Overall%20Summary%20of%20Treatment-Emergent%20Adverse%20Events%20Overall%20and%20by%20Hyperoxaluria%20Sub.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.1 Incidence of Treatment-Emergent Adverse Events by System Organ Class and Preferred.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.1%20Incidence%20of%20Treatment-Emergent%20Adverse%20Events%20by%20System%20Organ%20Class%20and%20Preferred.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.2 Incidence of Related Treatment-Emergent Adverse Events by System Organ Class and Pr.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.2%20Incidence%20of%20Related%20Treatment-Emergent%20Adverse%20Events%20by%20System%20Organ%20Class%20and%20Pr.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.3 Incidence of Treatment-Emergent Adverse Events Leading to Discontinuation of Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.3%20Incidence%20of%20Treatment-Emergent%20Adverse%20Events%20Leading%20to%20Discontinuation%20of%20Study.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.4 Incidence of Treatment-Emergent Serious Adverse Events by System Organ Class and Pr.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.4%20Incidence%20of%20Treatment-Emergent%20Serious%20Adverse%20Events%20by%20System%20Organ%20Class%20and%20Pr.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.5 Incidence of Treatment-Emergent Adverse Events of Special Interest by System Organ.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.5%20Incidence%20of%20Treatment-Emergent%20Adverse%20Events%20of%20Special%20Interest%20by%20System%20Organ.pdf) (pdf) [ALLN-177]
                - [Table 14.3.3.1.6 Incidence of Treatment-Emergent Adverse Events by System Organ Class and Preferred.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.3.3.1.6%20Incidence%20of%20Treatment-Emergent%20Adverse%20Events%20by%20System%20Organ%20Class%20and%20Preferred.pdf) (pdf) [ALLN-177]
                - [Table 14.4.1 Hematology Parameters and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.4.1%20Hematology%20Parameters%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.2 Chemistry Parameters and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.4.2%20Chemistry%20Parameters%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.3 Liver Enzyme Parameters and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.4.3%20Liver%20Enzyme%20Parameters%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.4.4 Abnormal Laboratory Results by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.4.4%20Abnormal%20Laboratory%20Results%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.5.1 Height, Weight, Vital Signs and Change from Baseline by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.5.1%20Height,%20Weight,%20Vital%20Signs%20and%20Change%20from%20Baseline%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.1 ECG and Change from Screening by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.6.1%20ECG%20and%20Change%20from%20Screening%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.2 ECG Overall Interpretation by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.6.2%20ECG%20Overall%20Interpretation%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.6.3 ECG Shift from Screening by Visit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.6.3%20ECG%20Shift%20from%20Screening%20by%20Visit.pdf) (pdf) [ALLN-177]
                - [Table 14.7.1 Diet History.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Outputs/Tables/Table%2014.7.1%20Diet%20History.pdf) (pdf) [ALLN-177]
            - **Programs/**
              - **Datasets/**
                - **ADaM/**
                  - [D206_6ADSL.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_6ADSL.sas) (sas) [ALLN-177]
                  - [D206_7ADAE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADAE.sas) (sas) [ALLN-177]
                  - [D206_7ADCM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADCM.sas) (sas) [ALLN-177]
                  - [D206_7ADDH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADDH.sas) (sas) [ALLN-177]
                  - [D206_7ADEF.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADEF.sas) (sas) [ALLN-177]
                  - [D206_7ADEG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADEG.sas) (sas) [ALLN-177]
                  - [D206_7ADEX.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADEX.sas) (sas) [ALLN-177]
                  - [D206_7ADLB.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADLB.sas) (sas) [ALLN-177]
                  - [D206_7ADLBX.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADLBX.sas) (sas) [ALLN-177]
                  - [D206_7ADMH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADMH.sas) (sas) [ALLN-177]
                  - [D206_7ADVS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/ADaM/D206_7ADVS.sas) (sas) [ALLN-177]
                - **SDTM/**
                  - [_Run_All_Production_Datasets.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/_Run_All_Production_Datasets.sas) (sas) [ALLN-177]
                  - [convert ACM data to excel.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert%20ACM%20data%20to%20excel.sas) (sas) [ALLN-177]
                  - [convert covance.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert%20covance.sas) (sas) [ALLN-177]
                  - [convert external xpt files.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert%20external%20xpt%20files.sas) (sas) [ALLN-177]
                  - [convert_mayo.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert_mayo.sas) (sas) [ALLN-177]
                  - [convert_protdev.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert_protdev.sas) (sas) [ALLN-177]
                  - [convert_TGA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/convert_TGA.sas) (sas) [ALLN-177]
                  - [D206_1TA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_1TA.sas) (sas) [ALLN-177]
                  - [D206_1TE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_1TE.sas) (sas) [ALLN-177]
                  - [D206_1TI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_1TI.sas) (sas) [ALLN-177]
                  - [D206_1TS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_1TS.sas) (sas) [ALLN-177]
                  - [D206_1TV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_1TV.sas) (sas) [ALLN-177]
                  - [D206_2DM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_2DM.sas) (sas) [ALLN-177]
                  - [D206_2SE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_2SE.sas) (sas) [ALLN-177]
                  - [D206_2SV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_2SV.sas) (sas) [ALLN-177]
                  - [D206_3DA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3DA.sas) (sas) [ALLN-177]
                  - [D206_3DS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3DS.sas) (sas) [ALLN-177]
                  - [D206_3DV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3DV.sas) (sas) [ALLN-177]
                  - [D206_3EC.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3EC.sas) (sas) [ALLN-177]
                  - [D206_3EG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3EG.sas) (sas) [ALLN-177]
                  - [D206_3FA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3FA.sas) (sas) [ALLN-177]
                  - [D206_3HO.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3HO.sas) (sas) [ALLN-177]
                  - [D206_3IE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3IE.sas) (sas) [ALLN-177]
                  - [D206_3LB.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3LB.sas) (sas) [ALLN-177]
                  - [D206_3PE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3PE.sas) (sas) [ALLN-177]
                  - [D206_3PR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3PR.sas) (sas) [ALLN-177]
                  - [D206_3RP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3RP.sas) (sas) [ALLN-177]
                  - [D206_3VS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_3VS.sas) (sas) [ALLN-177]
                  - [D206_4EX.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_4EX.sas) (sas) [ALLN-177]
                  - [D206_5AE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_5AE.sas) (sas) [ALLN-177]
                  - [D206_5CM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_5CM.sas) (sas) [ALLN-177]
                  - [D206_5MH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/SDTM/D206_5MH.sas) (sas) [ALLN-177]
                - **TXT Versions/**
                  - [ALLN-177-206_D206_1TA_25MAY2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_1TA_25MAY2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_1TE_23APR2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_1TE_23APR2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_1TI_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_1TI_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_1TS_07NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_1TS_07NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_1TV_22APR2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_1TV_22APR2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_2DM_26APR2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_2DM_26APR2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_2SE_25OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_2SE_25OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_2SV_25OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_2SV_25OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3DA_04NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3DA_04NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3DS_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3DS_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3DV_21NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3DV_21NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3EC_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3EC_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3EG_01NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3EG_01NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3FA_31OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3FA_31OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3HO_31OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3HO_31OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3IE_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3IE_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3LB_05NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3LB_05NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3PE_31OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3PE_31OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3PR_01NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3PR_01NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3RP_31OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3RP_31OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_3VS_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_3VS_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_4EX_01NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_4EX_01NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_5AE_30OCT2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_5AE_30OCT2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_5CM_01NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_5CM_01NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_5MH_04NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_5MH_04NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_6ADSL_12NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_6ADSL_12NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADAE_19NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADAE_19NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADCM_18NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADCM_18NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADDH_19NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADDH_19NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADEF_06DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADEF_06DEC2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADEG_15NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADEG_15NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADEX_21NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADEX_21NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADLB_21NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADLB_21NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADLBX_26NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADLBX_26NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADMH_18NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADMH_18NOV2019.txt) (txt) [ALLN-177]
                  - [ALLN-177-206_D206_7ADVS_19NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/Datasets/TXT%20Versions/ALLN-177-206_D206_7ADVS_19NOV2019.txt) (txt) [ALLN-177]
              - **TLs/**
                - **Listings/**
                  - [L206AE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206AE.sas) (sas) [ALLN-177]
                  - [L206AEDISC.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206AEDISC.sas) (sas) [ALLN-177]
                  - [L206AESI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206AESI.sas) (sas) [ALLN-177]
                  - [L206AEW.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206AEW.sas) (sas) [ALLN-177]
                  - [L206BLOODRES.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206BLOODRES.sas) (sas) [ALLN-177]
                  - [L206CM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206CM.sas) (sas) [ALLN-177]
                  - [L206COMPDI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206COMPDI.sas) (sas) [ALLN-177]
                  - [L206COMPDR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206COMPDR.sas) (sas) [ALLN-177]
                  - [L206COMPDRDI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206COMPDRDI.sas) (sas) [ALLN-177]
                  - [L206CPR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206CPR.sas) (sas) [ALLN-177]
                  - [L206DA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206DA.sas) (sas) [ALLN-177]
                  - [L206DCS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206DCS.sas) (sas) [ALLN-177]
                  - [L206DH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206DH.sas) (sas) [ALLN-177]
                  - [L206DM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206DM.sas) (sas) [ALLN-177]
                  - [L206DV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206DV.sas) (sas) [ALLN-177]
                  - [L206ECG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206ECG.sas) (sas) [ALLN-177]
                  - [L206ELIG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206ELIG.sas) (sas) [ALLN-177]
                  - [L206EOS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206EOS.sas) (sas) [ALLN-177]
                  - [L206EPRO.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206EPRO.sas) (sas) [ALLN-177]
                  - [L206HXH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206HXH.sas) (sas) [ALLN-177]
                  - [L206KS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206KS.sas) (sas) [ALLN-177]
                  - [L206LB.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206LB.sas) (sas) [ALLN-177]
                  - [L206LBABN.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206LBABN.sas) (sas) [ALLN-177]
                  - [L206LBCRABN.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206LBCRABN.sas) (sas) [ALLN-177]
                  - [L206MH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206MH.sas) (sas) [ALLN-177]
                  - [L206PAPER.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PAPER.sas) (sas) [ALLN-177]
                  - [L206PE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PE.sas) (sas) [ALLN-177]
                  - [L206PLASMA.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PLASMA.sas) (sas) [ALLN-177]
                  - [L206PLASRES.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PLASRES.sas) (sas) [ALLN-177]
                  - [L206POP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206POP.sas) (sas) [ALLN-177]
                  - [L206PREG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PREG.sas) (sas) [ALLN-177]
                  - [L206PROCREV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206PROCREV.sas) (sas) [ALLN-177]
                  - [L206SAE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206SAE.sas) (sas) [ALLN-177]
                  - [L206URINE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206URINE.sas) (sas) [ALLN-177]
                  - [L206URINRES.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206URINRES.sas) (sas) [ALLN-177]
                  - [L206VS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/L206VS.sas) (sas) [ALLN-177]
                  - **TXT Versions/**
                    - [ALLN-177-206_L206AE_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206AE_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206AEDISC_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206AEDISC_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206AESI_27NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206AESI_27NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206AEW_27NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206AEW_27NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206BLOODRES_26DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206BLOODRES_26DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206CM_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206CM_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206COMPDI_ 09DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206COMPDI_%2009DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206COMPDR_11DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206COMPDR_11DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206COMPDRDI_04JUN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206COMPDRDI_04JUN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206CPR_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206CPR_25NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206DA_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206DA_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206DCS_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206DCS_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206DH_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206DH_25NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206DM_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206DM_25NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206DV_16APR2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206DV_16APR2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206ECG_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206ECG_25NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206ELIG_21NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206ELIG_21NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206EOS_19NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206EOS_19NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206EPRO_26NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206EPRO_26NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206HXH_29NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206HXH_29NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206KS_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206KS_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206LB_03DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206LB_03DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206LBABN_04DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206LBABN_04DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206LBCRABN_04DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206LBCRABN_04DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206MH_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206MH_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PAPER_26NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PAPER_26NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PE_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PE_25NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PLASMA_18MAR2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PLASMA_18MAR2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PLASRES_16DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PLASRES_16DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206POP_21NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206POP_21NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PREG_04DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PREG_04DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206PROCREV_26NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206PROCREV_26NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206SAE_22NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206SAE_22NOV2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206URINE_26MAR2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206URINE_26MAR2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206URINRES_18DEC2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206URINRES_18DEC2019.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_L206VS_25NOV2019.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Listings/TXT%20Versions/ALLN-177-206_L206VS_25NOV2019.txt) (txt) [ALLN-177]
                - **Tables/**
                  - [__fast_change.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/__fast_change.sas) (sas) [ALLN-177]
                  - [__pox_change.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/__pox_change.sas) (sas) [ALLN-177]
                  - [__uox_change.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/__uox_change.sas) (sas) [ALLN-177]
                  - [_incuoxcr.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/_incuoxcr.sas) (sas) [ALLN-177]
                  - [T206CHEM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206CHEM.sas) (sas) [ALLN-177]
                  - [T206CM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206CM.sas) (sas) [ALLN-177]
                  - [T206COMP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206COMP.sas) (sas) [ALLN-177]
                  - [T206COMPCADI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206COMPCADI.sas) (sas) [ALLN-177]
                  - [T206COMPDI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206COMPDI.sas) (sas) [ALLN-177]
                  - [T206DEMAGE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206DEMAGE.sas) (sas) [ALLN-177]
                  - [T206DEMMITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206DEMMITT.sas) (sas) [ALLN-177]
                  - [T206DEMO.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206DEMO.sas) (sas) [ALLN-177]
                  - [T206DIET.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206DIET.sas) (sas) [ALLN-177]
                  - [T206DISP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206DISP.sas) (sas) [ALLN-177]
                  - [T206ECG.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206ECG.sas) (sas) [ALLN-177]
                  - [T206ECGINT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206ECGINT.sas) (sas) [ALLN-177]
                  - [T206ECGSHF.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206ECGSHF.sas) (sas) [ALLN-177]
                  - [T206EGFR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206EGFR.sas) (sas) [ALLN-177]
                  - [T206EXP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206EXP.sas) (sas) [ALLN-177]
                  - [T206EXPMITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206EXPMITT.sas) (sas) [ALLN-177]
                  - [T206EXPPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206EXPPP.sas) (sas) [ALLN-177]
                  - [T206FASAGE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206FASAGE.sas) (sas) [ALLN-177]
                  - [T206FASCKD.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206FASCKD.sas) (sas) [ALLN-177]
                  - [T206HEM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206HEM.sas) (sas) [ALLN-177]
                  - [T206LBABN.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206LBABN.sas) (sas) [ALLN-177]
                  - [T206LIV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206LIV.sas) (sas) [ALLN-177]
                  - [T206MH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206MH.sas) (sas) [ALLN-177]
                  - [T206OXR_PR_EHAGE_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXR_PR_EHAGE_MITT.sas) (sas) [ALLN-177]
                  - [T206OXR_PR_EHPH_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXR_PR_EHPH_MITT.sas) (sas) [ALLN-177]
                  - [T206OXR_PR_EHPH_PP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXR_PR_EHPH_PP.sas) (sas) [ALLN-177]
                  - [T206OXR_PR_PHAGE_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXR_PR_PHAGE_MITT.sas) (sas) [ALLN-177]
                  - [T206OXRAGEEH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXRAGEEH.sas) (sas) [ALLN-177]
                  - [T206OXRAGEPH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXRAGEPH.sas) (sas) [ALLN-177]
                  - [T206OXRCKDITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXRCKDITT.sas) (sas) [ALLN-177]
                  - [T206OXRCKDPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206OXRCKDPP.sas) (sas) [ALLN-177]
                  - [T206POX.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX.sas) (sas) [ALLN-177]
                  - [T206POX_PR_EH_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_EH_MITT.sas) (sas) [ALLN-177]
                  - [T206POX_PR_EH_PP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_EH_PP.sas) (sas) [ALLN-177]
                  - [T206POX_PR_EHAGE_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_EHAGE_MITT.sas) (sas) [ALLN-177]
                  - [T206POX_PR_PH_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_PH_MITT.sas) (sas) [ALLN-177]
                  - [T206POX_PR_PH_PP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_PH_PP.sas) (sas) [ALLN-177]
                  - [T206POX_PR_PHAGE_MITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POX_PR_PHAGE_MITT.sas) (sas) [ALLN-177]
                  - [T206POXAGEEH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POXAGEEH.sas) (sas) [ALLN-177]
                  - [T206POXAGEPH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POXAGEPH.sas) (sas) [ALLN-177]
                  - [T206POXCKDEH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POXCKDEH.sas) (sas) [ALLN-177]
                  - [T206POXCKDPH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POXCKDPH.sas) (sas) [ALLN-177]
                  - [T206POXPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206POXPP.sas) (sas) [ALLN-177]
                  - [T206TEAE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAE.sas) (sas) [ALLN-177]
                  - [T206TEAEDISC.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAEDISC.sas) (sas) [ALLN-177]
                  - [T206TEAEREL.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAEREL.sas) (sas) [ALLN-177]
                  - [T206TEAESEV.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAESEV.sas) (sas) [ALLN-177]
                  - [T206TEAESI.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAESI.sas) (sas) [ALLN-177]
                  - [T206TEAESUM.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TEAESUM.sas) (sas) [ALLN-177]
                  - [T206TESAE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206TESAE.sas) (sas) [ALLN-177]
                  - [T206U24E.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206U24E.sas) (sas) [ALLN-177]
                  - [T206U24EPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206U24EPP.sas) (sas) [ALLN-177]
                  - [T206UOXAGEEH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXAGEEH.sas) (sas) [ALLN-177]
                  - [T206UOXAGEPH.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXAGEPH.sas) (sas) [ALLN-177]
                  - [T206UOXCKDITT.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCKDITT.sas) (sas) [ALLN-177]
                  - [T206UOXCKDPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCKDPP.sas) (sas) [ALLN-177]
                  - [T206UOXCR.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCR.sas) (sas) [ALLN-177]
                  - [T206UOXCRAGEE.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCRAGEE.sas) (sas) [ALLN-177]
                  - [T206UOXCRAGEP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCRAGEP.sas) (sas) [ALLN-177]
                  - [T206UOXCRPP.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206UOXCRPP.sas) (sas) [ALLN-177]
                  - [T206VS.sas](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/T206VS.sas) (sas) [ALLN-177]
                  - **TXT Versions/**
                    - [ALLN-177-206___fast_change_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206___fast_change_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206___pox_change_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206___pox_change_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206___uox_change_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206___uox_change_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206__incuoxcr_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206__incuoxcr_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206CHEM_21JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206CHEM_21JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206CM_16JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206CM_16JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206COMP_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206COMP_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206COMPCADI_03JUN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206COMPCADI_03JUN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206COMPDI_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206COMPDI_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206DEMAGE_16JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206DEMAGE_16JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206DEMMITT_15JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206DEMMITT_15JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206DEMO_13JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206DEMO_13JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206DIET_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206DIET_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206DISP_13JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206DISP_13JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206ECG_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206ECG_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206ECGINT_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206ECGINT_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206ECGSHF_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206ECGSHF_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206EGFR_28JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206EGFR_28JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206EXP_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206EXP_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206EXPMITT_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206EXPMITT_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206EXPPP_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206EXPPP_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206FASAGE_31JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206FASAGE_31JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206FASCKD_31JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206FASCKD_31JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206HEM_21JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206HEM_21JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206LBABN_21JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206LBABN_21JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206LIV_21JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206LIV_21JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206MH_16JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206MH_16JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXR_PR_EHAGE_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXR_PR_EHAGE_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXR_PR_EHPH_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXR_PR_EHPH_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXR_PR_EHPH_PP_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXR_PR_EHPH_PP_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXR_PR_PHAGE_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXR_PR_PHAGE_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXRAGEEH_31JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXRAGEEH_31JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXRAGEPH_31JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXRAGEPH_31JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXRCKDITT_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXRCKDITT_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206OXRCKDPP_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206OXRCKDPP_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_27JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_27JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_EH_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_EH_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_EH_PP_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_EH_PP_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_EHAGE_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_EHAGE_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_PH_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_PH_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_PH_PP_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_PH_PP_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POX_PR_PHAGE_MITT_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POX_PR_PHAGE_MITT_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POXAGEEH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POXAGEEH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POXAGEPH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POXAGEPH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POXCKDEH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POXCKDEH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POXCKDPH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POXCKDPH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206POXPP_27JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206POXPP_27JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAE_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAE_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAEDISC_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAEDISC_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAEREL_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAEREL_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAESEV_20JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAESEV_20JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAESI_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAESI_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TEAESUM_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TEAESUM_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206TESAE_08JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206TESAE_08JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206U24E_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206U24E_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206U24EPP_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206U24EPP_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXAGEEH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXAGEEH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXAGEPH_29JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXAGEPH_29JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCKDITT_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCKDITT_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCKDPP_30JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCKDPP_30JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCR_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCR_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCRAGEE_31JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCRAGEE_31JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCRAGEP_03FEB2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCRAGEP_03FEB2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206UOXCRPP_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206UOXCRPP_23JAN2020.txt) (txt) [ALLN-177]
                    - [ALLN-177-206_T206VS_23JAN2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Programs/TLs/Tables/TXT%20Versions/ALLN-177-206_T206VS_23JAN2020.txt) (txt) [ALLN-177]
            - **QC Checklists/**
              - [ALLN-177-206_Final Delivery Issue Log_23JUN2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_Final%20Delivery%20Issue%20Log_23JUN2020.xlsx) (xlsx) [ALLN-177]
              - [ALLN-177-206_ST-F-009A Ver. 1.2 QC Checklist for TLFs_23JUN2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_ST-F-009A%20Ver.%201.2%20QC%20Checklist%20for%20TLFs_23JUN2020.pdf) (pdf) [ALLN-177]
              - [ALLN-177-206_ST-F-014A Ver. 1.1 QC Checklist for SDTM and ADaM Datasets Form 23JUN2020.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_ST-F-014A%20Ver.%201.1%20QC%20Checklist%20for%20SDTM%20and%20ADaM%20Datasets%20Form%2023JUN2020.docx) (docx) [ALLN-177]
              - [ALLN-177-206_ST-F-015A Ver. 1.1 QC Checklist for SDTM Dataset Specifications Form 07JUL2020.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_ST-F-015A%20Ver.%201.1%20QC%20Checklist%20for%20SDTM%20Dataset%20Specifications%20Form%2007JUL2020.docx) (docx) [ALLN-177]
              - [ALLN-177-206_ST-F-015B Ver. 1.1 QC Checklist for ADaM Dataset Specifications Form 09JUL2020.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_ST-F-015B%20Ver.%201.1%20QC%20Checklist%20for%20ADaM%20Dataset%20Specifications%20Form%2009JUL2020.docx) (docx) [ALLN-177]
              - [ALLN-177-206_ST-T-006B  Ver. 1.1 Statistical Output Validation Documentation Form 31JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_ST-T-006B%20%20Ver.%201.1%20Statistical%20Output%20Validation%20Documentation%20Form%2031JUL2020.pdf) (pdf) [ALLN-177]
              - [ALLN-177-206_Statistical Output Tracker_01JUL2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/QC%20Checklists/ALLN-177-206_Statistical%20Output%20Tracker_01JUL2020.xlsx) (xlsx) [ALLN-177]
            - **Submission Documents/**
              - **ADaM/**
                - [ALLN-177-206_ADaM Define XML_09JUL2020.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/ADaM/ALLN-177-206_ADaM%20Define%20XML_09JUL2020.xml) (xml) [ALLN-177]
                - [ALLN-177-206_adrg_22JUN2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/ADaM/ALLN-177-206_adrg_22JUN2020.pdf) (pdf) [ALLN-177]
                - [ALLN-177-206_define2-0-0_ADaM Stylesheet_24APR2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/ADaM/ALLN-177-206_define2-0-0_ADaM%20Stylesheet_24APR2020.txt) (txt) [ALLN-177]
                - [ALLN-177-206_define2-0-0_ADaM Stylesheet_24APR2020.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/ADaM/ALLN-177-206_define2-0-0_ADaM%20Stylesheet_24APR2020.xsl) (xsl) [ALLN-177]
                - [ALLN-177-206 SAP Final 3.0 08MAY2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/ADaM/ALLN-177-206%20SAP%20Final%203.0%2008MAY2020.pdf) (pdf) [ALLN-177]
              - **SDTM/**
                - [ALLN-177-206_acrf_06JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/SDTM/ALLN-177-206_acrf_06JUL2020.pdf) (pdf) [ALLN-177]
                - [ALLN-177-206_csdrg_22JUN_2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/SDTM/ALLN-177-206_csdrg_22JUN_2020.pdf) (pdf) [ALLN-177]
                - [ALLN-177-206_define2-0-0 SDTM Stylesheet_24APR2020.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/SDTM/ALLN-177-206_define2-0-0%20SDTM%20Stylesheet_24APR2020.txt) (txt) [ALLN-177]
                - [ALLN-177-206_define2-0-0 SDTM Stylesheet_24APR2020.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/SDTM/ALLN-177-206_define2-0-0%20SDTM%20Stylesheet_24APR2020.xsl) (xsl) [ALLN-177]
                - [ALLN-177-206_SDTM Define_07JUL2020.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/206/Datasets/CRO%20Datasets%20and%20Programming/Submission%20Documents/SDTM/ALLN-177-206_SDTM%20Define_07JUL2020.xml) (xml) [ALLN-177]
      - **301/**
        - **ADaM-Data/**
          - **ALLN-177-301_ADaM_DEFINE_20210823/**
            - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adae.xpt) (xpt) [ALLN-177]
            - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adcm.xpt) (xpt) [ALLN-177]
            - [adeff.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adeff.xpt) (xpt) [ALLN-177]
            - [adeff2.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adeff2.xpt) (xpt) [ALLN-177]
            - [adex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adex.xpt) (xpt) [ALLN-177]
            - [adexaval.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adexaval.pdf) (pdf) [ALLN-177]
            - [adexparam.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adexparam.pdf) (pdf) [ALLN-177]
            - [adfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adfa.xpt) (xpt) [ALLN-177]
            - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adlb.xpt) (xpt) [ALLN-177]
            - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/admh.xpt) (xpt) [ALLN-177]
            - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adpe.xpt) (xpt) [ALLN-177]
            - [adrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adrg.pdf) (pdf) [ALLN-177]
            - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/adsl.xpt) (xpt) [ALLN-177]
            - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/advs.xpt) (xpt) [ALLN-177]
            - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/define.xml) (xml) [ALLN-177]
            - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/define2-0-0.xsl) (xsl) [ALLN-177]
            - [irtranddata.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/irtranddata.pdf) (pdf) [ALLN-177]
            - **Programs/**
              - **ADaM/**
                - [adae.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adae.txt) (txt) [ALLN-177]
                - [adcm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adcm.txt) (txt) [ALLN-177]
                - [adeff.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adeff.txt) (txt) [ALLN-177]
                - [adeff2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adeff2.txt) (txt) [ALLN-177]
                - [adex.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adex.txt) (txt) [ALLN-177]
                - [adfa.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adfa.txt) (txt) [ALLN-177]
                - [adlb.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adlb.txt) (txt) [ALLN-177]
                - [admh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/admh.txt) (txt) [ALLN-177]
                - [adpe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adpe.txt) (txt) [ALLN-177]
                - [adsl.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/adsl.txt) (txt) [ALLN-177]
                - [advs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/ADaM/advs.txt) (txt) [ALLN-177]
              - **Macro/**
                - [ALLN7301_utility.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/Macro/ALLN7301_utility.txt) (txt) [ALLN-177]
                - [QC_macro.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/Macro/QC_macro.txt) (txt) [ALLN-177]
              - **TFL/**
                - [aeover.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/aeover.txt) (txt) [ALLN-177]
                - [aesi.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/aesi.txt) (txt) [ALLN-177]
                - [aesum.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/aesum.txt) (txt) [ALLN-177]
                - [cm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/cm.txt) (txt) [ALLN-177]
                - [cm_new.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/cm_new.txt) (txt) [ALLN-177]
                - [demog.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/demog.txt) (txt) [ALLN-177]
                - [diet.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/diet.txt) (txt) [ALLN-177]
                - [disp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/disp.txt) (txt) [ALLN-177]
                - [dv.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/dv.txt) (txt) [ALLN-177]
                - [eff_ANCOVA.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_ANCOVA.txt) (txt) [ALLN-177]
                - [eff_LogReg.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_LogReg.txt) (txt) [ALLN-177]
                - [eff_LogReg2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_LogReg2.txt) (txt) [ALLN-177]
                - [eff_MMRM.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_MMRM.txt) (txt) [ALLN-177]
                - [eff_MMRM2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_MMRM2.txt) (txt) [ALLN-177]
                - [eff_Summary.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_Summary.txt) (txt) [ALLN-177]
                - [eff_Tipping.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/eff_Tipping.txt) (txt) [ALLN-177]
                - [exp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/exp.txt) (txt) [ALLN-177]
                - [lab.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/lab.txt) (txt) [ALLN-177]
                - [list.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/list.txt) (txt) [ALLN-177]
                - [list16.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/list16.txt) (txt) [ALLN-177]
                - [list_EHH.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/list_EHH.txt) (txt) [ALLN-177]
                - [mh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/mh.txt) (txt) [ALLN-177]
                - [pe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/pe.txt) (txt) [ALLN-177]
                - [pr.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/pr.txt) (txt) [ALLN-177]
                - [prescreen.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/prescreen.txt) (txt) [ALLN-177]
                - [vs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/Programs/TFL/vs.txt) (txt) [ALLN-177]
            - [rosc.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/ADaM-Data/ALLN-177-301_ADaM_DEFINE_20210823/rosc.pdf) (pdf) [ALLN-177]
        - **CSR/**
          - **Study 301 Final Appendices & CSR/**
            - **ALLN-177-301 CSR Data Listings/**
              - **ALLN-177-301 Datasets/**
                - **ALLN-177-301 data analysis adam/**
                  - **adam/**
                    - **datasets/**
                      - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adae.xpt) (xpt) [ALLN-177]
                      - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adcm.xpt) (xpt) [ALLN-177]
                      - [adeff.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adeff.xpt) (xpt) [ALLN-177]
                      - [adeff2.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adeff2.xpt) (xpt) [ALLN-177]
                      - [adex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adex.xpt) (xpt) [ALLN-177]
                      - [adexaval.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adexaval.pdf) (pdf) [ALLN-177]
                      - [adexparam.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adexparam.pdf) (pdf) [ALLN-177]
                      - [adfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adfa.xpt) (xpt) [ALLN-177]
                      - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adlb.xpt) (xpt) [ALLN-177]
                      - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/admh.xpt) (xpt) [ALLN-177]
                      - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adpe.xpt) (xpt) [ALLN-177]
                      - [adrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adrg.pdf) (pdf) [ALLN-177]
                      - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/adsl.xpt) (xpt) [ALLN-177]
                      - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/advs.xpt) (xpt) [ALLN-177]
                      - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/define.xml) (xml) [ALLN-177]
                      - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/define2-0-0.xsl) (xsl) [ALLN-177]
                      - [irtranddata.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/irtranddata.pdf) (pdf) [ALLN-177]
                      - [rosc.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/datasets/rosc.pdf) (pdf) [ALLN-177]
                    - **programs/**
                      - [adae.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adae.txt) (txt) [ALLN-177]
                      - [adcm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adcm.txt) (txt) [ALLN-177]
                      - [adeff.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adeff.txt) (txt) [ALLN-177]
                      - [adeff2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adeff2.txt) (txt) [ALLN-177]
                      - [adex.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adex.txt) (txt) [ALLN-177]
                      - [adfa.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adfa.txt) (txt) [ALLN-177]
                      - [adlb.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adlb.txt) (txt) [ALLN-177]
                      - [admh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/admh.txt) (txt) [ALLN-177]
                      - [adpe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adpe.txt) (txt) [ALLN-177]
                      - [adsl.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/adsl.txt) (txt) [ALLN-177]
                      - [advs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/advs.txt) (txt) [ALLN-177]
                      - [aeover.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/aeover.txt) (txt) [ALLN-177]
                      - [aesi.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/aesi.txt) (txt) [ALLN-177]
                      - [aesum.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/aesum.txt) (txt) [ALLN-177]
                      - [alln7301-utility.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/alln7301-utility.txt) (txt) [ALLN-177]
                      - [cm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/cm.txt) (txt) [ALLN-177]
                      - [cm_new.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/cm_new.txt) (txt) [ALLN-177]
                      - [demog.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/demog.txt) (txt) [ALLN-177]
                      - [diet.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/diet.txt) (txt) [ALLN-177]
                      - [disp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/disp.txt) (txt) [ALLN-177]
                      - [dv.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/dv.txt) (txt) [ALLN-177]
                      - [eff-ancova.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-ancova.txt) (txt) [ALLN-177]
                      - [eff-logreg.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-logreg.txt) (txt) [ALLN-177]
                      - [eff-logreg2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-logreg2.txt) (txt) [ALLN-177]
                      - [eff-mmrm.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-mmrm.txt) (txt) [ALLN-177]
                      - [eff-mmrm2.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-mmrm2.txt) (txt) [ALLN-177]
                      - [eff-summary.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-summary.txt) (txt) [ALLN-177]
                      - [eff-tipping.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/eff-tipping.txt) (txt) [ALLN-177]
                      - [exp.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/exp.txt) (txt) [ALLN-177]
                      - [lab.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/lab.txt) (txt) [ALLN-177]
                      - [list-ehh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/list-ehh.txt) (txt) [ALLN-177]
                      - [list.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/list.txt) (txt) [ALLN-177]
                      - [list16.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/list16.txt) (txt) [ALLN-177]
                      - [mh.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/mh.txt) (txt) [ALLN-177]
                      - [pe.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/pe.txt) (txt) [ALLN-177]
                      - [pr.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/pr.txt) (txt) [ALLN-177]
                      - [prescreen.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/prescreen.txt) (txt) [ALLN-177]
                      - [qc-macro.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/qc-macro.txt) (txt) [ALLN-177]
                      - [vs.txt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20analysis%20adam/adam/programs/vs.txt) (txt) [ALLN-177]
                - **ALLN-177-301 data tabulations sdtm/**
                  - **sdtm/**
                    - [acrf.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/acrf.pdf) (pdf) [ALLN-177]
                    - [ae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ae.xpt) (xpt) [ALLN-177]
                    - [cm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/cm.xpt) (xpt) [ALLN-177]
                    - [co.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/co.xpt) (xpt) [ALLN-177]
                    - [csdrg.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/csdrg.pdf) (pdf) [ALLN-177]
                    - [da.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/da.xpt) (xpt) [ALLN-177]
                    - [define.xml](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/define.xml) (xml) [ALLN-177]
                    - [define2-0-0.xsl](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/define2-0-0.xsl) (xsl) [ALLN-177]
                    - [dm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/dm.xpt) (xpt) [ALLN-177]
                    - [ds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ds.xpt) (xpt) [ALLN-177]
                    - [dv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/dv.xpt) (xpt) [ALLN-177]
                    - [ec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ec.xpt) (xpt) [ALLN-177]
                    - [ex.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ex.xpt) (xpt) [ALLN-177]
                    - [fa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/fa.xpt) (xpt) [ALLN-177]
                    - [ho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ho.xpt) (xpt) [ALLN-177]
                    - [ie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ie.xpt) (xpt) [ALLN-177]
                    - [lb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/lb.xpt) (xpt) [ALLN-177]
                    - [mh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/mh.xpt) (xpt) [ALLN-177]
                    - [pe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/pe.xpt) (xpt) [ALLN-177]
                    - [pr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/pr.xpt) (xpt) [ALLN-177]
                    - [qs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/qs.xpt) (xpt) [ALLN-177]
                    - [relrec.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/relrec.xpt) (xpt) [ALLN-177]
                    - [rp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/rp.xpt) (xpt) [ALLN-177]
                    - [se.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/se.xpt) (xpt) [ALLN-177]
                    - [suppae.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppae.xpt) (xpt) [ALLN-177]
                    - [suppcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppcm.xpt) (xpt) [ALLN-177]
                    - [suppdm.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppdm.xpt) (xpt) [ALLN-177]
                    - [suppds.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppds.xpt) (xpt) [ALLN-177]
                    - [suppdv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppdv.xpt) (xpt) [ALLN-177]
                    - [suppfa.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppfa.xpt) (xpt) [ALLN-177]
                    - [suppho.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppho.xpt) (xpt) [ALLN-177]
                    - [suppie.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppie.xpt) (xpt) [ALLN-177]
                    - [supplb.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/supplb.xpt) (xpt) [ALLN-177]
                    - [suppmh.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppmh.xpt) (xpt) [ALLN-177]
                    - [supppe.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/supppe.xpt) (xpt) [ALLN-177]
                    - [supppr.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/supppr.xpt) (xpt) [ALLN-177]
                    - [suppqs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppqs.xpt) (xpt) [ALLN-177]
                    - [supprp.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/supprp.xpt) (xpt) [ALLN-177]
                    - [suppsv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/suppsv.xpt) (xpt) [ALLN-177]
                    - [sv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/sv.xpt) (xpt) [ALLN-177]
                    - [ta.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ta.xpt) (xpt) [ALLN-177]
                    - [te.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/te.xpt) (xpt) [ALLN-177]
                    - [ti.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ti.xpt) (xpt) [ALLN-177]
                    - [ts.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/ts.xpt) (xpt) [ALLN-177]
                    - [tv.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/tv.xpt) (xpt) [ALLN-177]
                    - [vs.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20Data%20Listings/ALLN-177-301%20Datasets/ALLN-177-301%20data%20tabulations%20sdtm/sdtm/vs.xpt) (xpt) [ALLN-177]
            - [ALLN-177-301 CSR FINAL 16Jun2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/ALLN-177-301%20CSR%20FINAL%2016Jun2021.pdf) (pdf) [ALLN-177]
            - **Appendix 16.1/**
              - [16-1-01 - Prot.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-01%20-%20Prot.pdf) (pdf) [ALLN-177]
              - [16-1-02 - crf.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-02%20-%20crf.pdf) (pdf) [ALLN-177]
              - [16.1.3 - irb.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16.1.3%20-%20irb.pdf) (pdf) [ALLN-177]
              - [16-1-04 - pi.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-04%20-%20pi.pdf) (pdf) [ALLN-177]
              - [16-1-05 - sig.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-05%20-%20sig.pdf) (pdf) [ALLN-177]
              - [16-1-06 - batch.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-06%20-%20batch.pdf) (pdf) [ALLN-177]
              - [16-1-07 - rand.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-07%20-%20rand.pdf) (pdf) [ALLN-177]
              - [16-1-08 - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-08%20-%20audit.pdf) (pdf) [ALLN-177]
              - [16-1-09 - sap.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-09%20-%20sap.pdf) (pdf) [ALLN-177]
              - [16-1-10 - qa.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-10%20-%20qa.pdf) (pdf) [ALLN-177]
              - [16-1-11 - Pub.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-11%20-%20Pub.pdf) (pdf) [ALLN-177]
              - [16-1-12 - ref.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.1/16-1-12%20-%20ref.pdf) (pdf) [ALLN-177]
            - **Appendix 16.2/**
              - [16-2-01 - disc.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-01%20-%20disc.pdf) (pdf) [ALLN-177]
              - [16-2-02 - dev.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-02%20-%20dev.pdf) (pdf) [ALLN-177]
              - [16-2-03 - excl.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-03%20-%20excl.pdf) (pdf) [ALLN-177]
              - [16-2-04 - dem.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-04%20-%20dem.pdf) (pdf) [ALLN-177]
              - [16-2-05 - drug.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-05%20-%20drug.pdf) (pdf) [ALLN-177]
              - [16-2-06 - eff.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-06%20-%20eff.pdf) (pdf) [ALLN-177]
              - [16-2-07 - ae.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-07%20-%20ae.pdf) (pdf) [ALLN-177]
              - [16-2-08 - lab.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-08%20-%20lab.pdf) (pdf) [ALLN-177]
              - [16-2-09 - Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.2/16-2-09%20-%20Other%20Safety%20Data.pdf) (pdf) [ALLN-177]
            - **Appendix 16.3/**
              - [16-3-01 - crfs.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.3/16-3-01%20-%20crfs.pdf) (pdf) [ALLN-177]
              - [16-3-02 - other crfs.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/Appendix%2016.3/16-3-02%20-%20other%20crfs.pdf) (pdf) [ALLN-177]
            - **CSR Section 14 Tables/**
              - [Section 14 Tables.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/CSR%20Section%2014%20Tables/Section%2014%20Tables.pdf) (pdf) [ALLN-177]
            - [studycode-body.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/studycode-body.pdf) (pdf) [ALLN-177]
            - [16-4 - Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/CSR/Study%20301%20Final%20Appendices%20&%20CSR/16-4%20-%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-177]
        - **SDTM-Data/**
          - **ALLN-177-301_SDTM/**
            - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ae.sas7bdat) (sas7bdat) [ALLN-177]
            - [ALLN7301_DBCRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ALLN7301_DBCRF.pdf) (pdf) [ALLN-177]
            - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/cm.sas7bdat) (sas7bdat) [ALLN-177]
            - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/co.sas7bdat) (sas7bdat) [ALLN-177]
            - [da.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/da.sas7bdat) (sas7bdat) [ALLN-177]
            - [DBGen_ALLN7301.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/DBGen_ALLN7301.xlsx) (xlsx) [ALLN-177]
            - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/dm.sas7bdat) (sas7bdat) [ALLN-177]
            - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ds.sas7bdat) (sas7bdat) [ALLN-177]
            - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/dv.sas7bdat) (sas7bdat) [ALLN-177]
            - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ec.sas7bdat) (sas7bdat) [ALLN-177]
            - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ex.sas7bdat) (sas7bdat) [ALLN-177]
            - [fa.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/fa.sas7bdat) (sas7bdat) [ALLN-177]
            - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ho.sas7bdat) (sas7bdat) [ALLN-177]
            - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ie.sas7bdat) (sas7bdat) [ALLN-177]
            - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/lb.sas7bdat) (sas7bdat) [ALLN-177]
            - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/mh.sas7bdat) (sas7bdat) [ALLN-177]
            - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/pe.sas7bdat) (sas7bdat) [ALLN-177]
            - [pr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/pr.sas7bdat) (sas7bdat) [ALLN-177]
            - [qs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/qs.sas7bdat) (sas7bdat) [ALLN-177]
            - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/relrec.sas7bdat) (sas7bdat) [ALLN-177]
            - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/rp.sas7bdat) (sas7bdat) [ALLN-177]
            - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/se.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppae.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppcm.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppdm.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppds.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppdv.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppfa.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppfa.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppho.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppie.sas7bdat) (sas7bdat) [ALLN-177]
            - [supplb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/supplb.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppmh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppmh.sas7bdat) (sas7bdat) [ALLN-177]
            - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/supppe.sas7bdat) (sas7bdat) [ALLN-177]
            - [supppr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/supppr.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppqs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppqs.sas7bdat) (sas7bdat) [ALLN-177]
            - [supprp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/supprp.sas7bdat) (sas7bdat) [ALLN-177]
            - [suppsv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/suppsv.sas7bdat) (sas7bdat) [ALLN-177]
            - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/sv.sas7bdat) (sas7bdat) [ALLN-177]
            - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ta.sas7bdat) (sas7bdat) [ALLN-177]
            - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/te.sas7bdat) (sas7bdat) [ALLN-177]
            - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ti.sas7bdat) (sas7bdat) [ALLN-177]
            - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/ts.sas7bdat) (sas7bdat) [ALLN-177]
            - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/tv.sas7bdat) (sas7bdat) [ALLN-177]
            - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/301/SDTM-Data/ALLN-177-301_SDTM/vs.sas7bdat) (sas7bdat) [ALLN-177]
      - **302/**
        - **DSMB-SSR1/**
          - **302 Final DSMB and SSR1/**
            - **20220411_ALLN7302/**
            - [20220411_ALLN7302.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/20220411_ALLN7302.zip) (zip) [ALLN-177]
            - [ALLN7302_Interim_#1_20220310.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/ALLN7302_Interim_#1_20220310.pdf) (pdf) [ALLN-177]
            - **ALLN7302_SSR_ADaM/**
              - **Data/**
            - [ALLN7302_SSR_ADaM.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/ALLN7302_SSR_ADaM.zip) (zip) [ALLN-177]
            - [Copy of Allena_ALLN-177-302 RandomizationDispensing Issues.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/Copy%20of%20Allena_ALLN-177-302%20RandomizationDispensing%20Issues.xlsx) (xlsx) [ALLN-177]
            - [Copy of UNBLINDED_Allena_ALLN-177-302_UnblindedPatientDataExport.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/Copy%20of%20UNBLINDED_Allena_ALLN-177-302_UnblindedPatientDataExport.xlsx) (xlsx) [ALLN-177]
            - [T14.2.1.1.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/302/DSMB-SSR1/302%20Final%20DSMB%20and%20SSR1/T14.2.1.1.rtf) (rtf) [ALLN-177]
      - **396/**
        - **396 Phase 2a 2014/**
          - **CSR/**
            - [A Phase 2a Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN 177 (1).pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/CSR/A%20Phase%202a%20Multicenter,%20Open%20Label,%20Single%20Arm%20Study%20Evaluating%20the%20Effect%20of%20ALLN%20177%20(1).pdf) (pdf) [ALLN-177]
          - **Final PDF TLFS/**
            - [0000396%20Final%20Figures.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20PDF%20TLFS/0000396%20Final%20Figures.pdf) (pdf) [ALLN-177]
            - [0000396%20Final%20Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20PDF%20TLFS/0000396%20Final%20Listings.pdf) (pdf) [ALLN-177]
            - [0000396%20Final%20Tables.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20PDF%20TLFS/0000396%20Final%20Tables.pdf) (pdf) [ALLN-177]
          - **Final TLFs/**
            - [F14.2.1.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.1.rtf) (rtf) [ALLN-177]
            - [F14.2.2.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.2.rtf) (rtf) [ALLN-177]
            - [F14.2.3.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.3.rtf) (rtf) [ALLN-177]
            - [F14.2.4.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.4.rtf) (rtf) [ALLN-177]
            - [F14.2.5.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.5.rtf) (rtf) [ALLN-177]
            - [F14.2.6.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/F14.2.6.rtf) (rtf) [ALLN-177]
            - [L16.2.1 Patient Population and Disposition.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.1%20Patient%20Population%20and%20Disposition.rtf) (rtf) [ALLN-177]
            - [L16.2.2 Inclusion and Exclusion Criteria Not Met.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.2%20Inclusion%20and%20Exclusion%20Criteria%20Not%20Met.rtf) (rtf) [ALLN-177]
            - [L16.2.3 Protocol Deviations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.3%20Protocol%20Deviations.rtf) (rtf) [ALLN-177]
            - [L16.2.4 Demographics and Baseline Characteristics.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.4%20Demographics%20and%20Baseline%20Characteristics.rtf) (rtf) [ALLN-177]
            - [L16.2.5.1 Medical and Surgical History.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.5.1%20Medical%20and%20Surgical%20History.rtf) (rtf) [ALLN-177]
            - [L16.2.5.2 Calcium Oxalate Kidney Stone History.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.5.2%20Calcium%20Oxalate%20Kidney%20Stone%20History.rtf) (rtf) [ALLN-177]
            - [L16.2.5.3 Hyperoxaluria Classification.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.5.3%20Hyperoxaluria%20Classification.rtf) (rtf) [ALLN-177]
            - [L16.2.5.4 Dates of Hyperoxaluria and Kidney Stone History.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.5.4%20Dates%20of%20Hyperoxaluria%20and%20Kidney%20Stone%20History.rtf) (rtf) [ALLN-177]
            - [L16.2.6 Concomitant Procedures.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.6%20Concomitant%20Procedures.rtf) (rtf) [ALLN-177]
            - [L16.2.7 Prior and Concomitant Medications.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.7%20Prior%20and%20Concomitant%20Medications.rtf) (rtf) [ALLN-177]
            - [L16.2.8 Study Drug Exposure and Compliance.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.2.8%20Study%20Drug%20Exposure%20and%20Compliance.rtf) (rtf) [ALLN-177]
            - [L16.3.1 24-Hour Urine Laboratory Evaluations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.3.1%2024-Hour%20Urine%20Laboratory%20Evaluations.rtf) (rtf) [ALLN-177]
            - [L16.3.2.1 Absolute Change and Percent Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.3.2.1%20Absolute%20Change%20and%20Percent%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [L16.3.2.2 Absolute Change and Percent Change from All Non-treated.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.3.2.2%20Absolute%20Change%20and%20Percent%20Change%20from%20All%20Non-treated.rtf) (rtf) [ALLN-177]
            - [L16.4.1.1 Adverse Events.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.1.1%20Adverse%20Events.rtf) (rtf) [ALLN-177]
            - [L16.4.1.2 Adverse Events Leading to Study Drug Withdrawal.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.1.2%20Adverse%20Events%20Leading%20to%20Study%20Drug%20Withdrawal.rtf) (rtf) [ALLN-177]
            - [L16.4.1.3 Serious Adverse Events.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.1.3%20Serious%20Adverse%20Events.rtf) (rtf) [ALLN-177]
            - [L16.4.1.4 Deaths.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.1.4%20Deaths.rtf) (rtf) [ALLN-177]
            - [L16.4.2.1 Hematology Laboratory Evaluations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.2.1%20Hematology%20Laboratory%20Evaluations.rtf) (rtf) [ALLN-177]
            - [L16.4.2.2 Serum Chemistry Laboratory Evaluations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.2.2%20Serum%20Chemistry%20Laboratory%20Evaluations.rtf) (rtf) [ALLN-177]
            - [L16.4.2.3 Urinalysis Laboratory Evaluations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.2.3%20Urinalysis%20Laboratory%20Evaluations.rtf) (rtf) [ALLN-177]
            - [L16.4.2.4 Pregnancy Test Results at Screening.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.2.4%20Pregnancy%20Test%20Results%20at%20Screening.rtf) (rtf) [ALLN-177]
            - [L16.4.2.5 Drug Screening.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.2.5%20Drug%20Screening.rtf) (rtf) [ALLN-177]
            - [L16.4.3 Vital Signs.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.3%20Vital%20Signs.rtf) (rtf) [ALLN-177]
            - [L16.4.4 Electrocardiogram (ECG) Results.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.4%20Electrocardiogram%20(ECG)%20Results.rtf) (rtf) [ALLN-177]
            - [L16.4.5 Physical Examinations.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.5%20Physical%20Examinations.rtf) (rtf) [ALLN-177]
            - [L16.4.6.1 Screening Diet Recall 1.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.6.1%20Screening%20Diet%20Recall%201.rtf) (rtf) [ALLN-177]
            - [L16.4.6.2 Diet Recall 2.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.6.2%20Diet%20Recall%202.rtf) (rtf) [ALLN-177]
            - [L16.4.7 Oxalate Intake and Excretion.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/L16.4.7%20Oxalate%20Intake%20and%20Excretion.rtf) (rtf) [ALLN-177]
            - [PT14.3.9 Summary of Concomitant Medications.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/PT14.3.9%20Summary%20of%20Concomitant%20Medications.rtf) (rtf) [ALLN-177]
            - [PT14.3.10 Summary of Medical History.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/PT14.3.10%20Summary%20of%20Medical%20History.rtf) (rtf) [ALLN-177]
            - [PT14.3.11 Summary of Oxalate Intake and Excretion by Day and Period.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/PT14.3.11%20Summary%20of%20Oxalate%20Intake%20and%20Excretion%20by%20Day%20and%20Period.rtf) (rtf) [ALLN-177]
            - [T14.1.1 Patient Population and Study Disposition.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.1%20Patient%20Population%20and%20Study%20Disposition.rtf) (rtf) [ALLN-177]
            - [T14.1.2 Demographics and Baseline Characteristics.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.2%20Demographics%20and%20Baseline%20Characteristics.rtf) (rtf) [ALLN-177]
            - [T14.1.3.1 Overall Study Drug Compliance and Exposure.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.3.1%20Overall%20Study%20Drug%20Compliance%20and%20Exposure.rtf) (rtf) [ALLN-177]
            - [T14.1.3.2 Study Drug Compliance and Exposure - Breakfast.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.3.2%20Study%20Drug%20Compliance%20and%20Exposure%20-%20Breakfast.rtf) (rtf) [ALLN-177]
            - [T14.1.3.3 Study Drug Compliance and Exposure - Lunch.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.3.3%20Study%20Drug%20Compliance%20and%20Exposure%20-%20Lunch.rtf) (rtf) [ALLN-177]
            - [T14.1.3.4 Study Drug Compliance and Exposure - Dinner.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.3.4%20Study%20Drug%20Compliance%20and%20Exposure%20-%20Dinner.rtf) (rtf) [ALLN-177]
            - [T14.1.3.5 Study Drug Compliance and Exposure - Snack.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.1.3.5%20Study%20Drug%20Compliance%20and%20Exposure%20-%20Snack.rtf) (rtf) [ALLN-177]
            - [T14.2.1.1 Change and Percent Change from Baseline in 24-hour Urinary Oxalate Excretion Safety.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.2.1.1%20Change%20and%20Percent%20Change%20from%20Baseline%20in%2024-hour%20Urinary%20Oxalate%20Excretion%20Safety.rtf) (rtf) [ALLN-177]
            - [T14.2.1.2 Change and Percent Change from Baseline in 24-hour Urinary Oxalate Excretion Patient.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.2.1.2%20Change%20and%20Percent%20Change%20from%20Baseline%20in%2024-hour%20Urinary%20Oxalate%20Excretion%20Patient.rtf) (rtf) [ALLN-177]
            - [T14.2.1.3 Change and Percent Change from Baseline in 24-hour Urinary Oxalate Excretion by Hyperoxaluria Type Safety Population.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.2.1.3%20Change%20and%20Percent%20Change%20from%20Baseline%20in%2024-hour%20Urinary%20Oxalate%20Excretion%20by%20Hyperoxaluria%20Type%20Safety%20Population.rtf) (rtf) [ALLN-177]
            - [T14.2.1.4 Change and Percent Change from Baseline in 24-hour Urinary Oxalate Excretion in Treated Period Safety Population.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.2.1.4%20Change%20and%20Percent%20Change%20from%20Baseline%20in%2024-hour%20Urinary%20Oxalate%20Excretion%20in%20Treated%20Period%20Safety%20Population.rtf) (rtf) [ALLN-177]
            - [T14.2.1.5 Change and Percent Change from All Non-treated results in 24-hour Urinary Oxalate Excretion.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.2.1.5%20Change%20and%20Percent%20Change%20from%20All%20Non-treated%20results%20in%2024-hour%20Urinary%20Oxalate%20Excretion.rtf) (rtf) [ALLN-177]
            - [T14.3.1 Summary of Adverse Events.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.1%20Summary%20of%20Adverse%20Events.rtf) (rtf) [ALLN-177]
            - [T14.3.2 Treatment Emergent Adverse Events.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.2%20Treatment%20Emergent%20Adverse%20Events.rtf) (rtf) [ALLN-177]
            - [T14.3.4.1.1 Hematology Evaluations - Results and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.1.1%20Hematology%20Evaluations%20-%20Results%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.1.2 Summary of Hematology Evaluations  Shifts from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.1.2%20Summary%20of%20Hematology%20Evaluations%20%20Shifts%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.2.1 Summary of Serum Chemistry Evaluations - Results and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.2.1%20Summary%20of%20Serum%20Chemistry%20Evaluations%20-%20Results%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.2.2 Summary of Serum Chemistry Evaluations - Shift from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.2.2%20Summary%20of%20Serum%20Chemistry%20Evaluations%20-%20Shift%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.3.1 Summary of Urinalysis Evaluations - Results and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.3.1%20Summary%20of%20Urinalysis%20Evaluations%20-%20Results%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.3.2 Summary of Urinalysis Evaluations - Shift from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.3.2%20Summary%20of%20Urinalysis%20Evaluations%20-%20Shift%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.4.4 24-Hour Urine Laboratory Evaluations - Results and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.4.4%2024-Hour%20Urine%20Laboratory%20Evaluations%20-%20Results%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.5.1 Summary of Vital Sign Measurements and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.5.1%20Summary%20of%20Vital%20Sign%20Measurements%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.6.1 Summary of Electrocardiogram (ECG) - Results and Change from Baseline.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.6.1%20Summary%20of%20Electrocardiogram%20(ECG)%20-%20Results%20and%20Change%20from%20Baseline.rtf) (rtf) [ALLN-177]
            - [T14.3.6.2 Summary of ECG Interpretation  Shifts from Baseline to Day 11.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.6.2%20Summary%20of%20ECG%20Interpretation%20%20Shifts%20from%20Baseline%20to%20Day%2011.rtf) (rtf) [ALLN-177]
            - [T14.3.7 Summary of Physical Exam  Shifts from Baseline to Day 11.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.7%20Summary%20of%20Physical%20Exam%20%20Shifts%20from%20Baseline%20to%20Day%2011.rtf) (rtf) [ALLN-177]
            - [T14.3.8.1 Summary of Diet Recall - Nutrients.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.8.1%20Summary%20of%20Diet%20Recall%20-%20Nutrients.rtf) (rtf) [ALLN-177]
            - [T14.3.8.2 Summary of Diet Recall - Success.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/T14.3.8.2%20Summary%20of%20Diet%20Recall%20-%20Success.rtf) (rtf) [ALLN-177]
            - [Tables_Listings_Figures guide.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Final%20TLFs/Tables_Listings_Figures%20guide.docx) (docx) [ALLN-177]
          - **Post hoc analysis/**
            - [posthoc_danica_396_egfr[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/Post%20hoc%20analysis/posthoc_danica_396_egfr[1].pdf) (pdf) [ALLN-177]
          - **SS/**
            - [Exploratory_Corr_Plots_24H_Oxalate_20150501.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/Exploratory_Corr_Plots_24H_Oxalate_20150501.pdf) (pdf) [ALLN-177]
            - [Exploratory_Corr_Plots_24H_RSRCaOx_20150501.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/Exploratory_Corr_Plots_24H_RSRCaOx_20150501.pdf) (pdf) [ALLN-177]
            - [Exploratory_Plots_24H_RSRCaOx_20150501.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/Exploratory_Plots_24H_RSRCaOx_20150501.pdf) (pdf) [ALLN-177]
            - [Export_Summ_Stats_20140501.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/Export_Summ_Stats_20140501.xlsx) (xlsx) [ALLN-177]
            - [RSR caox index Phase 2a 20April.pptx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/RSR%20caox%20index%20Phase%202a%2020April.pptx) (pptx) [ALLN-177]
            - [ss index 20Phase 2a 20Feb2015.pptx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/ss%20index%2020Phase%202a%2020Feb2015.pptx) (pptx) [ALLN-177]
            - [Summary ResultsSupersaturation_20150.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/SS/Summary%20ResultsSupersaturation_20150.docx) (docx) [ALLN-177]
          - **02 Central Trial Documents/**
            - **02.02 Subject Documents/**
              - **02.02.03 Informed Consent Form/**
                - [Allena ICF Core Template Final v5 0_10Sep2014 (Clean)v2[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/Allena%20ICF%20Core%20Template%20Final%20v5%200_10Sep2014%20(Clean)v2[1].pdf) (pdf) [ALLN-177]
                - [ICF Approval Form_0000396_1.0_20140425.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF%20Approval%20Form_0000396_1.0_20140425.pdf) (pdf) [ALLN-177]
                - [ICF Approval Form_0000396_Amend1_v3.0_20140619.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF%20Approval%20Form_0000396_Amend1_v3.0_20140619.pdf) (pdf) [ALLN-177]
                - [ICF Approval Form_0000396_Amend2 v3.0_20140812.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF%20Approval%20Form_0000396_Amend2%20v3.0_20140812.pdf) (pdf) [ALLN-177]
                - [ICF Approval Form_0000396_Amend3_v5.0_20140910.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF%20Approval%20Form_0000396_Amend3_v5.0_20140910.pdf) (pdf) [ALLN-177]
                - [ICF Approval Form_0000396_Initial_v2.0_20140514.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF%20Approval%20Form_0000396_Initial_v2.0_20140514.pdf) (pdf) [ALLN-177]
                - [ICF_0000396_1.0_20140423.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF_0000396_1.0_20140423.pdf) (pdf) [ALLN-177]
                - [ICF_0000396_Amend1_v3.0_20140620.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF_0000396_Amend1_v3.0_20140620.pdf) (pdf) [ALLN-177]
                - [ICF_0000396_Amend2_v4.0_20140812.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF_0000396_Amend2_v4.0_20140812.pdf) (pdf) [ALLN-177]
                - [ICF_0000396_Amend3_v5.0_20140910.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF_0000396_Amend3_v5.0_20140910.pdf) (pdf) [ALLN-177]
                - [ICF_0000396_Initial_v2.0 13May2014_20140610.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/396/396%20Phase%202a%202014/02%20Central%20Trial%20Documents/02.02%20Subject%20Documents/02.02.03%20Informed%20Consent%20Form/ICF_0000396_Initial_v2.0%2013May2014_20140610.pdf) (pdf) [ALLN-177]
      - **649/**
        - **CSR-TLFs/**
          - **CSR/**
            - [Allena abbreviated Draft 2_v2.00 - RP 01 03 2019.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/Allena%20abbreviated%20Draft%202_v2.00%20-%20RP%2001%2003%202019.docx) (docx) [ALLN-177]
            - [14 Tables, Figures, and Graphs Referred to but not Included in the Text.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/14%20Tables,%20Figures,%20and%20Graphs%20Referred%20to%20but%20not%20Included%20in%20the%20Text.pdf) (pdf) [ALLN-177]
            - [16 APPENDICES.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16%20APPENDICES.pdf) (pdf) [ALLN-177]
            - [16.1.1 Protocol and Protocol Amendments.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.1%20Protocol%20and%20Protocol%20Amendments.pdf) (pdf) [ALLN-177]
            - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-177]
            - [16.1.3 List of Independent Ethics Committees or Institutional Review Boards.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.3%20List%20of%20Independent%20Ethics%20Committees%20or%20Institutional%20Review%20Boards.pdf) (pdf) [ALLN-177]
            - [16.1.4 Description of Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.4%20Description%20of%20Investigators.pdf) (pdf) [ALLN-177]
            - [16.1.5 Signatures of Principal or Coordinating Investigator(s) or Sponsor's Responsible Medical Officer, Depending on the Regulatory Authority's Requirement.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.5%20Signatures%20of%20Principal%20or%20Coordinating%20Investigator(s)%20or%20Sponsor's%20Responsible%20Medical%20Officer,%20Depending%20on%20the%20Regulatory%20Authority's%20Requirement.pdf) (pdf) [ALLN-177]
            - [16.1.6 Listing of Subjects Receiving Test Drug(s) Investigational Product(s) from Specific Batches, Whre More Than 1 Batch Was Used.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.6%20Listing%20of%20Subjects%20Receiving%20Test%20Drug(s)%20Investigational%20Product(s)%20from%20Specific%20Batches,%20Whre%20More%20Than%201%20Batch%20Was%20Used.pdf) (pdf) [ALLN-177]
            - [16.1.7 Randomization Scheme and Codes.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.7%20Randomization%20Scheme%20and%20Codes.pdf) (pdf) [ALLN-177]
            - [16.1.8 Audit Certificates.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.8%20Audit%20Certificates.pdf) (pdf) [ALLN-177]
            - [16.1.9 Documentation of Statistical Methods.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.9%20Documentation%20of%20Statistical%20Methods.pdf) (pdf) [ALLN-177]
            - [16.1.10 Documentation of Inter-laboratory Standardization Methods and Quality Assurance Procedures if Used.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.1.10%20Documentation%20of%20Inter-laboratory%20Standardization%20Methods%20and%20Quality%20Assurance%20Procedures%20if%20Used.pdf) (pdf) [ALLN-177]
            - [16.2 Subject Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.2%20Subject%20Data%20Listings.pdf) (pdf) [ALLN-177]
            - [16.3.1 Case Report Forms for Deaths, Other Serious Adverse Events and Withdrawals for Adverse Events.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/CSR-TLFs/CSR/16.3.1%20Case%20Report%20Forms%20for%20Deaths,%20Other%20Serious%20Adverse%20Events%20and%20Withdrawals%20for%20Adverse%20Events.pdf) (pdf) [ALLN-177]
        - **Datasets/**
          - **11.03 Analysis/**
            - **11.03.02 Analysis QC Documentation/**
              - [AD-ST-42.01 Record of Validation_Analysis QC_Validation Documentation_00000649_20170118.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/AD-ST-42.01%20Record%20of%20Validation_Analysis%20QC_Validation%20Documentation_00000649_20170118.pdf) (pdf) [ALLN-177]
              - [AD-ST-46.01 Statistics Delivery Checklist_Analysis QC_Validation Documentation_00000649_20170126.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/AD-ST-46.01%20Statistics%20Delivery%20Checklist_Analysis%20QC_Validation%20Documentation_00000649_20170126.pdf) (pdf) [ALLN-177]
              - [Posthoc TLFs Approval form_Analysis QC_Validation Documentation_00000649_20170510.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Posthoc%20TLFs%20Approval%20form_Analysis%20QC_Validation%20Documentation_00000649_20170510.pdf) (pdf) [ALLN-177]
            - **11.03.07 Final Analysis Raw Datasets/**
              - **Final Analysis Raw Datasets_00000649_Final_20170118/**
                - **Data/**
                  - [acmlab.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/acmlab.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/ae.sas7bdat) (sas7bdat) [ALLN-177]
                  - [bioclnct.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/bioclnct.sas7bdat) (sas7bdat) [ALLN-177]
                  - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/cm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [cp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/cp.sas7bdat) (sas7bdat) [ALLN-177]
                  - [da.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/da.sas7bdat) (sas7bdat) [ALLN-177]
                  - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/dm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [dr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/dr.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/ds.sas7bdat) (sas7bdat) [ALLN-177]
                  - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/eg.sas7bdat) (sas7bdat) [ALLN-177]
                  - [event.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/event.sas7bdat) (sas7bdat) [ALLN-177]
                  - [eventdt.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/eventdt.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/ex.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/ie.sas7bdat) (sas7bdat) [ALLN-177]
                  - [im.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/im.sas7bdat) (sas7bdat) [ALLN-177]
                  - [invalid.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/invalid.sas7bdat) (sas7bdat) [ALLN-177]
                  - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/lb.sas7bdat) (sas7bdat) [ALLN-177]
                  - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/mh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/pe.sas7bdat) (sas7bdat) [ALLN-177]
                  - [qs_dh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/qs_dh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [rand.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/rand.sas7bdat) (sas7bdat) [ALLN-177]
                  - [statfrm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/statfrm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/sv.sas7bdat) (sas7bdat) [ALLN-177]
                  - [tc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/tc.sas7bdat) (sas7bdat) [ALLN-177]
                  - [utsw24.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/utsw24.sas7bdat) (sas7bdat) [ALLN-177]
                  - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118/Data/vs.sas7bdat) (sas7bdat) [ALLN-177]
              - [Final Analysis Raw Datasets_00000649_Final_20170118.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_00000649_Final_20170118.zip) (zip) [ALLN-177]
            - **11.03.09 Final Analysis Datasets/**
              - **Final Analysis Datasets_00000649_Final_20170118/**
                - **Data/**
                  - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adae.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adcm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [addr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/addr.sas7bdat) (sas7bdat) [ALLN-177]
                  - [addv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/addv.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adeff.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adeff.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adex.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adlb.sas7bdat) (sas7bdat) [ALLN-177]
                  - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/admh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/adsl.sas7bdat) (sas7bdat) [ALLN-177]
                  - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118/Data/advs.sas7bdat) (sas7bdat) [ALLN-177]
              - [Final Analysis Datasets_00000649_Final_20170118.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_00000649_Final_20170118.zip) (zip) [ALLN-177]
            - **11.03.10 Final Analysis Output/**
              - [Final Analysis Output_00000649_24 Jan 2017_20170124.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_00000649_24%20Jan%202017_20170124.pdf) (pdf) [ALLN-177]
              - [Final Analysis Output_00000649_Final_20170118.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_00000649_Final_20170118.pdf) (pdf) [ALLN-177]
              - [Final Analysis Output_00000649_Final_20170510.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_00000649_Final_20170510.pdf) (pdf) [ALLN-177]
            - **11.03.11 Subject Evaluability Criteria & Subject Classification/**
              - [Protocol Adherence Document_00000649_Final_20160928.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/649/Datasets/11.03%20Analysis/11.03.11%20Subject%20Evaluability%20Criteria%20&%20Subject%20Classification/Protocol%20Adherence%20Document_00000649_Final_20160928.pdf) (pdf) [ALLN-177]
      - **713/**
        - **CSR/**
          - **713 CSR/**
            - **Appendix 16.1/**
              - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-177]
              - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-177]
              - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-177]
              - [16.1.4 Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.4%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-177]
              - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-177]
              - [16.1.6 List Subjects With Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.6%20List%20Subjects%20With%20Batches.pdf) (pdf) [ALLN-177]
              - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-177]
              - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-177]
              - [16.1.9 Statistical Methods Interim Analysis Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.9%20Statistical%20Methods%20Interim%20Analysis%20Plan.pdf) (pdf) [ALLN-177]
              - [16.1.10 Documentation of Inter-Laboratory Standardization Methods & Quality Assurance Procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.10%20Documentation%20of%20Inter-Laboratory%20Standardization%20Methods%20&%20Quality%20Assurance%20Procedures.pdf) (pdf) [ALLN-177]
              - [16.1.11 Publications based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.11%20Publications%20based%20on%20Study.pdf) (pdf) [ALLN-177]
              - [16.1.12 Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.1/16.1.12%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-177]
            - **Appendix 16.2/**
              - [16.2.1 Discontinued Subjects.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.1%20Discontinued%20Subjects.pdf) (pdf) [ALLN-177]
              - [16.2.2 Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.2%20Protocol%20Deviations.pdf) (pdf) [ALLN-177]
              - [16.2.3 Subjects Excluded From Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.3%20Subjects%20Excluded%20From%20Efficacy%20Analysis.pdf) (pdf) [ALLN-177]
              - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-177]
              - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-177]
              - [16.2.6 Individual Efficacy Response Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.6%20Individual%20Efficacy%20Response%20Data.pdf) (pdf) [ALLN-177]
              - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-177]
              - [16.2.8 Listings of Individual Laboratory Measurements by Subjects.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.2/16.2.8%20Listings%20of%20Individual%20Laboratory%20Measurements%20by%20Subjects.pdf) (pdf) [ALLN-177]
            - **Appendix 16.3/**
              - [16.3.1-Crfs.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Appendix%2016.3/16.3.1-Crfs.pdf) (pdf) [ALLN-177]
            - [Section 14 Tables.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Section%2014%20Tables.pdf) (pdf) [ALLN-177]
            - [Study 713 CSR FINAL 19Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/CSR/713%20CSR/Study%20713%20CSR%20FINAL%2019Nov2021.pdf) (pdf) [ALLN-177]
        - **Datasets/**
          - **DM Reports/**
            - **Excel/**
              - [Adverse Events Coding Report.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Adverse%20Events%20Coding%20Report.xlsx) (xlsx) [ALLN-177]
              - [Adverse Events.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Adverse%20Events.xlsx) (xlsx) [ALLN-177]
              - [Clinical Laboratory Tests.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Clinical%20Laboratory%20Tests.xlsx) (xlsx) [ALLN-177]
              - [Concomitant Medications Coding Report.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Concomitant%20Medications%20Coding%20Report.xlsx) (xlsx) [ALLN-177]
              - [Concomitant Procedures.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Concomitant%20Procedures.xlsx) (xlsx) [ALLN-177]
              - [CT Kidney.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/CT%20Kidney.xlsx) (xlsx) [ALLN-177]
              - [Demography.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Demography.xlsx) (xlsx) [ALLN-177]
              - [Diet History Questionnaire.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Diet%20History%20Questionnaire.xlsx) (xlsx) [ALLN-177]
              - [Inclusion.Exclusion Criteria.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Inclusion.Exclusion%20Criteria.xlsx) (xlsx) [ALLN-177]
              - [Informed Consent.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Informed%20Consent.xlsx) (xlsx) [ALLN-177]
              - [Lab Reconcilliation.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Lab%20Reconcilliation.xlsx) (xlsx) [ALLN-177]
              - [Medical History Coding Report.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Medical%20History%20Coding%20Report.xlsx) (xlsx) [ALLN-177]
              - [Medical History incl. Surgical.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Medical%20History%20incl.%20Surgical.xlsx) (xlsx) [ALLN-177]
              - [Physical Examination.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Physical%20Examination.xlsx) (xlsx) [ALLN-177]
              - [Pregnancy Test . Urine.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Pregnancy%20Test%20.%20Urine.xlsx) (xlsx) [ALLN-177]
              - [Premier Pay Metrics.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Premier%20Pay%20Metrics.xlsx) (xlsx) [ALLN-177]
              - [Prior.Concomitant Medications.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Prior.Concomitant%20Medications.xlsx) (xlsx) [ALLN-177]
              - [Randomization.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Randomization.xlsx) (xlsx) [ALLN-177]
              - [SDV_Completed.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/SDV_Completed.xlsx) (xlsx) [ALLN-177]
              - [Study Completion.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Study%20Completion.xlsx) (xlsx) [ALLN-177]
              - [Study Drug Accountability Dispensed.Returned.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Study%20Drug%20Accountability%20Dispensed.Returned.xlsx) (xlsx) [ALLN-177]
              - [Study Drug Administration 1.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Study%20Drug%20Administration%201.xlsx) (xlsx) [ALLN-177]
              - [Study Drug Administration 2.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Study%20Drug%20Administration%202.xlsx) (xlsx) [ALLN-177]
              - [Telephone Contact.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Telephone%20Contact.xlsx) (xlsx) [ALLN-177]
              - [Visit Date.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Visit%20Date.xlsx) (xlsx) [ALLN-177]
              - [Vital Signs.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/Vital%20Signs.xlsx) (xlsx) [ALLN-177]
              - [WFServlet (13)](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/WFServlet%20(13)) (unknown) [ALLN-177]
              - [12-Lead Safety ECG.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/12-Lead%20Safety%20ECG.xlsx) (xlsx) [ALLN-177]
              - [24 Hour Urine.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/Excel/24%20Hour%20Urine.xlsx) (xlsx) [ALLN-177]
            - **WFservlet/**
              - [Adverse Events](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Adverse%20Events) (unknown) [ALLN-177]
              - [Adverse Events Coding Reports](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Adverse%20Events%20Coding%20Reports) (unknown) [ALLN-177]
              - [Clinical Laboratory Tests](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Clinical%20Laboratory%20Tests) (unknown) [ALLN-177]
              - [Concomitant Medicaitons Coding Report](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Concomitant%20Medicaitons%20Coding%20Report) (unknown) [ALLN-177]
              - [Concomitant Procedures](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Concomitant%20Procedures) (unknown) [ALLN-177]
              - [CT Kidney](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/CT%20Kidney) (unknown) [ALLN-177]
              - [Demography](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Demography) (unknown) [ALLN-177]
              - [Diet History Questionnaire](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Diet%20History%20Questionnaire) (unknown) [ALLN-177]
              - [Diet Recall](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Diet%20Recall) (unknown) [ALLN-177]
              - [Inclusion.Exclusion Criteria](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Inclusion.Exclusion%20Criteria) (exclusion criteria) [ALLN-177]
              - [Informed Consent](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Informed%20Consent) (unknown) [ALLN-177]
              - [Lab Reconcilliation](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Lab%20Reconcilliation) (unknown) [ALLN-177]
              - [Medical History Coding Report](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Medical%20History%20Coding%20Report) (unknown) [ALLN-177]
              - [Medical History incl. Surgical](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Medical%20History%20incl.%20Surgical) ( surgical) [ALLN-177]
              - [Physical Examination](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Physical%20Examination) (unknown) [ALLN-177]
              - [Pregnancy Test-Urine](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Pregnancy%20Test-Urine) (unknown) [ALLN-177]
              - [Premier Pay Metrics](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Premier%20Pay%20Metrics) (unknown) [ALLN-177]
              - [Prior.Concomitant Medications](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Prior.Concomitant%20Medications) (concomitant medications) [ALLN-177]
              - [Randomization](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Randomization) (unknown) [ALLN-177]
              - [SDV_Completed](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/SDV_Completed) (unknown) [ALLN-177]
              - [Study Completion](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Study%20Completion) (unknown) [ALLN-177]
              - [Study Drug Accountability Dispensed.Returned](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Study%20Drug%20Accountability%20Dispensed.Returned) (returned) [ALLN-177]
              - [Study Drug Administration 1](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Study%20Drug%20Administration%201) (unknown) [ALLN-177]
              - [Study Drug Administration 2](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Study%20Drug%20Administration%202) (unknown) [ALLN-177]
              - [Telephone Contact](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Telephone%20Contact) (unknown) [ALLN-177]
              - [Visit Date](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Visit%20Date) (unknown) [ALLN-177]
              - [Vital Signs](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/Vital%20Signs) (unknown) [ALLN-177]
              - [12-Lead safety ECG](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/12-Lead%20safety%20ECG) (unknown) [ALLN-177]
              - [24 Hour Urine](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/DM%20Reports/WFservlet/24%20Hour%20Urine) (unknown) [ALLN-177]
          - **11.03 Analysis/**
            - **11.03.01 Data Definitions for Analysis Datasets/**
              - [ADaM Dataset Specifications_0000713_1.0_20170713.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.01%20Data%20Definitions%20for%20Analysis%20Datasets/ADaM%20Dataset%20Specifications_0000713_1.0_20170713.pdf) (pdf) [ALLN-177]
            - **11.03.02 Analysis QC Documentation/**
              - [Final_Analysis QC_Validation Documentation_0000713_20170713.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Final_Analysis%20QC_Validation%20Documentation_0000713_20170713.pdf) (pdf) [ALLN-177]
              - [Record of Validation_Analysis QC_Validation Documentation_0000713_20170713.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.02%20Analysis%20QC%20Documentation/Record%20of%20Validation_Analysis%20QC_Validation%20Documentation_0000713_20170713.pdf) (pdf) [ALLN-177]
            - **11.03.07 Final Analysis Raw Datasets/**
              - **Final Analysis Raw Datasets_0000713_1.0_20170221/**
                - **Data/**
                  - [acmlab.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/acmlab.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/ae.sas7bdat) (sas7bdat) [ALLN-177]
                  - [bioclnct.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/bioclnct.sas7bdat) (sas7bdat) [ALLN-177]
                  - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/cm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [cp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/cp.sas7bdat) (sas7bdat) [ALLN-177]
                  - [da.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/da.sas7bdat) (sas7bdat) [ALLN-177]
                  - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/dm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [dr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/dr.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/ds.sas7bdat) (sas7bdat) [ALLN-177]
                  - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/eg.sas7bdat) (sas7bdat) [ALLN-177]
                  - [event.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/event.sas7bdat) (sas7bdat) [ALLN-177]
                  - [eventdt.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/eventdt.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/ex.sas7bdat) (sas7bdat) [ALLN-177]
                  - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/ie.sas7bdat) (sas7bdat) [ALLN-177]
                  - [im.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/im.sas7bdat) (sas7bdat) [ALLN-177]
                  - [invalid.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/invalid.sas7bdat) (sas7bdat) [ALLN-177]
                  - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/lb.sas7bdat) (sas7bdat) [ALLN-177]
                  - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/mh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/pe.sas7bdat) (sas7bdat) [ALLN-177]
                  - [qs_dh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/qs_dh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [rand.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/rand.sas7bdat) (sas7bdat) [ALLN-177]
                  - [statfrm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/statfrm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/sv.sas7bdat) (sas7bdat) [ALLN-177]
                  - [tc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/tc.sas7bdat) (sas7bdat) [ALLN-177]
                  - [utsw24.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/utsw24.sas7bdat) (sas7bdat) [ALLN-177]
                  - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221/Data/vs.sas7bdat) (sas7bdat) [ALLN-177]
              - [Final Analysis Raw Datasets_0000713_1.0_20170221.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.07%20Final%20Analysis%20Raw%20Datasets/Final%20Analysis%20Raw%20Datasets_0000713_1.0_20170221.zip) (zip) [ALLN-177]
            - **11.03.09 Final Analysis Datasets/**
              - **Final Analysis Datasets_0000713_1.0_20170713/**
                - **Data/**
                  - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adae.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adcm.sas7bdat) (sas7bdat) [ALLN-177]
                  - [addr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/addr.sas7bdat) (sas7bdat) [ALLN-177]
                  - [addv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/addv.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adeff.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adeff.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adegpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adegpe.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adex.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adlb.sas7bdat) (sas7bdat) [ALLN-177]
                  - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/admh.sas7bdat) (sas7bdat) [ALLN-177]
                  - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/adsl.sas7bdat) (sas7bdat) [ALLN-177]
                  - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713/Data/advs.sas7bdat) (sas7bdat) [ALLN-177]
              - [Final Analysis Datasets_0000713_1.0_20170713.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.09%20Final%20Analysis%20Datasets/Final%20Analysis%20Datasets_0000713_1.0_20170713.zip) (zip) [ALLN-177]
            - **11.03.10 Final Analysis Output/**
              - [Final Analysis Output_0000713_Final_Table 14.2.2.1P1_20170814.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_0000713_Final_Table%2014.2.2.1P1_20170814.pdf) (pdf) [ALLN-177]
              - [Final Analysis Output_0000713_Final_Updated AE Listing_16.2.6.1 (w SF SAE)_20170921.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_0000713_Final_Updated%20AE%20Listing_16.2.6.1%20(w%20SF%20SAE)_20170921.pdf) (pdf) [ALLN-177]
              - [Final Analysis Output_0000713_Final_Updated SAE Listing_16.2.6.3_20170921.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_0000713_Final_Updated%20SAE%20Listing_16.2.6.3_20170921.pdf) (pdf) [ALLN-177]
              - [Final Analysis Output_0000713_TLFs_1.0_20170713.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/Final%20Analysis%20Output_0000713_TLFs_1.0_20170713.pdf) (pdf) [ALLN-177]
              - **713 TLF 0530 2019-updated eGFR chem+demog/**
                - [l16_2_7_2_chem.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/713%20TLF%200530%202019-updated%20eGFR%20chem+demog/l16_2_7_2_chem.rtf) (rtf) [ALLN-177]
                - [t14_1_3_demog.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/713%20TLF%200530%202019-updated%20eGFR%20chem+demog/t14_1_3_demog.rtf) (rtf) [ALLN-177]
                - [t14_1_3P_demoghypgrp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/713%20TLF%200530%202019-updated%20eGFR%20chem+demog/t14_1_3P_demoghypgrp.rtf) (rtf) [ALLN-177]
                - [t14_3_2_2_chem.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/713%20TLF%200530%202019-updated%20eGFR%20chem+demog/t14_3_2_2_chem.rtf) (rtf) [ALLN-177]
                - [t14_3_2_2P_chem.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.10%20Final%20Analysis%20Output/713%20TLF%200530%202019-updated%20eGFR%20chem+demog/t14_3_2_2P_chem.rtf) (rtf) [ALLN-177]
            - **11.03.11 Subject Evaluability Criteria & Subject Classification/**
              - [Protocol Adherence Document_0000713_Addendum_Final_20170221.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.11%20Subject%20Evaluability%20Criteria%20&%20Subject%20Classification/Protocol%20Adherence%20Document_0000713_Addendum_Final_20170221.pdf) (pdf) [ALLN-177]
              - [Protocol Adherence Document_0000713_Final_20170221.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/Datasets/11.03%20Analysis/11.03.11%20Subject%20Evaluability%20Criteria%20&%20Subject%20Classification/Protocol%20Adherence%20Document_0000713_Final_20170221.pdf) (pdf) [ALLN-177]
        - **TLFs/**
          - [ALLN-177-206 CSR FINAL 14Feb2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/ALLN-177-206%20CSR%20FINAL%2014Feb2022.pdf) (pdf) [ALLN-177]
          - [CSR ALLN-177-204-review 2021-1101-CT 1102 updateDG 1103DG 11102021-dg-ct.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/CSR%20ALLN-177-204-review%202021-1101-CT%201102%20updateDG%201103DG%2011102021-dg-ct.docx) (docx) [ALLN-177]
          - [f14_2_3_1_cumresp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/f14_2_3_1_cumresp.docx) (docx) [ALLN-177]
          - [f14_2_3_2_cumrespbyhyp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/f14_2_3_2_cumrespbyhyp.docx) (docx) [ALLN-177]
          - [f14_2_3_3P_pctcumresphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/f14_2_3_3P_pctcumresphypgrp.docx) (docx) [ALLN-177]
          - [f14_2_3_4P_mgcumresphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/f14_2_3_4P_mgcumresphypgrp.docx) (docx) [ALLN-177]
          - [f14_2_3_7P_oxalthypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/f14_2_3_7P_oxalthypgrp.docx) (docx) [ALLN-177]
          - [Final Analysis Output_0000713_Final_Table 14.2.2.1P1_20170814.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/Final%20Analysis%20Output_0000713_Final_Table%2014.2.2.1P1_20170814.pdf) (pdf) [ALLN-177]
          - [Final Analysis Output_0000713_Final_Updated AE Listing_16.2.6.1 (w SF SAE)_20170921.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/Final%20Analysis%20Output_0000713_Final_Updated%20AE%20Listing_16.2.6.1%20(w%20SF%20SAE)_20170921.pdf) (pdf) [ALLN-177]
          - [Final Analysis Output_0000713_Final_Updated SAE Listing_16.2.6.3_20170921.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/Final%20Analysis%20Output_0000713_Final_Updated%20SAE%20Listing_16.2.6.3_20170921.pdf) (pdf) [ALLN-177]
          - [l16_2_10_1_conproc.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_10_1_conproc.docx) (docx) [ALLN-177]
          - [l16_2_11_1_conmeds.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_11_1_conmeds.docx) (docx) [ALLN-177]
          - [l16_2_1_1_1_pop.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_1_1_1_pop.docx) (docx) [ALLN-177]
          - [l16_2_1_1_1_pop.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_1_1_1_pop.rtf) (rtf) [ALLN-177]
          - [l16_2_1_1_2_screenfail.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_1_1_2_screenfail.docx) (docx) [ALLN-177]
          - [l16_2_1_2_disp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_1_2_disp.docx) (docx) [ALLN-177]
          - [l16_2_2_1_protdev.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_2_1_protdev.docx) (docx) [ALLN-177]
          - [l16_2_3_1_demog.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_1_demog.docx) (docx) [ALLN-177]
          - [l16_2_3_2_Illspchist.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_2_Illspchist.docx) (docx) [ALLN-177]
          - [l16_2_3_3_medhis.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_3_medhis.docx) (docx) [ALLN-177]
          - [l16_2_3_4_diethis.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_4_diethis.docx) (docx) [ALLN-177]
          - [l16_2_3_5_ecg.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_5_ecg.docx) (docx) [ALLN-177]
          - [l16_2_3_6_ct.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_6_ct.docx) (docx) [ALLN-177]
          - [l16_2_3_7_1_droxalate.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_7_1_droxalate.docx) (docx) [ALLN-177]
          - [l16_2_3_7_2_drnonoxal.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_3_7_2_drnonoxal.docx) (docx) [ALLN-177]
          - [l16_2_4_1_exp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_4_1_exp.docx) (docx) [ALLN-177]
          - [l16_2_4_2_comp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_4_2_comp.docx) (docx) [ALLN-177]
          - [l16_2_4_2_comp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_4_2_comp.rtf) (rtf) [ALLN-177]
          - [l16_2_4_3_drugaccount.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_4_3_drugaccount.docx) (docx) [ALLN-177]
          - [l16_2_5_1_urine24h.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_1_urine24h.docx) (docx) [ALLN-177]
          - [l16_2_5_2_urine_avg24h.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_2_urine_avg24h.docx) (docx) [ALLN-177]
          - [l16_2_5_3_nonoxal_avg.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_3_nonoxal_avg.docx) (docx) [ALLN-177]
          - [l16_2_5_4_supersat.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_4_supersat.docx) (docx) [ALLN-177]
          - [l16_2_5_5_sas_primary.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_5_sas_primary.docx) (docx) [ALLN-177]
          - [l16_2_5_6_sas_senspp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_6_sas_senspp.docx) (docx) [ALLN-177]
          - [l16_2_5_7_sas_senspercoxab.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_7_sas_senspercoxab.docx) (docx) [ALLN-177]
          - [l16_2_5_8_sas_senshyperoxaluriatype.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_5_8_sas_senshyperoxaluriatype.docx) (docx) [ALLN-177]
          - [l16_2_6_2_aewithdrwl.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_6_2_aewithdrwl.docx) (docx) [ALLN-177]
          - [l16_2_6_4_death.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_6_4_death.docx) (docx) [ALLN-177]
          - [l16_2_7_1_hema.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_1_hema.docx) (docx) [ALLN-177]
          - [l16_2_7_2_chem.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_2_chem.docx) (docx) [ALLN-177]
          - [l16_2_7_3_urinalysis.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_3_urinalysis.docx) (docx) [ALLN-177]
          - [l16_2_7_4_explabs.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_4_explabs.docx) (docx) [ALLN-177]
          - [l16_2_7_5_abnormlabs.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_5_abnormlabs.docx) (docx) [ALLN-177]
          - [l16_2_7_6_preg.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_7_6_preg.docx) (docx) [ALLN-177]
          - [l16_2_8_1_vs.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_8_1_vs.docx) (docx) [ALLN-177]
          - [l16_2_9_1_pe.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/l16_2_9_1_pe.docx) (docx) [ALLN-177]
          - [posthoc_danica_396_egfr[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/posthoc_danica_396_egfr[1].pdf) (pdf) [ALLN-177]
          - [t14_1_1_disp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_1_disp.docx) (docx) [ALLN-177]
          - [t14_1_1P_disphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_1P_disphypgrp.docx) (docx) [ALLN-177]
          - [t14_1_2_protdev.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_2_protdev.docx) (docx) [ALLN-177]
          - [t14_1_2P_protdevhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_2P_protdevhypgrp.docx) (docx) [ALLN-177]
          - [t14_1_3_demog.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_3_demog.docx) (docx) [ALLN-177]
          - [t14_1_3P_demoghypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_3P_demoghypgrp.docx) (docx) [ALLN-177]
          - [t14_1_4_mhis.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_4_mhis.docx) (docx) [ALLN-177]
          - [t14_1_4P_mhishypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_4P_mhishypgrp.docx) (docx) [ALLN-177]
          - [t14_1_5_diethis.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_5_diethis.docx) (docx) [ALLN-177]
          - [t14_1_5P_diethishypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_5P_diethishypgrp.docx) (docx) [ALLN-177]
          - [t14_1_6_ct.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_6_ct.docx) (docx) [ALLN-177]
          - [t14_1_6P_cthypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_6P_cthypgrp.docx) (docx) [ALLN-177]
          - [t14_1_7_1_dr_oxintake.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_1_dr_oxintake.docx) (docx) [ALLN-177]
          - [t14_1_7_1P_dr_oxintakehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_1P_dr_oxintakehypgrp.docx) (docx) [ALLN-177]
          - [t14_1_7_2_dr_nonoxintake.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_2_dr_nonoxintake.docx) (docx) [ALLN-177]
          - [t14_1_7_2P_dr_nonoxintakehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_2P_dr_nonoxintakehypgrp.docx) (docx) [ALLN-177]
          - [t14_1_7_3_dr_mealsnacks.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_3_dr_mealsnacks.docx) (docx) [ALLN-177]
          - [t14_1_7_3P_dr_mealsnackshypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_7_3P_dr_mealsnackshypgrp.docx) (docx) [ALLN-177]
          - [t14_1_8_1_drugexposure.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_8_1_drugexposure.docx) (docx) [ALLN-177]
          - [t14_1_8_1P_drugexposurehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_8_1P_drugexposurehypgrp.docx) (docx) [ALLN-177]
          - [t14_1_9_1_drugcompliance.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_9_1_drugcompliance.docx) (docx) [ALLN-177]
          - [t14_1_9_1P_drugcompliancehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_9_1P_drugcompliancehypgrp.docx) (docx) [ALLN-177]
          - [t14_1_9_2_doseinstrcomp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_9_2_doseinstrcomp.docx) (docx) [ALLN-177]
          - [t14_1_9_2P_doseinstrcomphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_1_9_2P_doseinstrcomphypgrp.docx) (docx) [ALLN-177]
          - [t14_2_1_1_oxalt_primary.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_1_oxalt_primary.docx) (docx) [ALLN-177]
          - [t14_2_1_1P1_oxalt_primaryhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_1P1_oxalt_primaryhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_1_1P2_oxcreatprimhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_1P2_oxcreatprimhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_1_2_oxalt_senspp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_2_oxalt_senspp.docx) (docx) [ALLN-177]
          - [t14_2_1_2P_oxalt_senspphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_2P_oxalt_senspphypgrp.docx) (docx) [ALLN-177]
          - [t14_2_1_3_oxalt_senspercoxab.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_3_oxalt_senspercoxab.docx) (docx) [ALLN-177]
          - [t14_2_1_3P_oxalt_senspercoxabhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_3P_oxalt_senspercoxabhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_1_4_oxalt_senshyperoxaluriatype.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_4_oxalt_senshyperoxaluriatype.docx) (docx) [ALLN-177]
          - [t14_2_1_5_oxalt_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_1_5_oxalt_summ.docx) (docx) [ALLN-177]
          - [t14_2_2_1_oxalt_twghtavg_ancova.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_1_oxalt_twghtavg_ancova.docx) (docx) [ALLN-177]
          - [t14_2_2_1P2_oxcreat_twghtavg_ancovahypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_1P2_oxcreat_twghtavg_ancovahypgrp.docx) (docx) [ALLN-177]
          - [t14_2_2_2_oxalt_pchg_mmrm.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_2_oxalt_pchg_mmrm.docx) (docx) [ALLN-177]
          - [t14_2_2_2P_oxalt_pchg_mmrmhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_2P_oxalt_pchg_mmrmhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_2_3_oxalt_75resp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_3_oxalt_75resp.docx) (docx) [ALLN-177]
          - [t14_2_2_4_oxalt_10resp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_4_oxalt_10resp.docx) (docx) [ALLN-177]
          - [t14_2_2_4P_oxalt_10resphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_4P_oxalt_10resphypgrp.docx) (docx) [ALLN-177]
          - [t14_2_2_5_supersat_ancova.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_5_supersat_ancova.docx) (docx) [ALLN-177]
          - [t14_2_2_6_supersat_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_6_supersat_summ.docx) (docx) [ALLN-177]
          - [t14_2_2_6P_supersat_summhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_6P_supersat_summhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_2_7_oxalt_20resp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_7_oxalt_20resp.docx) (docx) [ALLN-177]
          - [t14_2_2_7P_tmwgtox_20presphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_7P_tmwgtox_20presphypgrp.docx) (docx) [ALLN-177]
          - [t14_2_2_8P_tmwgtox_20mgresphypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_2_8P_tmwgtox_20mgresphypgrp.docx) (docx) [ALLN-177]
          - [t14_2_3_1_oxalt_pretrt_mmrm.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_1_oxalt_pretrt_mmrm.docx) (docx) [ALLN-177]
          - [t14_2_3_2_oxalt_twghtavg_pretrt_ancova.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_2_oxalt_twghtavg_pretrt_ancova.docx) (docx) [ALLN-177]
          - [t14_2_3_2P_oxalt_twghtavg_pretrt_ancovahypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_2P_oxalt_twghtavg_pretrt_ancovahypgrp.docx) (docx) [ALLN-177]
          - [t14_2_3_3_oxalt_hyperoxaluriatype_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_3_oxalt_hyperoxaluriatype_summ.docx) (docx) [ALLN-177]
          - [t14_2_3_4_oxalt_baseoxalt_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_4_oxalt_baseoxalt_summ.docx) (docx) [ALLN-177]
          - [t14_2_3_4P_oxalt_baseoxalt_summhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_4P_oxalt_baseoxalt_summhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_3_5_oxalt_scrnoxaltabsorp_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_5_oxalt_scrnoxaltabsorp_summ.docx) (docx) [ALLN-177]
          - [t14_2_3_5P_oxalt_scrnoxaltabsorp_summhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_5P_oxalt_scrnoxaltabsorp_summhypgrp.docx) (docx) [ALLN-177]
          - [t14_2_3_6_nonoxalt_summ.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_6_nonoxalt_summ.docx) (docx) [ALLN-177]
          - [t14_2_3_6P_nonoxalt_summhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_2_3_6P_nonoxalt_summhypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_1_summ_ae.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_1_summ_ae.docx) (docx) [ALLN-177]
          - [t14_3_1_1P_summ_aehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_1P_summ_aehypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_2_teae.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_2_teae.docx) (docx) [ALLN-177]
          - [t14_3_1_2P_teaehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_2P_teaehypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_3_related_teae.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_3_related_teae.docx) (docx) [ALLN-177]
          - [t14_3_1_3P_related_teaehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_3P_related_teaehypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_4_severe_teae.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_4_severe_teae.docx) (docx) [ALLN-177]
          - [t14_3_1_4P_severe_teaehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_4P_severe_teaehypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_5_teae_withdrwl.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_5_teae_withdrwl.docx) (docx) [ALLN-177]
          - [t14_3_1_5P_teae_withdrwlhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_5P_teae_withdrwlhypgrp.docx) (docx) [ALLN-177]
          - [t14_3_1_6_sae.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_6_sae.docx) (docx) [ALLN-177]
          - [t14_3_1_6P_saehypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_1_6P_saehypgrp.docx) (docx) [ALLN-177]
          - [t14_3_2_1_hema.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_2_1_hema.docx) (docx) [ALLN-177]
          - [t14_3_2_2_chem.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_2_2_chem.docx) (docx) [ALLN-177]
          - [t14_3_2_3_abnormlab.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_2_3_abnormlab.docx) (docx) [ALLN-177]
          - [t14_3_3_1_vs.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_3_1_vs.docx) (docx) [ALLN-177]
          - [t14_3_4_1_pe.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_4_1_pe.docx) (docx) [ALLN-177]
          - [t14_3_5_1_conmed.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_5_1_conmed.docx) (docx) [ALLN-177]
          - [t14_3_5_1P_conmedhypgrp.docx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_5_1P_conmedhypgrp.docx) (docx) [ALLN-177]
          - [t14_3_5_1P_conmedhypgrp.rtf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/t14_3_5_1P_conmedhypgrp.rtf) (rtf) [ALLN-177]
          - [713 CSR studycode-body.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/713%20CSR%20studycode-body.pdf) (pdf) [ALLN-177]
          - [713 final TLF 17Jul2017+Aug+Sep 2017](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/713%20final%20TLF%2017Jul2017+Aug+Sep%202017) (unknown) [ALLN-177]
          - [713 final TLF 17Jul2017+Aug+Sep 2017.zip](https://archive.icosian.net/#documents/RDCP-26-0001/files/Clinical-Studies/713/TLFs/713%20final%20TLF%2017Jul2017+Aug+Sep%202017.zip) (zip) [ALLN-177]
    - **Medpace-Data-2024/**
      - **Additional Raw Data Sent Jan 30, 2024/**
        - **ALLN7302unblind pw=Allena/**
          - [mrl_unblind.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%2030,%202024/ALLN7302unblind%20pw=Allena/mrl_unblind.sas7bdat) (sas7bdat) [ALLN-177]
          - **Randlist/**
            - [GridData-2022-03-04.csv](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%2030,%202024/ALLN7302unblind%20pw=Allena/Randlist/GridData-2022-03-04.csv) (csv) [ALLN-177]
        - [xae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%2030,%202024/xae.sas7bdat) (sas7bdat) [ALLN-177]
      - **Additional Raw Data Sent Jan 4 2024/**
        - **ALLN6101 ADaM/**
          - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adae.sas7bdat) (sas7bdat) [ALLN-177]
          - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [adeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adeg.sas7bdat) (sas7bdat) [ALLN-177]
          - [adis.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adis.sas7bdat) (sas7bdat) [ALLN-177]
          - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adlb.sas7bdat) (sas7bdat) [ALLN-177]
          - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/admh.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adpc.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpd.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adpd.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adpe.sas7bdat) (sas7bdat) [ALLN-177]
          - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/adsl.sas7bdat) (sas7bdat) [ALLN-177]
          - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20ADaM/advs.sas7bdat) (sas7bdat) [ALLN-177]
        - **ALLN6101 SDTM/**
          - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ae.sas7bdat) (sas7bdat) [ALLN-177]
          - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/cm.sas7bdat) (sas7bdat) [ALLN-177]
          - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/co.sas7bdat) (sas7bdat) [ALLN-177]
          - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/dm.sas7bdat) (sas7bdat) [ALLN-177]
          - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ds.sas7bdat) (sas7bdat) [ALLN-177]
          - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/dv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ec.sas7bdat) (sas7bdat) [ALLN-177]
          - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/eg.sas7bdat) (sas7bdat) [ALLN-177]
          - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ex.sas7bdat) (sas7bdat) [ALLN-177]
          - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ho.sas7bdat) (sas7bdat) [ALLN-177]
          - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ie.sas7bdat) (sas7bdat) [ALLN-177]
          - [is.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/is.sas7bdat) (sas7bdat) [ALLN-177]
          - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/lb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/mb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/mh.sas7bdat) (sas7bdat) [ALLN-177]
          - [ml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ml.sas7bdat) (sas7bdat) [ALLN-177]
          - [pc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/pc.sas7bdat) (sas7bdat) [ALLN-177]
          - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/pe.sas7bdat) (sas7bdat) [ALLN-177]
          - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/relrec.sas7bdat) (sas7bdat) [ALLN-177]
          - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/rp.sas7bdat) (sas7bdat) [ALLN-177]
          - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/se.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppae.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppdm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppds.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppdv.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppec.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppeg.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppmb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppmb.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppml.sas7bdat) (sas7bdat) [ALLN-177]
          - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/supppe.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/suppve.sas7bdat) (sas7bdat) [ALLN-177]
          - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/sv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ta.sas7bdat) (sas7bdat) [ALLN-177]
          - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/te.sas7bdat) (sas7bdat) [ALLN-177]
          - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ti.sas7bdat) (sas7bdat) [ALLN-177]
          - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ts.sas7bdat) (sas7bdat) [ALLN-177]
          - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/tv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/ve.sas7bdat) (sas7bdat) [ALLN-177]
          - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101%20SDTM/vs.sas7bdat) (sas7bdat) [ALLN-177]
        - [ALLN6101_DBCRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6101_DBCRF.pdf) (pdf) [ALLN-177]
        - **ALLN6102 ADaM/**
          - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adae.sas7bdat) (sas7bdat) [ALLN-177]
          - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [adeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adeg.sas7bdat) (sas7bdat) [ALLN-177]
          - [adis.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adis.sas7bdat) (sas7bdat) [ALLN-177]
          - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adlb.sas7bdat) (sas7bdat) [ALLN-177]
          - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/admh.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adpc.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpd.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adpd.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adpe.sas7bdat) (sas7bdat) [ALLN-177]
          - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/adsl.sas7bdat) (sas7bdat) [ALLN-177]
          - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20ADaM/advs.sas7bdat) (sas7bdat) [ALLN-177]
        - **ALLN6102 SDTM/**
          - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ae.sas7bdat) (sas7bdat) [ALLN-177]
          - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/cm.sas7bdat) (sas7bdat) [ALLN-177]
          - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/co.sas7bdat) (sas7bdat) [ALLN-177]
          - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/dm.sas7bdat) (sas7bdat) [ALLN-177]
          - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ds.sas7bdat) (sas7bdat) [ALLN-177]
          - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/dv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ec.sas7bdat) (sas7bdat) [ALLN-177]
          - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/eg.sas7bdat) (sas7bdat) [ALLN-177]
          - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ex.sas7bdat) (sas7bdat) [ALLN-177]
          - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ho.sas7bdat) (sas7bdat) [ALLN-177]
          - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ie.sas7bdat) (sas7bdat) [ALLN-177]
          - [is.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/is.sas7bdat) (sas7bdat) [ALLN-177]
          - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/lb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/mb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/mh.sas7bdat) (sas7bdat) [ALLN-177]
          - [ml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ml.sas7bdat) (sas7bdat) [ALLN-177]
          - [pc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/pc.sas7bdat) (sas7bdat) [ALLN-177]
          - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/pe.sas7bdat) (sas7bdat) [ALLN-177]
          - [pr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/pr.sas7bdat) (sas7bdat) [ALLN-177]
          - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/relrec.sas7bdat) (sas7bdat) [ALLN-177]
          - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/rp.sas7bdat) (sas7bdat) [ALLN-177]
          - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/se.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppae.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppdm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppds.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppdv.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppec.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppeg.sas7bdat) (sas7bdat) [ALLN-177]
          - [supplb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/supplb.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppmb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppmb.sas7bdat) (sas7bdat) [ALLN-177]
          - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/supppe.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/suppve.sas7bdat) (sas7bdat) [ALLN-177]
          - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/sv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ta.sas7bdat) (sas7bdat) [ALLN-177]
          - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/te.sas7bdat) (sas7bdat) [ALLN-177]
          - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ti.sas7bdat) (sas7bdat) [ALLN-177]
          - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ts.sas7bdat) (sas7bdat) [ALLN-177]
          - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/tv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/ve.sas7bdat) (sas7bdat) [ALLN-177]
          - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM/vs.sas7bdat) (sas7bdat) [ALLN-177]
        - **ALLN6102 SDTM copy/**
          - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ae.sas7bdat) (sas7bdat) [ALLN-177]
          - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/cm.sas7bdat) (sas7bdat) [ALLN-177]
          - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/co.sas7bdat) (sas7bdat) [ALLN-177]
          - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/dm.sas7bdat) (sas7bdat) [ALLN-177]
          - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ds.sas7bdat) (sas7bdat) [ALLN-177]
          - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/dv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ec.sas7bdat) (sas7bdat) [ALLN-177]
          - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/eg.sas7bdat) (sas7bdat) [ALLN-177]
          - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ex.sas7bdat) (sas7bdat) [ALLN-177]
          - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ho.sas7bdat) (sas7bdat) [ALLN-177]
          - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ie.sas7bdat) (sas7bdat) [ALLN-177]
          - [is.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/is.sas7bdat) (sas7bdat) [ALLN-177]
          - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/lb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/mb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/mh.sas7bdat) (sas7bdat) [ALLN-177]
          - [ml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ml.sas7bdat) (sas7bdat) [ALLN-177]
          - [pc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/pc.sas7bdat) (sas7bdat) [ALLN-177]
          - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/pe.sas7bdat) (sas7bdat) [ALLN-177]
          - [pr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/pr.sas7bdat) (sas7bdat) [ALLN-177]
          - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/relrec.sas7bdat) (sas7bdat) [ALLN-177]
          - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/rp.sas7bdat) (sas7bdat) [ALLN-177]
          - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/se.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppae.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppdm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppds.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppdv.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppec.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppeg.sas7bdat) (sas7bdat) [ALLN-177]
          - [supplb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/supplb.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppmb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppmb.sas7bdat) (sas7bdat) [ALLN-177]
          - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/supppe.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/suppve.sas7bdat) (sas7bdat) [ALLN-177]
          - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/sv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ta.sas7bdat) (sas7bdat) [ALLN-177]
          - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/te.sas7bdat) (sas7bdat) [ALLN-177]
          - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ti.sas7bdat) (sas7bdat) [ALLN-177]
          - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ts.sas7bdat) (sas7bdat) [ALLN-177]
          - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/tv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/ve.sas7bdat) (sas7bdat) [ALLN-177]
          - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102%20SDTM%20copy/vs.sas7bdat) (sas7bdat) [ALLN-177]
        - [ALLN6102_DBCRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6102_DBCRF.pdf) (pdf) [ALLN-177]
        - [ALLN6202 MRL DTA v5.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN6202%20MRL%20DTA%20v5.0.pdf) (pdf) [ALLN-177]
        - [ALLN620220221013.xpt](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN620220221013.xpt) (xpt) [ALLN-177]
        - **ALLN7301 ADaM/**
          - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adae.sas7bdat) (sas7bdat) [ALLN-177]
          - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [adeff.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adeff.sas7bdat) (sas7bdat) [ALLN-177]
          - [adeff2.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adeff2.sas7bdat) (sas7bdat) [ALLN-177]
          - [adex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adex.sas7bdat) (sas7bdat) [ALLN-177]
          - [adfa.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adfa.sas7bdat) (sas7bdat) [ALLN-177]
          - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adlb.sas7bdat) (sas7bdat) [ALLN-177]
          - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/admh.sas7bdat) (sas7bdat) [ALLN-177]
          - [adpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adpe.sas7bdat) (sas7bdat) [ALLN-177]
          - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/adsl.sas7bdat) (sas7bdat) [ALLN-177]
          - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20ADaM/advs.sas7bdat) (sas7bdat) [ALLN-177]
        - **ALLN7301 SDTM/**
          - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ae.sas7bdat) (sas7bdat) [ALLN-177]
          - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/cm.sas7bdat) (sas7bdat) [ALLN-177]
          - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/co.sas7bdat) (sas7bdat) [ALLN-177]
          - [da.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/da.sas7bdat) (sas7bdat) [ALLN-177]
          - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/dm.sas7bdat) (sas7bdat) [ALLN-177]
          - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ds.sas7bdat) (sas7bdat) [ALLN-177]
          - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/dv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ec.sas7bdat) (sas7bdat) [ALLN-177]
          - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ex.sas7bdat) (sas7bdat) [ALLN-177]
          - [fa.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/fa.sas7bdat) (sas7bdat) [ALLN-177]
          - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ho.sas7bdat) (sas7bdat) [ALLN-177]
          - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ie.sas7bdat) (sas7bdat) [ALLN-177]
          - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/lb.sas7bdat) (sas7bdat) [ALLN-177]
          - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/mh.sas7bdat) (sas7bdat) [ALLN-177]
          - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/pe.sas7bdat) (sas7bdat) [ALLN-177]
          - [pr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/pr.sas7bdat) (sas7bdat) [ALLN-177]
          - [qs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/qs.sas7bdat) (sas7bdat) [ALLN-177]
          - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/relrec.sas7bdat) (sas7bdat) [ALLN-177]
          - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/rp.sas7bdat) (sas7bdat) [ALLN-177]
          - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/se.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppae.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppcm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppdm.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppds.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppdv.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppfa.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppfa.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppho.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppie.sas7bdat) (sas7bdat) [ALLN-177]
          - [supplb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/supplb.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppmh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppmh.sas7bdat) (sas7bdat) [ALLN-177]
          - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/supppe.sas7bdat) (sas7bdat) [ALLN-177]
          - [supppr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/supppr.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppqs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppqs.sas7bdat) (sas7bdat) [ALLN-177]
          - [supprp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/supprp.sas7bdat) (sas7bdat) [ALLN-177]
          - [suppsv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/suppsv.sas7bdat) (sas7bdat) [ALLN-177]
          - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/sv.sas7bdat) (sas7bdat) [ALLN-177]
          - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ta.sas7bdat) (sas7bdat) [ALLN-177]
          - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/te.sas7bdat) (sas7bdat) [ALLN-177]
          - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ti.sas7bdat) (sas7bdat) [ALLN-177]
          - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/ts.sas7bdat) (sas7bdat) [ALLN-177]
          - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/tv.sas7bdat) (sas7bdat) [ALLN-177]
          - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301%20SDTM/vs.sas7bdat) (sas7bdat) [ALLN-177]
        - [ALLN7301_DBCRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7301_DBCRF.pdf) (pdf) [ALLN-177]
        - [ALLN7302 MRL DTA v6.0 copy.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7302%20MRL%20DTA%20v6.0%20copy.pdf) (pdf) [ALLN-177]
        - [ALLN7302 MRL DTA v6.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/ALLN7302%20MRL%20DTA%20v6.0.pdf) (pdf) [ALLN-177]
        - [alln7302_20220218.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/alln7302_20220218.sas7bdat) (sas7bdat) [ALLN-177]
        - [alln7302_20220218.sas7bdat copy](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/alln7302_20220218.sas7bdat%20copy) (sas7bdat copy) [ALLN-177]
        - [Cover email #1.png](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/Cover%20email%20#1.png) (png) [ALLN-177]
        - [Cover email #2.png](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/Cover%20email%20#2.png) (png) [ALLN-177]
        - [Cover email #3.png](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/Cover%20email%20#3.png) (png) [ALLN-177]
        - [Cover email #4.png](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/Cover%20email%20#4.png) (png) [ALLN-177]
        - [Cover email #5.png](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Additional%20Raw%20Data%20Sent%20Jan%204%202024/Cover%20email%20#5.png) (png) [ALLN-177]
      - **ALLN-177/**
        - [ALLN7301__Data.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/ALLN-177/ALLN7301__Data.xlsx) (xlsx) [ALLN-177]
        - [ALLN7301_ECRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/ALLN-177/ALLN7301_ECRF.pdf) (pdf) [ALLN-177]
        - [ALLN7302__Data.xlsx](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/ALLN-177/ALLN7302__Data.xlsx) (xlsx) [ALLN-177]
        - [ALLN7302_ECRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/ALLN-177/ALLN7302_ECRF.pdf) (pdf) [ALLN-177]
      - [Lumen_DataTransferLetter_12DEC2023_FE.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Lumen_DataTransferLetter_12DEC2023_FE.pdf) (pdf) [ALLN-177]
      - [Medpace, Inc.  Data Transfer Letter  2023.12.21.pdf](https://archive.icosian.net/#documents/RDCP-26-0001/files/Medpace-Data-2024/Medpace,%20Inc.%20%20Data%20Transfer%20Letter%20%202023.12.21.pdf) (pdf) [ALLN-177]
# RDCP-26-0002 - ALLN-346 Urate Oxidase (RDCP-26-0002)

  Engineered uricase enzyme for treatment of hyperuricemia and gout in patients with chronic kidney disease. Received FDA Fast Track designation.
  - **By-Date/**
    - **2019/**
      - [2019-11-25 PreIND Mtg Minutes WRO S. Rhee.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-11-25%20PreIND%20Mtg%20Minutes%20WRO%20S.%20Rhee.pdf) (pdf) [ALLN-346]
      - **2019-12-31/**
        - **Original IND submis ubmitted/**
          - **Module 2/**
            - **Drug Product/**
              - [2.3.P Drug Product FINAL 25Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%202/Drug%20Product/2.3.P%20Drug%20Product%20FINAL%2025Dec2019.pdf) (pdf) [ALLN-346]
            - **Drug Substance/**
              - [2.3.S Drug Substance FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%202/Drug%20Substance/2.3.S%20Drug%20Substance%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
            - **Placebo/**
              - [2.3.P Placebo FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%202/Placebo/2.3.P%20Placebo%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
          - **Module 3/**
            - **Drug Product/**
              - [3.2.P.1 DP Description FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.1%20DP%20Description%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.2 PharmDev FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.2%20PharmDev%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2 Batch Formula FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.3.2%20Batch%20Formula%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2 Batch Formula FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.3.2%20Batch%20Formula%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.3 Description _ntrols FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.3.3%20Description%20_ntrols%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.4 Controls of Critical Steps FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.3.4%20Controls%20of%20Critical%20Steps%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.1 Excipient Specifications FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.4.1%20Excipient%20Specifications%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.5 Excipients of_Origin FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.4.5%20Excipients%20of_Origin%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.1 Specifications FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.5.1%20Specifications%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.2 Analytical Procedures FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.5.2%20Analytical%20Procedures%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.4 Batch Analyses FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.5.4%20Batch%20Analyses%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.5 Impurities FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.5.5%20Impurities%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.6 Justificati_ions FINAL 16Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.5.6%20Justificati_ions%20FINAL%2016Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.7 Container Closure System FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.7%20Container%20Closure%20System%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.1 Stability FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Product/3.2.P.8.1%20Stability%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
            - **Drug Substance/**
              - [3.2.S.1.1 Nomenclature.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.1.1%20Nomenclature.pdf) (pdf) [ALLN-346]
              - [3.2.S.1.2 Structure FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.1.2%20Structure%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.1.3 General Properties.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.1.3%20General%20Properties.pdf) (pdf) [ALLN-346]
              - [3.2.S.2.1 Manufacturers.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.2.1%20Manufacturers.pdf) (pdf) [ALLN-346]
              - [3.2.S.2.2 Manufacturin_ntrols FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.2.2%20Manufacturin_ntrols%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.2.3 Control of Materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.2.3%20Control%20of%20Materials.pdf) (pdf) [ALLN-346]
              - [3.2.S.2.4 Control of Critical Steps.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.2.4%20Control%20of%20Critical%20Steps.pdf) (pdf) [ALLN-346]
              - [3.2.S.3.1 Elucidation of Structure FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.3.1%20Elucidation%20of%20Structure%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.3.2 Impurities FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.3.2%20Impurities%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.4.1 Specification FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.4.1%20Specification%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.4.2 Analytical Procedures FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.4.2%20Analytical%20Procedures%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.4.4 Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.4.4%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.4.5 Justificati_tion FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.4.5%20Justificati_tion%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.5 Reference Standard FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.5%20Reference%20Standard%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.6 Container Closure System FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.6%20Container%20Closure%20System%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.7.1 Stability Summary FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.7.1%20Stability%20Summary%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.S.7.3 Stability Data FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Drug%20Substance/3.2.S.7.3%20Stability%20Data%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
            - **Placebo/**
              - [3.2.P.1 PBO Descript_tion FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.1%20PBO%20Descript_tion%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.1 PBO Manufacturers FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.3.1%20PBO%20Manufacturers%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2 PBO Batch Formula FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.3.2%20PBO%20Batch%20Formula%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.3 PBO Descriptio_ontrols FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.3.3%20PBO%20Descriptio_ontrols%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.4 PBO Control of Critical Steps FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.3.4%20PBO%20Control%20of%20Critical%20Steps%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.1 PBO Exceipent Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.4.1%20PBO%20Exceipent%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.5 PBO Excipients_l Origin FINAL 11Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.4.5%20PBO%20Excipients_l%20Origin%20FINAL%2011Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.1 PBO Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.5.1%20PBO%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.2 PBO Analytical Methods FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.5.2%20PBO%20Analytical%20Methods%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.4 PBO Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.5.4%20PBO%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.5 PBO Characte_rities FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.5.5%20PBO%20Characte_rities%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.6 PBO Justific_ations FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.5.6%20PBO%20Justific_ations%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.7.1 PBO Container Closure FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.7.1%20PBO%20Container%20Closure%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.1 PBO Stability Summary FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/Original%20IND%20submis%20ubmitted/Module%203/Placebo/3.2.P.8.1%20PBO%20Stability%20Summary%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
        - **SN-0001 (Clinical)/**
          - [Module 2.5 Clinical Overview FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Clinical)/Module%202.5%20Clinical%20Overview%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-101 FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Clinical)/Protocol%20ALLN-346-101%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
          - [SN 0001 Cover Ltr FINAL 30Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Clinical)/SN%200001%20Cover%20Ltr%20FINAL%2030Dec2019.pdf) (pdf) [ALLN-346]
          - [1.20 General Investigational Plan Initial IND FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Clinical)/1.20%20General%20Investigational%20Plan%20Initial%20IND%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
        - **SN-0001 (Preclinical)/**
          - [2.6.1 Pharmacology Intro FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Preclinical)/2.6.1%20Pharmacology%20Intro%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
          - [2.6.2 Pharmacology Written Summary FINAL 09Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Preclinical)/2.6.2%20Pharmacology%20Written%20Summary%20FINAL%2009Dec2019.pdf) (pdf) [ALLN-346]
          - [2.6.3 Pharmacology Tabulated Summary FINAL 25Nov2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Preclinical)/2.6.3%20Pharmacology%20Tabulated%20Summary%20FINAL%2025Nov2019.pdf) (pdf) [ALLN-346]
          - [2.6.6 Toxicology Written Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Preclinical)/2.6.6%20Toxicology%20Written%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
          - [2.6.7 Toxicology Tabulated Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2019/2019-12-31/SN-0001%20(Preclinical)/2.6.7%20Toxicology%20Tabulated%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
    - **2020/**
      - [2020-01-15 CMC Information Request S. Rhee.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-01-15%20CMC%20Information%20Request%20S.%20Rhee.pdf) (pdf) [ALLN-346]
      - [2020-01-22 Clinical-Nonclnical Information Request S. Rhee..pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-01-22%20Clinical-Nonclnical%20Information%20Request%20S.%20Rhee..pdf) (pdf) [ALLN-346]
      - **2020-06-01 CMC Amendment DP SN-0007/**
        - **Module 2/**
          - [2.3.P Drug Product SN 0007 FINAL 13Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%202/2.3.P%20Drug%20Product%20SN%200007%20FINAL%2013Jul2020.pdf) (pdf) [ALLN-346]
        - **Module 3/**
          - [3.2.P.1 DP Description FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.1%20DP%20Description%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.3.1 Manufacturers FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.3.1%20Manufacturers%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.3.2 Batch Formula FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.3.2%20Batch%20Formula%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.3.3 Description of Mfg Process Controls FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.3.3%20Description%20of%20Mfg%20Process%20Controls%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.3.4 Controls of Critical Steps FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.3.4%20Controls%20of%20Critical%20Steps%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.5.1 Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.5.1%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.5.4 Batch Analyses FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.5.4%20Batch%20Analyses%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.5.6 Justification of Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.5.6%20Justification%20of%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.8.1 Stability Summary FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.8.1%20Stability%20Summary%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - [3.2.P.8.3 Stability Data FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-01%20CMC%20Amendment%20DP%20SN-0007/Module%203/3.2.P.8.3%20Stability%20Data%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
      - **2020-06-08 SN-0006/**
        - [ALLN-346-101 Protocol Amendment SOC FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-08%20SN-0006/ALLN-346-101%20Protocol%20Amendment%20SOC%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-101 Amendment 1 FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-08%20SN-0006/Protocol%20ALLN-346-101%20Amendment%201%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
        - [SN 0006 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-06-08%20SN-0006/SN%200006%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2020-08-24 SN-0009/**
        - [ALLN-346-101 Protocol Amendment 2 SOC FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-08-24%20SN-0009/ALLN-346-101%20Protocol%20Amendment%202%20SOC%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-101 Amendment 2 FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-08-24%20SN-0009/Protocol%20ALLN-346-101%20Amendment%202%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
        - [SN 0009 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2020/2020-08-24%20SN-0009/SN%200009%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
    - **2021/**
      - **2021-02-19 SN-0013/**
        - [Protocol ALLN-346-102 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-02-19%20SN-0013/Protocol%20ALLN-346-102%20FINAL.pdf) (pdf) [ALLN-346]
        - [SN 0013 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-02-19%20SN-0013/SN%200013%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - [2021-04-02 FDA CMC Information Request H. Toure.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-04-02%20FDA%20CMC%20Information%20Request%20H.%20Toure.pdf) (pdf) [ALLN-346]
      - [2021-04-28 FDA Response-Comments Nonclinical S. Barnes.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-04-28%20FDA%20Response-Comments%20Nonclinical%20S.%20Barnes.pdf) (pdf) [ALLN-346]
      - **2021-05-25 SN-0020/**
        - [Protocol ALLN-346-201 FINAL 22May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-05-25%20SN-0020/Protocol%20ALLN-346-201%20FINAL%2022May2021.pdf) (pdf) [ALLN-346]
        - [SN 0020 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-05-25%20SN-0020/SN%200020%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2021-06-03 SN-0021/**
        - [Protocol ALLN-346-202 FINAL 28May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-06-03%20SN-0021/Protocol%20ALLN-346-202%20FINAL%2028May2021.pdf) (pdf) [ALLN-346]
        - [SN 0021 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-06-03%20SN-0021/SN%200021%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2021-07-20 SN-0022/**
        - [ALLN-346-201 Protocol Amendment 1 SOC FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-20%20SN-0022/ALLN-346-201%20Protocol%20Amendment%201%20SOC%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-201 Amendment 1 FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-20%20SN-0022/Protocol%20ALLN-346-201%20Amendment%201%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
        - [SN 0022 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-20%20SN-0022/SN%200022%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2021-07-27 SN-0024/**
        - [ALLN-346-202 Protocol Amendment 1 SOC FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-27%20SN-0024/ALLN-346-202%20Protocol%20Amendment%201%20SOC%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-202 Amendment 1 FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-27%20SN-0024/Protocol%20ALLN-346-202%20Amendment%201%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
        - [SN 0024 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-07-27%20SN-0024/SN%200024%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2021-08-24 SN-0028/**
        - [Module 2.6.2 SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/Module%202.6.2%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
        - [Module 2.6.3 SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/Module%202.6.3%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
        - [NCLN-00071 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/NCLN-00071%20FINAL.pdf) (pdf) [ALLN-346]
        - [NCLN-00072 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/NCLN-00072%20FINAL.pdf) (pdf) [ALLN-346]
        - [NCLN-00074 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/NCLN-00074%20FINAL.pdf) (pdf) [ALLN-346]
        - [185507.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-08-24%20SN-0028/185507.pdf) (pdf) [ALLN-346]
      - **2021-10-05 SN-0033/**
        - [ALLN-346-201 Protocol Amendment 2 SOC FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-05%20SN-0033/ALLN-346-201%20Protocol%20Amendment%202%20SOC%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-201 Amendment 2 FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-05%20SN-0033/Protocol%20ALLN-346-201%20Amendment%202%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
        - [SN 0033 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-05%20SN-0033/SN%200033%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - **2021-10-14 SN-0034/**
        - [Protocol ALLN-346-202 Amendment 2 FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-14%20SN-0034/Protocol%20ALLN-346-202%20Amendment%202%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-202 Amendment 2 SOC FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-14%20SN-0034/Protocol%20ALLN-346-202%20Amendment%202%20SOC%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
        - [SN 0034 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-14%20SN-0034/SN%200034%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - [2021-10-21 FDA Type C Meeting Grant WRO S. Choi.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-21%20FDA%20Type%20C%20Meeting%20Grant%20WRO%20S.%20Choi.pdf) (pdf) [ALLN-346]
      - [2021-10-28 FDA Grant Fast Track Designation N. Nikolov.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-10-28%20FDA%20Grant%20Fast%20Track%20Designation%20N.%20Nikolov.pdf) (pdf) [ALLN-346]
      - **2021-12-01 SN-0038/**
        - [ALLN-346-201 Protocol Amendment 3 SOC FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-12-01%20SN-0038/ALLN-346-201%20Protocol%20Amendment%203%20SOC%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
        - [Protocol ALLN-346-201 Amendment 3 FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-12-01%20SN-0038/Protocol%20ALLN-346-201%20Amendment%203%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
        - [SN 0038 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-12-01%20SN-0038/SN%200038%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
      - [2021-12-28 FDA Type C Meeting Minutes WRO S. Choi.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2021/2021-12-28%20FDA%20Type%20C%20Meeting%20Minutes%20WRO%20S.%20Choi.pdf) (pdf) [ALLN-346]
    - **2022-01-28 SN-0043/**
      - [ALLN-346-202 Protocol Amendment 3 SOC FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2022-01-28%20SN-0043/ALLN-346-202%20Protocol%20Amendment%203%20SOC%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
      - [Module 1.11.3 Clinical  Info Amnd FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2022-01-28%20SN-0043/Module%201.11.3%20Clinical%20%20Info%20Amnd%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
      - [Protocol ALLN-346-202 Amendment 3 FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2022-01-28%20SN-0043/Protocol%20ALLN-346-202%20Amendment%203%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
      - [SN 0043 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/By-Date/2022-01-28%20SN-0043/SN%200043%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
  - **CTD/**
    - **1) Administrative/**
      - [1.11.3) Clinical  Info Amnd FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/1)%20Administrative/1.11.3)%20Clinical%20%20Info%20Amnd%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
      - [1.13.3) Annual Report FINAL 21Mar2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/1)%20Administrative/1.13.3)%20Annual%20Report%20FINAL%2021Mar2021.pdf) (pdf) [ALLN-346]
      - [1.20) General Investigational Plan Initial IND FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/1)%20Administrative/1.20)%20General%20Investigational%20Plan%20Initial%20IND%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
    - **2) Summaries/**
      - **2.3) Quality-Overall-Summary/**
        - **2.3.P/**
          - [2.3.P) Drug Product FINAL 25Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.3)%20Quality-Overall-Summary/2.3.P/2.3.P)%20Drug%20Product%20FINAL%2025Dec2019.pdf) (pdf) [ALLN-346]
          - [2.3.P) Drug Product SN 0007 FINAL 13Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.3)%20Quality-Overall-Summary/2.3.P/2.3.P)%20Drug%20Product%20SN%200007%20FINAL%2013Jul2020.pdf) (pdf) [ALLN-346]
          - [2.3.P) Placebo FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.3)%20Quality-Overall-Summary/2.3.P/2.3.P)%20Placebo%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
        - [2.3.S) Drug Substance FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.3)%20Quality-Overall-Summary/2.3.S)%20Drug%20Substance%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
      - [2.5) Clinical Overview FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.5)%20Clinical%20Overview%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
      - **2.6) Nonclinical-Summaries/**
        - **2.6.1) Introduction/**
          - [2.6.1) Pharmacology Intro FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.1)%20Introduction/2.6.1)%20Pharmacology%20Intro%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
        - **2.6.2) Pharmacology-Summary/**
          - [2.6.2) Pharmacology Written Summary FINAL 09Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.2)%20Pharmacology-Summary/2.6.2)%20Pharmacology%20Written%20Summary%20FINAL%2009Dec2019.pdf) (pdf) [ALLN-346]
          - [2.6.2) Pharmacology Written Summary SN 0028 submitted 2021Aug24.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.2)%20Pharmacology-Summary/2.6.2)%20Pharmacology%20Written%20Summary%20SN%200028%20submitted%202021Aug24.pdf) (pdf) [ALLN-346]
          - [2.6.2) SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.2)%20Pharmacology-Summary/2.6.2)%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
        - **2.6.3) Pharmacokinetics-Summary/**
          - [2.6.3) Pharmacology Tabulated Summary FINAL 25Nov2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.3)%20Pharmacokinetics-Summary/2.6.3)%20Pharmacology%20Tabulated%20Summary%20FINAL%2025Nov2019.pdf) (pdf) [ALLN-346]
          - [2.6.3) Pharmacology Tabulated Summary SN 0028 submitted 2021Aug24.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.3)%20Pharmacokinetics-Summary/2.6.3)%20Pharmacology%20Tabulated%20Summary%20SN%200028%20submitted%202021Aug24.pdf) (pdf) [ALLN-346]
          - [2.6.3) SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.3)%20Pharmacokinetics-Summary/2.6.3)%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
        - **2.6.6) Pharmacology-Tables/**
          - [2.6.6) Toxicology Written Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.6)%20Pharmacology-Tables/2.6.6)%20Toxicology%20Written%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
        - **2.6.7) Pharmacokinetics-Tables/**
          - [2.6.7) Toxicology Tabulated Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.7)%20Pharmacokinetics-Tables/2.6.7)%20Toxicology%20Tabulated%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
    - **3) Quality/**
      - **3.2) Body-of-Data/**
        - **3.2.P) Drug-Product/**
          - **3.2.P.1) Description-and-Composition/**
            - [3.2.P.1) DP Description FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.1)%20Description-and-Composition/3.2.P.1)%20DP%20Description%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
            - [3.2.P.1) DP Description FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.1)%20Description-and-Composition/3.2.P.1)%20DP%20Description%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.P.1) PBO Descript_tion FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.1)%20Description-and-Composition/3.2.P.1)%20PBO%20Descript_tion%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
          - [3.2.P.2) PharmDev FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20PharmDev%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.P.3) Manufacture/**
            - **3.2.P.3.1/**
              - [3.2.P.3.1) Manufacturers FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.1/3.2.P.3.1)%20Manufacturers%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.1) PBO Manufacturers FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.1/3.2.P.3.1)%20PBO%20Manufacturers%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.3.2/**
              - [3.2.P.3.2) Batch Formula FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.2/3.2.P.3.2)%20Batch%20Formula%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2) Batch Formula FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.2/3.2.P.3.2)%20Batch%20Formula%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2) Batch Formula FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.2/3.2.P.3.2)%20Batch%20Formula%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2) PBO Batch Formula FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.2/3.2.P.3.2)%20PBO%20Batch%20Formula%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.3.3/**
              - [3.2.P.3.3) Description _ntrols FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.3/3.2.P.3.3)%20Description%20_ntrols%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.3) Description of Mfg Process Controls FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.3/3.2.P.3.3)%20Description%20of%20Mfg%20Process%20Controls%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.3) PBO Descriptio_ontrols FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.3/3.2.P.3.3)%20PBO%20Descriptio_ontrols%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.3.4/**
              - [3.2.P.3.4) Controls of Critical Steps FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.4/3.2.P.3.4)%20Controls%20of%20Critical%20Steps%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.4) Controls of Critical Steps FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.4/3.2.P.3.4)%20Controls%20of%20Critical%20Steps%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.4) PBO Control of Critical Steps FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.4/3.2.P.3.4)%20PBO%20Control%20of%20Critical%20Steps%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.P.4) Control-of-Excipients/**
            - **3.2.P.4.1/**
              - [3.2.P.4.1) Excipient Specifications FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.4)%20Control-of-Excipients/3.2.P.4.1/3.2.P.4.1)%20Excipient%20Specifications%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.1) PBO Exceipent Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.4)%20Control-of-Excipients/3.2.P.4.1/3.2.P.4.1)%20PBO%20Exceipent%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.4.5/**
              - [3.2.P.4.5) Excipients of_Origin FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.4)%20Control-of-Excipients/3.2.P.4.5/3.2.P.4.5)%20Excipients%20of_Origin%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.4.5) PBO Excipients_l Origin FINAL 11Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.4)%20Control-of-Excipients/3.2.P.4.5/3.2.P.4.5)%20PBO%20Excipients_l%20Origin%20FINAL%2011Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.P.5) Control-of-Drug-Product/**
            - **3.2.P.5.1/**
              - [3.2.P.5.1) PBO Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.1/3.2.P.5.1)%20PBO%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.1) Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.1/3.2.P.5.1)%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.1) Specifications FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.1/3.2.P.5.1)%20Specifications%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.5.2/**
              - [3.2.P.5.2) Analytical Procedures FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.2/3.2.P.5.2)%20Analytical%20Procedures%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.2) PBO Analytical Methods FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.2/3.2.P.5.2)%20PBO%20Analytical%20Methods%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.5.4/**
              - [3.2.P.5.4) Batch Analyses FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.4/3.2.P.5.4)%20Batch%20Analyses%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.4) Batch Analyses FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.4/3.2.P.5.4)%20Batch%20Analyses%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.4) PBO Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.4/3.2.P.5.4)%20PBO%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.5.5/**
              - [3.2.P.5.5) Impurities FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.5/3.2.P.5.5)%20Impurities%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.5) PBO Characte_rities FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.5/3.2.P.5.5)%20PBO%20Characte_rities%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - **3.2.P.5.6/**
              - [3.2.P.5.6) Justificati_ions FINAL 16Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.6/3.2.P.5.6)%20Justificati_ions%20FINAL%2016Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.6) Justification of Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.6/3.2.P.5.6)%20Justification%20of%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.6) PBO Justific_ations FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.6/3.2.P.5.6)%20PBO%20Justific_ations%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.P.7) Container-Closure-System/**
            - [3.2.P.7) Container Closure System FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.7)%20Container-Closure-System/3.2.P.7)%20Container%20Closure%20System%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.P.7.1) PBO Container Closure FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.7)%20Container-Closure-System/3.2.P.7.1)%20PBO%20Container%20Closure%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.P.8) Stability/**
            - **3.2.P.8.1/**
              - [3.2.P.8.1) PBO Stability Summary FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.1/3.2.P.8.1)%20PBO%20Stability%20Summary%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.1) Stability FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.1/3.2.P.8.1)%20Stability%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.1) Stability Summary FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.1/3.2.P.8.1)%20Stability%20Summary%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
            - [3.2.P.8.3) Stability Data FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.3)%20Stability%20Data%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
        - **3.2.S) Drug-Substance/**
          - **3.2.S.1) General-Information/**
            - [3.2.S.1.1) Nomenclature.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.1)%20Nomenclature.pdf) (pdf) [ALLN-346]
            - [3.2.S.1.2) Structure FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.2)%20Structure%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.1.3) General Properties.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.3)%20General%20Properties.pdf) (pdf) [ALLN-346]
          - **3.2.S.2) Manufacture/**
            - [3.2.S.2.1) Manufacturers.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.1)%20Manufacturers.pdf) (pdf) [ALLN-346]
            - [3.2.S.2.2) Manufacturin_ntrols FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.2)%20Manufacturin_ntrols%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.2.3) Control of Materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.3)%20Control%20of%20Materials.pdf) (pdf) [ALLN-346]
            - [3.2.S.2.4) Control of Critical Steps.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.4)%20Control%20of%20Critical%20Steps.pdf) (pdf) [ALLN-346]
          - **3.2.S.3) Characterisation/**
            - [3.2.S.3.1) Elucidation of Structure FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.3)%20Characterisation/3.2.S.3.1)%20Elucidation%20of%20Structure%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.3.2) Impurities FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.3)%20Characterisation/3.2.S.3.2)%20Impurities%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.S.4) Control-of-Drug-Substance/**
            - [3.2.S.4.1) Specification FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.1)%20Specification%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.4.2) Analytical Procedures FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.2)%20Analytical%20Procedures%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.4.4) Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.4)%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.4.5) Justificati_tion FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.5)%20Justificati_tion%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
          - [3.2.S.5) Reference Standard FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.5)%20Reference%20Standard%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
          - [3.2.S.6) Container Closure System FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.6)%20Container%20Closure%20System%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
          - **3.2.S.7) Stability/**
            - [3.2.S.7.1) Stability Summary FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.7)%20Stability/3.2.S.7.1)%20Stability%20Summary%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
            - [3.2.S.7.3) Stability Data FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.7)%20Stability/3.2.S.7.3)%20Stability%20Data%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
    - **5) Clinical/**
      - **5.3) Clinical-Study-Reports/**
        - **5.3.5) Efficacy-Safety-Studies/**
          - **16/**
            - **16.1/**
              - **16.1.1/**
                - [16.1.1) Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.1/16.1.1)%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
              - **16.1.2/**
                - [16.1.2) Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.2/16.1.2)%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
              - **16.1.3/**
                - [16.1.3) IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.3/16.1.3)%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
              - **16.1.4/**
                - [16.1.4) List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.4/16.1.4)%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
              - **16.1.5/**
                - [16.1.5) Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.5/16.1.5)%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
                - [16.1.5) Signatures Investigators_346-102.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.5/16.1.5)%20Signatures%20Investigators_346-102.pdf) (pdf) [ALLN-346]
              - **16.1.6/**
                - [16.1.6) List Patients with Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.6/16.1.6)%20List%20Patients%20with%20Batches.pdf) (pdf) [ALLN-346]
                - [16.1.6) List Patients with Batches TO UPDATE WITH BATCH NUMBERS.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.6/16.1.6)%20List%20Patients%20with%20Batches%20TO%20UPDATE%20WITH%20BATCH%20NUMBERS.pdf) (pdf) [ALLN-346]
              - **16.1.7/**
                - [16.1.7) Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.7/16.1.7)%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
              - **16.1.8/**
                - [16.1.8) Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.8/16.1.8)%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
              - **16.1.9/**
                - [16.1.9) Statistical Methods Interim Analysis Plan- INCLUDES DATA.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.9/16.1.9)%20Statistical%20Methods%20Interim%20Analysis%20Plan-%20INCLUDES%20DATA.pdf) (pdf) [ALLN-346]
                - [16.1.9) Statistical Methods Interim Analysis Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.9/16.1.9)%20Statistical%20Methods%20Interim%20Analysis%20Plan.pdf) (pdf) [ALLN-346]
              - **16.1.10/**
                - [16.1.10) Inter-Laboratory Standardization Methods Quality Assurance-NOT INCLUDE URINE UA CR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.10/16.1.10)%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance-NOT%20INCLUDE%20URINE%20UA%20CR.pdf) (pdf) [ALLN-346]
                - [16.1.10) Inter-Laboratory Standardization Methods Quality Assurance.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.10/16.1.10)%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance.pdf) (pdf) [ALLN-346]
              - **16.1.11/**
                - [16.1.11) Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.11/16.1.11)%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
              - **16.1.12/**
                - [16.1.12) Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.12/16.1.12)%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-346]
              - **16.1.13/**
                - [16.1.13) Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.1/16.1.13/16.1.13)%20Other%20Reports.pdf) (pdf) [ALLN-346]
            - **16.2/**
              - **16.2.1/**
                - [16.2.1) Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.1/16.2.1)%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
              - **16.2.2/**
                - [16.2.2) Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.2/16.2.2)%20Protocol%20Deviations.pdf) (pdf) [ALLN-346]
              - **16.2.3/**
                - [16.2.3) Patients Excluded from Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.3/16.2.3)%20Patients%20Excluded%20from%20Efficacy%20Analysis.pdf) (pdf) [ALLN-346]
                - [16.2.3) Patients Excluded from Efficacy Analysis TO CHANGE TO NONE.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.3/16.2.3)%20Patients%20Excluded%20from%20Efficacy%20Analysis%20TO%20CHANGE%20TO%20NONE.pdf) (pdf) [ALLN-346]
              - **16.2.4/**
                - [16.2.4) Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.4/16.2.4)%20Demographic%20Data.pdf) (pdf) [ALLN-346]
              - **16.2.5/**
                - [16.2.5) Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.5/16.2.5)%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
              - **16.2.6/**
                - [16.2.6) Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.6/16.2.6)%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
              - **16.2.7/**
                - [16.2.7) Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.7/16.2.7)%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
              - **16.2.8/**
                - [16.2.8) Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.8/16.2.8)%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
              - **16.2.9/**
                - [16.2.9) Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.2/16.2.9/16.2.9)%20Other%20Safety%20Data.pdf) (pdf) [ALLN-346]
            - **16.3/**
              - **16.3.1/**
                - [16.3.1) CRFs for Deaths, SAEs, and Withdrawals.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.3/16.3.1/16.3.1)%20CRFs%20for%20Deaths,%20SAEs,%20and%20Withdrawals.pdf) (pdf) [ALLN-346]
            - **16.4/**
              - [16.4) Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/16/16.4/16.4)%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-346]
  - **files/**
    - **Clinical-Studies/**
      - **Development-Plans/**
        - **ALLN-346 Development Plan/**
          - [ALLN-346 Investigators Brochure August 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/ALLN-346%20Development%20Plan/ALLN-346%20Investigators%20Brochure%20August%202021.pdf) (pdf) [ALLN-346]
          - [ALLN-346 Program Roadmap - Jan 2022.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/ALLN-346%20Development%20Plan/ALLN-346%20Program%20Roadmap%20-%20Jan%202022.pptx) (pptx) [ALLN-346]
        - **Clinical Trials/**
          - **Study 101/**
            - [ALLN 346 DatabaseLockApproval November 20 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/ALLN%20346%20DatabaseLockApproval%20November%2020%202020.pdf) (pdf) [ALLN-346]
            - [ALLN-346-101 ELISA Data Transfer 18Nov2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/ALLN-346-101%20ELISA%20Data%20Transfer%2018Nov2020.pdf) (pdf) [ALLN-346]
            - [ALLN-346-101 End of Study Data Review_Revised_17Nov2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/ALLN-346-101%20End%20of%20Study%20Data%20Review_Revised_17Nov2020.pdf) (pdf) [ALLN-346]
            - [ALLN-346-101 Protocol Amendment SOC FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/ALLN-346-101%20Protocol%20Amendment%20SOC%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
            - [ALLN-346-101 Protocol Amendment 2 SOC FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/ALLN-346-101%20Protocol%20Amendment%202%20SOC%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-101 Amendment 1 FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/Protocol%20ALLN-346-101%20Amendment%201%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-101 Amendment 2 FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/Protocol%20ALLN-346-101%20Amendment%202%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
            - [SR-83-04-01 Quantitation of Urate Oxidase (AL_for Sponsor B003 Sample Analysis Report Final.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20101/SR-83-04-01%20Quantitation%20of%20Urate%20Oxidase%20(AL_for%20Sponsor%20B003%20Sample%20Analysis%20Report%20Final.pdf) (pdf) [ALLN-346]
          - **Study 102/**
            - [Protocol ALLN-346-102 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20102/Protocol%20ALLN-346-102%20FINAL.pdf) (pdf) [ALLN-346]
          - **Study 201/**
            - [ALLN-346-201 (CA34272) Finalized Protocol Review Forms.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/ALLN-346-201%20(CA34272)%20Finalized%20Protocol%20Review%20Forms.pdf) (pdf) [ALLN-346]
            - [ALLN-346-201 Protocol Amendment 1 SOC FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/ALLN-346-201%20Protocol%20Amendment%201%20SOC%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
            - [ALLN-346-201 Protocol Amendment 2 SOC FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/ALLN-346-201%20Protocol%20Amendment%202%20SOC%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
            - [ALLN-346-201 Protocol Amendment 3 SOC FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/ALLN-346-201%20Protocol%20Amendment%203%20SOC%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
            - [ALN_346_201_tables_13Jul2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/ALN_346_201_tables_13Jul2022.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201Amendment 1 FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/Protocol%20ALLN-346-201Amendment%201%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 Amendment 2 FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/Protocol%20ALLN-346-201%20Amendment%202%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 Amendment 3 Track Change FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/Protocol%20ALLN-346-201%20Amendment%203%20Track%20Change%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 FINAL 22May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/Protocol%20ALLN-346-201%20FINAL%2022May2021.pdf) (pdf) [ALLN-346]
            - [2022-04-26_safetynumtabCA34272-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20201/2022-04-26_safetynumtabCA34272-noPW.docx) (docx) [ALLN-346]
          - **Study 202/**
            - [ADSUA_02aug22.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/ADSUA_02aug22.xlsx) (xlsx) [ALLN-346]
            - **Allena Labs Study 202/**
              - [202-101-006.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-101-006.xls) (xls) [ALLN-346]
              - [202-106-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-106-003.xls) (xls) [ALLN-346]
              - [202-106-008.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-106-008.xls) (xls) [ALLN-346]
              - [202-107-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-107-003.xls) (xls) [ALLN-346]
              - [202-107-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-107-004.xls) (xls) [ALLN-346]
              - [202-107-006.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-107-006.xls) (xls) [ALLN-346]
              - [202-108-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-108-001.xls) (xls) [ALLN-346]
              - [202-110-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-110-003.xls) (xls) [ALLN-346]
              - [202-110-007.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-110-007.xls) (xls) [ALLN-346]
              - [202-110-113.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-110-113.xls) (xls) [ALLN-346]
              - [202-111-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-111-001.xls) (xls) [ALLN-346]
              - [202-115-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-115-003.xls) (xls) [ALLN-346]
              - [202-118-002.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-118-002.xls) (xls) [ALLN-346]
              - [202-120-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-120-001.xls) (xls) [ALLN-346]
              - [202-120-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-120-004.xls) (xls) [ALLN-346]
              - [202-124-002.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-124-002.xls) (xls) [ALLN-346]
              - [202-124-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-124-004.xls) (xls) [ALLN-346]
              - [202-127-005.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-127-005.xls) (xls) [ALLN-346]
              - [202-127-111.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Allena%20Labs%20Study%20202/202-127-111.xls) (xls) [ALLN-346]
            - [ALLN-346-202 Protocol Amendment 3 SOC FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/ALLN-346-202%20Protocol%20Amendment%203%20SOC%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
            - [ALLN-346-202 SRC review form_5Aug2022_final - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/ALLN-346-202%20SRC%20review%20form_5Aug2022_final%20-%20audit.pdf) (pdf) [ALLN-346]
            - [ALLN-346-202 SRC review form_5Aug2022_final (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/ALLN-346-202%20SRC%20review%20form_5Aug2022_final%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
            - [ALN346_202_Tables_02aug22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/ALN346_202_Tables_02aug22.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 1 FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20Amendment%201%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 1 SOC FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20Amendment%201%20SOC%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 2 FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20Amendment%202%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 2 SOC FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20Amendment%202%20SOC%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 3 FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20Amendment%203%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 FINAL 28May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Protocol%20ALLN-346-202%20FINAL%2028May2021.pdf) (pdf) [ALLN-346]
            - **Safety profiles 29Jul2022 Study 202/**
              - [SubjectProfile-202-101 006-Safety-29Jul2022 1607.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-101%20006-Safety-29Jul2022%201607.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-106 003-Safety-29Jul2022 1630.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-106%20003-Safety-29Jul2022%201630.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-106 008-Safety-29Jul2022 1618.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-106%20008-Safety-29Jul2022%201618.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 003-Safety-29Jul2022 1606.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-107%20003-Safety-29Jul2022%201606.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 004-Safety-29Jul2022 1635.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-107%20004-Safety-29Jul2022%201635.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 006-Safety-29Jul2022 1624.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-107%20006-Safety-29Jul2022%201624.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-108 001-Safety-29Jul2022 1617.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-108%20001-Safety-29Jul2022%201617.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 003-Safety-29Jul2022 1620.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-110%20003-Safety-29Jul2022%201620.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 007-Safety-29Jul2022 1645.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-110%20007-Safety-29Jul2022%201645.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 013-Safety-29Jul2022 1616.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-110%20013-Safety-29Jul2022%201616.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-111 001-Safety-29Jul2022 1656.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-111%20001-Safety-29Jul2022%201656.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-115 003-Safety-29Jul2022 1628.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-115%20003-Safety-29Jul2022%201628.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-118 002-Safety-29Jul2022 1601.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-118%20002-Safety-29Jul2022%201601.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-120 001-Safety-29Jul2022 1639.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-120%20001-Safety-29Jul2022%201639.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-120 004-Safety-29Jul2022 1625.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-120%20004-Safety-29Jul2022%201625.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-124 002-Safety-29Jul2022 1650.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-124%20002-Safety-29Jul2022%201650.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-124 004-Safety-29Jul2022 1604.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-124%20004-Safety-29Jul2022%201604.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-127 005-Safety-29Jul2022 1638.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-127%20005-Safety-29Jul2022%201638.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-127 011-Safety-29Jul2022 1605.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Development-Plans/Clinical%20Trials/Study%20202/Safety%20profiles%2029Jul2022%20Study%20202/SubjectProfile-202-127%20011-Safety-29Jul2022%201605.pdf) (pdf) [ALLN-346]
      - **Investigators-Brochure/**
        - [ALLN-346 Investigators Brochure FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Investigators-Brochure/ALLN-346%20Investigators%20Brochure%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
        - [ALLN-346 Investigators Brochure Ver 2 FINAL 01Mar2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Investigators-Brochure/ALLN-346%20Investigators%20Brochure%20Ver%202%20FINAL%2001Mar2021.pdf) (pdf) [ALLN-346]
        - [ALLN-346 Investigators Brochure Version 3 FINAL 04Aug2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/Investigators-Brochure/ALLN-346%20Investigators%20Brochure%20Version%203%20FINAL%2004Aug2021.pdf) (pdf) [ALLN-346]
      - **101-SAD/**
        - **Datasets/**
          - **11.03-Analysis/**
            - **11.03.01-DataDefinitionsforAnalysisDatasets/**
              - [ALLN-346-101_AnalysisDataDefs_05MAY2021.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-101_AnalysisDataDefs_05MAY2021.rtf) (rtf) [ALLN-346]
              - [ALLN-346-101_AnalysisDataDefs_11JUN2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-101_AnalysisDataDefs_11JUN2021.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-101_AnalysisDataDefs_26OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-101_AnalysisDataDefs_26OCT2020.pdf) (pdf) [ALLN-346]
              - [ALLN-346-101_AnalysisDataDefs_V01_22OCT2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-101_AnalysisDataDefs_V01_22OCT2020.xlsx) (xlsx) [ALLN-346]
            - **11.03.02-AnalysisQCDocumentation/**
              - [ALLN-346-101_AnalysisTrackingSpreadsheet_06OCT2020.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_06OCT2020.docx) (docx) [ALLN-346]
              - [ALLN-346-101_AnalysisTrackingSpreadsheet_15OCT2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_15OCT2021.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-101_AnalysisTrackingSpreadsheet_16AUG2022.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_16AUG2022.xlsx) (xlsx) [ALLN-346]
            - **11.03.07-FinalAnalysisRawDatasets/**
              - **ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/**
                - **Data/**
                  - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/cm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/co.sas7bdat) (sas7bdat) [ALLN-346]
                  - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/dm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ds.sas7bdat) (sas7bdat) [ALLN-346]
                  - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/dv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/eg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ex.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ho.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ie.sas7bdat) (sas7bdat) [ALLN-346]
                  - [is.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/is.sas7bdat) (sas7bdat) [ALLN-346]
                  - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/lb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [mb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/mb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/mh.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ml.sas7bdat) (sas7bdat) [ALLN-346]
                  - [pc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/pc.sas7bdat) (sas7bdat) [ALLN-346]
                  - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/pe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/relrec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/rp.sas7bdat) (sas7bdat) [ALLN-346]
                  - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/se.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppcm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppdm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppds.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppdv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppeg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppmb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppmb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppml.sas7bdat) (sas7bdat) [ALLN-346]
                  - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/supppe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/suppve.sas7bdat) (sas7bdat) [ALLN-346]
                  - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/sv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ta.sas7bdat) (sas7bdat) [ALLN-346]
                  - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/te.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ti.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ts.sas7bdat) (sas7bdat) [ALLN-346]
                  - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/tv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/ve.sas7bdat) (sas7bdat) [ALLN-346]
                  - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021/Data/vs.sas7bdat) (sas7bdat) [ALLN-346]
              - [ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021.zip) (zip) [ALLN-346]
            - **11.03.08-FinalAnalysisPrograms/**
              - **ALLN-346-101_FinalAnalysisProgs_16AUG2022/**
                - [adae.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adae.sas) (sas) [ALLN-346]
                - [adcm.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adcm.sas) (sas) [ALLN-346]
                - [adeg.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adeg.sas) (sas) [ALLN-346]
                - [adis.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adis.sas) (sas) [ALLN-346]
                - [adlb.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adlb.sas) (sas) [ALLN-346]
                - [admh.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/admh.sas) (sas) [ALLN-346]
                - [adpc.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adpc.sas) (sas) [ALLN-346]
                - [adpd.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adpd.sas) (sas) [ALLN-346]
                - [adpe.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adpe.sas) (sas) [ALLN-346]
                - [adsl.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/adsl.sas) (sas) [ALLN-346]
                - [advs.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/advs.sas) (sas) [ALLN-346]
                - [AE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/AE01.sas) (sas) [ALLN-346]
                - [AE11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/AE11.sas) (sas) [ALLN-346]
                - [AE12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/AE12.sas) (sas) [ALLN-346]
                - [AE13.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/AE13.sas) (sas) [ALLN-346]
                - [CM01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/CM01.sas) (sas) [ALLN-346]
                - [CM11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/CM11.sas) (sas) [ALLN-346]
                - [DM01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DM01.sas) (sas) [ALLN-346]
                - [DM11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DM11.sas) (sas) [ALLN-346]
                - [DS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DS01.sas) (sas) [ALLN-346]
                - [DS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DS11.sas) (sas) [ALLN-346]
                - [DV01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DV01.sas) (sas) [ALLN-346]
                - [DV11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/DV11.sas) (sas) [ALLN-346]
                - [EC01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EC01.sas) (sas) [ALLN-346]
                - [EF11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EF11.sas) (sas) [ALLN-346]
                - [EG01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EG01.sas) (sas) [ALLN-346]
                - [EG11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EG11.sas) (sas) [ALLN-346]
                - [EG12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EG12.sas) (sas) [ALLN-346]
                - [EX11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/EX11.sas) (sas) [ALLN-346]
                - [IE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/IE01.sas) (sas) [ALLN-346]
                - [IS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/IS01.sas) (sas) [ALLN-346]
                - [IS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/IS11.sas) (sas) [ALLN-346]
                - [IS12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/IS12.sas) (sas) [ALLN-346]
                - [IS13.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/IS13.sas) (sas) [ALLN-346]
                - [LB01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/LB01.sas) (sas) [ALLN-346]
                - [LB11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/LB11.sas) (sas) [ALLN-346]
                - [LB12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/LB12.sas) (sas) [ALLN-346]
                - [LB13.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/LB13.sas) (sas) [ALLN-346]
                - [LB21.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/LB21.sas) (sas) [ALLN-346]
                - [macro_sc.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/macro_sc.sas) (sas) [ALLN-346]
                - [MH01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/MH01.sas) (sas) [ALLN-346]
                - [MH11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/MH11.sas) (sas) [ALLN-346]
                - [PC01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/PC01.sas) (sas) [ALLN-346]
                - [PC11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/PC11.sas) (sas) [ALLN-346]
                - [PD01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/PD01.sas) (sas) [ALLN-346]
                - [PE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/PE01.sas) (sas) [ALLN-346]
                - [PE11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/PE11.sas) (sas) [ALLN-346]
                - [SV01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/SV01.sas) (sas) [ALLN-346]
                - [utility.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/utility.sas) (sas) [ALLN-346]
                - [VS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/VS01.sas) (sas) [ALLN-346]
                - [VS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/VS11.sas) (sas) [ALLN-346]
                - [VS12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022/VS12.sas) (sas) [ALLN-346]
              - [ALLN-346-101_FinalAnalysisProgs_16AUG2022.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022.zip) (zip) [ALLN-346]
            - **11.03.09-FinalAnalysisDatasets/**
              - **ALLN-346-101_FinalAnalysisDatasets_13OCT2021/**
                - **Data/**
                  - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adae.xpt) (xpt) [ALLN-346]
                  - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adcm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adcm.xpt) (xpt) [ALLN-346]
                  - [adeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adeg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adeg.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adeg.xpt) (xpt) [ALLN-346]
                  - [adis.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adis.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adis.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adis.xpt) (xpt) [ALLN-346]
                  - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adlb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adlb.xpt) (xpt) [ALLN-346]
                  - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/admh.sas7bdat) (sas7bdat) [ALLN-346]
                  - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/admh.xpt) (xpt) [ALLN-346]
                  - [adpc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpc.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpc.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpc.xpt) (xpt) [ALLN-346]
                  - [adpd.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpd.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpd.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpd.xpt) (xpt) [ALLN-346]
                  - [adpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adpe.xpt) (xpt) [ALLN-346]
                  - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adsl.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/adsl.xpt) (xpt) [ALLN-346]
                  - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/advs.sas7bdat) (sas7bdat) [ALLN-346]
                  - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021/Data/advs.xpt) (xpt) [ALLN-346]
              - [ALLN-346-101_FinalAnalysisDatasets_13OCT2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021.zip) (zip) [ALLN-346]
            - **11.03.10-FinalAnalysisOutput/**
              - **ALLN-346-101_FinalAnalysisOutput_16AUG2022/**
                - [F14.2.1.1_urate.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/F14.2.1.1_urate.rtf) (rtf) [ALLN-346]
                - [L16.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.1.1_disp.rtf) (rtf) [ALLN-346]
                - [L16.1.2_ie.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.1.2_ie.rtf) (rtf) [ALLN-346]
                - [L16.1.3_visits.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.1.3_visits.rtf) (rtf) [ALLN-346]
                - [L16.2.1_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.1_prot_dev.rtf) (rtf) [ALLN-346]
                - [L16.2.2_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.2_demo.rtf) (rtf) [ALLN-346]
                - [L16.2.3_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.3_medhist.rtf) (rtf) [ALLN-346]
                - [L16.2.4_conmeds.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.4_conmeds.rtf) (rtf) [ALLN-346]
                - [L16.2.5_drug_adamin.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.5_drug_adamin.rtf) (rtf) [ALLN-346]
                - [L16.2.6_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.6_pk.rtf) (rtf) [ALLN-346]
                - [L16.2.7_urate.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.7_urate.rtf) (rtf) [ALLN-346]
                - [L16.2.8_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.2.8_crp.rtf) (rtf) [ALLN-346]
                - [L16.3.1_ae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.1_ae.rtf) (rtf) [ALLN-346]
                - [L16.3.3_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.3_vital.rtf) (rtf) [ALLN-346]
                - [L16.3.4_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.4_ecg.rtf) (rtf) [ALLN-346]
                - [L16.3.5_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.5_pe.rtf) (rtf) [ALLN-346]
                - [L16.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.4_critlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.2.4_critlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.5_otherlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/L16.3.2.5_otherlab.rtf) (rtf) [ALLN-346]
                - [T14.1.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.1.1_disp.rtf) (rtf) [ALLN-346]
                - [T14.1.2.1_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.2.1_prot_dev.rtf) (rtf) [ALLN-346]
                - [T14.1.3.1_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.3.1_demo.rtf) (rtf) [ALLN-346]
                - [T14.1.4.1_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.4.1_medhist.rtf) (rtf) [ALLN-346]
                - [T14.1.5.1_priormed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.5.1_priormed.rtf) (rtf) [ALLN-346]
                - [T14.1.5.2_conmed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.5.2_conmed.rtf) (rtf) [ALLN-346]
                - [T14.1.6.1_expcomp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.1.6.1_expcomp.rtf) (rtf) [ALLN-346]
                - [T14.2.1.1_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.2.1.1_pk.rtf) (rtf) [ALLN-346]
                - [T14.2.2.1_urate.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.2.2.1_urate.rtf) (rtf) [ALLN-346]
                - [T14.2.3.1_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.2.3.1_crp.rtf) (rtf) [ALLN-346]
                - [T14.3.1.1_aesumm.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.1_aesumm.rtf) (rtf) [ALLN-346]
                - [T14.3.1.2_teae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.2_teae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.3_teae_sev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.3_teae_sev.rtf) (rtf) [ALLN-346]
                - [T14.3.1.4_ae_cov19.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.4_ae_cov19.rtf) (rtf) [ALLN-346]
                - [T14.3.1.5_ae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.5_ae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.6_sae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.6_sae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.7_tesae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.7_tesae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.8_teae_discont.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.8_teae_discont.rtf) (rtf) [ALLN-346]
                - [T14.3.1.9_ae_death.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.1.9_ae_death.rtf) (rtf) [ALLN-346]
                - [T14.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.4_abnorm_lab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.2.4_abnorm_lab.rtf) (rtf) [ALLN-346]
                - [T14.3.3.1_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.3.1_vital.rtf) (rtf) [ALLN-346]
                - [T14.3.3.2_abnorm_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.3.2_abnorm_vital.rtf) (rtf) [ALLN-346]
                - [T14.3.4.1_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.4.1_ecg.rtf) (rtf) [ALLN-346]
                - [T14.3.5.1_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022/T14.3.5.1_pe.rtf) (rtf) [ALLN-346]
              - [ALLN-346-101_FinalAnalysisOutput_16AUG2022.ZIP](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022.ZIP) (zip) [ALLN-346]
        - **346-101 CSR and TLF/**
          - [Allena_ALLN-346-101_CSR_v1.0_2022Aug29 final2.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Allena_ALLN-346-101_CSR_v1.0_2022Aug29%20final2.pdf) (pdf) [ALLN-346]
          - **Appendices for Sponsor Review 08 July 2022/**
            - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
            - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
            - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
            - [16.1.4 List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.4%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
            - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
            - [16.1.6 List Patients with Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.6%20List%20Patients%20with%20Batches.pdf) (pdf) [ALLN-346]
            - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
            - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
            - [16.1.9 Statistical Methods Interim Analysis Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.9%20Statistical%20Methods%20Interim%20Analysis%20Plan.pdf) (pdf) [ALLN-346]
            - [16.1.10 Inter-Laboratory Standardization Methods Quality Assurance.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.10%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance.pdf) (pdf) [ALLN-346]
            - [16.1.11 Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.11%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
            - [16.1.12 Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.12%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-346]
            - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
            - [16.2.1 Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.1%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
            - [16.2.2 Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.2%20Protocol%20Deviations.pdf) (pdf) [ALLN-346]
            - [16.2.3 Patients Excluded from Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.3%20Patients%20Excluded%20from%20Efficacy%20Analysis.pdf) (pdf) [ALLN-346]
            - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-346]
            - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
            - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
            - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
            - [16.2.8 Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.8%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
            - [16.2.9 Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.2.9%20Other%20Safety%20Data.pdf) (pdf) [ALLN-346]
            - [16.3.1 CRFs for Deaths, SAEs, and Withdrawals.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.3.1%20CRFs%20for%20Deaths,%20SAEs,%20and%20Withdrawals.pdf) (pdf) [ALLN-346]
            - [16.4 Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2008%20July%202022/16.4%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-346]
          - [Appendices for Sponsor Review 25 August 2022](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Appendices%20for%20Sponsor%20Review%2025%20August%202022) (unknown) [ALLN-346]
          - **CRFs and CSR Appendices/**
            - [ALLN-346-101 Appendices new and updated ones only_OneDrive_2022-08-29.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20Appendices%20new%20and%20updated%20ones%20only_OneDrive_2022-08-29.zip) (zip) [ALLN-346]
            - **ALLN-346-101 CRFs and most CSR Appendices/**
              - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
              - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
              - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
              - [16.1.4 List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.4%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
              - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
              - [16.1.6 List Patients with Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.6%20List%20Patients%20with%20Batches.pdf) (pdf) [ALLN-346]
              - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
              - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
              - [16.1.9 Statistical Methods Interim Analysis Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.9%20Statistical%20Methods%20Interim%20Analysis%20Plan.pdf) (pdf) [ALLN-346]
              - [16.1.10 Inter-Laboratory Standardization Methods Quality Assurance.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.10%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance.pdf) (pdf) [ALLN-346]
              - [16.1.11 Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.11%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
              - [16.1.12 Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.12%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-346]
              - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
              - [16.2.1 Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.1%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
              - [16.2.2 Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.2%20Protocol%20Deviations.pdf) (pdf) [ALLN-346]
              - [16.2.3 Patients Excluded from Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.3%20Patients%20Excluded%20from%20Efficacy%20Analysis.pdf) (pdf) [ALLN-346]
              - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-346]
              - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
              - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
              - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
              - [16.2.8 Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.8%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
              - [16.2.9 Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.2.9%20Other%20Safety%20Data.pdf) (pdf) [ALLN-346]
              - [16.3.1 CRFs for Deaths, SAEs, and Withdrawals.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.3.1%20CRFs%20for%20Deaths,%20SAEs,%20and%20Withdrawals.pdf) (pdf) [ALLN-346]
              - [16.4 Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/16.4%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-346]
              - [001030.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices/001030.pdf) (pdf) [ALLN-346]
            - [ALLN-346-101 CRFs and most CSR Appendices.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/ALLN-346-101%20CRFs%20and%20most%20CSR%20Appendices.zip) (zip) [ALLN-346]
            - [Appendices for Sponsor Review 25 August 2022](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/Appendices%20for%20Sponsor%20Review%2025%20August%202022) (unknown) [ALLN-346]
            - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
            - [346-101 CRFs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/346-101%20CRFs.pdf) (pdf) [ALLN-346]
            - [001030.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/CRFs%20and%20CSR%20Appendices/001030.pdf) (pdf) [ALLN-346]
          - **Please_DocuSign_Allena_346-101-CSR_Signature_Page_AL/**
            - [Allena_CSR_Signature_Page_ALLN-346-101.docx.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Please_DocuSign_Allena_346-101-CSR_Signature_Page_AL/Allena_CSR_Signature_Page_ALLN-346-101.docx.pdf) (pdf) [ALLN-346]
            - [Summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Please_DocuSign_Allena_346-101-CSR_Signature_Page_AL/Summary.pdf) (pdf) [ALLN-346]
          - [Please_DocuSign_Allena_346-101-CSR_Signature_Page_AL.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/Please_DocuSign_Allena_346-101-CSR_Signature_Page_AL.zip) (zip) [ALLN-346]
          - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
          - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
          - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
          - [346-101 CRFs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20CRFs.pdf) (pdf) [ALLN-346]
          - **346-101 data- TLF 19JAN2021 FINAL (no ADA uricase)/**
            - **ALLN-346-101 Prefinal_TFLs_15OCT2021/**
              - [ALLN-346-101 Prefinal Figure.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/ALLN-346-101%20Prefinal%20Figure.PDF) (pdf) [ALLN-346]
              - [ALLN-346-101 Prefinal Listings.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/ALLN-346-101%20Prefinal%20Listings.PDF) (pdf) [ALLN-346]
              - [F14.2.1.1_urate.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/F14.2.1.1_urate.docx) (docx) [ALLN-346]
              - [F14.2.1.1_urate.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/F14.2.1.1_urate.rtf) (rtf) [ALLN-346]
              - [L16.1.1_disp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.1.1_disp.docx) (docx) [ALLN-346]
              - [L16.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.1.1_disp.rtf) (rtf) [ALLN-346]
              - [L16.1.2_ie.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.1.2_ie.docx) (docx) [ALLN-346]
              - [L16.1.3_visits.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.1.3_visits.docx) (docx) [ALLN-346]
              - [L16.2.1_prot_dev.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.1_prot_dev.docx) (docx) [ALLN-346]
              - [L16.2.2_demo.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.2_demo.docx) (docx) [ALLN-346]
              - [L16.2.3_medhist.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.3_medhist.docx) (docx) [ALLN-346]
              - [L16.2.4_conmeds.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.4_conmeds.docx) (docx) [ALLN-346]
              - [L16.2.5_drug_adamin.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.5_drug_adamin.docx) (docx) [ALLN-346]
              - [L16.2.6_pk.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.6_pk.docx) (docx) [ALLN-346]
              - [L16.2.7_urate.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.7_urate.docx) (docx) [ALLN-346]
              - [L16.2.8_crp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.2.8_crp.docx) (docx) [ALLN-346]
              - [L16.3.1_ae.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.1_ae.docx) (docx) [ALLN-346]
              - [L16.3.3_vital.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.3_vital.docx) (docx) [ALLN-346]
              - [L16.3.4_ecg.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.4_ecg.docx) (docx) [ALLN-346]
              - [L16.3.5_pe.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.5_pe.docx) (docx) [ALLN-346]
              - [L16.3.2.1_chemlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.2.1_chemlab.docx) (docx) [ALLN-346]
              - [L16.3.2.2_hemalab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.2.2_hemalab.docx) (docx) [ALLN-346]
              - [L16.3.2.3_urlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.2.3_urlab.docx) (docx) [ALLN-346]
              - [L16.3.2.4_critlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.2.4_critlab.docx) (docx) [ALLN-346]
              - [L16.3.2.5_otherlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/L16.3.2.5_otherlab.docx) (docx) [ALLN-346]
              - **Prefinal Tables/**
                - [ALLN-346-101 Prefinal Tables.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/ALLN-346-101%20Prefinal%20Tables.PDF) (pdf) [ALLN-346]
                - [T14.1.1.1_disp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.1.1_disp.docx) (docx) [ALLN-346]
                - [T14.1.2.1_prot_dev.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.2.1_prot_dev.docx) (docx) [ALLN-346]
                - [T14.1.3.1_demo.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.3.1_demo.docx) (docx) [ALLN-346]
                - [T14.1.4.1_medhist.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.4.1_medhist.docx) (docx) [ALLN-346]
                - [T14.1.5.1_priormed.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.5.1_priormed.docx) (docx) [ALLN-346]
                - [T14.1.5.2_conmed.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.5.2_conmed.docx) (docx) [ALLN-346]
                - [T14.1.6.1_expcomp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.1.6.1_expcomp.docx) (docx) [ALLN-346]
                - [T14.2.1.1_pk.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.2.1.1_pk.docx) (docx) [ALLN-346]
                - [T14.2.2.1_urate.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.2.2.1_urate.docx) (docx) [ALLN-346]
                - [T14.2.3.1_crp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.2.3.1_crp.docx) (docx) [ALLN-346]
                - [T14.3.1.1_aesumm.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.1_aesumm.docx) (docx) [ALLN-346]
                - [T14.3.1.2_teae.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.2_teae.docx) (docx) [ALLN-346]
                - [T14.3.1.3_teae_sev.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.3_teae_sev.docx) (docx) [ALLN-346]
                - [T14.3.1.4_ae_cov19.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.4_ae_cov19.docx) (docx) [ALLN-346]
                - [T14.3.1.5_ae_rel.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.5_ae_rel.docx) (docx) [ALLN-346]
                - [T14.3.1.6_sae.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.6_sae.docx) (docx) [ALLN-346]
                - [T14.3.1.7_tesae_rel.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.7_tesae_rel.docx) (docx) [ALLN-346]
                - [T14.3.1.8_teae_discont.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.8_teae_discont.docx) (docx) [ALLN-346]
                - [T14.3.1.9_ae_death.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.1.9_ae_death.docx) (docx) [ALLN-346]
                - [T14.3.2.1_chemlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.2.1_chemlab.docx) (docx) [ALLN-346]
                - [T14.3.2.2_hemalab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.2.2_hemalab.docx) (docx) [ALLN-346]
                - [T14.3.2.3_urlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.2.3_urlab.docx) (docx) [ALLN-346]
                - [T14.3.2.4_abnorm_lab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.2.4_abnorm_lab.docx) (docx) [ALLN-346]
                - [T14.3.3.1_vital.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.3.1_vital.docx) (docx) [ALLN-346]
                - [T14.3.3.2_abnorm_vital.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.3.2_abnorm_vital.docx) (docx) [ALLN-346]
                - [T14.3.4.1_ecg.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.4.1_ecg.docx) (docx) [ALLN-346]
                - [T14.3.5.1_pe.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15OCT2021/Prefinal%20Tables/T14.3.5.1_pe.docx) (docx) [ALLN-346]
            - [ALLN-346-101 Prefinal_TFLs_15Oct2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20CSR%20and%20TLF/346-101%20data-%20TLF%2019JAN2021%20FINAL%20(no%20ADA%20uricase)/ALLN-346-101%20Prefinal_TFLs_15Oct2021.zip) (zip) [ALLN-346]
        - **346-101-protocols/**
          - [Protocol ALLN-346-101 Amendment 1 FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101-protocols/Protocol%20ALLN-346-101%20Amendment%201%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-101 Amendment 2 FINAL 17Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101-protocols/Protocol%20ALLN-346-101%20Amendment%202%20FINAL%2017Aug2020.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-101 FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101-protocols/Protocol%20ALLN-346-101%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
        - **346-101 TMF/**
          - [Acknowledgment of Receipt TMFs 346-101 _-102_Allena.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/Acknowledgment%20of%20Receipt%20TMFs%20346-101%20_-102_Allena.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-101_ TMF Package Return.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/Allena%20ALLN-346-101_%20TMF%20Package%20Return.pdf) (pdf) [ALLN-346]
          - **app/**
            - [3rdpartylicenses.txt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/3rdpartylicenses.txt) (txt) [ALLN-346]
            - **assets/**
              - **medpace-brand/**
                - [medpace_logo.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/assets/medpace-brand/medpace_logo.svg) (svg) [ALLN-346]
            - [favicon.ico](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/favicon.ico) (ico) [ALLN-346]
            - [inline.40e39102d7108e4e6d60.bundle.js](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/inline.40e39102d7108e4e6d60.bundle.js) (js) [ALLN-346]
            - [main.a8c717cc5f8320ec3fef.bundle.js](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/main.a8c717cc5f8320ec3fef.bundle.js) (js) [ALLN-346]
            - [polyfills.2919380d9cea9f1c56fa.bundle.js](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/polyfills.2919380d9cea9f1c56fa.bundle.js) (js) [ALLN-346]
            - [styles.dd3f3cbc84126402b2f7.bundle.css](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/app/styles.dd3f3cbc84126402b2f7.bundle.css) (css) [ALLN-346]
          - **AuditReports/**
            - [TMFVersionHistory_ALLN6101_2022-11-17T14-39-01_Filterable.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/AuditReports/TMFVersionHistory_ALLN6101_2022-11-17T14-39-01_Filterable.xlsx) (xlsx) [ALLN-346]
            - [TMFVersionHistory_ALLN6101_2022-11-17T14-39-01.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/AuditReports/TMFVersionHistory_ALLN6101_2022-11-17T14-39-01.xlsx) (xlsx) [ALLN-346]
          - **GeneralFiles/**
            - **01-TrialManagement/**
              - **01.01-TrialOversight/**
                - **01.01.01-TrialMasterFilePlan/**
                  - [ALLN-346-101_InternalQualRevCert_03FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_03FEB2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_03MAR2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_03MAR2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_04MAR2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_04MAR2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_07MAR2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_07MAR2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_07MAR2022_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_07MAR2022_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_10FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_10FEB2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_15FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_15FEB2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_19OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_19OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_21OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_21OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_22OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_22OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_27JAN2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_27JAN2021.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_InternalQualRevCert_28FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_InternalQualRevCert_28FEB2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_TMFOtherDoc_01FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFOtherDoc_01FEB2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_TMFOtherDoc_07OCT2020.msg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFOtherDoc_07OCT2020.msg) (msg) [ALLN-346]
                  - [ALLN-346-101_TMFOtherDoc_07OCT2020_[1].msg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFOtherDoc_07OCT2020_[1].msg) (msg) [ALLN-346]
                  - [ALLN-346-101_TMFOtherDoc_07OCT2020_[2].msg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFOtherDoc_07OCT2020_[2].msg) (msg) [ALLN-346]
                  - [ALLN-346-101_TMFOtherDoc_07OCT2020_[3].msg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFOtherDoc_07OCT2020_[3].msg) (msg) [ALLN-346]
                  - [ALLN-346-101_TMFSpecs_V1.0_28SEP2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFSpecs_V1.0_28SEP2020.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_TMFSpecs_V2.0_21OCT2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFSpecs_V2.0_21OCT2020.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_TMFSpecs_V3.0_31JAN2022.XLS](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFSpecs_V3.0_31JAN2022.XLS) (xls) [ALLN-346]
                  - [ALLN-346-101_TMFSpecs_V4.0_03MAR2022.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFSpecs_V4.0_03MAR2022.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_TMFSpecsApv_22JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.01-TrialMasterFilePlan/ALLN-346-101_TMFSpecsApv_22JUL2020.pdf) (pdf) [ALLN-346]
                - **01.01.02-TrialManagementPlan/**
                  - [ALLN-346-101_ProjTimelines_17AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_17AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_17SEP2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_17SEP2021.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_19MAY2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_19MAY2021.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_25NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_25NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_27OCT2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_27OCT2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_27OCT2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_27OCT2021.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProjTimelines_31AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProjTimelines_31AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProtDevPlan_V1.0_26AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProtDevPlan_V1.0_26AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_ProtDevPlanApv_V1.0_31AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.02-TrialManagementPlan/ALLN-346-101_ProtDevPlanApv_V1.0_31AUG2020.pdf) (pdf) [ALLN-346]
                - **01.01.08-MonitoringPlan/**
                  - [ALLN-346-101_MonPlan_V1.0_15JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlan_V1.0_15JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlan_V2.0_05AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlan_V2.0_05AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlan_V3.0_26OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlan_V3.0_26OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlan_Vxx_13JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlan_Vxx_13JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanApv_V2.0_06AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlanApv_V2.0_06AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanApv_V2.0_07AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.01-TrialOversight/01.01.08-MonitoringPlan/ALLN-346-101_MonPlanApv_V2.0_07AUG2020.PDF) (pdf) [ALLN-346]
              - **01.02-TrialTeam/**
                - **01.02.01-TrialTeamDetails/**
                  - [ALLN-346-101_ProjTeamList_01FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.02-TrialTeam/01.02.01-TrialTeamDetails/ALLN-346-101_ProjTeamList_01FEB2022.pdf) (pdf) [ALLN-346]
              - **01.03-TrialCommittee/**
                - **01.03.03-CommitteeOutput/**
                  - [ALLN-346-101_CmteCorresp_03SEP2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteCorresp_03SEP2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_CmteCorresp_08OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteCorresp_08OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CmteCorresp_22SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteCorresp_22SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900_[1].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900_[1].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900_[2].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900_[2].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900_[3].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900_[3].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900_[4].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900_[4].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1900_[5].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1900_[5].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1990.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1990.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_01JAN1990_[1].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_01JAN1990_[1].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_13OCT2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_13OCT2020.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_13OCT2020_[1].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_13OCT2020_[1].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_14SEP2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_14SEP2020.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_28SEP2020.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_28SEP2020.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteDataPackage_28SEP2020_[1].xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteDataPackage_28SEP2020_[1].xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_CmteMtgMins_14OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteMtgMins_14OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CmteMtgMins_16SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteMtgMins_16SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CmteMtgMins_30SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.03-TrialCommittee/01.03.03-CommitteeOutput/ALLN-346-101_CmteMtgMins_30SEP2020.pdf) (pdf) [ALLN-346]
              - **01.04-Meetings/**
                - **01.04.04-TrialTeamEvidenceofTraining/**
                  - [ALLN-346-101_ProjTeamTrainRec_28FEB2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.04-Meetings/01.04.04-TrialTeamEvidenceofTraining/ALLN-346-101_ProjTeamTrainRec_28FEB2022.pdf) (pdf) [ALLN-346]
              - **01.05-General/**
                - **01.05.01-RelevantCommunications/**
                  - [ALLN-346-101_SpsrCorr_06JAN2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_06JAN2021.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_08OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_08OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_15OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_15OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_23NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_23NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_24NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_24NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_25NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_25NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_27JUL2020.MSG](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_27JUL2020.MSG) (msg) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_31JAN2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_31JAN2022.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_31JAN2022_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_31JAN2022_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SpsrCorr_31JAN2022_[2].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.01-RelevantCommunications/ALLN-346-101_SpsrCorr_31JAN2022_[2].pdf) (pdf) [ALLN-346]
                - **01.05.03-OtherMeetingMaterial/**
                  - [ALLN-346-101_MonPlanMtgAgenda_12AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_12AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgAgenda_17JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_17JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgAgenda_19OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_19OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgAgenda_24NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_24NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgAgenda_24SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_24SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgAgenda_26AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgAgenda_26AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_12AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_12AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_17JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_17JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_19OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_19OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_24NOV2020_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_24NOV2020_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_24SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_24SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MonPlanMtgKeyDiscussions_26AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_MonPlanMtgKeyDiscussions_26AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_02SEP2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_02SEP2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_05AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_05AUG2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_07OCT2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_07OCT2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_09SEP2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_09SEP2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_12AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_12AUG2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_14OCT2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_14OCT2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_16SEP2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_16SEP2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_23SEP2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_23SEP2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_26AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_26AUG2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_26AUG2020_[1].PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_26AUG2020_[1].PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgAgenda_29JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgAgenda_29JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_02SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_02SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_05AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_05AUG2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_05AUG2020_[1].PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_05AUG2020_[1].PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_07OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_07OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_09SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_09SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_12AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_12AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_14OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_14OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_16SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_16SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_19AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_19AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_23SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_23SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_26AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_26AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_29JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_29JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_RoutProjTeamMtgMins_30SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/01-TrialManagement/01.05-General/01.05.03-OtherMeetingMaterial/ALLN-346-101_RoutProjTeamMtgMins_30SEP2020.pdf) (pdf) [ALLN-346]
            - **02-CentralTrialDocuments/**
              - **02.03-Reports/**
                - **02.03.01-ClinicalStudyReport/**
                  - [ALLN-346-101_CSR_01JAN1900.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[10].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[10].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[11].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[11].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[12].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[12].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[13].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[13].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[14].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[14].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[15].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[15].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[16].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[16].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[17].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[17].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[18].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[18].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[19].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[19].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[20].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[20].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[21].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[21].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[22].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[22].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[23].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[23].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[24].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[24].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[2].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[2].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[3].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[3].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[4].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[4].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[5].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[5].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[6].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[6].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[7].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[7].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[8].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[8].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CSR_01JAN1900_[9].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.03-Reports/02.03.01-ClinicalStudyReport/ALLN-346-101_CSR_01JAN1900_[9].pdf) (pdf) [ALLN-346]
              - **02.04-General/**
                - **02.04.01-RelevantCommunications/**
                  - [ALLN-346-101_CentralTrialDocsCorresp_04AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.04-General/02.04.01-RelevantCommunications/ALLN-346-101_CentralTrialDocsCorresp_04AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CentralTrialDocsCorresp_14JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.04-General/02.04.01-RelevantCommunications/ALLN-346-101_CentralTrialDocsCorresp_14JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CentralTrialDocsCorresp_14SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.04-General/02.04.01-RelevantCommunications/ALLN-346-101_CentralTrialDocsCorresp_14SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CentralTrialDocsCorresp_25AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/02-CentralTrialDocuments/02.04-General/02.04.01-RelevantCommunications/ALLN-346-101_CentralTrialDocsCorresp_25AUG2020.pdf) (pdf) [ALLN-346]
            - **05-SiteManagement/**
              - **05.03-SiteInitiation/**
                - **05.03.02-SiteTrainingMaterial/**
                  - [ALLN-346-101_SiteTrainMtl_01JAN1900.PPT](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.03-SiteInitiation/05.03.02-SiteTrainingMaterial/ALLN-346-101_SiteTrainMtl_01JAN1900.PPT) (ppt) [ALLN-346]
                  - [ALLN-346-101_SiteTrainMtl_15JUL2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.03-SiteInitiation/05.03.02-SiteTrainingMaterial/ALLN-346-101_SiteTrainMtl_15JUL2021.pdf) (pdf) [ALLN-346]
              - **05.04-SiteManagement/**
                - **05.04.06-ProtocolDeviations/**
                  - [ALLN-346-101_ProtDevListing_31JAN2022.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.04-SiteManagement/05.04.06-ProtocolDeviations/ALLN-346-101_ProtDevListing_31JAN2022.xlsx) (xlsx) [ALLN-346]
              - **05.05-General/**
                - **05.05.03-MeetingMaterial/**
                  - [ALLN-346-101_PICRCMtgAgenda_02DEC2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_02DEC2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_04NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_04NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_11NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_11NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_14OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_14OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_16DEC2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_16DEC2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_18NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_18NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_21OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_21OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgAgenda_28OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgAgenda_28OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_02DEC2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_02DEC2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_04NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_04NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_11NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_11NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_14OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_14OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_16DEC2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_16DEC2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_18NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_18NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_21OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_21OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_PICRCMtgMins_28OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/05-SiteManagement/05.05-General/05.05.03-MeetingMaterial/ALLN-346-101_PICRCMtgMins_28OCT2020.pdf) (pdf) [ALLN-346]
            - **06-IPandTrialSupplies/**
              - **06.01-IPDocumentation/**
                - **06.01.03-IPSampleLabel/**
                  - [ALLN-346-101_FinalLblProofs_30JUN2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/06-IPandTrialSupplies/06.01-IPDocumentation/06.01.03-IPSampleLabel/ALLN-346-101_FinalLblProofs_30JUN2020.pdf) (pdf) [ALLN-346]
              - **06.07-General/**
                - **06.07.01-RelevantCommunications/**
                  - [ALLN-346-101_IPandTrialSuppliesCorresp_20AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/06-IPandTrialSupplies/06.07-General/06.07.01-RelevantCommunications/ALLN-346-101_IPandTrialSuppliesCorresp_20AUG2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_IPandTrialSuppliesCorresp_20AUG2020_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/06-IPandTrialSupplies/06.07-General/06.07.01-RelevantCommunications/ALLN-346-101_IPandTrialSuppliesCorresp_20AUG2020_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_IPandTrialSuppliesCorresp_26OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/06-IPandTrialSupplies/06.07-General/06.07.01-RelevantCommunications/ALLN-346-101_IPandTrialSuppliesCorresp_26OCT2020.pdf) (pdf) [ALLN-346]
            - **07-SafetyReporting/**
              - **07.03-General/**
                - **07.03.01-RelevantCommunications/**
                  - [ALLN-346-101_SafetyCorresp_02OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_02OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SafetyCorresp_12NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_12NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SafetyCorresp_13OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_13OCT2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SafetyCorresp_14SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_14SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SafetyCorresp_21SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_21SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_SafetyCorresp_27OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/07-SafetyReporting/07.03-General/07.03.01-RelevantCommunications/ALLN-346-101_SafetyCorresp_27OCT2020.pdf) (pdf) [ALLN-346]
            - **09-Thirdparties/**
              - **09.02-ThirdPartySet-up/**
                - **09.02.03-ContractualAgreement/**
                  - [ALLN-346-101_TaskOrder_01MAY2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/09-Thirdparties/09.02-ThirdPartySet-up/09.02.03-ContractualAgreement/ALLN-346-101_TaskOrder_01MAY2020.PDF) (pdf) [ALLN-346]
                  - [ALLN-346-101_TaskOrder_01MAY2020_[1].PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/09-Thirdparties/09.02-ThirdPartySet-up/09.02.03-ContractualAgreement/ALLN-346-101_TaskOrder_01MAY2020_[1].PDF) (pdf) [ALLN-346]
            - **10-DataManagement/**
              - **10.02-DataCapture/**
                - **10.02.01-CRFCompletionRequirements/**
                  - [ALLN-346-101_CRFComplGls_V1.0_01SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.02-DataCapture/10.02.01-CRFCompletionRequirements/ALLN-346-101_CRFComplGls_V1.0_01SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_CRFComplGlsApv_V1.0_01SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.02-DataCapture/10.02.01-CRFCompletionRequirements/ALLN-346-101_CRFComplGlsApv_V1.0_01SEP2020.pdf) (pdf) [ALLN-346]
                - **10.02.02-AnnotatedCRF/**
                  - [ALLN-346-101_DataEntryAnnotatedCRFs_02SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.02-DataCapture/10.02.02-AnnotatedCRF/ALLN-346-101_DataEntryAnnotatedCRFs_02SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_DataEntryAnnotatedCRFs_08SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.02-DataCapture/10.02.02-AnnotatedCRF/ALLN-346-101_DataEntryAnnotatedCRFs_08SEP2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_DataEntryAnnotatedCRFs_12AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.02-DataCapture/10.02.02-AnnotatedCRF/ALLN-346-101_DataEntryAnnotatedCRFs_12AUG2020.pdf) (pdf) [ALLN-346]
              - **10.03-Database/**
                - **10.03.01-DatabaseSpecifications/**
                  - [ALLN-346-101_DataEntryDesignSpecs_15JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.01-DatabaseSpecifications/ALLN-346-101_DataEntryDesignSpecs_15JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_DataEntryReqmtSpecs_15JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.01-DatabaseSpecifications/ALLN-346-101_DataEntryReqmtSpecs_15JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_DBDefCover_27OCT2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.01-DatabaseSpecifications/ALLN-346-101_DBDefCover_27OCT2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_DBStructure_05MAY2021.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.01-DatabaseSpecifications/ALLN-346-101_DBStructure_05MAY2021.rtf) (rtf) [ALLN-346]
                  - [ALLN-346-101_MappedAnnotatedCRFs_26OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.01-DatabaseSpecifications/ALLN-346-101_MappedAnnotatedCRFs_26OCT2020.pdf) (pdf) [ALLN-346]
                - **10.03.02-EditCheckPlan/**
                  - [ALLN-346-101_EditCheckSpecs_V1.0_01SEP2020.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.02-EditCheckPlan/ALLN-346-101_EditCheckSpecs_V1.0_01SEP2020.xls) (xls) [ALLN-346]
                  - [ALLN-346-101_EditCheckSpecsApv_V1.0_01SEP2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.02-EditCheckPlan/ALLN-346-101_EditCheckSpecsApv_V1.0_01SEP2020.pdf) (pdf) [ALLN-346]
                - **10.03.04-EditCheckTesting/**
                  - [ALLN-346-101_IntegrationTestingResult_05AUG2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_IntegrationTestingResult_05AUG2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_IntegrationTestingResult_17JUL2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_IntegrationTestingResult_17JUL2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_IntegrationTestingResult_24AUG2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_IntegrationTestingResult_24AUG2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_TestPlan_15JUL2020.docm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_TestPlan_15JUL2020.docm) (docm) [ALLN-346]
                  - [ALLN-346-101_TestPlan_29JUL2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_TestPlan_29JUL2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_UATestResult_20JUL2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_UATestResult_20JUL2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_UATestResult_24AUG2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_UATestResult_24AUG2020.doc) (doc) [ALLN-346]
                  - [ALLN-346-101_UATestResult_31AUG2020.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.04-EditCheckTesting/ALLN-346-101_UATestResult_31AUG2020.doc) (doc) [ALLN-346]
                - **10.03.08-SAEReconciliation/**
                  - [ALLN-346-101_SAEReconciliation_23NOV2020.msg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.08-SAEReconciliation/ALLN-346-101_SAEReconciliation_23NOV2020.msg) (msg) [ALLN-346]
                - **10.03.09-DictionaryCoding/**
                  - [ALLN-346-101_MedCodingApv_23NOV2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.09-DictionaryCoding/ALLN-346-101_MedCodingApv_23NOV2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MedCodingApv_23NOV2020_[1].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.09-DictionaryCoding/ALLN-346-101_MedCodingApv_23NOV2020_[1].pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_MedCodingApv_23NOV2020_[2].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.03-Database/10.03.09-DictionaryCoding/ALLN-346-101_MedCodingApv_23NOV2020_[2].pdf) (pdf) [ALLN-346]
              - **10.04-EDCManagement/**
                - **10.04.01-SystemAccountManagement/**
                  - [ALLN-346-101_UserList_07MAR2022.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.01-SystemAccountManagement/ALLN-346-101_UserList_07MAR2022.xls) (xls) [ALLN-346]
                - **10.04.02-TechnicalDesignDocument/**
                  - [ALLN-346-101_CRFSpecs_V1.0_14JUL2020.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.02-TechnicalDesignDocument/ALLN-346-101_CRFSpecs_V1.0_14JUL2020.xlsm) (xlsm) [ALLN-346]
                  - [ALLN-346-101_CRFSpecsApv_V1.0_15JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.02-TechnicalDesignDocument/ALLN-346-101_CRFSpecsApv_V1.0_15JUL2020.pdf) (pdf) [ALLN-346]
                - **10.04.03-ValidationDocuments/**
                  - [ALLN-346-101_EDCIntegrationTestingResult_17JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.03-ValidationDocuments/ALLN-346-101_EDCIntegrationTestingResult_17JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_EDCTestPlan_15JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.03-ValidationDocuments/ALLN-346-101_EDCTestPlan_15JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_EDCUATestResult_20JUL2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.03-ValidationDocuments/ALLN-346-101_EDCUATestResult_20JUL2020.pdf) (pdf) [ALLN-346]
                  - [ALLN-346-101_EDCValidationRpt_17AUG2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/10-DataManagement/10.04-EDCManagement/10.04.03-ValidationDocuments/ALLN-346-101_EDCValidationRpt_17AUG2020.pdf) (pdf) [ALLN-346]
            - **11-Statistics/**
              - **11.02-Randomization/**
                - **11.02.01-RandomizationPlan/**
                  - [ALLN-346-101_RandPlan_V1.0_06JUL2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.02-Randomization/11.02.01-RandomizationPlan/ALLN-346-101_RandPlan_V1.0_06JUL2020.PDF) (pdf) [ALLN-346]
                - **11.02.03-MasterRandomizationList/**
                  - [ALLN-346-101_RandList_03AUG2020.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.02-Randomization/11.02.03-MasterRandomizationList/ALLN-346-101_RandList_03AUG2020.PDF) (pdf) [ALLN-346]
                - **11.02.04-RandomizationProgramming/**
                  - [ALLN-346-101_RandProgram_09JUL2020.txt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.02-Randomization/11.02.04-RandomizationProgramming/ALLN-346-101_RandProgram_09JUL2020.txt) (txt) [ALLN-346]
              - **11.03-Analysis/**
                - **11.03.02-AnalysisQCDocumentation/**
                  - [ALLN-346-101_AnalysisTrackingSpreadsheet_06OCT2020.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_06OCT2020.docx) (docx) [ALLN-346]
                  - [ALLN-346-101_AnalysisTrackingSpreadsheet_15OCT2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_15OCT2021.xlsx) (xlsx) [ALLN-346]
                  - [ALLN-346-101_AnalysisTrackingSpreadsheet_16AUG2022.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-101_AnalysisTrackingSpreadsheet_16AUG2022.xlsx) (xlsx) [ALLN-346]
                - **11.03.07-FinalAnalysisRawDatasets/**
                  - [ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-101_FinalAnalysisRawDatasets_23SEP2021.zip) (zip) [ALLN-346]
                - **11.03.08-FinalAnalysisPrograms/**
                  - [ALLN-346-101_FinalAnalysisProgs_16AUG2022.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-101_FinalAnalysisProgs_16AUG2022.zip) (zip) [ALLN-346]
                - **11.03.09-FinalAnalysisDatasets/**
                  - [ALLN-346-101_FinalAnalysisDatasets_13OCT2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-101_FinalAnalysisDatasets_13OCT2021.zip) (zip) [ALLN-346]
                - **11.03.10-FinalAnalysisOutput/**
                  - [ALLN-346-101_FinalAnalysisOutput_16AUG2022.ZIP](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/GeneralFiles/11-Statistics/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-101_FinalAnalysisOutput_16AUG2022.ZIP) (zip) [ALLN-346]
          - [index.html](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/index.html) (html) [ALLN-346]
          - [IndexReport.csv](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/IndexReport.csv) (csv) [ALLN-346]
          - **SiteFiles/**
            - **001Vrishabhendra/**
              - **05-SiteManagement/**
                - **05.02-SiteSet-up/**
                  - **05.02.08-FormFDA1572/**
                    - [ALLN-346-101_001_FDA1572_15OCT2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/SiteFiles/001Vrishabhendra/05-SiteManagement/05.02-SiteSet-up/05.02.08-FormFDA1572/ALLN-346-101_001_FDA1572_15OCT2020.pdf) (pdf) [ALLN-346]
          - [SummaryRun.txt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/SummaryRun.txt) (txt) [ALLN-346]
          - [TMFFiles_IndexReport.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/101-SAD/346-101%20TMF/TMFFiles_IndexReport.xlsx) (xlsx) [ALLN-346]
      - **102-MAD/**
        - **CSR and TLF/**
          - [Allena ALLN-346-102_CSR_v1.0_2022 August 29 final2.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/Allena%20ALLN-346-102_CSR_v1.0_2022%20August%2029%20final2.pdf) (pdf) [ALLN-346]
          - **ALLN-346-102 TLF data/**
            - **ALLN-346-102 Prefinal_TFL_15Oct2021/**
              - **ALLN-346-102 Prefinal Figure/**
                - [ALLN-346-102 Prefinal Figure.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Figure/ALLN-346-102%20Prefinal%20Figure.PDF) (pdf) [ALLN-346]
                - [F14.2.1.1_urate.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Figure/F14.2.1.1_urate.rtf) (rtf) [ALLN-346]
              - [ALLN-346-102 Prefinal Figure.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Figure.zip) (zip) [ALLN-346]
              - **ALLN-346-102 Prefinal Listings/**
                - [ALLN-346-102 Prefinal Listings.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/ALLN-346-102%20Prefinal%20Listings.PDF) (pdf) [ALLN-346]
                - [L16.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.1.1_disp.rtf) (rtf) [ALLN-346]
                - [L16.1.2_ie.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.1.2_ie.rtf) (rtf) [ALLN-346]
                - [L16.1.3_visits.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.1.3_visits.rtf) (rtf) [ALLN-346]
                - [L16.2.1_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.1_prot_dev.rtf) (rtf) [ALLN-346]
                - [L16.2.2_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.2_demo.rtf) (rtf) [ALLN-346]
                - [L16.2.3_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.3_medhist.rtf) (rtf) [ALLN-346]
                - [L16.2.4_conmeds.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.4_conmeds.rtf) (rtf) [ALLN-346]
                - [L16.2.5_conprocedures.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.5_conprocedures.rtf) (rtf) [ALLN-346]
                - [L16.2.6_drug_adamin.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.6_drug_adamin.rtf) (rtf) [ALLN-346]
                - [L16.2.7_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.7_pk.rtf) (rtf) [ALLN-346]
                - [L16.2.9_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.9_crp.rtf) (rtf) [ALLN-346]
                - [L16.2.8.1_pd.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.8.1_pd.rtf) (rtf) [ALLN-346]
                - [L16.2.8.2_24h_urine.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.2.8.2_24h_urine.rtf) (rtf) [ALLN-346]
                - [L16.3.1_ae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.1_ae.rtf) (rtf) [ALLN-346]
                - [L16.3.3_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.3_vital.rtf) (rtf) [ALLN-346]
                - [L16.3.4_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.4_ecg.rtf) (rtf) [ALLN-346]
                - [L16.3.5_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.5_pe.rtf) (rtf) [ALLN-346]
                - [L16.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.4_critlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.2.4_critlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.5_otherlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings/L16.3.2.5_otherlab.rtf) (rtf) [ALLN-346]
              - [ALLN-346-102 Prefinal Listings.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Listings.zip) (zip) [ALLN-346]
              - **ALLN-346-102 Prefinal Tables/**
                - [ALLN-346-102 Prefinal Tables.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/ALLN-346-102%20Prefinal%20Tables.PDF) (pdf) [ALLN-346]
                - [T14.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.1_disp.rtf) (rtf) [ALLN-346]
                - [T14.1.2_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.2_prot_dev.rtf) (rtf) [ALLN-346]
                - [T14.1.4_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.4_medhist.rtf) (rtf) [ALLN-346]
                - [T14.1.6_expcomp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.6_expcomp.rtf) (rtf) [ALLN-346]
                - [T14.1.3.1_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.3.1_demo.rtf) (rtf) [ALLN-346]
                - [T14.1.5.1_priormed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.5.1_priormed.rtf) (rtf) [ALLN-346]
                - [T14.1.5.2_conmed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.5.2_conmed.rtf) (rtf) [ALLN-346]
                - [T14.1.5.3_conpro.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.1.5.3_conpro.rtf) (rtf) [ALLN-346]
                - [T14.2.1.1_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.2.1.1_pk.rtf) (rtf) [ALLN-346]
                - [T14.2.2.1_pd.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.2.2.1_pd.rtf) (rtf) [ALLN-346]
                - [T14.2.2.2_pd_secondary.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.2.2.2_pd_secondary.rtf) (rtf) [ALLN-346]
                - [T14.2.3.1_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.2.3.1_crp.rtf) (rtf) [ALLN-346]
                - [T14.3.4_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.4_ecg.rtf) (rtf) [ALLN-346]
                - [T14.3.5_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.5_pe.rtf) (rtf) [ALLN-346]
                - [T14.3.1.1_aesumm.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.1_aesumm.rtf) (rtf) [ALLN-346]
                - [T14.3.1.2_teae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.2_teae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.3_teae_sev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.3_teae_sev.rtf) (rtf) [ALLN-346]
                - [T14.3.1.4_ae_cov19.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.4_ae_cov19.rtf) (rtf) [ALLN-346]
                - [T14.3.1.5_ae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.5_ae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.6_sae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.6_sae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.7_tesae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.7_tesae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.8_teae_discont.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.8_teae_discont.rtf) (rtf) [ALLN-346]
                - [T14.3.1.9_ae_death.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.1.9_ae_death.rtf) (rtf) [ALLN-346]
                - [T14.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.4_abnorm_lab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.2.4_abnorm_lab.rtf) (rtf) [ALLN-346]
                - [T14.3.3.1_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.3.1_vital.rtf) (rtf) [ALLN-346]
                - [T14.3.3.2_abnorm_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables/T14.3.3.2_abnorm_vital.rtf) (rtf) [ALLN-346]
              - [ALLN-346-102 Prefinal Tables.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021/ALLN-346-102%20Prefinal%20Tables.zip) (zip) [ALLN-346]
            - [ALLN-346-102 Prefinal_TFL_15Oct2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/ALLN-346-102%20Prefinal_TFL_15Oct2021.zip) (zip) [ALLN-346]
            - **Prefinal Items/**
              - **Prefinal Figures/**
                - [ALLN-346-102 Prefinal Figure.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Figures/ALLN-346-102%20Prefinal%20Figure.PDF) (pdf) [ALLN-346]
                - [F14.2.1.1_urate.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Figures/F14.2.1.1_urate.docx) (docx) [ALLN-346]
              - **Prefinal Listings/**
                - [ALLN-346-102 Prefinal Listings.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/ALLN-346-102%20Prefinal%20Listings.PDF) (pdf) [ALLN-346]
                - [L16.1.1_disp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.1.1_disp.docx) (docx) [ALLN-346]
                - [L16.1.2_ie.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.1.2_ie.docx) (docx) [ALLN-346]
                - [L16.1.3_visits.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.1.3_visits.docx) (docx) [ALLN-346]
                - [L16.2.1_prot_dev.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.1_prot_dev.docx) (docx) [ALLN-346]
                - [L16.2.2_demo.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.2_demo.docx) (docx) [ALLN-346]
                - [L16.2.3_medhist.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.3_medhist.docx) (docx) [ALLN-346]
                - [L16.2.4_conmeds.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.4_conmeds.docx) (docx) [ALLN-346]
                - [L16.2.5_conprocedures.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.5_conprocedures.docx) (docx) [ALLN-346]
                - [L16.2.6_drug_adamin.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.6_drug_adamin.docx) (docx) [ALLN-346]
                - [L16.2.7_pk.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.7_pk.docx) (docx) [ALLN-346]
                - [L16.2.9_crp.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.9_crp.docx) (docx) [ALLN-346]
                - [L16.2.8.1_pd.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.8.1_pd.docx) (docx) [ALLN-346]
                - [L16.2.8.2_24h_urine.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.2.8.2_24h_urine.docx) (docx) [ALLN-346]
                - [L16.3.1_ae.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.1_ae.docx) (docx) [ALLN-346]
                - [L16.3.3_vital.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.3_vital.docx) (docx) [ALLN-346]
                - [L16.3.4_ecg.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.4_ecg.docx) (docx) [ALLN-346]
                - [L16.3.5_pe.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.5_pe.docx) (docx) [ALLN-346]
                - [L16.3.2.1_chemlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.2.1_chemlab.docx) (docx) [ALLN-346]
                - [L16.3.2.2_hemalab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.2.2_hemalab.docx) (docx) [ALLN-346]
                - [L16.3.2.3_urlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.2.3_urlab.docx) (docx) [ALLN-346]
                - [L16.3.2.4_critlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.2.4_critlab.docx) (docx) [ALLN-346]
                - [L16.3.2.5_otherlab.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Listings/L16.3.2.5_otherlab.docx) (docx) [ALLN-346]
              - **Prefinal Tables/**
                - [ALLN-346-102 Prefinal Tables.PDF](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/ALLN-346-102%20TLF%20data/Prefinal%20Items/Prefinal%20Tables/ALLN-346-102%20Prefinal%20Tables.PDF) (pdf) [ALLN-346]
          - [PI_Allena_Sign_ALLN346102CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/PI_Allena_Sign_ALLN346102CSR.pdf) (pdf) [ALLN-346]
          - **346-102 CRFs and Appendices/**
            - **alln-346-102 Appendices new and updated-OneDrive_2022-08-29 (1)/**
              - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/alln-346-102%20Appendices%20new%20and%20updated-OneDrive_2022-08-29%20(1)/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
              - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/alln-346-102%20Appendices%20new%20and%20updated-OneDrive_2022-08-29%20(1)/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
              - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/alln-346-102%20Appendices%20new%20and%20updated-OneDrive_2022-08-29%20(1)/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
              - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/alln-346-102%20Appendices%20new%20and%20updated-OneDrive_2022-08-29%20(1)/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
            - [alln-346-102 Appendices new and updated-OneDrive_2022-08-29 (1).zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/alln-346-102%20Appendices%20new%20and%20updated-OneDrive_2022-08-29%20(1).zip) (zip) [ALLN-346]
            - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
            - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
            - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
            - [16.1.4 List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.4%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
            - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
            - [16.1.5 Signatures Investigators_346-102.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.5%20Signatures%20Investigators_346-102.pdf) (pdf) [ALLN-346]
            - [16.1.6 List Patients with Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.6%20List%20Patients%20with%20Batches.pdf) (pdf) [ALLN-346]
            - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
            - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
            - [16.1.10 Inter-Laboratory Standardization Methods Quality Assurance.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.10%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance.pdf) (pdf) [ALLN-346]
            - [16.1.11 Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.11%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
            - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
            - [16.2.1 Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.1%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
            - [16.2.2 Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.2%20Protocol%20Deviations.pdf) (pdf) [ALLN-346]
            - [16.2.3 Patients Excluded from Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.3%20Patients%20Excluded%20from%20Efficacy%20Analysis.pdf) (pdf) [ALLN-346]
            - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-346]
            - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
            - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
            - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
            - [16.2.8 Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.8%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
            - [16.2.9 Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.2.9%20Other%20Safety%20Data.pdf) (pdf) [ALLN-346]
            - [16.3.1 CRFs for Deaths, SAEs, and Withdrawals.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.3.1%20CRFs%20for%20Deaths,%20SAEs,%20and%20Withdrawals.pdf) (pdf) [ALLN-346]
            - [16.4 Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/16.4%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-346]
            - **346-102 Appendices_OneDrive_2022-08-05/**
              - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
              - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
              - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
              - [16.1.4 List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.4%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
              - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
              - [16.1.6 List Patients with Batches.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.6%20List%20Patients%20with%20Batches.pdf) (pdf) [ALLN-346]
              - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
              - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
              - [16.1.9 Statistical Methods Interim Analysis Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.9%20Statistical%20Methods%20Interim%20Analysis%20Plan.pdf) (pdf) [ALLN-346]
              - [16.1.10 Inter-Laboratory Standardization Methods Quality Assurance.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.10%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance.pdf) (pdf) [ALLN-346]
              - [16.1.11 Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.11%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
              - [16.1.12 Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.12%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-346]
              - [16.1.13 Other Reports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.1.13%20Other%20Reports.pdf) (pdf) [ALLN-346]
              - [16.2.1 Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.1%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
              - [16.2.2 Protocol Deviations.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.2%20Protocol%20Deviations.pdf) (pdf) [ALLN-346]
              - [16.2.3 Patients Excluded from Efficacy Analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.3%20Patients%20Excluded%20from%20Efficacy%20Analysis.pdf) (pdf) [ALLN-346]
              - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-346]
              - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
              - [16.2.6 Individual Efficacy Response Data Phase II-III.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.6%20Individual%20Efficacy%20Response%20Data%20Phase%20II-III.pdf) (pdf) [ALLN-346]
              - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
              - [16.2.8 Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.8%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
              - [16.2.9 Other Safety Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.2.9%20Other%20Safety%20Data.pdf) (pdf) [ALLN-346]
              - [16.3.1 CRFs for Deaths, SAEs, and Withdrawals.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.3.1%20CRFs%20for%20Deaths,%20SAEs,%20and%20Withdrawals.pdf) (pdf) [ALLN-346]
              - [16.4 Individual Patient Data Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05/16.4%20Individual%20Patient%20Data%20Listings.pdf) (pdf) [ALLN-346]
            - [346-102 Appendices_OneDrive_2022-08-05.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/CSR%20and%20TLF/346-102%20CRFs%20and%20Appendices/346-102%20Appendices_OneDrive_2022-08-05.zip) (zip) [ALLN-346]
        - **Datasets/**
          - **11.03-Analysis/**
            - **11.03.01-DataDefinitionsforAnalysisDatasets/**
              - [ALLN-346-102_ADaMSpecs_V01_10MAY2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-102_ADaMSpecs_V01_10MAY2021.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-102_AnnotatedCRFs_20MAY2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-102_AnnotatedCRFs_20MAY2021.pdf) (pdf) [ALLN-346]
              - [ALLN-346-102_SDTMDBSpecs_21MAY2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-102_SDTMDBSpecs_21MAY2021.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-102_SDTMDBStructure_20MAY2021.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.01-DataDefinitionsforAnalysisDatasets/ALLN-346-102_SDTMDBStructure_20MAY2021.rtf) (rtf) [ALLN-346]
            - **11.03.02-AnalysisQCDocumentation/**
              - [ALLN-346-102_AnalysisTrackingSpreadsheet_14OCT2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-102_AnalysisTrackingSpreadsheet_14OCT2021.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-102_SDTMValidationRpt_10MAY2021.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.02-AnalysisQCDocumentation/ALLN-346-102_SDTMValidationRpt_10MAY2021.docx) (docx) [ALLN-346]
            - **11.03.07-FinalAnalysisRawDatasets/**
              - **ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/**
                - **New folder/**
                  - [ae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [cm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/cm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [co.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/co.sas7bdat) (sas7bdat) [ALLN-346]
                  - [dm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/dm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ds.sas7bdat) (sas7bdat) [ALLN-346]
                  - [dv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/dv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [eg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/eg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ex.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ex.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ho.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ho.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ie.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ie.sas7bdat) (sas7bdat) [ALLN-346]
                  - [is.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/is.sas7bdat) (sas7bdat) [ALLN-346]
                  - [lb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/lb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [mb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/mb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [mh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/mh.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ml.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ml.sas7bdat) (sas7bdat) [ALLN-346]
                  - [pc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/pc.sas7bdat) (sas7bdat) [ALLN-346]
                  - [pe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/pe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [pr.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/pr.sas7bdat) (sas7bdat) [ALLN-346]
                  - [relrec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/relrec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [rp.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/rp.sas7bdat) (sas7bdat) [ALLN-346]
                  - [se.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/se.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppcm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppdm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppdm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppds.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppds.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppdv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppdv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppec.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppec.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppeg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [supplb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/supplb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppmb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppmb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [supppe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/supppe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [suppve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/suppve.sas7bdat) (sas7bdat) [ALLN-346]
                  - [sv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/sv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ta.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ta.sas7bdat) (sas7bdat) [ALLN-346]
                  - [te.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/te.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ti.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ti.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ts.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ts.sas7bdat) (sas7bdat) [ALLN-346]
                  - [tv.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/tv.sas7bdat) (sas7bdat) [ALLN-346]
                  - [ve.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/ve.sas7bdat) (sas7bdat) [ALLN-346]
                  - [vs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/vs.sas7bdat) (sas7bdat) [ALLN-346]
                  - **XPT/**
                    - [ae.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ae.xpt) (xpt) [ALLN-346]
                    - [cm.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/cm.xpt) (xpt) [ALLN-346]
                    - [co.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/co.xpt) (xpt) [ALLN-346]
                    - [dm.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/dm.xpt) (xpt) [ALLN-346]
                    - [ds.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ds.xpt) (xpt) [ALLN-346]
                    - [dv.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/dv.xpt) (xpt) [ALLN-346]
                    - [ec.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ec.xpt) (xpt) [ALLN-346]
                    - [eg.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/eg.xpt) (xpt) [ALLN-346]
                    - [ex.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ex.xpt) (xpt) [ALLN-346]
                    - [is.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/is.xpt) (xpt) [ALLN-346]
                    - [lb.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/lb.xpt) (xpt) [ALLN-346]
                    - [mb.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/mb.xpt) (xpt) [ALLN-346]
                    - [mh.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/mh.xpt) (xpt) [ALLN-346]
                    - [ml.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ml.xpt) (xpt) [ALLN-346]
                    - [pc.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/pc.xpt) (xpt) [ALLN-346]
                    - [pe.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/pe.xpt) (xpt) [ALLN-346]
                    - [relrec.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/relrec.xpt) (xpt) [ALLN-346]
                    - [rp.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/rp.xpt) (xpt) [ALLN-346]
                    - [se.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/se.xpt) (xpt) [ALLN-346]
                    - [suppae.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppae.xpt) (xpt) [ALLN-346]
                    - [suppcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppcm.xpt) (xpt) [ALLN-346]
                    - [suppds.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppds.xpt) (xpt) [ALLN-346]
                    - [suppdv.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppdv.xpt) (xpt) [ALLN-346]
                    - [suppec.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppec.xpt) (xpt) [ALLN-346]
                    - [suppeg.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppeg.xpt) (xpt) [ALLN-346]
                    - [supppe.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/supppe.xpt) (xpt) [ALLN-346]
                    - [suppve.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/suppve.xpt) (xpt) [ALLN-346]
                    - [sv.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/sv.xpt) (xpt) [ALLN-346]
                    - [ta.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ta.xpt) (xpt) [ALLN-346]
                    - [te.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/te.xpt) (xpt) [ALLN-346]
                    - [ti.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ti.xpt) (xpt) [ALLN-346]
                    - [ts.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ts.xpt) (xpt) [ALLN-346]
                    - [tv.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/tv.xpt) (xpt) [ALLN-346]
                    - [ve.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/ve.xpt) (xpt) [ALLN-346]
                    - [vs.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021/New%20folder/XPT/vs.xpt) (xpt) [ALLN-346]
              - [ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.07-FinalAnalysisRawDatasets/ALLN-346-102_FinalAnalysisRawDatasets_26OCT2021.zip) (zip) [ALLN-346]
            - **11.03.08-FinalAnalysisPrograms/**
              - **ALLN-346-102_FinalAnalysisProgs_04NOV2021/**
                - [adae.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adae.sas) (sas) [ALLN-346]
                - [adcm.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adcm.sas) (sas) [ALLN-346]
                - [adeg.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adeg.sas) (sas) [ALLN-346]
                - [adis.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adis.sas) (sas) [ALLN-346]
                - [adlb.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adlb.sas) (sas) [ALLN-346]
                - [admh.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/admh.sas) (sas) [ALLN-346]
                - [adpc.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adpc.sas) (sas) [ALLN-346]
                - [adpd.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adpd.sas) (sas) [ALLN-346]
                - [adpe.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adpe.sas) (sas) [ALLN-346]
                - [adsl.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/adsl.sas) (sas) [ALLN-346]
                - [advs.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/advs.sas) (sas) [ALLN-346]
                - [AE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/AE01.sas) (sas) [ALLN-346]
                - [AE11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/AE11.sas) (sas) [ALLN-346]
                - [AE12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/AE12.sas) (sas) [ALLN-346]
                - [AE13.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/AE13.sas) (sas) [ALLN-346]
                - [CM01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/CM01.sas) (sas) [ALLN-346]
                - [CM11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/CM11.sas) (sas) [ALLN-346]
                - [DM01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DM01.sas) (sas) [ALLN-346]
                - [DM11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DM11.sas) (sas) [ALLN-346]
                - [DS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DS01.sas) (sas) [ALLN-346]
                - [DS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DS11.sas) (sas) [ALLN-346]
                - [DV01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DV01.sas) (sas) [ALLN-346]
                - [DV11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/DV11.sas) (sas) [ALLN-346]
                - [EC01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/EC01.sas) (sas) [ALLN-346]
                - [EF11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/EF11.sas) (sas) [ALLN-346]
                - [EG01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/EG01.sas) (sas) [ALLN-346]
                - [EG11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/EG11.sas) (sas) [ALLN-346]
                - [EX11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/EX11.sas) (sas) [ALLN-346]
                - [IE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/IE01.sas) (sas) [ALLN-346]
                - [IS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/IS01.sas) (sas) [ALLN-346]
                - [IS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/IS11.sas) (sas) [ALLN-346]
                - [IS12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/IS12.sas) (sas) [ALLN-346]
                - [LB01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/LB01.sas) (sas) [ALLN-346]
                - [LB11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/LB11.sas) (sas) [ALLN-346]
                - [LB12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/LB12.sas) (sas) [ALLN-346]
                - [LB13.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/LB13.sas) (sas) [ALLN-346]
                - [LB21.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/LB21.sas) (sas) [ALLN-346]
                - [macro_sc.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/macro_sc.sas) (sas) [ALLN-346]
                - [MH01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/MH01.sas) (sas) [ALLN-346]
                - [MH11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/MH11.sas) (sas) [ALLN-346]
                - [PC01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/PC01.sas) (sas) [ALLN-346]
                - [PC11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/PC11.sas) (sas) [ALLN-346]
                - [PD01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/PD01.sas) (sas) [ALLN-346]
                - [PE01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/PE01.sas) (sas) [ALLN-346]
                - [PE11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/PE11.sas) (sas) [ALLN-346]
                - [SV01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/SV01.sas) (sas) [ALLN-346]
                - [utility.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/utility.sas) (sas) [ALLN-346]
                - [VS01.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/VS01.sas) (sas) [ALLN-346]
                - [VS11.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/VS11.sas) (sas) [ALLN-346]
                - [VS12.sas](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021/VS12.sas) (sas) [ALLN-346]
              - [ALLN-346-102_FinalAnalysisProgs_04NOV2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.08-FinalAnalysisPrograms/ALLN-346-102_FinalAnalysisProgs_04NOV2021.zip) (zip) [ALLN-346]
            - **11.03.09-FinalAnalysisDatasets/**
              - **ALLN-346-102_FinalAnalysisDatasets_30SEP2021/**
                - **Data/**
                  - [adae.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adae.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adae.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adae.xpt) (xpt) [ALLN-346]
                  - [adcm.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adcm.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adcm.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adcm.xpt) (xpt) [ALLN-346]
                  - [adeg.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adeg.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adeg.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adeg.xpt) (xpt) [ALLN-346]
                  - [adis.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adis.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adis.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adis.xpt) (xpt) [ALLN-346]
                  - [adlb.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adlb.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adlb.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adlb.xpt) (xpt) [ALLN-346]
                  - [admh.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/admh.sas7bdat) (sas7bdat) [ALLN-346]
                  - [admh.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/admh.xpt) (xpt) [ALLN-346]
                  - [adpc.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpc.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpc.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpc.xpt) (xpt) [ALLN-346]
                  - [adpd.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpd.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpd.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpd.xpt) (xpt) [ALLN-346]
                  - [adpe.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpe.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adpe.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adpe.xpt) (xpt) [ALLN-346]
                  - [adsl.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adsl.sas7bdat) (sas7bdat) [ALLN-346]
                  - [adsl.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/adsl.xpt) (xpt) [ALLN-346]
                  - [advs.sas7bdat](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/advs.sas7bdat) (sas7bdat) [ALLN-346]
                  - [advs.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021/Data/advs.xpt) (xpt) [ALLN-346]
              - [ALLN-346-102_FinalAnalysisDatasets_30SEP2021.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.09-FinalAnalysisDatasets/ALLN-346-102_FinalAnalysisDatasets_30SEP2021.zip) (zip) [ALLN-346]
            - **11.03.10-FinalAnalysisOutput/**
              - **ALLN-346-102_FinalAnalysisOutput_16AUG2022/**
                - [F14.2.1.1_pd.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/F14.2.1.1_pd.rtf) (rtf) [ALLN-346]
                - [L16.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.1.1_disp.rtf) (rtf) [ALLN-346]
                - [L16.1.2_ie.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.1.2_ie.rtf) (rtf) [ALLN-346]
                - [L16.1.3_visits.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.1.3_visits.rtf) (rtf) [ALLN-346]
                - [L16.2.1_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.1_prot_dev.rtf) (rtf) [ALLN-346]
                - [L16.2.2_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.2_demo.rtf) (rtf) [ALLN-346]
                - [L16.2.3_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.3_medhist.rtf) (rtf) [ALLN-346]
                - [L16.2.4_conmeds.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.4_conmeds.rtf) (rtf) [ALLN-346]
                - [L16.2.5_conprocedures.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.5_conprocedures.rtf) (rtf) [ALLN-346]
                - [L16.2.6_drug_adamin.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.6_drug_adamin.rtf) (rtf) [ALLN-346]
                - [L16.2.7_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.7_pk.rtf) (rtf) [ALLN-346]
                - [L16.2.9_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.9_crp.rtf) (rtf) [ALLN-346]
                - [L16.2.8.1_pd.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.8.1_pd.rtf) (rtf) [ALLN-346]
                - [L16.2.8.2_24h_urine.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.2.8.2_24h_urine.rtf) (rtf) [ALLN-346]
                - [L16.3.1_ae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.1_ae.rtf) (rtf) [ALLN-346]
                - [L16.3.3_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.3_vital.rtf) (rtf) [ALLN-346]
                - [L16.3.4_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.4_ecg.rtf) (rtf) [ALLN-346]
                - [L16.3.5_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.5_pe.rtf) (rtf) [ALLN-346]
                - [L16.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.4_critlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.2.4_critlab.rtf) (rtf) [ALLN-346]
                - [L16.3.2.5_otherlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/L16.3.2.5_otherlab.rtf) (rtf) [ALLN-346]
                - [T14.1.1_disp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.1_disp.rtf) (rtf) [ALLN-346]
                - [T14.1.2_prot_dev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.2_prot_dev.rtf) (rtf) [ALLN-346]
                - [T14.1.4_medhist.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.4_medhist.rtf) (rtf) [ALLN-346]
                - [T14.1.6_expcomp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.6_expcomp.rtf) (rtf) [ALLN-346]
                - [T14.1.3.1_demo.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.3.1_demo.rtf) (rtf) [ALLN-346]
                - [T14.1.5.1_priormed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.5.1_priormed.rtf) (rtf) [ALLN-346]
                - [T14.1.5.2_conmed.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.5.2_conmed.rtf) (rtf) [ALLN-346]
                - [T14.1.5.3_conpro.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.1.5.3_conpro.rtf) (rtf) [ALLN-346]
                - [T14.2.1.1_pk.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.2.1.1_pk.rtf) (rtf) [ALLN-346]
                - [T14.2.2.1_pd.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.2.2.1_pd.rtf) (rtf) [ALLN-346]
                - [T14.2.2.2_pd_secondary.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.2.2.2_pd_secondary.rtf) (rtf) [ALLN-346]
                - [T14.2.3.1_crp.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.2.3.1_crp.rtf) (rtf) [ALLN-346]
                - [T14.3.4_ecg.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.4_ecg.rtf) (rtf) [ALLN-346]
                - [T14.3.5_pe.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.5_pe.rtf) (rtf) [ALLN-346]
                - [T14.3.1.1_aesumm.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.1_aesumm.rtf) (rtf) [ALLN-346]
                - [T14.3.1.2_teae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.2_teae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.3_teae_sev.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.3_teae_sev.rtf) (rtf) [ALLN-346]
                - [T14.3.1.4_ae_cov19.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.4_ae_cov19.rtf) (rtf) [ALLN-346]
                - [T14.3.1.5_ae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.5_ae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.6_sae.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.6_sae.rtf) (rtf) [ALLN-346]
                - [T14.3.1.7_tesae_rel.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.7_tesae_rel.rtf) (rtf) [ALLN-346]
                - [T14.3.1.8_teae_discont.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.8_teae_discont.rtf) (rtf) [ALLN-346]
                - [T14.3.1.9_ae_death.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.1.9_ae_death.rtf) (rtf) [ALLN-346]
                - [T14.3.2.1_chemlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.2.1_chemlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.2_hemalab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.2.2_hemalab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.3_urlab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.2.3_urlab.rtf) (rtf) [ALLN-346]
                - [T14.3.2.4_abnorm_lab.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.2.4_abnorm_lab.rtf) (rtf) [ALLN-346]
                - [T14.3.3.1_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.3.1_vital.rtf) (rtf) [ALLN-346]
                - [T14.3.3.2_abnorm_vital.rtf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022/T14.3.3.2_abnorm_vital.rtf) (rtf) [ALLN-346]
              - [ALLN-346-102_FinalAnalysisOutput_16AUG2022.ZIP](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/Datasets/11.03-Analysis/11.03.10-FinalAnalysisOutput/ALLN-346-102_FinalAnalysisOutput_16AUG2022.ZIP) (zip) [ALLN-346]
        - **protocol/**
          - [Protocol ALLN-346-102 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/102-MAD/protocol/Protocol%20ALLN-346-102%20FINAL.pdf) (pdf) [ALLN-346]
      - **103-BBD/**
        - [BDD20261_Data_Management_Plan_Version_1.0_08Dec2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/BDD20261_Data_Management_Plan_Version_1.0_08Dec2021.pdf) (pdf) [ALLN-346]
        - **CSR/**
          - [CSR_Allena_v1.0_18Jan2023-CT signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/CSR/CSR_Allena_v1.0_18Jan2023-CT%20signed.pdf) (pdf) [ALLN-346]
          - [Summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/CSR/Summary.pdf) (pdf) [ALLN-346]
        - **protocol/**
          - [favourable_opinion_rec.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/protocol/favourable_opinion_rec.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-103 Administrative Amendment 1 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/protocol/Protocol%20ALLN-346-103%20Administrative%20Amendment%201%20FINAL.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-103 Administrative Amendment 2 FINAL 08Feb2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/protocol/Protocol%20ALLN-346-103%20Administrative%20Amendment%202%20FINAL%2008Feb2022.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-103 Amendment 1 FINAL 17Sep2021_signed - Copy.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/protocol/Protocol%20ALLN-346-103%20Amendment%201%20FINAL%2017Sep2021_signed%20-%20Copy.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-103 FINAL 14Aug2021_fully signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/protocol/Protocol%20ALLN-346-103%20FINAL%2014Aug2021_fully%20signed.pdf) (pdf) [ALLN-346]
        - [Summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/103-BBD/Summary.pdf) (pdf) [ALLN-346]
      - **201/**
        - **Absorption PK/**
          - [SR-83-04-03 Quantitation of Urate Oxidase (ALLN-346) in Human Serum by ELISA for Sponsor B003 Sample Analysis Report Final.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Absorption%20PK/SR-83-04-03%20Quantitation%20of%20Urate%20Oxidase%20(ALLN-346)%20in%20Human%20Serum%20by%20ELISA%20for%20Sponsor%20B003%20Sample%20Analysis%20Report%20Final.pdf) (pdf) [ALLN-346]
        - **Data ADaM SDTM/**
          - [RE_ ALLN-346 (CA34272) safety ADaM pakage PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Data%20ADaM%20SDTM/RE_%20ALLN-346%20(CA34272)%20safety%20ADaM%20pakage%20PW.pdf) (pdf) [ALLN-346]
        - **Datasets/**
          - **201 Data ADaM SDTM/**
            - **Allena_CA34272_SDTM_Safety_PD_26APR2022/**
            - [Allena_CA34272_SDTM_Safety_PD_26APR2022.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Datasets/201%20Data%20ADaM%20SDTM/Allena_CA34272_SDTM_Safety_PD_26APR2022.zip) (zip) [ALLN-346]
            - **Draft ADaM Package Allena CA34272 26APR22/**
              - **Data/**
            - [Draft ADaM Package Allena CA34272 26APR22.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Datasets/201%20Data%20ADaM%20SDTM/Draft%20ADaM%20Package%20Allena%20CA34272%2026APR22.zip) (zip) [ALLN-346]
            - [RE_ ALLN-346 (CA34272) safety ADaM pakage PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Datasets/201%20Data%20ADaM%20SDTM/RE_%20ALLN-346%20(CA34272)%20safety%20ADaM%20pakage%20PW.pdf) (pdf) [ALLN-346]
            - [RE_ ALLN-346 (CA34272) safety and PD SDTM package-PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Datasets/201%20Data%20ADaM%20SDTM/RE_%20ALLN-346%20(CA34272)%20safety%20and%20PD%20SDTM%20package-PW.pdf) (pdf) [ALLN-346]
        - **draft CSR and appendices/**
          - [CA34272 Deviations - CJN - CT - CJN 15Nov2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/CA34272%20Deviations%20-%20CJN%20-%20CT%20-%20CJN%2015Nov2021.xlsx) (xlsx) [ALLN-346]
          - [ca34272-study-report-body 346--201_CT 20221019.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/ca34272-study-report-body%20346--201_CT%2020221019.docx) (docx) [ALLN-346]
          - [Section 14 Tables-Figures.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/Section%2014%20Tables-Figures.pdf) (pdf) [ALLN-346]
          - [16.1.1 Protocol or Amendment.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.1%20Protocol%20or%20Amendment.pdf) (pdf) [ALLN-346]
          - [16.1.2 Sample Case Report Form.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.2%20Sample%20Case%20Report%20Form.pdf) (pdf) [ALLN-346]
          - [16.1.3 IEC-IRB Consent Form List.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.3%20IEC-IRB%20Consent%20Form%20List.pdf) (pdf) [ALLN-346]
          - [16.1.4 List Description Investigator Site.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.4%20List%20Description%20Investigator%20Site.pdf) (pdf) [ALLN-346]
          - [16.1.5 Signatures Investigators.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.5%20Signatures%20Investigators.pdf) (pdf) [ALLN-346]
          - [16.1.6 List Patients with Batches TO UPDATE WITH BATCH NUMBERS.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.6%20List%20Patients%20with%20Batches%20TO%20UPDATE%20WITH%20BATCH%20NUMBERS.pdf) (pdf) [ALLN-346]
          - [16.1.7 Randomization Scheme.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.7%20Randomization%20Scheme.pdf) (pdf) [ALLN-346]
          - [16.1.8 Audit Certificates Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.8%20Audit%20Certificates%20Report.pdf) (pdf) [ALLN-346]
          - [16.1.9 Statistical Methods Interim Analysis Plan- INCLUDES DATA.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.9%20Statistical%20Methods%20Interim%20Analysis%20Plan-%20INCLUDES%20DATA.pdf) (pdf) [ALLN-346]
          - [16.1.10 Inter-Laboratory Standardization Methods Quality Assurance-NOT INCLUDE URINE UA CR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.10%20Inter-Laboratory%20Standardization%20Methods%20Quality%20Assurance-NOT%20INCLUDE%20URINE%20UA%20CR.pdf) (pdf) [ALLN-346]
          - [16.1.11 Publications Based on Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.11%20Publications%20Based%20on%20Study.pdf) (pdf) [ALLN-346]
          - [16.1.12 Publications Referenced in Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.1.12%20Publications%20Referenced%20in%20Report.pdf) (pdf) [ALLN-346]
          - [16.2.1 Discontinued Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.1%20Discontinued%20Patients.pdf) (pdf) [ALLN-346]
          - [16.2.3 Patients Excluded from Efficacy Analysis TO CHANGE TO NONE.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.3%20Patients%20Excluded%20from%20Efficacy%20Analysis%20TO%20CHANGE%20TO%20NONE.pdf) (pdf) [ALLN-346]
          - [16.2.4 Demographic Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.4%20Demographic%20Data.pdf) (pdf) [ALLN-346]
          - [16.2.5 Compliance and Drug Concentration Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.5%20Compliance%20and%20Drug%20Concentration%20Data.pdf) (pdf) [ALLN-346]
          - [16.2.7 Adverse Event Listings.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.7%20Adverse%20Event%20Listings.pdf) (pdf) [ALLN-346]
          - [16.2.8 Individual Laboratory Measurements.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/draft%20CSR%20and%20appendices/16.2.8%20Individual%20Laboratory%20Measurements.pdf) (pdf) [ALLN-346]
        - **Essential Docs & IRB/**
          - [CA34272 Allena Blank ICF - English, 29 Jun 2021 (1).docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/CA34272%20Allena%20Blank%20ICF%20-%20English,%2029%20Jun%202021%20(1).docx) (docx) [ALLN-346]
          - [CA34272 Allena  Response, 09 Jul 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/CA34272%20Allena%20%20Response,%2009%20Jul%202021.pdf) (pdf) [ALLN-346]
          - [CA34272 Allena  Response, 09 Jul 2021 (1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/CA34272%20Allena%20%20Response,%2009%20Jul%202021%20(1).pdf) (pdf) [ALLN-346]
          - [CA34272 Allena  Response, 29 Jul 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/CA34272%20Allena%20%20Response,%2029%20Jul%202021.pdf) (pdf) [ALLN-346]
          - [CA34272 Allena  Response, 30 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/CA34272%20Allena%20%20Response,%2030%20Jun%202021.pdf) (pdf) [ALLN-346]
          - **Celerion SiteVault/**
            - **2021-07-19T1814 - Celerion SiteVault (1)/**
              - [Advarra Composition, 28 May 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Advarra%20Composition,%2028%20May%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena 1572, 24 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%201572,%2024%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(1).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(2).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(2).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(3).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(3).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(4).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(4).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(5).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(5).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 18 Jun 2021(6).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2018%20Jun%202021(6).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 21 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2021%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 21 Jun 2021(1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2021%20Jun%202021(1).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 21 Jun 2021(2).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2021%20Jun%202021(2).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 22 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2022%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 25 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2025%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena   FDF, 25 Jun 2021(1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20%20FDF,%2025%20Jun%202021(1).pdf) (pdf) [ALLN-346]
              - [CA34272 Allena  Response, 09 Jul 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20Response,%2009%20Jul%202021.pdf) (pdf) [ALLN-346]
              - [CA34272 Allena  Response, 30 Jun 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/CA34272%20Allena%20%20Response,%2030%20Jun%202021.pdf) (pdf) [ALLN-346]
              - [Danielle Armas, MD CV, 10 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Danielle%20Armas,%20MD%20CV,%2010%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [Danielle Armas, MD GCP Training Certificate, 24 Dec 2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Danielle%20Armas,%20MD%20GCP%20Training%20Certificate,%2024%20Dec%202019.pdf) (pdf) [ALLN-346]
              - [Danielle Armas, MD GCP Training Certificate, 31 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Danielle%20Armas,%20MD%20GCP%20Training%20Certificate,%2031%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [Danielle Armas, MD GCP Training Certificate, 31 Dec 2020(1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Danielle%20Armas,%20MD%20GCP%20Training%20Certificate,%2031%20Dec%202020(1).pdf) (pdf) [ALLN-346]
              - [Danielle Armas, MD Medical License, 05 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Danielle%20Armas,%20MD%20Medical%20License,%2005%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [export_results.txt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/export_results.txt) (txt) [ALLN-346]
              - [Janelle Weyer, MD CV, 10 May 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Janelle%20Weyer,%20MD%20CV,%2010%20May%202021.pdf) (pdf) [ALLN-346]
              - [Janelle Weyer, MD GCP Training Certificate, 14 Apr 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Janelle%20Weyer,%20MD%20GCP%20Training%20Certificate,%2014%20Apr%202021.pdf) (pdf) [ALLN-346]
              - [Janelle Weyer, MD Medical License, 19 Aug 2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Janelle%20Weyer,%20MD%20Medical%20License,%2019%20Aug%202019.pdf) (pdf) [ALLN-346]
              - [Janelle Weyer, MD Signature & Initials, 04 May 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Janelle%20Weyer,%20MD%20Signature%20&%20Initials,%2004%20May%202021.pdf) (pdf) [ALLN-346]
              - [Jeanmarie Ricks, MSN, CRNP CV, 13 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jeanmarie%20Ricks,%20MSN,%20CRNP%20CV,%2013%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [Jeanmarie Ricks, MSN, CRNP GCP Training Certificate, 02 Jun .pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jeanmarie%20Ricks,%20MSN,%20CRNP%20GCP%20Training%20Certificate,%2002%20Jun%20.pdf) (pdf) [ALLN-346]
              - [Jeanmarie Ricks, MSN, CRNP GCP Training Certificate, 17 Jun .pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jeanmarie%20Ricks,%20MSN,%20CRNP%20GCP%20Training%20Certificate,%2017%20Jun%20.pdf) (pdf) [ALLN-346]
              - [Jeanmarie Ricks, MSN, CRNP Medical License, 18 May 2017.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jeanmarie%20Ricks,%20MSN,%20CRNP%20Medical%20License,%2018%20May%202017.pdf) (pdf) [ALLN-346]
              - [Jill Patterson, MSN, FNP-C CV, 11 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jill%20Patterson,%20MSN,%20FNP-C%20CV,%2011%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [Jill Patterson, MSN, FNP-C GCP Training Certificate, 03 Dec .pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jill%20Patterson,%20MSN,%20FNP-C%20GCP%20Training%20Certificate,%2003%20Dec%20.pdf) (pdf) [ALLN-346]
              - [Jill Patterson, MSN, FNP-C Medical License, 18 Apr 2017.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Jill%20Patterson,%20MSN,%20FNP-C%20Medical%20License,%2018%20Apr%202017.pdf) (pdf) [ALLN-346]
              - [John Laabs, MD CV, 10 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/John%20Laabs,%20MD%20CV,%2010%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [John Laabs, MD GCP Training Certificate, 17 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/John%20Laabs,%20MD%20GCP%20Training%20Certificate,%2017%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [John Laabs, MD Medical License, 15 Mar 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/John%20Laabs,%20MD%20Medical%20License,%2015%20Mar%202021.pdf) (pdf) [ALLN-346]
              - [Karen Worzel, DO CV, 08 Mar 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Karen%20Worzel,%20DO%20CV,%2008%20Mar%202021.pdf) (pdf) [ALLN-346]
              - [Karen Worzel, DO GCP Training Certificate, 09 Mar 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Karen%20Worzel,%20DO%20GCP%20Training%20Certificate,%2009%20Mar%202021.pdf) (pdf) [ALLN-346]
              - [Karen Worzel, DO Medical License, 22 Apr 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Karen%20Worzel,%20DO%20Medical%20License,%2022%20Apr%202021.pdf) (pdf) [ALLN-346]
              - [Mark Allison, MD CV, 14 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mark%20Allison,%20MD%20CV,%2014%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [Mark Allison, MD GCP Training Certificate, 22 Jan 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mark%20Allison,%20MD%20GCP%20Training%20Certificate,%2022%20Jan%202021.pdf) (pdf) [ALLN-346]
              - [Mark Allison, MD Medical License, 10 Dec 2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mark%20Allison,%20MD%20Medical%20License,%2010%20Dec%202019.pdf) (pdf) [ALLN-346]
              - [Mayra Alvarado, MSN, FNP-C CV, 20 Oct 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mayra%20Alvarado,%20MSN,%20FNP-C%20CV,%2020%20Oct%202020.pdf) (pdf) [ALLN-346]
              - [Mayra Alvarado, MSN, FNP-C GCP Training Certificate, 29 Apr .pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mayra%20Alvarado,%20MSN,%20FNP-C%20GCP%20Training%20Certificate,%2029%20Apr%20.pdf) (pdf) [ALLN-346]
              - [Mayra Alvarado, MSN, FNP-C Medical License, 04 Sep 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Mayra%20Alvarado,%20MSN,%20FNP-C%20Medical%20License,%2004%20Sep%202020.pdf) (pdf) [ALLN-346]
              - [Nicole Bartreau, MSN, FNP-C CV, 20 Oct 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Nicole%20Bartreau,%20MSN,%20FNP-C%20CV,%2020%20Oct%202020.pdf) (pdf) [ALLN-346]
              - [Nicole Bartreau, MSN, FNP-C GCP Training Certificate, 15 Sep.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Nicole%20Bartreau,%20MSN,%20FNP-C%20GCP%20Training%20Certificate,%2015%20Sep.pdf) (pdf) [ALLN-346]
              - [Nicole Bartreau, MSN, FNP-C Medical License, 19 Sep 2013.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Nicole%20Bartreau,%20MSN,%20FNP-C%20Medical%20License,%2019%20Sep%202013.pdf) (pdf) [ALLN-346]
              - [Terry O'Reilly, MD CV, 06 Nov 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Terry%20O'Reilly,%20MD%20CV,%2006%20Nov%202020.pdf) (pdf) [ALLN-346]
              - [Terry O'Reilly, MD GCP Training Certificate, 29 Sep 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Terry%20O'Reilly,%20MD%20GCP%20Training%20Certificate,%2029%20Sep%202020.pdf) (pdf) [ALLN-346]
              - [Terry O'Reilly, MD Medical License, 16 Jul 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Terry%20O'Reilly,%20MD%20Medical%20License,%2016%20Jul%202020.pdf) (pdf) [ALLN-346]
              - [Tracy Vincent, PA-C CV, 10 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Tracy%20Vincent,%20PA-C%20CV,%2010%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [Tracy Vincent, PA-C GCP Training Certificate, 03 Feb 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Tracy%20Vincent,%20PA-C%20GCP%20Training%20Certificate,%2003%20Feb%202020.pdf) (pdf) [ALLN-346]
              - [Tracy Vincent, PA-C GCP Training Certificate, 16 Feb 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Tracy%20Vincent,%20PA-C%20GCP%20Training%20Certificate,%2016%20Feb%202021.pdf) (pdf) [ALLN-346]
              - [Tracy Vincent, PA-C Medical License, 09 Jan 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Tracy%20Vincent,%20PA-C%20Medical%20License,%2009%20Jan%202020.pdf) (pdf) [ALLN-346]
              - [Trisha Tavares, MD CV, 04 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Trisha%20Tavares,%20MD%20CV,%2004%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [Trisha Tavares, MD GCP Training Certificate, 17 Mar 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Trisha%20Tavares,%20MD%20GCP%20Training%20Certificate,%2017%20Mar%202020.pdf) (pdf) [ALLN-346]
              - [Trisha Tavares, MD GCP Training Certificate, 25 Feb 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Trisha%20Tavares,%20MD%20GCP%20Training%20Certificate,%2025%20Feb%202021.pdf) (pdf) [ALLN-346]
              - [Trisha Tavares, MD Medical License, 09 Mar 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Trisha%20Tavares,%20MD%20Medical%20License,%2009%20Mar%202021.pdf) (pdf) [ALLN-346]
              - [Weston Young, D.O. CV, 11 Dec 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Weston%20Young,%20D.O.%20CV,%2011%20Dec%202020.pdf) (pdf) [ALLN-346]
              - [Weston Young, D.O. GCP Training Certificate, 22 Jun 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Weston%20Young,%20D.O.%20GCP%20Training%20Certificate,%2022%20Jun%202020.pdf) (pdf) [ALLN-346]
              - [Weston Young, D.O. Medical License, 25 Jan 2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1)/Weston%20Young,%20D.O.%20Medical%20License,%2025%20Jan%202021.pdf) (pdf) [ALLN-346]
            - [2021-07-19T1814 - Celerion SiteVault (1).zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/Celerion%20SiteVault/2021-07-19T1814%20-%20Celerion%20SiteVault%20(1).zip) (zip) [ALLN-346]
          - [IP approval sig page DA10  Allena Pharm.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/Essential%20Docs%20&%20IRB/IP%20approval%20sig%20page%20DA10%20%20Allena%20Pharm.pdf) (pdf) [ALLN-346]
        - **protocol/**
          - [Protocol ALLN-346-201Amendment 1 FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/protocol/Protocol%20ALLN-346-201Amendment%201%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-201 Amendment 2 FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/protocol/Protocol%20ALLN-346-201%20Amendment%202%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-201 Amendment 3 FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/protocol/Protocol%20ALLN-346-201%20Amendment%203%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-201 FINAL 22May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/protocol/Protocol%20ALLN-346-201%20FINAL%2022May2021.pdf) (pdf) [ALLN-346]
        - **TLF/**
          - **ALLN-346-201 Final Signed CRFs/**
            - [Final Subject Data_1-60 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_1-60%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_10-100 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_10-100%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_11-110 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_11-110%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_13-227 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_13-227%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_14-298 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_14-298%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_15-373 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_15-373%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_16-392 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_16-392%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_17-452 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_17-452%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_2-18 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_2-18%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_3-55 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_3-55%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_4-57 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_4-57%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_5-21 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_5-21%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_6-35 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_6-35%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_7-82 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_7-82%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_8-99 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_8-99%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
            - [Final Subject Data_9-98 Final CRF_Final Signed CRF_08 Apr 2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALLN-346-201%20Final%20Signed%20CRFs/Final%20Subject%20Data_9-98%20Final%20CRF_Final%20Signed%20CRF_08%20Apr%202022.pdf) (pdf) [ALLN-346]
          - [ALN_346_201_tables_13Jul2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/ALN_346_201_tables_13Jul2022.pdf) (pdf) [ALLN-346]
          - **CA34272 Draft PK and PD TFLs/**
            - [2022-05-05_CRPnumtabCA34272.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/CA34272%20Draft%20PK%20and%20PD%20TFLs/2022-05-05_CRPnumtabCA34272.docx) (docx) [ALLN-346]
            - [2022-06-11_pknumtabCA34272.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/CA34272%20Draft%20PK%20and%20PD%20TFLs/2022-06-11_pknumtabCA34272.docx) (docx) [ALLN-346]
            - [2022-07-22_pdnumtabCA34272.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/CA34272%20Draft%20PK%20and%20PD%20TFLs/2022-07-22_pdnumtabCA34272.docx) (docx) [ALLN-346]
            - [2022-07-22_pdurinenumtabCA34272.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/CA34272%20Draft%20PK%20and%20PD%20TFLs/2022-07-22_pdurinenumtabCA34272.docx) (docx) [ALLN-346]
          - **MarkVB stat data/**
            - [ALLN346_201_rmanova_n11_n16 25may22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/ALLN346_201_rmanova_n11_n16%2025may22.pdf) (pdf) [ALLN-346]
            - [ALN_346_201_corr_egr_sua 03Jun2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/ALN_346_201_corr_egr_sua%2003Jun2022.pdf) (pdf) [ALLN-346]
            - [ALN_346_201_RM_Corr.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/ALN_346_201_RM_Corr.pdf) (pdf) [ALLN-346]
            - [FW_ 346-201-Mark-DataReduction sUA-eGFR data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/FW_%20346-201-Mark-DataReduction%20sUA-eGFR%20data.pdf) (pdf) [ALLN-346]
            - [RE_ Allena CA34272 346-201 PD TFLs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/RE_%20Allena%20CA34272%20346-201%20PD%20TFLs.pdf) (pdf) [ALLN-346]
            - [RE_ sUA stratification by eGFR at 2, 6, 8,  pls can you do stat analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/MarkVB%20stat%20data/RE_%20sUA%20stratification%20by%20eGFR%20at%202,%206,%208,%20%20pls%20can%20you%20do%20stat%20analysis.pdf) (pdf) [ALLN-346]
          - [mhbuild_346 201 medhistory.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/mhbuild_346%20201%20medhistory.pdf) (pdf) [ALLN-346]
          - **POSTHOCK MARK V/**
            - [ADSUA.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/POSTHOCK%20MARK%20V/ADSUA.xlsx) (xlsx) [ALLN-346]
            - [ALN_346_201_tables_13Jul2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/POSTHOCK%20MARK%20V/ALN_346_201_tables_13Jul2022.pdf) (pdf) [ALLN-346]
          - **safety TLF no pw/**
            - [ALN_346_201_tables_13Jul2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/safety%20TLF%20no%20pw/ALN_346_201_tables_13Jul2022.pdf) (pdf) [ALLN-346]
            - [2022-04-26_safetynumlis-cvr-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/safety%20TLF%20no%20pw/2022-04-26_safetynumlis-cvr-noPW.docx) (docx) [ALLN-346]
            - [2022-04-26_safetynumlisCA34272-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/safety%20TLF%20no%20pw/2022-04-26_safetynumlisCA34272-noPW.docx) (docx) [ALLN-346]
            - [2022-04-26_safetynumtab_cvr-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/safety%20TLF%20no%20pw/2022-04-26_safetynumtab_cvr-noPW.docx) (docx) [ALLN-346]
            - [2022-04-26_safetynumtabCA34272-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/safety%20TLF%20no%20pw/2022-04-26_safetynumtabCA34272-noPW.docx) (docx) [ALLN-346]
          - [2022-04-26_safetynumlis-cvr-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/2022-04-26_safetynumlis-cvr-noPW.docx) (docx) [ALLN-346]
          - [2022-04-26_safetynumlisCA34272-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/2022-04-26_safetynumlisCA34272-noPW.docx) (docx) [ALLN-346]
          - [2022-04-26_safetynumtab_cvr-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/2022-04-26_safetynumtab_cvr-noPW.docx) (docx) [ALLN-346]
          - [2022-04-26_safetynumtabCA34272-noPW.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/TLF/2022-04-26_safetynumtabCA34272-noPW.docx) (docx) [ALLN-346]
        - [346-201 sUA _David.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/201/346-201%20sUA%20_David.pptx) (pptx) [ALLN-346]
      - **202/**
        - [Allena IM_General Session_Master Deck_FINAL.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Allena%20IM_General%20Session_Master%20Deck_FINAL.pptx) (pptx) [ALLN-346]
        - [ALLN 346-202 ProtocolDeviationPlan_Final Version 1.0_13-Jul-2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/ALLN%20346-202%20ProtocolDeviationPlan_Final%20Version%201.0_13-Jul-2021.pdf) (pdf) [ALLN-346]
        - **DATA-202 cohort A-B/**
          - [ADSUA_02aug22.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/ADSUA_02aug22.xlsx) (xlsx) [ALLN-346]
          - [ALLN620220220728-ct.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/ALLN620220220728-ct.xlsx) (xlsx) [ALLN-346]
          - [ALLN6202_All_Datasets_20220729.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/ALLN6202_All_Datasets_20220729.xlsx) (xlsx) [ALLN-346]
          - [ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs%20-%20audit.pdf) (pdf) [ALLN-346]
          - [ALN346_202_Tables_02aug22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/ALN346_202_Tables_02aug22.pdf) (pdf) [ALLN-346]
          - [Copy of Protocol deviation listing_29Jul2022-ct.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Copy%20of%20Protocol%20deviation%20listing_29Jul2022-ct.xlsx) (xlsx) [ALLN-346]
          - **mark V stats/**
            - [ADSUA_02aug22.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/mark%20V%20stats/ADSUA_02aug22.xlsx) (xlsx) [ALLN-346]
            - [ALN346_202_Tables_02aug22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/mark%20V%20stats/ALN346_202_Tables_02aug22.pdf) (pdf) [ALLN-346]
            - [MarkV -Re_ 202 Data verification email.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/mark%20V%20stats/MarkV%20-Re_%20202%20Data%20verification%20email.pdf) (pdf) [ALLN-346]
            - [RE_ ALLN6202 - Jul2022 Interim Datacut. Looks like we have all we need from Medpace.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/mark%20V%20stats/RE_%20ALLN6202%20-%20Jul2022%20Interim%20Datacut.%20Looks%20like%20we%20have%20all%20we%20need%20from%20Medpace.pdf) (pdf) [ALLN-346]
            - [RE_  email 346-202 sUA-0731.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/mark%20V%20stats/RE_%20%20email%20346-202%20sUA-0731.pdf) (pdf) [ALLN-346]
          - [Medpace - Allena ALLN-346-202 Unblinded Exports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Medpace%20-%20Allena%20ALLN-346-202%20Unblinded%20Exports.pdf) (pdf) [ALLN-346]
          - **Medpace unblinded exports cohorts A-B/**
            - [ALLN-346-202 Unblinded Study Product Assignment Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Study%20Product%20Assignment%20Export.xlsx) (xlsx) [ALLN-346]
            - [ALLN-346-202 Unblinded Subject Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Subject%20Export.xlsx) (xlsx) [ALLN-346]
            - [RE_ Allena ALLN-346-202 Unblinded Exports - PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/RE_%20Allena%20ALLN-346-202%20Unblinded%20Exports%20-%20PW.pdf) (pdf) [ALLN-346]
          - **MRL lab UA unmasked transfer/**
            - [ALLN620220220801_unblind-verify.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20lab%20UA%20unmasked%20transfer/ALLN620220220801_unblind-verify.xlsx) (xlsx) [ALLN-346]
            - [RE_ ALLN6202 Unblinded UA Transfer PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20lab%20UA%20unmasked%20transfer/RE_%20ALLN6202%20Unblinded%20UA%20Transfer%20PW.pdf) (pdf) [ALLN-346]
          - [MRL 202 IA sUA_verification_20220801-2ND.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801-2ND.xlsx) (xlsx) [ALLN-346]
          - [MRL 202 IA sUA_verification_20220801-3rd.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801-3rd.xlsx) (xlsx) [ALLN-346]
          - [MRL 202 IA sUA_verification_20220801.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801.xlsx) (xlsx) [ALLN-346]
          - [MRL 202 IA sUA_verification_20220802.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220802.xlsx) (xlsx) [ALLN-346]
          - [RE_ Allena ALLN-346-202 Unblinded Exports PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/RE_%20Allena%20ALLN-346-202%20Unblinded%20Exports%20PW.pdf) (pdf) [ALLN-346]
          - [RE_ 202 Data verification..pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/RE_%20202%20Data%20verification..pdf) (pdf) [ALLN-346]
          - **SUA MRL exports/**
            - [ALLN-346-202_IA_Plan_2022Jul28.docx.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/ALLN-346-202_IA_Plan_2022Jul28.docx.pdf) (pdf) [ALLN-346]
            - [202-101-006 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-101-006%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-101-006 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-101-006%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-106-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-003%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-106-003 sUA Graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-003%20sUA%20Graph.svg) (svg) [ALLN-346]
            - [202-106-008 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-008%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-106-008 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-008%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-107-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-003%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-107-003 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-003%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-107-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-004%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-107-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-004%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-107-006 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-006%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-107-006 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-006%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-108-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-108-001%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-108-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-108-001%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-110-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-003%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-110-003 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-003%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-110-007 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-007%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-110-007 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-007%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-110-013 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-013%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-110-013 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-013%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-111-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-111-001%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-111-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-111-001%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-115-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-115-003%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-115-003 sUa graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-115-003%20sUa%20graph.svg) (svg) [ALLN-346]
            - [202-118-002 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-118-002%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-118-002 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-118-002%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-120-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-001%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-120-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-001%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-120-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-004%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-120-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-004%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-124-002 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-002%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-124-002 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-002%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-124-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-004%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-124-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-004%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-127-005 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-005%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-127-005 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-005%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202-127-011 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-011%20eGFR.pdf) (pdf) [ALLN-346]
            - [202-127-011 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-011%20sUA%20graph.svg) (svg) [ALLN-346]
          - [Summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/Summary.pdf) (pdf) [ALLN-346]
          - [202 SUA PD Analysis Tables and Excel analysis file.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/DATA-202%20cohort%20A-B/202%20SUA%20PD%20Analysis%20Tables%20and%20Excel%20analysis%20file.pdf) (pdf) [ALLN-346]
        - **Datasets/**
          - **DATA-202 cohort A-B/**
            - [ADSUA_02aug22.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ADSUA_02aug22.xlsx) (xlsx) [ALLN-346]
            - [ALLN-346-202_IA_mvb_signature.jpg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN-346-202_IA_mvb_signature.jpg) (jpg) [ALLN-346]
            - [ALLN620220220728-ct.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN620220220728-ct.xlsx) (xlsx) [ALLN-346]
            - **ALLN6202_20220729/**
              - [ALLN6202_All_Datasets_20220729.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_20220729/ALLN6202_All_Datasets_20220729.xlsx) (xlsx) [ALLN-346]
              - **Data/**
                - [ALLN620220220728.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_20220729/Data/ALLN620220220728.xpt) (xpt) [ALLN-346]
                - [ALLN6202_Archive_20220728.xpt](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_20220729/Data/ALLN6202_Archive_20220728.xpt) (xpt) [ALLN-346]
            - [ALLN6202_20220729.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_20220729.zip) (zip) [ALLN-346]
            - [ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs%20-%20audit.pdf) (pdf) [ALLN-346]
            - [ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALLN6202_UnblindingAuthorizationForm_01Aug2022_cfs%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
            - [ALN346_202_Tables_02aug22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/ALN346_202_Tables_02aug22.pdf) (pdf) [ALLN-346]
            - [Copy of Protocol deviation listing_29Jul2022-ct.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Copy%20of%20Protocol%20deviation%20listing_29Jul2022-ct.xlsx) (xlsx) [ALLN-346]
            - **mark V stats/**
              - [ADSUA_02aug22.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/mark%20V%20stats/ADSUA_02aug22.xlsx) (xlsx) [ALLN-346]
              - [ALN346_202_Tables_02aug22.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/mark%20V%20stats/ALN346_202_Tables_02aug22.pdf) (pdf) [ALLN-346]
              - [MarkV -Re_ 202 Data verification email.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/mark%20V%20stats/MarkV%20-Re_%20202%20Data%20verification%20email.pdf) (pdf) [ALLN-346]
              - [RE_ ALLN6202 - Jul2022 Interim Datacut. Looks like we have all we need from Medpace.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/mark%20V%20stats/RE_%20ALLN6202%20-%20Jul2022%20Interim%20Datacut.%20Looks%20like%20we%20have%20all%20we%20need%20from%20Medpace.pdf) (pdf) [ALLN-346]
              - [RE_  email 346-202 sUA-0731.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/mark%20V%20stats/RE_%20%20email%20346-202%20sUA-0731.pdf) (pdf) [ALLN-346]
            - [Medpace - Allena ALLN-346-202 Unblinded Exports.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20-%20Allena%20ALLN-346-202%20Unblinded%20Exports.pdf) (pdf) [ALLN-346]
            - **Medpace unblinded exports cohorts A-B/**
              - **ALLN-346-202 Unblinded Exports/**
                - [ALLN-346-202 Unblinded Study Product Assignment Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Exports/ALLN-346-202%20Unblinded%20Study%20Product%20Assignment%20Export.xlsx) (xlsx) [ALLN-346]
                - [ALLN-346-202 Unblinded Subject Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Exports/ALLN-346-202%20Unblinded%20Subject%20Export.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-202 Unblinded Exports.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Exports.zip) (zip) [ALLN-346]
              - [ALLN-346-202 Unblinded Study Product Assignment Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Study%20Product%20Assignment%20Export.xlsx) (xlsx) [ALLN-346]
              - [ALLN-346-202 Unblinded Subject Export.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/ALLN-346-202%20Unblinded%20Subject%20Export.xlsx) (xlsx) [ALLN-346]
              - [RE_ Allena ALLN-346-202 Unblinded Exports - PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Medpace%20unblinded%20exports%20cohorts%20A-B/RE_%20Allena%20ALLN-346-202%20Unblinded%20Exports%20-%20PW.pdf) (pdf) [ALLN-346]
            - **MRL lab UA unmasked transfer/**
              - **ALLN620220220801_unblind/**
              - [ALLN620220220801_unblind-verify.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20lab%20UA%20unmasked%20transfer/ALLN620220220801_unblind-verify.xlsx) (xlsx) [ALLN-346]
              - [ALLN620220220801_unblind.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20lab%20UA%20unmasked%20transfer/ALLN620220220801_unblind.zip) (zip) [ALLN-346]
              - [RE_ ALLN6202 Unblinded UA Transfer PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20lab%20UA%20unmasked%20transfer/RE_%20ALLN6202%20Unblinded%20UA%20Transfer%20PW.pdf) (pdf) [ALLN-346]
            - [MRL 202 IA sUA_verification_20220801-2ND.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801-2ND.xlsx) (xlsx) [ALLN-346]
            - [MRL 202 IA sUA_verification_20220801-3rd.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801-3rd.xlsx) (xlsx) [ALLN-346]
            - [MRL 202 IA sUA_verification_20220801.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220801.xlsx) (xlsx) [ALLN-346]
            - [MRL 202 IA sUA_verification_20220802.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL%20202%20IA%20sUA_verification_20220802.xlsx) (xlsx) [ALLN-346]
            - **MRL_xlsx/**
              - [ALLN620220220728.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL_xlsx/ALLN620220220728.xlsx) (xlsx) [ALLN-346]
              - [ALLN6202_Archive_20220728.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL_xlsx/ALLN6202_Archive_20220728.xlsx) (xlsx) [ALLN-346]
            - [MRL_xlsx.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/MRL_xlsx.zip) (zip) [ALLN-346]
            - **Please_DocuSign_ALLN-346-202_IA_Plan_2022Jul/**
              - [ALLN-346-202_IA_Plan_2022Jul28.docx.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Please_DocuSign_ALLN-346-202_IA_Plan_2022Jul/ALLN-346-202_IA_Plan_2022Jul28.docx.pdf) (pdf) [ALLN-346]
              - [Summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Please_DocuSign_ALLN-346-202_IA_Plan_2022Jul/Summary.pdf) (pdf) [ALLN-346]
            - [Please_DocuSign_ALLN-346-202_IA_Plan_2022Jul.zip](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/Please_DocuSign_ALLN-346-202_IA_Plan_2022Jul.zip) (zip) [ALLN-346]
            - [RE_ Allena ALLN-346-202 Unblinded Exports PW.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/RE_%20Allena%20ALLN-346-202%20Unblinded%20Exports%20PW.pdf) (pdf) [ALLN-346]
            - [RE_ 202 Data verification..pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/RE_%20202%20Data%20verification..pdf) (pdf) [ALLN-346]
            - **SUA MRL exports/**
              - [202-101-006 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-101-006%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-101-006 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-101-006%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-106-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-003%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-106-003 sUA Graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-003%20sUA%20Graph.svg) (svg) [ALLN-346]
              - [202-106-008 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-008%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-106-008 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-106-008%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-107-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-003%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-107-003 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-003%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-107-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-004%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-107-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-004%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-107-006 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-006%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-107-006 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-107-006%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-108-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-108-001%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-108-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-108-001%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-110-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-003%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-110-003 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-003%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-110-007 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-007%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-110-007 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-007%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-110-013 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-013%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-110-013 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-110-013%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-111-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-111-001%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-111-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-111-001%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-115-003 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-115-003%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-115-003 sUa graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-115-003%20sUa%20graph.svg) (svg) [ALLN-346]
              - [202-118-002 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-118-002%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-118-002 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-118-002%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-120-001 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-001%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-120-001 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-001%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-120-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-004%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-120-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-120-004%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-124-002 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-002%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-124-002 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-002%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-124-004 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-004%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-124-004 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-124-004%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-127-005 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-005%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-127-005 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-005%20sUA%20graph.svg) (svg) [ALLN-346]
              - [202-127-011 eGFR.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-011%20eGFR.pdf) (pdf) [ALLN-346]
              - [202-127-011 sUA graph.svg](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/SUA%20MRL%20exports/202-127-011%20sUA%20graph.svg) (svg) [ALLN-346]
            - [202 SUA PD Analysis Tables and Excel analysis file.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Datasets/DATA-202%20cohort%20A-B/202%20SUA%20PD%20Analysis%20Tables%20and%20Excel%20analysis%20file.pdf) (pdf) [ALLN-346]
        - **Protocol/**
          - [ALLN-346-202 Protocol Amendment 1 SOC FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/ALLN-346-202%20Protocol%20Amendment%201%20SOC%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202 Protocol Amendment 3 SOC FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/ALLN-346-202%20Protocol%20Amendment%203%20SOC%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-202 Amendment 1 FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/Protocol%20ALLN-346-202%20Amendment%201%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-202 Amendment 2 FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/Protocol%20ALLN-346-202%20Amendment%202%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-202 Amendment 2 SOC FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/Protocol%20ALLN-346-202%20Amendment%202%20SOC%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-202 Amendment 3 FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/Protocol%20ALLN-346-202%20Amendment%203%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
          - [Protocol ALLN-346-202 FINAL 28May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Protocol/Protocol%20ALLN-346-202%20FINAL%2028May2021.pdf) (pdf) [ALLN-346]
        - **recruitment material/**
          - [Brochure_ALLN6202_V0.4_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/recruitment%20material/Brochure_ALLN6202_V0.4_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
          - [ParticipantHandbook_ALLN6202_V0.2_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/recruitment%20material/ParticipantHandbook_ALLN6202_V0.2_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
          - [ParticipantJourney_ALLN6202_V0.2_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/recruitment%20material/ParticipantJourney_ALLN6202_V0.2_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
        - [slidedeck_ ALLN-346-202 KOM draft 0331 2021.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/slidedeck_%20ALLN-346-202%20KOM%20draft%200331%202021.pptx) (pptx) [ALLN-346]
        - **SRC Data/**
          - [2021USALLENA0001_MW_11Mar2022-AESI.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/2021USALLENA0001_MW_11Mar2022-AESI.pdf) (pdf) [ALLN-346]
          - [2022USALLENA0002_MW_19May2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/2022USALLENA0002_MW_19May2022.pdf) (pdf) [ALLN-346]
          - **21Dec2022_2 cohort A/**
            - [ALLN-346-202 SRC review form_21Dec2021_Ammie_Nancy_Boris - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/ALLN-346-202%20SRC%20review%20form_21Dec2021_Ammie_Nancy_Boris%20-%20audit.pdf) (pdf) [ALLN-346]
            - [ALLN-346-202 SRC review form_21Dec2021_signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/ALLN-346-202%20SRC%20review%20form_21Dec2021_signed.pdf) (pdf) [ALLN-346]
            - [Patient 110-003 BMI and screening creatinine.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/Patient%20110-003%20BMI%20and%20screening%20creatinine.xlsx) (xlsx) [ALLN-346]
            - [Patient 111-001 BMI and screening creatinine.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/Patient%20111-001%20BMI%20and%20screening%20creatinine.xlsx) (xlsx) [ALLN-346]
            - [SubjectProfile-202-110 003-Safety-14Dec2021 1125.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/SubjectProfile-202-110%20003-Safety-14Dec2021%201125.pdf) (pdf) [ALLN-346]
            - [SubjectProfile-202-111 001-Safety-14Dec2021 1146.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/SubjectProfile-202-111%20001-Safety-14Dec2021%201146.pdf) (pdf) [ALLN-346]
            - [110-003 cumulative lab report.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/110-003%20cumulative%20lab%20report.xls) (xls) [ALLN-346]
            - [111-001 cumulative lab results.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/21Dec2022_2%20cohort%20A/111-001%20cumulative%20lab%20results.xls) (xls) [ALLN-346]
          - **AESI gout flare/**
            - [12_2021USALLENA0001 MW_02Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/AESI%20gout%20flare/12_2021USALLENA0001%20MW_02Nov2021.pdf) (pdf) [ALLN-346]
            - [2021USALLENA0001_MW_11Mar2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/AESI%20gout%20flare/2021USALLENA0001_MW_11Mar2022.pdf) (pdf) [ALLN-346]
            - [2022USALLENA0002_MW_02Sep2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/AESI%20gout%20flare/2022USALLENA0002_MW_02Sep2022.pdf) (pdf) [ALLN-346]
            - [2022USALLENA0002_MW_19May2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/AESI%20gout%20flare/2022USALLENA0002_MW_19May2022.pdf) (pdf) [ALLN-346]
            - [2022USALLENA0002_MW_29Apr2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/AESI%20gout%20flare/2022USALLENA0002_MW_29Apr2022.pdf) (pdf) [ALLN-346]
          - **SRC Cohorts A-B Safety Profiles/**
            - **Allena Labs/**
              - [202-101-006.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-101-006.xls) (xls) [ALLN-346]
              - [202-106-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-106-003.xls) (xls) [ALLN-346]
              - [202-106-008.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-106-008.xls) (xls) [ALLN-346]
              - [202-107-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-107-003.xls) (xls) [ALLN-346]
              - [202-107-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-107-004.xls) (xls) [ALLN-346]
              - [202-107-006.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-107-006.xls) (xls) [ALLN-346]
              - [202-108-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-108-001.xls) (xls) [ALLN-346]
              - [202-110-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-110-003.xls) (xls) [ALLN-346]
              - [202-110-007.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-110-007.xls) (xls) [ALLN-346]
              - [202-110-113.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-110-113.xls) (xls) [ALLN-346]
              - [202-111-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-111-001.xls) (xls) [ALLN-346]
              - [202-115-003.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-115-003.xls) (xls) [ALLN-346]
              - [202-118-002.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-118-002.xls) (xls) [ALLN-346]
              - [202-120-001.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-120-001.xls) (xls) [ALLN-346]
              - [202-120-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-120-004.xls) (xls) [ALLN-346]
              - [202-124-002.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-124-002.xls) (xls) [ALLN-346]
              - [202-124-004.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-124-004.xls) (xls) [ALLN-346]
              - [202-127-005.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-127-005.xls) (xls) [ALLN-346]
              - [202-127-111.xls](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Allena%20Labs/202-127-111.xls) (xls) [ALLN-346]
            - [ALLN-346-202 SRC review form_5Aug2022_final - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/ALLN-346-202%20SRC%20review%20form_5Aug2022_final%20-%20audit.pdf) (pdf) [ALLN-346]
            - **Safety Profiles 29Jul2022/**
              - [SubjectProfile-202-101 006-Safety-29Jul2022 1607.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-101%20006-Safety-29Jul2022%201607.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-106 003-Safety-29Jul2022 1630.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-106%20003-Safety-29Jul2022%201630.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-106 008-Safety-29Jul2022 1618.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-106%20008-Safety-29Jul2022%201618.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 003-Safety-29Jul2022 1606.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-107%20003-Safety-29Jul2022%201606.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 004-Safety-29Jul2022 1635.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-107%20004-Safety-29Jul2022%201635.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-107 006-Safety-29Jul2022 1624.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-107%20006-Safety-29Jul2022%201624.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-108 001-Safety-29Jul2022 1617.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-108%20001-Safety-29Jul2022%201617.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 003-Safety-29Jul2022 1620.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-110%20003-Safety-29Jul2022%201620.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 007-Safety-29Jul2022 1645.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-110%20007-Safety-29Jul2022%201645.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-110 013-Safety-29Jul2022 1616.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-110%20013-Safety-29Jul2022%201616.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-111 001-Safety-29Jul2022 1656.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-111%20001-Safety-29Jul2022%201656.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-115 003-Safety-29Jul2022 1628.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-115%20003-Safety-29Jul2022%201628.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-118 002-Safety-29Jul2022 1601.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-118%20002-Safety-29Jul2022%201601.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-120 001-Safety-29Jul2022 1639.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-120%20001-Safety-29Jul2022%201639.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-120 004-Safety-29Jul2022 1625.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-120%20004-Safety-29Jul2022%201625.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-124 002-Safety-29Jul2022 1650.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-124%20002-Safety-29Jul2022%201650.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-124 004-Safety-29Jul2022 1604.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-124%20004-Safety-29Jul2022%201604.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-127 005-Safety-29Jul2022 1638.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-127%20005-Safety-29Jul2022%201638.pdf) (pdf) [ALLN-346]
              - [SubjectProfile-202-127 011-Safety-29Jul2022 1605.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/Safety%20Profiles%2029Jul2022/SubjectProfile-202-127%20011-Safety-29Jul2022%201605.pdf) (pdf) [ALLN-346]
            - [SubjectProfile-202-101 006-Safety-02Sep2022 1250.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/SubjectProfile-202-101%20006-Safety-02Sep2022%201250.pdf) (pdf) [ALLN-346]
            - [SubjectProfile-202-110 013-Safety-02Sep2022 1206.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/SubjectProfile-202-110%20013-Safety-02Sep2022%201206.pdf) (pdf) [ALLN-346]
            - [202 Safety profiles and labs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/SRC%20Data/SRC%20Cohorts%20A-B%20Safety%20Profiles/202%20Safety%20profiles%20and%20labs.pdf) (pdf) [ALLN-346]
        - **Study Plans docs/**
          - [Allena ALLN-346-202_EIU.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202_EIU.doc) (doc) [ALLN-346]
          - [Allena ALLN-346-202_Narrative.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202_Narrative.docx) (docx) [ALLN-346]
          - [Allena ALLN-346-202_SAE form.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202_SAE%20form.doc) (doc) [ALLN-346]
          - [Allena ALLN-346-202_Site Specific Recruitment Plan Template_V1.0 02Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202_Site%20Specific%20Recruitment%20Plan%20Template_V1.0%2002Jul2021.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-202_SMP_v1_09Aug2021 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202_SMP_v1_09Aug2021%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-202 Programming Specifications - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202%20Programming%20Specifications%20-%20audit.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-202 Programming Specifications (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202%20Programming%20Specifications%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-202 SAP (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202%20SAP%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena ALLN-346-202 Study Checklist V1.0_13-Aug-2021.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20ALLN-346-202%20Study%20Checklist%20V1.0_13-Aug-2021.docx) (docx) [ALLN-346]
          - [Allena Pharmaceuticals_ RSProcessDocument_V1_FINAL-30Apr2021.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20Pharmaceuticals_%20RSProcessDocument_V1_FINAL-30Apr2021.docx) (docx) [ALLN-346]
          - [Allena Pharmaceuticals_ RSProcessDocument_V1_FINAL-30Apr2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20Pharmaceuticals_%20RSProcessDocument_V1_FINAL-30Apr2021.pdf) (pdf) [ALLN-346]
          - [Allena 346-202 Pharmacy Manual Version 1.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena%20346-202%20Pharmacy%20Manual%20Version%201.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO Screenshots_Approval_v1.0 - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO%20Screenshots_Approval_v1.0%20-%20audit.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO Screenshots_Approval_v1.0 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO%20Screenshots_Approval_v1.0%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO Screenshots_v1.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO%20Screenshots_v1.0.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO Screenshots_v1.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO%20Screenshots_v1.0.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_Approval_v1.0 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_Approval_v1.0%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_v1.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_v1.0.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_v2.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Quick_Reference_Guide_v2.0.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Site_Reference_Guide_v1.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Site_Reference_Guide_v1.0.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Site_Reference_Guide_v2.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Site_Reference_Guide_v2.0.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_ePRO_Specifications.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_ePRO_Specifications.xlsm) (xlsm) [ALLN-346]
          - [Allena_ALLN-346-202_IRT Change Request UA_CR #20211021-01.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_IRT%20Change%20Request%20UA_CR%20#20211021-01.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_IRT QRG.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_IRT%20QRG.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_IRT QRG.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_IRT%20QRG.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification%20-%20audit.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_v1.2.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_v1.2.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_V2.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_V2.0.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_V2.0 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_V2.0%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_v2.2.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_v2.2.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0 - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0%20-%20audit.pdf) (pdf) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0.docx) (docx) [ALLN-346]
          - [Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALLN-346-202_RSPM_RequirementsSpecification_v3.0%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [Allena_ALNN-346-202_IG Estimate_27May2021.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Allena_ALNN-346-202_IG%20Estimate_27May2021.xlsx) (xlsx) [ALLN-346]
          - [ALLN-202 CommunicationPlan_V1.0 05-Apr-2021 Final.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-202%20CommunicationPlan_V1.0%2005-Apr-2021%20Final.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_ Pharmacy Manual_V1-0_2021Jun30 draft-ct.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_%20Pharmacy%20Manual_V1-0_2021Jun30%20draft-ct.docx) (docx) [ALLN-346]
          - [ALLN-346-202_Data Management Plan_V1.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_Data%20Management%20Plan_V1.0.docx) (docx) [ALLN-346]
          - [ALLN-346-202_eCCGs_V1.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V1.0.docx) (docx) [ALLN-346]
          - [ALLN-346-202_eCCGs_V2.0_PDF.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V2.0_PDF.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCCGs_V3.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V3.0.docx) (docx) [ALLN-346]
          - [ALLN-346-202_eCCGs_V3.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V3.0.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCCGs_V4.1_Clean.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V4.1_Clean.docx) (docx) [ALLN-346]
          - [ALLN-346-202_eCCGs_V4.1_TC.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V4.1_TC.docx) (docx) [ALLN-346]
          - [ALLN-346-202_eCCGs_V5.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCCGs_V5.0.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCRF Completion Guidelines_Approval_V2.0 - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRF%20Completion%20Guidelines_Approval_V2.0%20-%20audit.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCRF Completion Guidelines_Approval_V2.0 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRF%20Completion%20Guidelines_Approval_V2.0%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications.xlsm) (xlsm) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_1.1.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_1.1.xlsx) (xlsx) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_Approval_V1_10Jun2021 - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_Approval_V1_10Jun2021%20-%20audit.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_Approval_V1_10Jun2021 (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_Approval_V1_10Jun2021%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_V1.0_09Jun2021.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_V1.0_09Jun2021.xlsm) (xlsm) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_v4.1.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_v4.1.xlsm) (xlsm) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_V4.1.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_V4.1.xlsx) (xlsx) [ALLN-346]
          - [ALLN-346-202_eCRFspecifications_V5.0.xlsm](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_eCRFspecifications_V5.0.xlsm) (xlsm) [ALLN-346]
          - [ALLN-346-202_ECS.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_ECS.xlsx) (xlsx) [ALLN-346]
          - [ALLN-346-202_ECS_V5.0.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_ECS_V5.0.xlsx) (xlsx) [ALLN-346]
          - [ALLN-346-202_MonitoringPlan_V1.0.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_MonitoringPlan_V1.0.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_MonitoringPlan_V2.0_31Aug2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_MonitoringPlan_V2.0_31Aug2021.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202_QV_Notes_V1.0.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_QV_Notes_V1.0.docx) (docx) [ALLN-346]
          - [ALLN-346-202_TMFPlan_V1.0_14APR2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202_TMFPlan_V1.0_14APR2021.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202 Diet  Lifestyle Questionnaire V 1 03June2021.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202%20Diet%20%20Lifestyle%20Questionnaire%20V%201%2003June2021.docx) (docx) [ALLN-346]
          - [ALLN-346-202 Final RiskManagementPlan-V1.0 11Jun2021.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202%20Final%20RiskManagementPlan-V1.0%2011Jun2021.docx) (docx) [ALLN-346]
          - [ALLN-346-202 Final RiskManagementPlan-V1.0 11Jun2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202%20Final%20RiskManagementPlan-V1.0%2011Jun2021.pdf) (pdf) [ALLN-346]
          - [ALLN 346-202 ProtocolDeviationPlan_Final Version 1.0_13-Jul-2021 .docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN%20346-202%20ProtocolDeviationPlan_Final%20Version%201.0_13-Jul-2021%20.docx) (docx) [ALLN-346]
          - [ALLN-346-202-RecruitmentRetentionPlan V1.0_25May2021_Final.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202-RecruitmentRetentionPlan%20V1.0_25May2021_Final.docx) (docx) [ALLN-346]
          - [ALLN-346-202-RecruitmentRetentionPlan V1.0_25May2021_Final.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202-RecruitmentRetentionPlan%20V1.0_25May2021_Final.pdf) (pdf) [ALLN-346]
          - [ALLN-346-202 SRC review form template V2_21Jul2022.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202%20SRC%20review%20form%20template%20V2_21Jul2022.docx) (docx) [ALLN-346]
          - [ALLN-346-202 Study Checklist _final 1Mar2022.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202%20Study%20Checklist%20_final%201Mar2022.docx) (docx) [ALLN-346]
          - [ALLN-346-202-UrineCollectionLog_Allena_01Jun2021_Final.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202-UrineCollectionLog_Allena_01Jun2021_Final.docx) (docx) [ALLN-346]
          - [ALLN-346-202-UrineCollectionLog_Allena_01Jun2021_Final.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN-346-202-UrineCollectionLog_Allena_01Jun2021_Final.pdf) (pdf) [ALLN-346]
          - [Alln346 ADA Serum Sample Collection Manual (ALLN-346-202)_29Jun2021.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Alln346%20ADA%20Serum%20Sample%20Collection%20Manual%20(ALLN-346-202)_29Jun2021.doc) (doc) [ALLN-346]
          - [Alln346 ADA Serum Sample Collection Manual (ALLN-346-202)_v2_19Jul2021.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Alln346%20ADA%20Serum%20Sample%20Collection%20Manual%20(ALLN-346-202)_v2_19Jul2021.doc) (doc) [ALLN-346]
          - [Alln346 ADA Serum Sample Collection Manual (ALLN-346-202)_v2_19Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Alln346%20ADA%20Serum%20Sample%20Collection%20Manual%20(ALLN-346-202)_v2_19Jul2021.pdf) (pdf) [ALLN-346]
          - [Alln346 PK ELISA Sample Collection Manual (ALLN-346-202)_V1_29JUN2021.doc](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Alln346%20PK%20ELISA%20Sample%20Collection%20Manual%20(ALLN-346-202)_V1_29JUN2021.doc) (doc) [ALLN-346]
          - [ALLN6202_LabManual_V1_13Aug2021_cfs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LabManual_V1_13Aug2021_cfs.pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V1_30Jun2021_cfs.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V1_30Jun2021_cfs.docx) (docx) [ALLN-346]
          - [ALLN6202_LSA_V1_30Jun2021_cfs[signed].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V1_30Jun2021_cfs[signed].pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V2_30Jul2021_cfs[signed].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V2_30Jul2021_cfs[signed].pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V3_03Nov2021_cfs (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V3_03Nov2021_cfs%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V3_03Nov2021_cfs[signed].pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V3_03Nov2021_cfs[signed].pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V4_23Feb2022_cfs - audit.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V4_23Feb2022_cfs%20-%20audit.pdf) (pdf) [ALLN-346]
          - [ALLN6202_LSA_V4_23Feb2022_cfs (part 1) - signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_LSA_V4_23Feb2022_cfs%20(part%201)%20-%20signed.pdf) (pdf) [ALLN-346]
          - [ALLN6202_QRC_V1_30Jun2021_cfs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_QRC_V1_30Jun2021_cfs.pdf) (pdf) [ALLN-346]
          - [ALLN6202_QRC_V1_30Jun2021_cfs.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ALLN6202_QRC_V1_30Jun2021_cfs.xlsx) (xlsx) [ALLN-346]
          - [Beckman COulter UA IFU OSR6098.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Beckman%20COulter%20UA%20IFU%20OSR6098.pdf) (pdf) [ALLN-346]
          - [Diet Questionnaire-v1.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Diet%20Questionnaire-v1.docx) (docx) [ALLN-346]
          - [FluidIntakeQuestionnaire_ALLN6202_draft.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/FluidIntakeQuestionnaire_ALLN6202_draft.docx) (docx) [ALLN-346]
          - [Handbook_Allena_ALLN6202_28JUL2021_V1.4.docx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/Handbook_Allena_ALLN6202_28JUL2021_V1.4.docx) (docx) [ALLN-346]
          - [MRL_SOP_GL-CH-76-S8.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/MRL_SOP_GL-CH-76-S8.pdf) (pdf) [ALLN-346]
          - [ParticipantHandbook_ALLN6202_V1.2_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ParticipantHandbook_ALLN6202_V1.2_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
          - [ParticipantHandbook_ALLN6202_V1.5_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ParticipantHandbook_ALLN6202_V1.5_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
          - [ParticipantJourney_ALLN6202_V1.1_CountryCode_Language_Working.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Clinical-Studies/202/Study%20Plans%20docs/ParticipantJourney_ALLN6202_V1.1_CountryCode_Language_Working.pdf) (pdf) [ALLN-346]
    - **CMC/**
      - **MSDS/**
        - [ALLN-346 Drug Product MSDS (1).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/CMC/MSDS/ALLN-346%20Drug%20Product%20MSDS%20(1).pdf) (pdf) [ALLN-346]
    - **Commercial/**
      - **Key ALLN-346 Publications/**
        - [Febuxostat phase 2.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20ALLN-346%20Publications/Febuxostat%20phase%202.pdf) (pdf) [ALLN-346]
        - [Pirzynowska Oral Treatment with ALLN-346 Reduces Hyperuricosuria and Hyepruricemia in URKO Mice Front In Biol 2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20ALLN-346%20Publications/Pirzynowska%20Oral%20Treatment%20with%20ALLN-346%20Reduces%20Hyperuricosuria%20and%20Hyepruricemia%20in%20URKO%20Mice%20Front%20In%20Biol%202020.pdf) (pdf) [ALLN-346]
      - **Key External Publications/**
        - [Bhatnagar V Analysis of ABCG2 in CKD and Uric acid homeostasis Clin Kidney J 2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Bhatnagar%20V%20Analysis%20of%20ABCG2%20in%20CKD%20and%20Uric%20acid%20homeostasis%20Clin%20Kidney%20J%202019.pdf) (pdf) [ALLN-346]
        - [Gonzales M why ULT are useless to stop CKD  Clin Kid J.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Gonzales%20M%20why%20ULT%20are%20useless%20to%20stop%20CKD%20%20Clin%20Kid%20J.pdf) (pdf) [ALLN-346]
        - **Health Advances Key References/**
          - [Edwards 2020 Management of Gout in the US A Claims Based Study.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Edwards%202020%20Management%20of%20Gout%20in%20the%20US%20A%20Claims%20Based%20Study.pdf) (pdf) [ALLN-346]
          - [Hart 2021 AM J Transplantation.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Hart%202021%20AM%20J%20Transplantation.pdf) (pdf) [ALLN-346]
          - [Jing 2015 Gout in CKD Patients.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Jing%202015%20Gout%20in%20CKD%20Patients.pdf) (pdf) [ALLN-346]
          - [Juraschek 2016 Gout ULT and Uric Acid Levels Among US Adults.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Juraschek%202016%20Gout%20ULT%20and%20Uric%20Acid%20Levels%20Among%20US%20Adults.pdf) (pdf) [ALLN-346]
          - [Mohammed 2019 PLOS One.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Mohammed%202019%20PLOS%20One.pdf) (pdf) [ALLN-346]
          - [Singh 2019 Gout and Hyperuricaemia in the USA Prevalence and Trends.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Singh%202019%20Gout%20and%20Hyperuricaemia%20in%20the%20USA%20Prevalence%20and%20Trends.pdf) (pdf) [ALLN-346]
          - [Tuttle 2019 JAMA Nephrology.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Health%20Advances%20Key%20References/Tuttle%202019%20JAMA%20Nephrology.pdf) (pdf) [ALLN-346]
        - [Sorensen  Role of the Intestinal Tract in the Elimination of Uric Acid Arther and Rheumat 1965.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Key%20External%20Publications/Sorensen%20%20Role%20of%20the%20Intestinal%20Tract%20in%20the%20Elimination%20of%20Uric%20Acid%20Arther%20and%20Rheumat%201965.pdf) (pdf) [ALLN-346]
      - **Market Opportunity/**
        - **KOL Events/**
          - [2022-01-04 KOL Event Terkeltaub_Goldfarb 346 Phase 2 Data.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Market%20Opportunity/KOL%20Events/2022-01-04%20KOL%20Event%20Terkeltaub_Goldfarb%20346%20Phase%202%20Data.pdf) (pdf) [ALLN-346]
        - **Market Research/**
          - [Fletcher Spaght ALLN 346 final report 11.6.18.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Market%20Opportunity/Market%20Research/Fletcher%20Spaght%20ALLN%20346%20final%20report%2011.6.18.pptx) (pptx) [ALLN-346]
          - [Health Advances ALLN-346 Final 2021May24 DR.pptx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Market%20Opportunity/Market%20Research/Health%20Advances%20ALLN-346%20Final%202021May24%20DR.pptx) (pptx) [ALLN-346]
          - [Tufts Ironwood CKD Gout Poster Presented at NKF Meeting Orlando FL April 2017.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Commercial/Market%20Opportunity/Market%20Research/Tufts%20Ironwood%20CKD%20Gout%20Poster%20Presented%20at%20NKF%20Meeting%20Orlando%20FL%20April%202017.pdf) (pdf) [ALLN-346]
    - **Medpace-Data-2024/**
      - [ALLN6101__Data.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6101__Data.xlsx) (xlsx) [ALLN-346]
      - [ALLN6101_ECRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6101_ECRF.pdf) (pdf) [ALLN-346]
      - [ALLN6102__Data.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6102__Data.xlsx) (xlsx) [ALLN-346]
      - [ALLN6102_ECRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6102_ECRF.pdf) (pdf) [ALLN-346]
      - [ALLN6202_Data.xlsx](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6202_Data.xlsx) (xlsx) [ALLN-346]
      - [ALLN6202_ECRF.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Medpace-Data-2024/ALLN6202_ECRF.pdf) (pdf) [ALLN-346]
    - **Preclinical Development/**
      - **Nonclinical Pharmacology/**
        - [NCLN-00071 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/NCLN-00071%20FINAL.pdf) (pdf) [ALLN-346]
        - [NCLN-00072 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/NCLN-00072%20FINAL.pdf) (pdf) [ALLN-346]
        - [NCLN-00074 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/NCLN-00074%20FINAL.pdf) (pdf) [ALLN-346]
        - [Report for Ur-02 Testing efficacy of oral treatment with ALLN-346 in UrKO mice.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/Report%20for%20Ur-02%20Testing%20efficacy%20of%20oral%20treatment%20with%20ALLN-346%20in%20UrKO%20mice.pdf) (pdf) [ALLN-346]
        - [Study Report ALLN-346 in URKO Mice (protocol NCLN-00051).pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/Study%20Report%20ALLN-346%20in%20URKO%20Mice%20(protocol%20NCLN-00051).pdf) (pdf) [ALLN-346]
        - [2.6.1 Pharmacology Intro FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/2.6.1%20Pharmacology%20Intro%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
        - [2.6.2 Pharmacology Written Summary SN 0028 submitted 2021Aug24.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/2.6.2%20Pharmacology%20Written%20Summary%20SN%200028%20submitted%202021Aug24.pdf) (pdf) [ALLN-346]
        - [2.6.3 Pharmacology Tabulated Summary SN 0028 submitted 2021Aug24.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/2.6.3%20Pharmacology%20Tabulated%20Summary%20SN%200028%20submitted%202021Aug24.pdf) (pdf) [ALLN-346]
        - [185507.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Nonclinical%20Pharmacology/185507.pdf) (pdf) [ALLN-346]
      - **Posters/**
        - [Final ALLN-346_ACR2019 handout .pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Posters/Final%20ALLN-346_ACR2019%20handout%20.pdf) (pdf) [ALLN-346]
        - [FINAL_ALLN-346_ACR18_181016-handout.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Posters/FINAL_ALLN-346_ACR18_181016-handout.pdf) (pdf) [ALLN-346]
      - **Toxicology/**
        - [A 4 Week Toxicity Study of ALLN-346 by Oral Gavage in Rats.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Toxicology/A%204%20Week%20Toxicity%20Study%20of%20ALLN-346%20by%20Oral%20Gavage%20in%20Rats.pdf) (pdf) [ALLN-346]
        - [A 4 Week Toxicity Study of ALLN-346 Enteric Coated Tablets Dosed by Oral Capsule in Dogs.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Toxicology/A%204%20Week%20Toxicity%20Study%20of%20ALLN-346%20Enteric%20Coated%20Tablets%20Dosed%20by%20Oral%20Capsule%20in%20Dogs.pdf) (pdf) [ALLN-346]
        - [2.6.6 Toxicology Written Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Toxicology/2.6.6%20Toxicology%20Written%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
        - [2.6.7 Toxicology Tabulated Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Preclinical%20Development/Toxicology/2.6.7%20Toxicology%20Tabulated%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
    - **Regulatory/**
      - [ALLN-346 Investigators Brochure Version 3 FINAL 04Aug2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/ALLN-346%20Investigators%20Brochure%20Version%203%20FINAL%2004Aug2021.pdf) (pdf) [ALLN-346]
      - **IND 143,480/**
        - **ALLN-346 Request for Fast Track Designation_/**
          - [2021Oct28 IND 143,480 FDA Grant Fast Track Designation_N. Nikolov.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/ALLN-346%20Request%20for%20Fast%20Track%20Designation_/2021Oct28%20IND%20143,480%20FDA%20Grant%20Fast%20Track%20Designation_N.%20Nikolov.pdf) (pdf) [ALLN-346]
          - [ALLN-346 Request for Fast Track Designation Gout - CKD FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/ALLN-346%20Request%20for%20Fast%20Track%20Designation_/ALLN-346%20Request%20for%20Fast%20Track%20Designation%20Gout%20-%20CKD%20FINAL.pdf) (pdf) [ALLN-346]
        - **Annual Report/**
          - [Annual Report Module 1.13.3 FINAL 21Mar2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Annual%20Report/Annual%20Report%20Module%201.13.3%20FINAL%2021Mar2021.pdf) (pdf) [ALLN-346]
        - **Clinical Submissions/**
          - **SN 0001 submitted 2019Dec31/**
            - [Module 2.5 Clinical Overview FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200001%20submitted%202019Dec31/Module%202.5%20Clinical%20Overview%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-101 FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200001%20submitted%202019Dec31/Protocol%20ALLN-346-101%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
            - [SN 0001 Cover Ltr FINAL 30Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200001%20submitted%202019Dec31/SN%200001%20Cover%20Ltr%20FINAL%2030Dec2019.pdf) (pdf) [ALLN-346]
            - [1.20 General Investigational Plan Initial IND FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200001%20submitted%202019Dec31/1.20%20General%20Investigational%20Plan%20Initial%20IND%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
          - **SN 0006 submitted 2020Jun08/**
            - [ALLN-346-101 Protocol Amendment SOC FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200006%20submitted%202020Jun08/ALLN-346-101%20Protocol%20Amendment%20SOC%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-101 Amendment 1 FINAL 08Jun2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200006%20submitted%202020Jun08/Protocol%20ALLN-346-101%20Amendment%201%20FINAL%2008Jun2020.pdf) (pdf) [ALLN-346]
            - [SN 0006 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200006%20submitted%202020Jun08/SN%200006%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0009 submitted 2020Aug24/**
            - [ALLN-346-101 Protocol Amendment 2 SOC FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200009%20submitted%202020Aug24/ALLN-346-101%20Protocol%20Amendment%202%20SOC%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-101 Amendment 2 FINAL 14Aug2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200009%20submitted%202020Aug24/Protocol%20ALLN-346-101%20Amendment%202%20FINAL%2014Aug2020.pdf) (pdf) [ALLN-346]
            - [SN 0009 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200009%20submitted%202020Aug24/SN%200009%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0013 submitted 2021Feb19/**
            - [Protocol ALLN-346-102 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200013%20submitted%202021Feb19/Protocol%20ALLN-346-102%20FINAL.pdf) (pdf) [ALLN-346]
            - [SN 0013 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200013%20submitted%202021Feb19/SN%200013%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0020 submitted 2021May25/**
            - [Protocol ALLN-346-201 FINAL 22May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200020%20submitted%202021May25/Protocol%20ALLN-346-201%20FINAL%2022May2021.pdf) (pdf) [ALLN-346]
            - [SN 0020 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200020%20submitted%202021May25/SN%200020%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0021 submitted 2021Jun03/**
            - [Protocol ALLN-346-202 FINAL 28May2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200021%20submitted%202021Jun03/Protocol%20ALLN-346-202%20FINAL%2028May2021.pdf) (pdf) [ALLN-346]
            - [SN 0021 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200021%20submitted%202021Jun03/SN%200021%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0022 submitted 2021Jul20/**
            - [ALLN-346-201 Protocol Amendment 1 SOC FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200022%20submitted%202021Jul20/ALLN-346-201%20Protocol%20Amendment%201%20SOC%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 Amendment 1 FINAL 16Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200022%20submitted%202021Jul20/Protocol%20ALLN-346-201%20Amendment%201%20FINAL%2016Jul2021.pdf) (pdf) [ALLN-346]
            - [SN 0022 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200022%20submitted%202021Jul20/SN%200022%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0024 submitted 2021Jul27/**
            - [ALLN-346-202 Protocol Amendment 1 SOC FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200024%20submitted%202021Jul27/ALLN-346-202%20Protocol%20Amendment%201%20SOC%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 1 FINAL 23Jul2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200024%20submitted%202021Jul27/Protocol%20ALLN-346-202%20Amendment%201%20FINAL%2023Jul2021.pdf) (pdf) [ALLN-346]
            - [SN 0024 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200024%20submitted%202021Jul27/SN%200024%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0033 submitted 2021Oct05/**
            - [ALLN-346-201 Protocol Amendment 2 SOC FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200033%20submitted%202021Oct05/ALLN-346-201%20Protocol%20Amendment%202%20SOC%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 Amendment 2 FINAL 29Sep2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200033%20submitted%202021Oct05/Protocol%20ALLN-346-201%20Amendment%202%20FINAL%2029Sep2021.pdf) (pdf) [ALLN-346]
            - [SN 0033 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200033%20submitted%202021Oct05/SN%200033%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0034 submitted 2021Oct14/**
            - [Protocol ALLN-346-202 Amendment 2 FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200034%20submitted%202021Oct14/Protocol%20ALLN-346-202%20Amendment%202%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 2 SOC FINAL 09Oct2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200034%20submitted%202021Oct14/Protocol%20ALLN-346-202%20Amendment%202%20SOC%20FINAL%2009Oct2021.pdf) (pdf) [ALLN-346]
            - [SN 0034 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200034%20submitted%202021Oct14/SN%200034%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0038 submitted 2021Dec01/**
            - [ALLN-346-201 Protocol Amendment 3 SOC FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200038%20submitted%202021Dec01/ALLN-346-201%20Protocol%20Amendment%203%20SOC%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-201 Amendment 3 FINAL 23Nov2021.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200038%20submitted%202021Dec01/Protocol%20ALLN-346-201%20Amendment%203%20FINAL%2023Nov2021.pdf) (pdf) [ALLN-346]
            - [SN 0038 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200038%20submitted%202021Dec01/SN%200038%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
          - **SN 0043 submitted 28Jan2022/**
            - [ALLN-346-202 Protocol Amendment 3 SOC FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200043%20submitted%2028Jan2022/ALLN-346-202%20Protocol%20Amendment%203%20SOC%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
            - [Module 1.11.3 Clinical  Info Amnd FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200043%20submitted%2028Jan2022/Module%201.11.3%20Clinical%20%20Info%20Amnd%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
            - [Protocol ALLN-346-202 Amendment 3 FINAL 24Jan2022.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200043%20submitted%2028Jan2022/Protocol%20ALLN-346-202%20Amendment%203%20FINAL%2024Jan2022.pdf) (pdf) [ALLN-346]
            - [SN 0043 Cover Ltr FINAL Signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Clinical%20Submissions/SN%200043%20submitted%2028Jan2022/SN%200043%20Cover%20Ltr%20FINAL%20Signed.pdf) (pdf) [ALLN-346]
        - **CMC Submissions/**
          - **CMC Amendment DP SN 0007 submitted 2020Jun01/**
            - **Module 2/**
              - [2.3.P Drug Product SN 0007 FINAL 13Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%202/2.3.P%20Drug%20Product%20SN%200007%20FINAL%2013Jul2020.pdf) (pdf) [ALLN-346]
            - **Module 3/**
              - [3.2.P.1 DP Description FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.1%20DP%20Description%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.1 Manufacturers FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.3.1%20Manufacturers%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.2 Batch Formula FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.3.2%20Batch%20Formula%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.3 Description of Mfg Process Controls FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.3.3%20Description%20of%20Mfg%20Process%20Controls%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.3.4 Controls of Critical Steps FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.3.4%20Controls%20of%20Critical%20Steps%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.1 Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.5.1%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.4 Batch Analyses FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.5.4%20Batch%20Analyses%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.5.6 Justification of Specifications FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.5.6%20Justification%20of%20Specifications%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.1 Stability Summary FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.8.1%20Stability%20Summary%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
              - [3.2.P.8.3 Stability Data FINAL 09Jul2020.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/CMC%20Amendment%20DP%20SN%200007%20submitted%202020Jun01/Module%203/3.2.P.8.3%20Stability%20Data%20FINAL%2009Jul2020.pdf) (pdf) [ALLN-346]
          - **Original IND submis_ubmitted 2019Dec31/**
            - **Module 2/**
              - **Drug Product/**
                - [2.3.P Drug Product FINAL 25Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%202/Drug%20Product/2.3.P%20Drug%20Product%20FINAL%2025Dec2019.pdf) (pdf) [ALLN-346]
              - **Drug Substance/**
                - [2.3.S Drug Substance FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%202/Drug%20Substance/2.3.S%20Drug%20Substance%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
              - **Placebo/**
                - [2.3.P Placebo FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%202/Placebo/2.3.P%20Placebo%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
            - **Module 3/**
              - **Drug Product/**
                - [3.2.P.1 DP Description FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.1%20DP%20Description%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.2 PharmDev FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.2%20PharmDev%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.2 Batch Formula FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.3.2%20Batch%20Formula%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.2 Batch Formula FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.3.2%20Batch%20Formula%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.3 Description _ntrols FINAL 26Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.3.3%20Description%20_ntrols%20FINAL%2026Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.4 Controls of Critical Steps FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.3.4%20Controls%20of%20Critical%20Steps%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.4.1 Excipient Specifications FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.4.1%20Excipient%20Specifications%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.4.5 Excipients of_Origin FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.4.5%20Excipients%20of_Origin%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.1 Specifications FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.5.1%20Specifications%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.2 Analytical Procedures FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.5.2%20Analytical%20Procedures%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.4 Batch Analyses FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.5.4%20Batch%20Analyses%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.5 Impurities FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.5.5%20Impurities%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.6 Justificati_ions FINAL 16Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.5.6%20Justificati_ions%20FINAL%2016Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.7 Container Closure System FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.7%20Container%20Closure%20System%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.8.1 Stability FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Product/3.2.P.8.1%20Stability%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
              - **Drug Substance/**
                - [3.2.S.1.1 Nomenclature.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.1.1%20Nomenclature.pdf) (pdf) [ALLN-346]
                - [3.2.S.1.2 Structure FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.1.2%20Structure%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.1.3 General Properties.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.1.3%20General%20Properties.pdf) (pdf) [ALLN-346]
                - [3.2.S.2.1 Manufacturers.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.2.1%20Manufacturers.pdf) (pdf) [ALLN-346]
                - [3.2.S.2.2 Manufacturin_ntrols FINAL 22Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.2.2%20Manufacturin_ntrols%20FINAL%2022Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.2.3 Control of Materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.2.3%20Control%20of%20Materials.pdf) (pdf) [ALLN-346]
                - [3.2.S.2.4 Control of Critical Steps.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.2.4%20Control%20of%20Critical%20Steps.pdf) (pdf) [ALLN-346]
                - [3.2.S.3.1 Elucidation of Structure FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.3.1%20Elucidation%20of%20Structure%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.3.2 Impurities FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.3.2%20Impurities%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.4.1 Specification FINAL 15Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.4.1%20Specification%20FINAL%2015Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.4.2 Analytical Procedures FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.4.2%20Analytical%20Procedures%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.4.4 Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.4.4%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.4.5 Justificati_tion FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.4.5%20Justificati_tion%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.5 Reference Standard FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.5%20Reference%20Standard%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.6 Container Closure System FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.6%20Container%20Closure%20System%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.7.1 Stability Summary FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.7.1%20Stability%20Summary%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.S.7.3 Stability Data FINAL 18Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Drug%20Substance/3.2.S.7.3%20Stability%20Data%20FINAL%2018Dec2019.pdf) (pdf) [ALLN-346]
              - **Placebo/**
                - [3.2.P.1 PBO Descript_tion FINAL 23Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.1%20PBO%20Descript_tion%20FINAL%2023Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.1 PBO Manufacturers FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.3.1%20PBO%20Manufacturers%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.2 PBO Batch Formula FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.3.2%20PBO%20Batch%20Formula%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.3 PBO Descriptio_ontrols FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.3.3%20PBO%20Descriptio_ontrols%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.3.4 PBO Control of Critical Steps FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.3.4%20PBO%20Control%20of%20Critical%20Steps%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.4.1 PBO Exceipent Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.4.1%20PBO%20Exceipent%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.4.5 PBO Excipients_l Origin FINAL 11Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.4.5%20PBO%20Excipients_l%20Origin%20FINAL%2011Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.1 PBO Specifications FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.5.1%20PBO%20Specifications%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.2 PBO Analytical Methods FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.5.2%20PBO%20Analytical%20Methods%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.4 PBO Batch Analyses FINAL 17Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.5.4%20PBO%20Batch%20Analyses%20FINAL%2017Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.5 PBO Characte_rities FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.5.5%20PBO%20Characte_rities%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.5.6 PBO Justific_ations FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.5.6%20PBO%20Justific_ations%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.7.1 PBO Container Closure FINAL 12Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.7.1%20PBO%20Container%20Closure%20FINAL%2012Dec2019.pdf) (pdf) [ALLN-346]
                - [3.2.P.8.1 PBO Stability Summary FINAL 13Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/CMC%20Submissions/Original%20IND%20submis_ubmitted%202019Dec31/Module%203/Placebo/3.2.P.8.1%20PBO%20Stability%20Summary%20FINAL%2013Dec2019.pdf) (pdf) [ALLN-346]
        - **FDA Correspondence/**
          - [2019Nov25 PreIND Mtg Minutes WRO_S. Rhee.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2019Nov25%20PreIND%20Mtg%20Minutes%20WRO_S.%20Rhee.pdf) (pdf) [ALLN-346]
          - [2020Jan15 CMC Information Request_S. Rhee.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2020Jan15%20CMC%20Information%20Request_S.%20Rhee.pdf) (pdf) [ALLN-346]
          - [2020Jan22 Clinical-Nonclnical Information Request_S. Rhee..pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2020Jan22%20Clinical-Nonclnical%20Information%20Request_S.%20Rhee..pdf) (pdf) [ALLN-346]
          - [2021Apr02 FDA IND 143,480 CMC Information Request_H. Toure.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2021Apr02%20FDA%20IND%20143,480%20CMC%20Information%20Request_H.%20Toure.pdf) (pdf) [ALLN-346]
          - [2021Apr28 IND 143,480 FDA Response-Comments Nonclinical_S. Barnes.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2021Apr28%20IND%20143,480%20FDA%20Response-Comments%20Nonclinical_S.%20Barnes.pdf) (pdf) [ALLN-346]
          - [2021Dec28 IND 143,480 FDA Type C Meeting Minutes WRO_S. Choi.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2021Dec28%20IND%20143,480%20FDA%20Type%20C%20Meeting%20Minutes%20WRO_S.%20Choi.pdf) (pdf) [ALLN-346]
          - [2021Oct21 IND 143,480 FDA Type C Meeting Grant WRO_S. Choi.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2021Oct21%20IND%20143,480%20FDA%20Type%20C%20Meeting%20Grant%20WRO_S.%20Choi.pdf) (pdf) [ALLN-346]
          - [2021Oct28 IND 143,480 FDA Grant Fast Track Designation_N. Nikolov.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/FDA%20Correspondence/2021Oct28%20IND%20143,480%20FDA%20Grant%20Fast%20Track%20Designation_N.%20Nikolov.pdf) (pdf) [ALLN-346]
        - **Preclinical Submissions/**
          - **SN 0001 submitted 2019Dec31/**
            - [2.6.1 Pharmacology Intro FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200001%20submitted%202019Dec31/2.6.1%20Pharmacology%20Intro%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
            - [2.6.2 Pharmacology Written Summary FINAL 09Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200001%20submitted%202019Dec31/2.6.2%20Pharmacology%20Written%20Summary%20FINAL%2009Dec2019.pdf) (pdf) [ALLN-346]
            - [2.6.3 Pharmacology Tabulated Summary FINAL 25Nov2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200001%20submitted%202019Dec31/2.6.3%20Pharmacology%20Tabulated%20Summary%20FINAL%2025Nov2019.pdf) (pdf) [ALLN-346]
            - [2.6.6 Toxicology Written Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200001%20submitted%202019Dec31/2.6.6%20Toxicology%20Written%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
            - [2.6.7 Toxicology Tabulated Summary FINAL 19Dec2019.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200001%20submitted%202019Dec31/2.6.7%20Toxicology%20Tabulated%20Summary%20FINAL%2019Dec2019.pdf) (pdf) [ALLN-346]
          - **SN 0028 submitted 2021Aug24/**
            - [Module 2.6.2 SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/Module%202.6.2%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
            - [Module 2.6.3 SN 0028 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/Module%202.6.3%20SN%200028%20FINAL.pdf) (pdf) [ALLN-346]
            - [NCLN-00071 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/NCLN-00071%20FINAL.pdf) (pdf) [ALLN-346]
            - [NCLN-00072 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/NCLN-00072%20FINAL.pdf) (pdf) [ALLN-346]
            - [NCLN-00074 FINAL.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/NCLN-00074%20FINAL.pdf) (pdf) [ALLN-346]
            - [185507.pdf](https://archive.icosian.net/#documents/RDCP-26-0002/files/Regulatory/IND%20143,480/Preclinical%20Submissions/SN%200028%20submitted%202021Aug24/185507.pdf) (pdf) [ALLN-346]
# RDCP-26-0003 - Divalent siRNA (RDCP-26-0003)

  Gene therapy for prion disease using divalent siRNA technology. IND cleared by FDA March 14, 2025. Open-source research project.
  - **CTD/**
    - [Form FDA 1571.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/Form%20FDA%201571.pdf) (pdf) [Divalent siRNA]
    - [Table Of Contents.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/Table%20Of%20Contents.pdf) (pdf) [Divalent siRNA]
    - **1) Administrative/**
      - [1) FDA-3454-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1)%20FDA-3454-signed.pdf) (pdf) [Divalent siRNA]
      - [1) FDA-3674-filled-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1)%20FDA-3674-filled-signed.pdf) (pdf) [Divalent siRNA]
      - [1.2) Cover-Letter.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1.2)%20Cover-Letter.pdf) (pdf) [Divalent siRNA]
      - **1.12) Other-Correspondence/**
        - [1.12.4) Request-For-Comments.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1.12)%20Other-Correspondence/1.12.4)%20Request-For-Comments.pdf) (pdf) [Divalent siRNA]
        - [1.12.14) Environmental-Assessment-Claim-For-Exclusion.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1.12)%20Other-Correspondence/1.12.14)%20Environmental-Assessment-Claim-For-Exclusion.pdf) (pdf) [Divalent siRNA]
      - [1.14.4) investigator-brochure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1.14.4)%20investigator-brochure.pdf) (pdf) [Divalent siRNA]
      - [1.20) General-Investigational-Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/1)%20Administrative/1.20)%20General-Investigational-Plan.pdf) (pdf) [Divalent siRNA]
    - **2) Summaries/**
      - [2.2) Introductory-Statement.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/2)%20Summaries/2.2)%20Introductory-Statement.pdf) (pdf) [Divalent siRNA]
      - [2.4) nonclinical-overview.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/2)%20Summaries/2.4)%20nonclinical-overview.pdf) (pdf) [Divalent siRNA]
      - **2.6) Nonclinical-Summaries/**
        - [2.6.2) pharmacology-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.2)%20pharmacology-written-summary.pdf) (pdf) [Divalent siRNA]
        - [2.6.4) pharmacokinetics-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.4)%20pharmacokinetics-written-summary.pdf) (pdf) [Divalent siRNA]
        - [2.6.6) toxicology-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/2)%20Summaries/2.6)%20Nonclinical-Summaries/2.6.6)%20toxicology-written-summary.pdf) (pdf) [Divalent siRNA]
    - **3) Quality/**
      - **3.2) Body-of-Data/**
        - **3.2.P) Drug-Product/**
          - [3.2.P) bse-tse-statement.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P)%20bse-tse-statement.pdf) (pdf) [Divalent siRNA]
          - [3.2.P) certificate-of-analysis-for-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P)%20certificate-of-analysis-for-dp.pdf) (pdf) [Divalent siRNA]
          - [3.2.P) certificate-of-compliance-for-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P)%20certificate-of-compliance-for-dp.pdf) (pdf) [Divalent siRNA]
          - [3.2.P.1) description-composition-of-the-drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.1)%20description-composition-of-the-drug-product.pdf) (pdf) [Divalent siRNA]
          - **3.2.P.2) Pharmaceutical-Development/**
            - [3.2.P.2.1) component-of-the-drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.1)%20component-of-the-drug-product.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.2.2) drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.2)%20drug-product.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.2.3) drug-product-manufacturing-process-development.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.3)%20drug-product-manufacturing-process-development.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.2.4) container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.4)%20container-closure-system.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.2.5) microbiological-attributes.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.5)%20microbiological-attributes.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.2.6) compatibility.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.2)%20Pharmaceutical-Development/3.2.P.2.6)%20compatibility.pdf) (pdf) [Divalent siRNA]
          - **3.2.P.3) Manufacture/**
            - [3.2.P.3.1) manufacturers.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.1)%20manufacturers.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.3.2) batch-formula.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.2)%20batch-formula.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.3.3) description-manufacturing-process-and-control.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.3)%20description-manufacturing-process-and-control.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.3.4) control-of-critical-steps-and-intermediates.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.4)%20control-of-critical-steps-and-intermediates.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.3.5) process-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.3)%20Manufacture/3.2.P.3.5)%20process-validation.pdf) (pdf) [Divalent siRNA]
          - [3.2.P.4) excipients.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.4)%20excipients.pdf) (pdf) [Divalent siRNA]
          - **3.2.P.5) Control-of-Drug-Product/**
            - [3.2.P.5.1) specification-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.1)%20specification-dp.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.5.2) analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.2)%20analytical-procedures.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.5.3) analytical-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.3)%20analytical-validation.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.5.4) batch-analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.4)%20batch-analysis.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.5.5) characterization-of-impurities.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.5)%20characterization-of-impurities.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.5.6) justification-of-specifications.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.5)%20Control-of-Drug-Product/3.2.P.5.6)%20justification-of-specifications.pdf) (pdf) [Divalent siRNA]
          - [3.2.P.6) reference-standards-materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.6)%20reference-standards-materials.pdf) (pdf) [Divalent siRNA]
          - [3.2.P.7) container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.7)%20container-closure-system.pdf) (pdf) [Divalent siRNA]
          - **3.2.P.8) Stability/**
            - [3.2.P.8.1) stability-summary-and-conclusions.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.1)%20stability-summary-and-conclusions.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.8.2) post-approval-stability.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.2)%20post-approval-stability.pdf) (pdf) [Divalent siRNA]
            - [3.2.P.8.3) stability-data.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.P)%20Drug-Product/3.2.P.8)%20Stability/3.2.P.8.3)%20stability-data.pdf) (pdf) [Divalent siRNA]
        - **3.2.S) Drug-Substance/**
          - **3.2.S.1) General-Information/**
            - [3.2.S.1.1) nomenclature.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.1)%20nomenclature.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.1.2) structure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.2)%20structure.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.1.3) general-properties.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.1)%20General-Information/3.2.S.1.3)%20general-properties.pdf) (pdf) [Divalent siRNA]
          - **3.2.S.2) Manufacture/**
            - [3.2.S.2.1) manufacturer.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.1)%20manufacturer.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.2.2) manufacturing-process.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.2)%20manufacturing-process.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.2.3) control-of-materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.3)%20control-of-materials.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.2.4) controls-of-critical-steps-and-intermediates.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.4)%20controls-of-critical-steps-and-intermediates.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.2.5) process-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.5)%20process-validation.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.2.6) manufacturing-process-development.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.2)%20Manufacture/3.2.S.2.6)%20manufacturing-process-development.pdf) (pdf) [Divalent siRNA]
          - **3.2.S.3) Characterisation/**
            - [3.2.S.3.1) elucidation-of-structure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.3)%20Characterisation/3.2.S.3.1)%20elucidation-of-structure.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.3.2) impurities.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.3)%20Characterisation/3.2.S.3.2)%20impurities.pdf) (pdf) [Divalent siRNA]
          - **3.2.S.4) Control-of-Drug-Substance/**
            - [3.2.S.4.1) specifications.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.1)%20specifications.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.4.2) analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.2)%20analytical-procedures.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.4.3) validation-analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.3)%20validation-analytical-procedures.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.4.4) batch-analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.4)%20batch-analysis.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.4.5) justif-of-spec.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.4)%20Control-of-Drug-Substance/3.2.S.4.5)%20justif-of-spec.pdf) (pdf) [Divalent siRNA]
          - [3.2.S.5) reference-standard.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.5)%20reference-standard.pdf) (pdf) [Divalent siRNA]
          - [3.2.S.6) container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.6)%20container-closure-system.pdf) (pdf) [Divalent siRNA]
          - **3.2.S.7) Stability/**
            - [3.2.S.7.1) stability-summary-and-conclusions.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.7)%20Stability/3.2.S.7.1)%20stability-summary-and-conclusions.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.7.2) post-approval-stability-protocol-and-stability-commitment.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.7)%20Stability/3.2.S.7.2)%20post-approval-stability-protocol-and-stability-commitment.pdf) (pdf) [Divalent siRNA]
            - [3.2.S.7.3) stability-data.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/3)%20Quality/3.2)%20Body-of-Data/3.2.S)%20Drug-Substance/3.2.S.7)%20Stability/3.2.S.7.3)%20stability-data.pdf) (pdf) [Divalent siRNA]
    - **4) Nonclinical/**
      - **4.2) Study-Reports/**
        - **4.2.1) Pharmacology/**
          - [4.2.1.1) primary-pharmacodynamics.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.1)%20Pharmacology/4.2.1.1)%20primary-pharmacodynamics.pdf) (pdf) [Divalent siRNA]
          - [4.2.1.2) secondary-pharmacodynamics.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.1)%20Pharmacology/4.2.1.2)%20secondary-pharmacodynamics.pdf) (pdf) [Divalent siRNA]
        - **4.2.2) Pharmacokinetics/**
          - **4.2.2.1) Analytical-Methods/**
            - [4.2.2.1.1) mdr_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.1)%20mdr_csf.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.2) mdr_dog_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.2)%20mdr_dog_plasma.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.3) mdr_dog_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.3)%20mdr_dog_tissue.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.4) mdr_rat_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.4)%20mdr_rat_plasma.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.5) mdr_rat_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.5)%20mdr_rat_tissue.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.6) mdr_cellcultures_ddi.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.6)%20mdr_cellcultures_ddi.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.7) mvr_dog_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.7)%20mvr_dog_csf.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.8) mvr_dog_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.8)%20mvr_dog_plasma.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.9) mvr_dog_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.9)%20mvr_dog_tissue.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.10) mvr_rat_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.10)%20mvr_rat_csf.pdf) (pdf) [Divalent siRNA]
            - [4.2.2.1.11) mvr_rat_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.2)%20Pharmacokinetics/4.2.2.1)%20Analytical-Methods/4.2.2.1.11)%20mvr_rat_plasma.pdf) (pdf) [Divalent siRNA]
        - **4.2.3) Toxicology/**
          - **4.2.3.2) Repeat-Dose-Toxicity/**
            - [A-703-01-Appendices.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-01-Appendices.pdf) (pdf) [Divalent siRNA]
            - [A-703-01-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-01-Report.pdf) (pdf) [Divalent siRNA]
            - [A-703-01-TK-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-01-TK-CSR.pdf) (pdf) [Divalent siRNA]
            - [A-703-02-Anatomic-Path-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-02-Anatomic-Path-CSR.pdf) (pdf) [Divalent siRNA]
            - [A-703-02-Appendices.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-02-Appendices.pdf) (pdf) [Divalent siRNA]
            - [A-703-02-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-02-Report.pdf) (pdf) [Divalent siRNA]
            - [A-703-02-TK-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-02-TK-CSR.pdf) (pdf) [Divalent siRNA]
            - [A-703-03-Summary-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.2)%20Repeat-Dose-Toxicity/A-703-03-Summary-Report.pdf) (pdf) [Divalent siRNA]
          - **4.2.3.3) Genotoxicity/**
            - [XT233111-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.3)%20Genotoxicity/XT233111-Final-Report.pdf) (pdf) [Divalent siRNA]
            - [XT235113-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.3)%20Genotoxicity/XT235113-Final-Report.pdf) (pdf) [Divalent siRNA]
            - [XT238083-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.3)%20Genotoxicity/XT238083-Final-Report.pdf) (pdf) [Divalent siRNA]
            - [56772-AmesTest-Draft-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.3)%20Genotoxicity/56772-AmesTest-Draft-Report.pdf) (pdf) [Divalent siRNA]
            - [56773-InVitroMicronucleus-Draft-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/4)%20Nonclinical/4.2)%20Study-Reports/4.2.3)%20Toxicology/4.2.3.3)%20Genotoxicity/56773-InVitroMicronucleus-Draft-Report.pdf) (pdf) [Divalent siRNA]
    - **5) Clinical/**
      - **5.3) Clinical-Study-Reports/**
        - **5.3.2) Human-Biomaterials/**
          - [5.3.2) CV_Arnold.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.2)%20Human-Biomaterials/5.3.2)%20CV_Arnold.pdf) (pdf) [Divalent siRNA]
          - [5.3.2) FDA-1572-Arnold-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.2)%20Human-Biomaterials/5.3.2)%20FDA-1572-Arnold-signed.pdf) (pdf) [Divalent siRNA]
        - **5.3.5) Efficacy-Safety-Studies/**
          - **5.3.5.1) Controlled-Clinical-Studies/**
            - **5.3.5.1.1) Symptomatic-Study/**
              - [5.3.5.1.1) symptomatic-icf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/5.3.5.1)%20Controlled-Clinical-Studies/5.3.5.1.1)%20Symptomatic-Study/5.3.5.1.1)%20symptomatic-icf.pdf) (pdf) [Divalent siRNA]
              - [5.3.5.1.1) symptomatic-protocol.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/CTD/5)%20Clinical/5.3)%20Clinical-Study-Reports/5.3.5)%20Efficacy-Safety-Studies/5.3.5.1)%20Controlled-Clinical-Studies/5.3.5.1.1)%20Symptomatic-Study/5.3.5.1.1)%20symptomatic-protocol.pdf) (pdf) [Divalent siRNA]
  - **files/**
    - **IND Application/**
      FDA Investigational New Drug application (IND 167326). 92 documents comprising the full IND submission, cleared March 14, 2025.
      - [__Table Of Contents_SD-11755.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/__Table%20Of%20Contents_SD-11755.pdf) (pdf) [Divalent siRNA]
      - [_Form_FDA_1571.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/_Form_FDA_1571.pdf) (pdf) [Divalent siRNA]
      - [A-703-01-Appendices.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-01-Appendices.pdf) (pdf) [Divalent siRNA]
      - [A-703-01-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-01-Report.pdf) (pdf) [Divalent siRNA]
      - [A-703-01-TK-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-01-TK-CSR.pdf) (pdf) [Divalent siRNA]
      - [A-703-02-Anatomic-Path-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-02-Anatomic-Path-CSR.pdf) (pdf) [Divalent siRNA]
      - [A-703-02-Appendices.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-02-Appendices.pdf) (pdf) [Divalent siRNA]
      - [A-703-02-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-02-Report.pdf) (pdf) [Divalent siRNA]
      - [A-703-02-TK-CSR.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-02-TK-CSR.pdf) (pdf) [Divalent siRNA]
      - [A-703-03-Summary-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/A-703-03-Summary-Report.pdf) (pdf) [Divalent siRNA]
      - [XT233111-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/XT233111-Final-Report.pdf) (pdf) [Divalent siRNA]
      - [XT235113-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/XT235113-Final-Report.pdf) (pdf) [Divalent siRNA]
      - [XT238083-Final-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/XT238083-Final-Report.pdf) (pdf) [Divalent siRNA]
      - [1.FDA-3454-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.FDA-3454-signed.pdf) (pdf) [Divalent siRNA]
      - [1.FDA-3674-filled-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.FDA-3674-filled-signed.pdf) (pdf) [Divalent siRNA]
      - [1.2.Cover-Letter.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.2.Cover-Letter.pdf) (pdf) [Divalent siRNA]
      - [1.12.4.Request-For-Comments.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.12.4.Request-For-Comments.pdf) (pdf) [Divalent siRNA]
      - [1.12.14.Environmental-Assessment-Claim-For-Exclusion.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.12.14.Environmental-Assessment-Claim-For-Exclusion.pdf) (pdf) [Divalent siRNA]
      - [1.14.4.investigator-brochure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.14.4.investigator-brochure.pdf) (pdf) [Divalent siRNA]
      - [1.20.General-Investigational-Plan.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/1.20.General-Investigational-Plan.pdf) (pdf) [Divalent siRNA]
      - [2.2.Introductory-Statement.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/2.2.Introductory-Statement.pdf) (pdf) [Divalent siRNA]
      - [2.4.nonclinical-overview.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/2.4.nonclinical-overview.pdf) (pdf) [Divalent siRNA]
      - [2.6.2.pharmacology-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/2.6.2.pharmacology-written-summary.pdf) (pdf) [Divalent siRNA]
      - [2.6.4.pharmacokinetics-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/2.6.4.pharmacokinetics-written-summary.pdf) (pdf) [Divalent siRNA]
      - [2.6.6.toxicology-written-summary.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/2.6.6.toxicology-written-summary.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.bse-tse-statement.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.bse-tse-statement.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.certificate-of-analysis-for-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.certificate-of-analysis-for-dp.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.certificate-of-compliance-for-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.certificate-of-compliance-for-dp.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.1.description-composition-of-the-drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.1.description-composition-of-the-drug-product.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.1.component-of-the-drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.1.component-of-the-drug-product.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.2.drug-product.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.2.drug-product.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.3.drug-product-manufacturing-process-development.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.3.drug-product-manufacturing-process-development.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.4.container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.4.container-closure-system.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.5.microbiological-attributes.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.5.microbiological-attributes.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.2.6.compatibility.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.2.6.compatibility.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.3.1.manufacturers.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.3.1.manufacturers.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.3.2.batch-formula.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.3.2.batch-formula.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.3.3.description-manufacturing-process-and-control.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.3.3.description-manufacturing-process-and-control.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.3.4.control-of-critical-steps-and-intermediates.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.3.4.control-of-critical-steps-and-intermediates.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.3.5.process-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.3.5.process-validation.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.4.excipients.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.4.excipients.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.1.specification-dp.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.1.specification-dp.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.2.analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.2.analytical-procedures.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.3.analytical-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.3.analytical-validation.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.4.batch-analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.4.batch-analysis.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.5.characterization-of-impurities.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.5.characterization-of-impurities.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.5.6.justification-of-specifications.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.5.6.justification-of-specifications.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.6.reference-standards-materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.6.reference-standards-materials.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.7.container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.7.container-closure-system.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.8.1.stability-summary-and-conclusions.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.8.1.stability-summary-and-conclusions.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.8.2.post-approval-stability.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.8.2.post-approval-stability.pdf) (pdf) [Divalent siRNA]
      - [3.2.P.8.3.stability-data.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.P.8.3.stability-data.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.1.1.nomenclature.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.1.1.nomenclature.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.1.2.structure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.1.2.structure.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.1.3.general-properties.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.1.3.general-properties.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.1.manufacturer.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.1.manufacturer.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.2.manufacturing-process.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.2.manufacturing-process.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.3.control-of-materials.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.3.control-of-materials.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.4.controls-of-critical-steps-and-intermediates.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.4.controls-of-critical-steps-and-intermediates.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.5.process-validation.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.5.process-validation.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.2.6.manufacturing-process-development.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.2.6.manufacturing-process-development.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.3.1.elucidation-of-structure.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.3.1.elucidation-of-structure.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.3.2.impurities.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.3.2.impurities.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.4.1.specifications.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.4.1.specifications.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.4.2.analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.4.2.analytical-procedures.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.4.3.validation-analytical-procedures.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.4.3.validation-analytical-procedures.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.4.4.batch-analysis.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.4.4.batch-analysis.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.4.5.justif-of-spec.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.4.5.justif-of-spec.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.5.reference-standard.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.5.reference-standard.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.6.container-closure-system.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.6.container-closure-system.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.7.1-stability-summary-and-conclusions.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.7.1-stability-summary-and-conclusions.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.7.2.post-approval-stability-protocol-and-stability-commitment.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.7.2.post-approval-stability-protocol-and-stability-commitment.pdf) (pdf) [Divalent siRNA]
      - [3.2.S.7.3.stability-data.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/3.2.S.7.3.stability-data.pdf) (pdf) [Divalent siRNA]
      - [4.2.1.1.primary-pharmacodynamics.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.1.1.primary-pharmacodynamics.pdf) (pdf) [Divalent siRNA]
      - [4.2.1.2.secondary-pharmacodynamics.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.1.2.secondary-pharmacodynamics.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.1.mdr_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.1.mdr_csf.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.2.mdr_dog_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.2.mdr_dog_plasma.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.3.mdr_dog_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.3.mdr_dog_tissue.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.4.mdr_rat_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.4.mdr_rat_plasma.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.5.mdr_rat_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.5.mdr_rat_tissue.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.6.mdr_cellcultures_ddi.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.6.mdr_cellcultures_ddi.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.7.mvr_dog_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.7.mvr_dog_csf.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.8.mvr_dog_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.8.mvr_dog_plasma.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.9.mvr_dog_tissue.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.9.mvr_dog_tissue.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.10.mvr_rat_csf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.10.mvr_rat_csf.pdf) (pdf) [Divalent siRNA]
      - [4.2.2.1.11.mvr_rat_plasma.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/4.2.2.1.11.mvr_rat_plasma.pdf) (pdf) [Divalent siRNA]
      - [5.3.2.CV_Arnold.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/5.3.2.CV_Arnold.pdf) (pdf) [Divalent siRNA]
      - [5.3.2.FDA-1572-Arnold-signed.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/5.3.2.FDA-1572-Arnold-signed.pdf) (pdf) [Divalent siRNA]
      - [5.3.5.1.1.symptomatic-icf.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/5.3.5.1.1.symptomatic-icf.pdf) (pdf) [Divalent siRNA]
      - [5.3.5.1.1.symptomatic-protocol.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/5.3.5.1.1.symptomatic-protocol.pdf) (pdf) [Divalent siRNA]
      - [56772-AmesTest-Draft-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/56772-AmesTest-Draft-Report.pdf) (pdf) [Divalent siRNA]
      - [56773-InVitroMicronucleus-Draft-Report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/IND-Application/56773-InVitroMicronucleus-Draft-Report.pdf) (pdf) [Divalent siRNA]
    - **Research Data/**
      Raw datasets and figures from the divalent siRNA research project.
      - **data/**
        - **analytic/**
          - [elisa.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/elisa.tsv) (tsv) [Divalent siRNA]
          - [elisa_qc.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/elisa_qc.tsv) (tsv) [Divalent siRNA]
          - [in_cellulo.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/in_cellulo.tsv) (tsv) [Divalent siRNA]
          - [meta.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/meta.tsv) (tsv) [Divalent siRNA]
          - [metadata_start.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/metadata_start.tsv) (tsv) [Divalent siRNA]
          - [qpcr.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/qpcr.tsv) (tsv) [Divalent siRNA]
          - [qpcr_name_mapping.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/qpcr_name_mapping.tsv) (tsv) [Divalent siRNA]
          - [qpcr_txes.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/qpcr_txes.tsv) (tsv) [Divalent siRNA]
          - [studysheets.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/studysheets.tsv) (tsv) [Divalent siRNA]
          - [weights.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/analytic/weights.tsv) (tsv) [Divalent siRNA]
        - **challenge/**
          - [YB_blind.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_blind.tsv) (tsv) [Divalent siRNA]
          - [YB_master.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_master.tsv) (tsv) [Divalent siRNA]
          - [YB_meta.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_meta.tsv) (tsv) [Divalent siRNA]
          - [YB_nests.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_nests.tsv) (tsv) [Divalent siRNA]
          - [YB_surgery_notes.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_surgery_notes.tsv) (tsv) [Divalent siRNA]
          - [YB_weights.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/challenge/YB_weights.tsv) (tsv) [Divalent siRNA]
        - **elisa/**
          - [026_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/026_summary.tsv) (tsv) [Divalent siRNA]
          - [027_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/027_summary.tsv) (tsv) [Divalent siRNA]
          - [043_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/043_summary.tsv) (tsv) [Divalent siRNA]
          - [044_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/044_summary.tsv) (tsv) [Divalent siRNA]
          - [047_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/047_summary.tsv) (tsv) [Divalent siRNA]
          - [049_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/049_summary.tsv) (tsv) [Divalent siRNA]
          - [050_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/050_summary.tsv) (tsv) [Divalent siRNA]
          - [052_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/052_summary.tsv) (tsv) [Divalent siRNA]
          - [053_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/053_summary.tsv) (tsv) [Divalent siRNA]
          - [064_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/064_summary.tsv) (tsv) [Divalent siRNA]
          - [084_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/084_summary.tsv) (tsv) [Divalent siRNA]
          - [085_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/085_summary.tsv) (tsv) [Divalent siRNA]
          - [087_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/087_summary.tsv) (tsv) [Divalent siRNA]
          - [088_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/088_summary.tsv) (tsv) [Divalent siRNA]
          - [106_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/106_summary.tsv) (tsv) [Divalent siRNA]
          - [114_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/114_summary.tsv) (tsv) [Divalent siRNA]
          - [124_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/124_summary.tsv) (tsv) [Divalent siRNA]
          - [126_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/126_summary.tsv) (tsv) [Divalent siRNA]
          - [138_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/138_summary.tsv) (tsv) [Divalent siRNA]
          - [188_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/188_summary.tsv) (tsv) [Divalent siRNA]
          - [193_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/193_summary.tsv) (tsv) [Divalent siRNA]
          - [222_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/222_summary.tsv) (tsv) [Divalent siRNA]
          - [224_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/224_summary.tsv) (tsv) [Divalent siRNA]
          - [233_summary.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/233_summary.tsv) (tsv) [Divalent siRNA]
          - [026.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/026.tsv) (tsv) [Divalent siRNA]
          - [027.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/027.tsv) (tsv) [Divalent siRNA]
          - [043.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/043.tsv) (tsv) [Divalent siRNA]
          - [044.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/044.tsv) (tsv) [Divalent siRNA]
          - [047.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/047.tsv) (tsv) [Divalent siRNA]
          - [049.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/049.tsv) (tsv) [Divalent siRNA]
          - [050.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/050.tsv) (tsv) [Divalent siRNA]
          - [052.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/052.tsv) (tsv) [Divalent siRNA]
          - [053.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/053.tsv) (tsv) [Divalent siRNA]
          - [064.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/064.tsv) (tsv) [Divalent siRNA]
          - [084.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/084.tsv) (tsv) [Divalent siRNA]
          - [085.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/085.tsv) (tsv) [Divalent siRNA]
          - [087.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/087.tsv) (tsv) [Divalent siRNA]
          - [088.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/088.tsv) (tsv) [Divalent siRNA]
          - [106.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/106.tsv) (tsv) [Divalent siRNA]
          - [114.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/114.tsv) (tsv) [Divalent siRNA]
          - [124.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/124.tsv) (tsv) [Divalent siRNA]
          - [126.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/126.tsv) (tsv) [Divalent siRNA]
          - [138.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/138.tsv) (tsv) [Divalent siRNA]
          - [188.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/188.tsv) (tsv) [Divalent siRNA]
          - [193.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/193.tsv) (tsv) [Divalent siRNA]
          - [222.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/222.tsv) (tsv) [Divalent siRNA]
          - [224.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/224.tsv) (tsv) [Divalent siRNA]
          - [233.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/elisa/233.tsv) (tsv) [Divalent siRNA]
        - **humanized/**
          - [CYAGEN307331_1.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/CYAGEN307331_1.tsv) (tsv) [Divalent siRNA]
          - [CYAGEN307331_depth.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/CYAGEN307331_depth.tsv) (tsv) [Divalent siRNA]
          - [mouse_genotypes.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/mouse_genotypes.tsv) (tsv) [Divalent siRNA]
          - [mouse_genotypes_params.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/mouse_genotypes_params.tsv) (tsv) [Divalent siRNA]
          - [Tg25109-transgene-mapping-report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/Tg25109-transgene-mapping-report.pdf) (pdf) [Divalent siRNA]
          - [Tg26372-transgene-mapping-report.pdf](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/Tg26372-transgene-mapping-report.pdf) (pdf) [Divalent siRNA]
          - [TGMB-160615-ACH-01_Jeff Carroll_pStart-K-PRNP.fa](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/TGMB-160615-ACH-01_Jeff%20Carroll_pStart-K-PRNP.fa) (fa) [Divalent siRNA]
          - [TGMB-160615-ACH-01_Jeff Carroll_pStart-K-PRNP.gb](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/humanized/TGMB-160615-ACH-01_Jeff%20Carroll_pStart-K-PRNP.gb) (gb) [Divalent siRNA]
        - **ind_enabling/**
          - [BioA_dog_CSF.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_dog_CSF.tsv) (tsv) [Divalent siRNA]
          - [BioA_dog_plasma.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_dog_plasma.tsv) (tsv) [Divalent siRNA]
          - [BioA_dog_tissue.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_dog_tissue.tsv) (tsv) [Divalent siRNA]
          - [BioA_rat_CSF.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_rat_CSF.tsv) (tsv) [Divalent siRNA]
          - [BioA_rat_plasma.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_rat_plasma.tsv) (tsv) [Divalent siRNA]
          - [BioA_rat_tissue.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/BioA_rat_tissue.tsv) (tsv) [Divalent siRNA]
          - [dog_organ_weights.csv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/dog_organ_weights.csv) (csv) [Divalent siRNA]
          - [rat_organ_weights.csv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/ind_enabling/rat_organ_weights.csv) (csv) [Divalent siRNA]
        - **miscellaneous/**
          - [h2h_plate_layout.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/h2h_plate_layout.tsv) (tsv) [Divalent siRNA]
          - [human_screen.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/human_screen.tsv) (tsv) [Divalent siRNA]
          - [ic50_hu.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/ic50_hu.tsv) (tsv) [Divalent siRNA]
          - [ic50_mo.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/ic50_mo.tsv) (tsv) [Divalent siRNA]
          - [mouse_initial_screen.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/mouse_initial_screen.tsv) (tsv) [Divalent siRNA]
          - [mouse_screen.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/miscellaneous/mouse_screen.tsv) (tsv) [Divalent siRNA]
        - **off_targets/**
          - [E90AWU40016-homo-sapiens.csv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/off_targets/E90AWU40016-homo-sapiens.csv) (csv) [Divalent siRNA]
        - **sequence/**
          - [Homo_sapiens_ENST00000379440_9_sequence.fa](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/sequence/Homo_sapiens_ENST00000379440_9_sequence.fa) (fa) [Divalent siRNA]
          - [Homo_sapiens_NM_000311_4_sequence.fa](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/sequence/Homo_sapiens_NM_000311_4_sequence.fa) (fa) [Divalent siRNA]
          - [Mus_musculus_ENSMUST00000091288_13_sequence.fa](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/sequence/Mus_musculus_ENSMUST00000091288_13_sequence.fa) (fa) [Divalent siRNA]
        - **supptables/**
          - [antisense_sequences.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/supptables/antisense_sequences.tsv) (tsv) [Divalent siRNA]
          - [tla_primers.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/data/supptables/tla_primers.tsv) (tsv) [Divalent siRNA]
      - **display_items/**
        - [figure-s01.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s01.png) (png) [Divalent siRNA]
        - [figure-s02.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s02.png) (png) [Divalent siRNA]
        - [figure-s03.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s03.png) (png) [Divalent siRNA]
        - [figure-s04.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s04.png) (png) [Divalent siRNA]
        - [figure-s05.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s05.png) (png) [Divalent siRNA]
        - [figure-s06.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s06.png) (png) [Divalent siRNA]
        - [figure-s07.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s07.png) (png) [Divalent siRNA]
        - [figure-s08.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s08.png) (png) [Divalent siRNA]
        - [figure-s09.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s09.png) (png) [Divalent siRNA]
        - [figure-s10.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s10.png) (png) [Divalent siRNA]
        - [figure-s11.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-s11.png) (png) [Divalent siRNA]
        - [figure-1.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-1.png) (png) [Divalent siRNA]
        - [figure-2.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-2.png) (png) [Divalent siRNA]
        - [figure-3.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-3.png) (png) [Divalent siRNA]
        - [figure-4.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-4.png) (png) [Divalent siRNA]
        - [figure-5.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-5.png) (png) [Divalent siRNA]
        - [figure-6.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-6.png) (png) [Divalent siRNA]
        - [figure-7.png](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/figure-7.png) (png) [Divalent siRNA]
        - [stats_for_text.txt](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/stats_for_text.txt) (txt) [Divalent siRNA]
        - [supplement.xlsx](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/supplement.xlsx) (xlsx) [Divalent siRNA]
        - [table-s01.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s01.tsv) (tsv) [Divalent siRNA]
        - [table-s02.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s02.tsv) (tsv) [Divalent siRNA]
        - [table-s03.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s03.tsv) (tsv) [Divalent siRNA]
        - [table-s04.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s04.tsv) (tsv) [Divalent siRNA]
        - [table-s05.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s05.tsv) (tsv) [Divalent siRNA]
        - [table-s06.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s06.tsv) (tsv) [Divalent siRNA]
        - [table-s07.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s07.tsv) (tsv) [Divalent siRNA]
        - [table-s08.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s08.tsv) (tsv) [Divalent siRNA]
        - [table-s09.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s09.tsv) (tsv) [Divalent siRNA]
        - [table-s10.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s10.tsv) (tsv) [Divalent siRNA]
        - [table-s11.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s11.tsv) (tsv) [Divalent siRNA]
        - [table-s12.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s12.tsv) (tsv) [Divalent siRNA]
        - [table-s13.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s13.tsv) (tsv) [Divalent siRNA]
        - [table-s14.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s14.tsv) (tsv) [Divalent siRNA]
        - [table-s15.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s15.tsv) (tsv) [Divalent siRNA]
        - [table-s16.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s16.tsv) (tsv) [Divalent siRNA]
        - [table-s17.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s17.tsv) (tsv) [Divalent siRNA]
        - [table-s18.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s18.tsv) (tsv) [Divalent siRNA]
        - [table-s19.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s19.tsv) (tsv) [Divalent siRNA]
        - [table-s20.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s20.tsv) (tsv) [Divalent siRNA]
        - [table-s21.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s21.tsv) (tsv) [Divalent siRNA]
        - [table-s22.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s22.tsv) (tsv) [Divalent siRNA]
        - [table-s23.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s23.tsv) (tsv) [Divalent siRNA]
        - [table-s24.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s24.tsv) (tsv) [Divalent siRNA]
        - [table-s25.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s25.tsv) (tsv) [Divalent siRNA]
        - [table-s26.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s26.tsv) (tsv) [Divalent siRNA]
        - [table-s27.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s27.tsv) (tsv) [Divalent siRNA]
        - [table-s28.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s28.tsv) (tsv) [Divalent siRNA]
        - [table-s29.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s29.tsv) (tsv) [Divalent siRNA]
        - [table-s30.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s30.tsv) (tsv) [Divalent siRNA]
        - [table-s31.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s31.tsv) (tsv) [Divalent siRNA]
        - [table-s32.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s32.tsv) (tsv) [Divalent siRNA]
        - [table-s33.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s33.tsv) (tsv) [Divalent siRNA]
        - [table-s34.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s34.tsv) (tsv) [Divalent siRNA]
        - [table-s35.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s35.tsv) (tsv) [Divalent siRNA]
        - [table-s36.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s36.tsv) (tsv) [Divalent siRNA]
        - [table-s37.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s37.tsv) (tsv) [Divalent siRNA]
        - [table-s38.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s38.tsv) (tsv) [Divalent siRNA]
        - [table-s39.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s39.tsv) (tsv) [Divalent siRNA]
        - [table-s40.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s40.tsv) (tsv) [Divalent siRNA]
        - [table-s41.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s41.tsv) (tsv) [Divalent siRNA]
        - [table-s42.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s42.tsv) (tsv) [Divalent siRNA]
        - [table-s43.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s43.tsv) (tsv) [Divalent siRNA]
        - [table-s44.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s44.tsv) (tsv) [Divalent siRNA]
        - [table-s45.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s45.tsv) (tsv) [Divalent siRNA]
        - [table-s46.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s46.tsv) (tsv) [Divalent siRNA]
        - [table-s47.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s47.tsv) (tsv) [Divalent siRNA]
        - [table-s48.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s48.tsv) (tsv) [Divalent siRNA]
        - [table-s49.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s49.tsv) (tsv) [Divalent siRNA]
        - [table-s50.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s50.tsv) (tsv) [Divalent siRNA]
        - [table-s51.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s51.tsv) (tsv) [Divalent siRNA]
        - [table-s52.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s52.tsv) (tsv) [Divalent siRNA]
        - [table-s53.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s53.tsv) (tsv) [Divalent siRNA]
        - [table-s54.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s54.tsv) (tsv) [Divalent siRNA]
        - [table-s55.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s55.tsv) (tsv) [Divalent siRNA]
        - [table-s56.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s56.tsv) (tsv) [Divalent siRNA]
        - [table-s57.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s57.tsv) (tsv) [Divalent siRNA]
        - [table-s58.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s58.tsv) (tsv) [Divalent siRNA]
        - [table-s59.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s59.tsv) (tsv) [Divalent siRNA]
        - [table-s60.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s60.tsv) (tsv) [Divalent siRNA]
        - [table-s61.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s61.tsv) (tsv) [Divalent siRNA]
        - [table-s62.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s62.tsv) (tsv) [Divalent siRNA]
        - [table-s63.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s63.tsv) (tsv) [Divalent siRNA]
        - [table-s64.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s64.tsv) (tsv) [Divalent siRNA]
        - [table-s65.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s65.tsv) (tsv) [Divalent siRNA]
        - [table-s66.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s66.tsv) (tsv) [Divalent siRNA]
        - [table-s67.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s67.tsv) (tsv) [Divalent siRNA]
        - [table-s68.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s68.tsv) (tsv) [Divalent siRNA]
        - [table-s69.tsv](https://archive.icosian.net/#documents/RDCP-26-0003/files/Research-Data/display_items/table-s69.tsv) (tsv) [Divalent siRNA]